Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-13-430417.txt : 20131106 0001193125-13-430417.hdr.sgml : 20131106 20131106171930 ACCESSION NUMBER: 0001193125-13-430417 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20130930 FILED AS OF DATE: 20131106 DATE AS OF CHANGE: 20131106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ANTARES PHARMA, INC. CENTRAL INDEX KEY: 0001016169 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 411350192 STATE OF INCORPORATION: DE FISCAL YEAR END: 1208 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32302 FILM NUMBER: 131197471 BUSINESS ADDRESS: STREET 1: 250 PHILLIPS BLVD STREET 2: SUITE 290 CITY: EWING STATE: NJ ZIP: 08618 BUSINESS PHONE: 609-359-3020 MAIL ADDRESS: STREET 1: 250 PHILLIPS BLVD STREET 2: SUITE 290 CITY: EWING STATE: NJ ZIP: 08618 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC DATE OF NAME CHANGE: 20060120 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC DATE OF NAME CHANGE: 20020520 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC /MN/ DATE OF NAME CHANGE: 20010604 10-Q 1 d600897d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended September 30, 2013

Commission File Number 1-32302

ANTARES PHARMA, INC.


A Delaware Corporation		IRS Employer Identification No. 41-1350192

100 Princeton South, Suite 300

Ewing, New Jersey 08628

(609) 359-3020

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of shares outstanding of the registrant’s Common Stock, $.01 par value, as of November 6, 2013 was 127,613,404.

ANTARES PHARMA, INC.

INDEX


		PAGE
PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements

	Consolidated Balance Sheets, as of September 30, 2013 (Unaudited) and December 31, 2012		3

	Consolidated Statements of Operations (Unaudited) for the three months and nine months ended September 30, 2013 and 2012		4

	Consolidated Statements of Comprehensive Loss (Unaudited) for the three months and nine months ended September 30, 2013 and 2012		5

	Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2013 and 2012		6

	Notes to Consolidated Financial Statements (Unaudited)		7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		13

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		20

Item 4.	Controls and Procedures		20

PART II.	OTHER INFORMATION

Item 1A.	Risk Factors		22

Item 6.	Exhibits		22

	SIGNATURES		23

PART I – FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

ANTARES PHARMA, INC.

CONSOLIDATED BALANCE SHEETS


	September 30,			December 31,
	2013			2012
	(Unaudited)
Assets
Current Assets:
Cash and cash equivalents	$	42,960,486		$	52,097,064
Short-term investments		27,053,333			21,112,623
Accounts receivable, net		3,405,395			2,228,650
Inventories, net		1,804,695			1,002,703
Deferred costs		317,514			755,159
Prepaid expenses and other current assets		1,001,195			463,033

Total current assets		76,542,618			77,659,232
Equipment, molds, furniture and fixtures, net		6,013,707			3,583,104
Patent rights, net		1,217,720			1,123,652
Goodwill		1,095,355			1,095,355
Long-term investments		—			12,015,906
Other assets		61,241			49,361

Total Assets	$	84,930,641		$	95,526,610

Liabilities and Stockholders’ Equity
Current Liabilities:
Accounts payable	$	4,689,615		$	2,864,507
Accrued expenses and other liabilities		4,863,980			2,916,700
Deferred revenue		633,970			2,157,016

Total current liabilities		10,187,565			7,938,223
Deferred revenue – long term		874,596			1,037,795

Total liabilities		11,062,161			8,976,018

Stockholders’ Equity:
Preferred Stock: $0.01 par, authorized 3,000,000 shares, none outstanding		—			—
Common Stock: $0.01 par; authorized 150,000,000 shares; 127,230,176 and 125,949,024 issued and outstanding at September 30, 2013 and December 31, 2012, respectively		1,272,302			1,259,490
Additional paid-in capital		240,919,182			238,745,612
Accumulated deficit		(167,660,826	)		(152,789,165	)
Accumulated other comprehensive loss		(662,178	)		(665,345	)

		73,868,480			86,550,592

Total Liabilities and Stockholders’ Equity	$	84,930,641		$	95,526,610

See accompanying notes to consolidated financial statements.

ANTARES PHARMA, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)


	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2013			2012			2013			2012
Revenue:
Product sales	$	3,047,091		$	2,052,398		$	10,052,458		$	7,758,463
Development revenue		1,299,328			2,606,482			2,681,202			6,329,967
Licensing revenue		69,231			77,284			207,238			812,196
Royalties		1,092,174			949,753			2,932,692			2,173,775

Total revenue		5,507,824			5,685,917			15,873,590			17,074,401
Cost of revenue:
Cost of product sales		1,909,060			1,673,849			6,519,468			5,071,007
Cost of development revenue		1,095,542			1,622,640			1,992,959			2,747,424

Total cost of revenue		3,004,602			3,296,489			8,512,427			7,818,431

Gross profit		2,503,222			2,389,428			7,361,163			9,255,970
Operating expenses:
Research and development		4,318,011			3,900,475			11,786,224			9,260,422
Sales and marketing		2,576,247			237,067			4,615,736			527,953
Business development		142,017			219,953			486,732			784,661
General and administrative		1,836,127			1,551,147			5,375,610			5,089,744

Total operating expenses		8,872,402			5,908,642			22,264,302			15,662,780

Operating loss		(6,369,180	)		(3,519,214	)		(14,903,139	)		(6,406,810	)
Other income (expense)		9,223			(15,025	)		31,478			(8,895	)

Net loss	$	(6,359,957	)	$	(3,534,239	)	$	(14,871,661	)	$	(6,415,705	)

Basic and diluted net loss per common share	$	(0.05	)	$	(0.03	)	$	(0.12	)	$	(0.06	)

Basic and diluted weighted average common shares outstanding		127,162,064			108,961,792			126,581,018			105,735,855

See accompanying notes to consolidated financial statements.

ANTARES PHARMA, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(UNAUDITED)


	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2013			2012			2013			2012
Net loss	$	(6,359,957	)	$	(3,534,239	)	$	(14,871,661	)	$	(6,415,705	)
Foreign currency translation adjustment		21,611			11,500			3,167			(93,948	)

Comprehensive loss	$	(6,338,346	)	$	(3,522,739	)	$	(14,868,494	)	$	(6,509,653	)

See accompanying notes to consolidated financial statements.

ANTARES PHARMA, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)


	For the Nine Months Ended September 30,
	2013			2012
Cash flows from operating activities:
Net loss	$	(14,871,661	)	$	(6,415,705	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		288,188			178,030
Stock-based compensation expense		1,534,100			1,464,225
Changes in operating assets and liabilities:
Accounts receivable		(1,176,745	)		484,020
Inventories		(804,009	)		(2,736	)
Prepaid expenses and other current assets		(349,833	)		(663,796	)
Deferred costs		440,051			423,856
Other assets		(11,844	)		(27,322	)
Accounts payable		1,387,543			321,607
Accrued expenses and other current liabilities		1,946,548			404,423
Deferred revenue		(1,676,365	)		(4,143,463	)

Net cash used in operating activities		(13,294,027	)		(7,976,861	)

Cash flows from investing activities:
Purchases of equipment, molds, furniture and fixtures		(2,184,568	)		(2,425,454	)
Additions to patent rights		(195,558	)		(283,871	)
Proceeds from maturities of investment securities		15,000,000			9,000,000
Purchases of investment securities		(9,118,161	)		(15,077,176	)

Net cash provided by (used in) investing activities		3,501,713			(8,786,501	)

Cash flows from financing activities:
Proceeds from exercise of stock options and warrants		756,611			9,601,723
Taxes paid related to net share settlement of equity awards		(104,329	)		(28,916	)

Net cash provided by financing activities		652,282			9,572,807

Effect of exchange rate changes on cash and cash equivalents		3,454			(7,475	)

Net decrease in cash and cash equivalents		(9,136,578	)		(7,198,030	)
Cash and cash equivalents:
Beginning of period		52,097,064			19,357,932

End of period	$	42,960,486		$	12,159,902

Noncash investing activities:
Purchases of equipment, molds, furniture and fixtures recorded in accounts payable and accrued expenses	$	437,504		$	358,828

See accompanying notes to consolidated financial statements.

ANTARES PHARMA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1.	Description of Business

Antares Pharma, Inc. (the “Company” or “Antares”) is an emerging specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies and topical gel-based products. The Company has numerous partnerships with pharmaceutical companies as well as multiple internal product development programs.

The Company has developed both subcutaneous and intramuscular injection technology systems which include Vibex^® disposable pressure-assisted auto injectors, Vision™ reusable needle-free injectors, and disposable multi-use pen injectors. The Company has licensed its reusable needle-free injection device for use with human growth hormone (“hGH”) to Teva Pharmaceutical Industries, Ltd. (“Teva”), Ferring Pharmaceuticals BV (“Ferring”) and JCR Pharmaceuticals Co., Ltd. (“JCR”), with Teva and Ferring being two of the Company’s primary customers. The Company’s needle-free injection device is marketed by Teva as the Tjet^® injector system to administer their 5mg Tev-Tropin^® brand hGH marketed in the U.S. The Company’s needle-free injection device is marketed by Ferring with their 4mg and 10mg hGH formulations as Zomajet^® 2 Vision and Zomajet^® Vision X, respectively, in Europe and Asia. The Company has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices.

In addition to development of products with partners, the Company is developing its own drug/device combination products. The Company’s lead product candidate, OTREXUP™, is a proprietary combination product comprised of a pre-filled methotrexate syringe and the Company’s Medi-Jet™ self-injection system. On October 14, 2013 the Company announced the approval of OTREXUP™ (methotrexate) injection by the U.S. Food and Drug Administration (“FDA”). OTREXUP™ is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. OTREXUP™ is indicated for adults with severe active rheumatoid arthritis or children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. The Company has worldwide marketing rights for OTREXUP™ and has provided Uman Pharma an exclusive license to commercialize the product in Canada. The Company’s strategy is to commercialize OTREXUP™ in the U.S. on its own and to enter into licensing or distribution agreements for commercialization outside the rheumatology area and outside the U.S. The Company is also developing Vibex^® QuickShot™ (“QST”) for testosterone replacement therapy for men suffering from symptomatic testosterone deficiency and announced on September 16, 2013 that the first patients have been dosed in a clinical study evaluating testosterone administered weekly by subcutaneous injection via the Vibex^® QST auto injector device. Up to 45 patients will be enrolled in the study at approximately eight investigative sites in the United States.

In the gel-based product area, the Company announced with Actavis (formerly Watson Pharmaceuticals) on April 26, 2012, the launch of Gelnique 3%™, the Company’s topical oxybutynin gel product for the treatment of overactive bladder (“OAB”). The Company has a licensing agreement with Actavis under which Actavis is currently marketing Gelnique 3%™ in the U.S. In January 2012, the Company entered into a licensing agreement with Daewoong Pharmaceuticals under which Daewoong will commercialize this product, once approved in South Korea. The Company’s gel portfolio also includes Elestrin^® (estradiol gel) currently marketed by Meda Pharma in the U.S. for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.

The Company has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted auto injector and pen injector systems. The Company’s corporate head office and Product Development and Commercial Groups are located in Ewing, New Jersey, where the Company’s gel based products were developed and where the Product Development and Commercial Groups direct the clinical, regulatory and commercial development of the Company’s internal drug/device combination products.

2.	Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of the Securities and Exchange Commission’s Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The accompanying consolidated financial statements and notes should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2012. Operating results for the nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013.

Investments

All short-term and long-term investments are U.S. Treasury bills or U.S. Treasury notes that are classified as held-to-maturity because the Company has the positive intent and ability to hold the securities to maturity. The securities are carried at their amortized cost. The fair value of all securities is determined by quoted market prices. All long-term investments mature in less than two years. At September 30, 2013 the short-term investments had a fair value of $27,070,089 and a carrying value of $27,053,333. At December 31, 2012 the short-term investments had a fair value of $21,116,952 and a carrying value of $21,112,623 and the long-term investments had a fair value of $12,016,530 and a carrying value of $12,015,906.

3.	Stockholders’ Equity

Stock Options

The Company records compensation expense associated with share based awards granted to employees at the fair value of the award on the date of grant. The expense is recognized over the period during which an employee is required to provide services in exchange for the award.

The Company’s 2008 Equity Compensation Plan (the “Plan”) allows for the grants of options, restricted stock, stock units, stock appreciation rights and/or performance awards to officers, directors, consultants and employees. Under the Plan, the maximum number of shares authorized for issuance is 15,000,000 and the maximum number of shares of stock that may be granted to any one participant during a calendar year is 1,000,000 shares. Options to purchase shares of common stock are granted at exercise prices not less than 100% of the fair market value on the dates of grant. The term of the options range from ten to eleven years and they vest in varying periods. As of September 30, 2013, the Plan had 389,363 shares available for grant. Stock option exercises are satisfied through the issuance of new shares.

A summary of stock option activity under the Plan as of September 30, 2013, and the changes during the nine months then ended is as follows:


	Number of Shares			Weighted Average Exercise Price ($)		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value ($)
Outstanding at December 31, 2012		7,814,561			1.49
Granted		904,380			4.01
Exercised		(707,285	)		0.72				2,379,554
Cancelled		(197,276	)		3.49

Outstanding at September 30, 2013		7,814,380			1.80		6.4		17,703,665

Exercisable at September 30, 2013		6,234,160			1.38		5.7		16,696,929

Total recognized compensation expense for stock options was approximately $982,000 and $799,000 for the first nine months of 2013 and 2012, respectively, and was approximately $401,000 and $295,000 for the three month periods ended September 30, 2013 and 2012, respectively. As of September 30, 2013, there was approximately $2,517,935 of total unrecognized compensation cost related to nonvested outstanding stock options that is expected to be recognized over a weighted average period of approximately 2.0 years.

The per share weighted average fair value of options granted during the first nine months of 2013 and 2012 was estimated as $2.27 and $1.63 on the date of grant using the Black-Scholes option pricing model based on the assumptions noted in the table below. Expected volatilities are based on the historical volatility of the Company’s stock price. The weighted average expected life is based on both historical and anticipated employee behavior.


	September 30,
	2013			2012
Risk-free interest rate		0.7	%		0.7	%
Annualized volatility		62.5	%		61.0	%
Weighted average expected life, in years		6.0			5.0
Expected dividend yield		0.0	%		0.0	%

Stock Awards

The employment agreements with certain members of executive management include stock-based incentives under which the executives could be awarded shares of common stock upon the occurrence of various triggering events. There were no shares awarded under these agreements in the first nine months of 2013 and 35,000 shares were awarded in the first nine months of 2012.

At times, the Company makes discretionary grants of its common stock to members of management and other employees in lieu of cash bonus awards or in recognition of special achievements. Discretionary grants of common stock totaled 60,000 in the first nine months of 2012 at a weighted average fair value of $2.59.

Expense is recognized on a straight line basis over the vesting period and is based on the fair value of the stock on the grant date. The fair value of each stock award is determined based on the number of shares granted and the market price of the Company’s common stock on the date of grant. Expense recognized in connection with performance and discretionary stock awards was approximately $8,700 and $288,000 in the first nine months of 2013 and 2012, respectively, and was $0 and $13,000 in the three month periods ended September 30, 2013 and 2012, respectively.

A portion of the discretionary stock grants vested in the first nine months of 2013 and 2012. Some of these grants were net-share settled such that the Company withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld were 30,153 and 11,165 in 2013 and 2012, respectively, and were based on the value of the shares on their vesting date as determined by the Company’s closing stock price. Total payments for the employees’ tax obligations to the taxing authorities were $104,329 and $28,916 in 2013 and 2012, respectively, and are reflected as a financing activity within the Consolidated Statements of Cash Flows. These net-share settlements had the effect of share repurchases by the Company as they reduced the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company.

In addition to the shares granted to members of management and employees, at times directors receive a portion of their annual compensation in shares of Company common stock. Expense is recognized on a straight line basis over the one year period that the compensation is earned. Expense recognized for stock-based compensation to directors was $470,000 and $377,200 in the nine month periods ended September 30, 2013 and 2012, respectively, and was $204,000 and $182,800 in the three month periods ended September 30, 2013 and 2012, respectively.

As of September 30, 2013, a total of 212,618 shares granted to directors were unvested. As of September 30, 2013, there was approximately $566,000 of total unrecognized compensation cost related to nonvested stock awards that is expected to be recognized over a weighted average period of approximately 8 months. The weighted average fair value of the shares granted in the first nine months of 2013 and 2012 was $4.01 and $3.25 per share, respectively.

Long Term Incentive Program

The Company’s Board of Directors has approved a long term incentive program for the benefit of the Company’s senior executives. Pursuant to the long term incentive program, the Company’s senior executives have been awarded stock options and performance stock units with a value targeted at the median level of the Company’s peer group. In 2013, the program was modified such that the value of the annual award for each senior executive was delivered one-third in the form of performance stock units, one-third in the form of shares of restricted stock and one-third in the form of stock options. In prior years, two thirds of the value for each senior executive was delivered in the form of stock options and one third of the value was delivered in the form of performance stock units. The stock options have a ten-year term, have an exercise price equal to the closing price of the Company’s common stock on the date of grant, vest in quarterly installments over three years, and were otherwise granted on the same standard terms and conditions as other stock options granted pursuant to the Plan. The restricted stock vests in three equal annual installments. Expense recognized in connection with the restricted stock in the three and nine-month periods ended September 30, 2013 was $46,000 and $73,000, respectively. The performance stock unit awards made to the senior executives will be vested and convert into actual shares of the Company’s common stock based on the Company’s attainment of certain performance goals over a performance period of three years. No expense has been recognized in connection with the performance stock unit awards as the defined performance goals are not yet considered probable of achievement. The performance stock unit awards, restricted stock and stock options granted under the long term incentive program are summarized in the following table:


	Performance Stock Units				Restricted Stock				Stock Options
Grant Date	Number of Shares		Fair Value on Grant Date		Number of Shares		Fair Value on Grant Date		Number of Options		Exercise Price
May 17, 2011		182,000	$	1.66		—		—		317,000	$	1.66
May 17, 2012		—		—		—		—		470,000	$	2.94
July 6, 2012		137,715	$	4.26		—		—		178,731	$	4.26
May 22, 2013		185,185	$	3.96		185,185	$	3.96		327,381	$	3.96

Warrants

In the first nine months of 2013, 234,541 warrants were exercised resulting in proceeds to the Company of $261,799. In the first nine months of 2012, the Company received proceeds of $8,962,270 from the exercise of 3,731,135 warrants. Warrants to purchase a total of 1,781,428 shares of common stock were outstanding at September 30, 2013, at a weighted average exercise price of $1.08.

4.	Net Loss Per Share

Basic loss per common share is computed by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per common share reflects the potential dilution from the exercise or conversion of securities into common stock. Potentially dilutive stock options and warrants excluded from dilutive loss per share because their effect was anti-dilutive totaled 9,595,808 and 12,765,470 at September 30, 2013 and 2012, respectively. The table below discloses the basic and diluted loss per common share.


	Three Months Ended September 30,						Nine Months Ended September 30,
	2013			2012			2013			2012
Net loss	$	(6,359,957	)	$	(3,534,239	)	$	(14,871,661	)	$	(6,415,705	)
Basic and diluted weighted average common shares outstanding		127,162,064			108,961,792			126,581,018			105,735,855

Basic and diluted net loss per common share	$	(0.05	)	$	(0.03	)	$	(0.12	)	$	(0.06	)

5.	Industry Segment and Operations by Geographic Areas

The Company has one operating segment, drug delivery, which includes the development of injection devices and injection based pharmaceutical products as well as transdermal gel products.

Revenues by customer location are summarized as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2013		2012		2013		2012
United States of America	$	4,390,966	$	4,881,106	$	13,063,929	$	13,083,259
Europe		1,047,748		787,368		2,585,655		3,448,121
Other		69,110		17,443		224,006		543,021

	$	5,507,824	$	5,685,917	$	15,873,590	$	17,074,401

Revenues by product type:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2013		2012		2013		2012
Injection devices and supplies	$	5,100,253	$	3,600,400	$	13,882,973	$	9,505,344
Transdermal products		407,571		2,085,517		1,990,617		7,569,057

Significant customers comprising 10% or more of total revenue are as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2013		2012		2013		2012
Teva	$	4,004,531	$	2,797,761	$	11,196,559	$	5,966,246
Ferring		1,047,750		783,757		2,511,332		3,444,510
Actavis (Watson)		202,813		1,171,633		1,301,929		5,859,488

6.	License Agreements

Daewoong Development and License Agreement

In January 2012, the Company entered into a licensing agreement with Daewoong Pharmaceuticals (“Daewoong”) under which Daewoong will commercialize the Company’s oxybutynin gel 3% product, once approved in South Korea. The agreement terms include an upfront payment, development and sales-based milestone payments and escalating royalties based on product sales in South Korea. Because the Company has no development responsibilities, the upfront and each milestone payment will be recognized as revenue when received. Royalties will be recognized as revenue when earned. The term of the agreement ends on the later of fifteen years following launch of the product or the expiration date of the last to expire patent. The Company recognized revenue of $442,859 in the nine months ended September 30, 2012 in connection with upfront and milestone payments.

Pfizer License Agreement

In December 2011, the Company licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. Pfizer assumed full cost and responsibility for all clinical development, manufacturing, and commercialization of the product in the licensed territory, which also includes certain non-exclusive territories outside of North America. The Company received an upfront payment, and will receive development milestones and sales based milestones, as well as royalties on net sales for three years post launch in the U.S. Because the Company has no development responsibilities, the upfront and each milestone payment will be recognized as revenue when received. Royalties will be recognized as revenue when earned. The Company recognized revenue of $750,000 in the nine months ended September 30, 2012, which was earned when Pfizer achieved a development milestone related to this undisclosed Consumer Healthcare product.

Actavis License and Commercialization Agreement

In July 2011, the Company entered into an exclusive licensing agreement with Actavis to commercialize, in the U.S. and Canada, the Company’s topical oxybutynin gel 3% product, which was subsequently approved by the FDA in December 2011.

Under this agreement the Company received payments for certain manufacturing start-up activities and delivery of launch quantities, and has received and is entitled to receive future royalties on both the Company’s oxybutynin gel 3% product and Actavis’ oxybutynin gel product Gelnique^® 10%, and will potentially receive sales based milestone payments. The milestone payment based on the achievement of regulatory approval was subject to reimbursement to Actavis if launch quantities were not delivered within a certain defined time period. The term of the agreement ends on the later of April 2024 or the expiration date of the last to expire patent.

The Company received a milestone payment from Actavis in December 2011 upon FDA approval, which was recorded as deferred revenue. This milestone payment was recognized as revenue in March of 2012, as launch quantities were delivered within the defined time period and the potential reimbursement liability was eliminated. In the nine months ended September 30, 2012, the Company recognized revenue of $5,859,488 in connection with product sales, development activities, and the milestone payment. In the nine months ended September 30, 2013, the Company recognized revenue of $1,301,929 in connection with product sales and royalties. Product sales to Actavis ended in the first quarter of 2013, as Actavis assumed all manufacturing of Gelnique 3% in 2013 as contracted.

Item 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

Management’s discussion and analysis of the significant changes in the consolidated results of operations, financial condition and cash flows of the Company is set forth below. Certain statements in this report may be considered to be “forward-looking statements” as that term is defined in the U.S. Private Securities Litigation Reform Act of 1995, such as statements that include the words “expect,” “estimate,” “project,” “anticipate,” “should,” “intend,” “probability,” “risk,” “target,” “objective” and other words and terms of similar meaning in connection with any discussion of, among other things, future operating or financial performance, strategic initiatives and business strategies, regulatory or competitive environments, our intellectual property and product development. In particular, these forward-looking statements include, among others, statements about:

•

our expectations regarding product development and commercialization of OTREXUP™;

•

our expectations regarding product development of Vibex^® QST;

•

our expectations regarding continued product development with Teva;

•

our plans regarding potential manufacturing and marketing partners;

•

our expectations regarding increases in our sales and marketing expenses in 2013;

•

our future cash flow and projected license, royalty and milestone revenue;

•

the impact of new accounting pronouncements; and

•

our expectations regarding the year ending December 31, 2013.

The words “may,” “will,” “expect,” “intend,” “anticipate,” “estimate,” “believe,” “continue,” and similar expressions may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements involve known and unknown risks, uncertainties and achievements, and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. While we believe that we have a reasonable basis for each forward-looking statement contained in this report, we caution you that these statements are based on a combination of facts and factors currently known by us and projections of the future about which we cannot be certain. Many factors may affect our ability to achieve our objectives, including:

•

delays in product introduction and marketing or interruptions in supply;

•

a decrease in business from our major customers and partners;

•

our inability to compete successfully against new and existing competitors or to leverage our research and development capabilities and our marketing capabilities;

•

our inability to effectively market our services or obtain and maintain arrangements with our customers, partners and manufacturers;

•

our inability to attract and retain key personnel;

•

adverse economic and political conditions; and

•

our inability to obtain additional financing, reduce expenses or generate funds when necessary.

In addition, you should refer to the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2012 for a discussion of other factors that may cause our actual results to differ materially from those described by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements contained in this report will prove to be accurate and, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material.

We encourage readers of this report to understand forward-looking statements to be strategic objectives rather than absolute targets of future performance. Forward-looking statements speak only as of the date they are made. We do not intend to update publicly any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made or to reflect the occurrence of unanticipated events except as required by law. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, if at all.

The following discussion and analysis, the purpose of which is to provide investors and others with information that we believe to be necessary for an understanding of our financial condition, changes in financial condition and results of operations, should be read in conjunction with the financial statements, notes and other information contained in this report.

Overview

Antares Pharma, Inc. is an emerging specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies and topical gel-based products. We have numerous partnerships with pharmaceutical companies as well as multiple internal product development programs.

We have developed both subcutaneous and intramuscular injection technology systems which include Vibex^® disposable pressure-assisted auto injectors, Vision™ reusable needle-free injectors, and disposable multi-use pen injectors. We have licensed our reusable needle-free injection device for use with human growth hormone (“hGH”) to Teva Pharmaceutical Industries, Ltd. (“Teva”), Ferring Pharmaceuticals BV (“Ferring”) and JCR Pharmaceuticals Co., Ltd. (“JCR”), with Teva and Ferring being two of our primary customers. Our needle-free injection device is marketed by Teva as the Tjet^® injector system to administer their 5mg Tev-Tropin^® brand hGH marketed in the U.S. Our needle-free injection device is marketed by Ferring with their 4mg and 10mg hGH formulations as Zomajet^® 2 Vision and Zomajet^® Vision X, respectively, in Europe and Asia. We have also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and are engaged in product development activities for Teva utilizing these devices. Sales in 2013 included shipments of Vibex^® auto-injector devices to Teva.

In addition to development of products with partners, we are developing our own drug/device combination products. Our lead product candidate, OTREXUP™, is a proprietary combination product comprised of a pre-filled methotrexate syringe and the Company’s Medi-Jet™ self-injection system. On October 14, 2013 we announced the approval of OTREXUP™ (methotrexate) injection by the U.S. Food and Drug Administration (“FDA”). OTREXUP™ is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. OTREXUP™ is indicated for adults with severe active rheumatoid arthritis or children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. We have worldwide marketing rights for OTREXUP™ and have provided Uman Pharma an exclusive license to commercialize the product in Canada. Our strategy is to commercialize OTREXUP™ in the U.S. on our own and to enter into licensing or distribution agreements for commercialization outside the rheumatology area and outside the U.S. We are also developing Vibex^® QuickShot™ (“QST”) for testosterone replacement therapy for men suffering from symptomatic testosterone deficiency and announced on September 16, 2013 that the first patients have been dosed in a clinical study evaluating testosterone administered weekly by subcutaneous injection via the Vibex^® QST auto injector device. Up to 45 patients will be enrolled in the study at approximately eight investigative sites in the United States.

In the gel-based product area, we announced with Actavis (formerly Watson Pharmaceuticals) on April 26, 2012, the launch of Gelnique 3%™, our topical oxybutynin gel product for the treatment of overactive bladder (“OAB”). We have a licensing agreement with Actavis under which Actavis is currently marketing Gelnique 3%™ in the U.S. In January 2012, we entered into a licensing agreement with Daewoong Pharmaceuticals under which Daewoong will commercialize this product, once approved in South Korea. Our gel portfolio also includes Elestrin^® (estradiol gel) currently marketed by Meda Pharma in the U.S. for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.

We have two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of our reusable needle-free injection devices and related disposables, and develops our disposable pressure-assisted auto injector and pen injector systems. Our corporate head office and Product Development and Commercial Groups are located in Ewing, New Jersey, where our gel based products were developed and where the Product Development and Commercial Groups direct the clinical, regulatory and commercial development of our internal drug/device combination products.

We have reported a net loss of $14,871,661 for the nine months ended September 30, 2013. Operating results for the nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013.

Results of Operations

Three and Nine Months Ended September 30, 2013 and 2012

Revenues

Total revenues for the three and nine-month periods ended September 30, 2013 were $5,507,824 and $15,873,590, respectively, compared to revenues for the same prior-year periods of $5,685,917 and $17,074,401, respectively. Product sales were $3,047,091 and $10,052,458 in the three and nine-month periods ended September 30, 2013, respectively, compared to $2,052,398 and $7,758,463, in the three and nine-month periods ended September 30, 2012, respectively. Product sales in the three and nine-month periods ended September 30, 2013 included $2,078,000 and $6,204,000, respectively, of initial sales to Teva of pre-launch quantities of our Vibex^® auto injector for Teva’s generic epinephrine auto injector product. Product sales for the nine-month periods ended September 30, 2013 and 2012 included $509,869 and $2,589,380, respectively, of sales of our topical oxybutynin gel 3% product to Actavis in connection with their marketing of Gelnique 3%, which was launched in April 2012. Product sales to Actavis ended in the first quarter of 2013, as Actavis assumed all manufacturing of Gelnique 3% in 2013 as contracted. Product revenue in the first nine months of 2013 also included approximately $300,000 of revenue that had previously been deferred. The balance of our product sales in each period were primarily sales of reusable needle-free injector devices and disposable components. Our sales of needle-free injector related products are generated primarily from sales to Ferring and Teva. Ferring uses our needle-free injector with their 4mg and 10mg hGH formulations marketed as Zomajet^® 2 Vision and Zomajet^® Vision X, respectively, in Europe and Asia. Teva uses our needle-free injector with the Tjet^® injector system to administer their 5mg Tev-Tropin^® brand hGH marketed in the U.S. Sales to Ferring increased in the three-month period ended September 30, 2013 compared to the same prior-year period, but sales to both Ferring and Teva decreased in the nine-month period ended September 30, 2013 compared to the same period of 2012. Sales of the hGH drug product for both Ferring and Teva continue to grow, but we do not control our partners’ inventory levels of our hGH injectors or disposable components and this can cause significant fluctuations in product sales.

Development revenue was $1,299,328 and $2,681,202 in the three and nine-month periods ended September 30, 2013, respectively, compared to $2,606,482 and $6,329,967 in the same periods of the prior year. The development revenue in the three and nine-month periods ended September 30, 2013 was primarily due to auto injector and pen injector development work for Teva. The development revenue in the three months ended September 30, 2012 was primarily due to auto injector and pen injector development work for Teva, but also included a $750,000 milestone payment from Pfizer. The development revenue in the first nine months of 2012 included a non-recurring FDA approval milestone payment of $2,500,000 recognized in connection with our license agreement with Actavis (Watson), and included auto injector and pen injector development work for Teva and the Pfizer development milestone.

Licensing revenue was $69,231 and $207,238 in the three and nine-month periods ended September 30, 2013, respectively, compared to $77,284 and $812,196 in the same periods of 2012. The licensing revenue in the third quarter and first nine months of 2013 was primarily due to recognition of revenue deferred in prior years under agreements with Ferring. The licensing revenue in the first nine months of 2012 was primarily due to an upfront license fee received in connection with our licensing agreement with Daewoong signed in January of 2012, along with license revenue recognized in connection with our license agreement with Actavis.

Royalty revenue was $1,092,174 and $2,932,692 in the three and nine-month periods ended September 30, 2013, respectively, compared to $949,753 and $2,173,775 in the same prior-year periods. We receive royalties from Teva and Ferring related to needle-free injector device sales and/or hGH sales, from Actavis on sales of Gelnique, and from Meda Pharma on sales of Elestrin^®. The increase in royalty revenue in the first nine months of 2013 compared

to 2012 was primarily the result of increases in royalties from Actavis and Teva. The increase in royalties from Actavis occurred because royalties were received in each of the first three quarters of 2013 while no royalties were received until the third quarter of 2012 as Gelnique 3% was launched in April 2012. The increase in royalties from Teva resulted from an increase in their net sales of hGH.

Cost of Revenues and Gross Profit

For the three and nine-month periods ended September 30, 2013, cost of product sales was $1,909,060 and $6,519,468, respectively, compared to $1,673,849 and $5,071,007 for the same periods of the prior year. Product gross margins were 37% and 18% in three-month periods ended September 30, 2013 and 2012, respectively, and were 35% in each of the nine-month periods ended September 30, 2013 and 2012. In the third quarter and first nine months of 2013, product gross margins were affected by a significant increase in sales to Teva of our Vibex^® auto injectors for epinephrine. In 2013, product gross margins related to this product were lower than we expect in the future due to quality release testing costs in connection with initial large scale production runs that we do not expect to incur in the future. Gross margins in 2013 have also been affected by increased manufacturing overhead expenses in anticipation of increased production activity related to Vibex^® auto injectors for epinephrine and OTREXUP™. Product gross margin in the first nine-months of 2013 was favorably impacted by the recognition of previously deferred product revenue of approximately $300,000 which had no related costs. The gross margins in the three and nine-month periods of 2012 included the effect of sales of our topical oxybutynin gel 3% product to Watson at a lower gross profit than is realized on injector related product sales.

The cost of development revenue consists primarily of direct external costs, some of which may have been previously incurred and deferred. Cost of development revenue was $1,095,542 and $1,992,959 for the three and nine-month periods ended September 30, 2013, respectively, compared to $1,622,640 and $2,747,424 for the same prior-year periods. In the first nine months of 2013, the development costs were primarily related to revenue recognized in connection with auto injector and pen injector development programs with Teva. In the first nine months of 2012, development costs were related to auto injector and pen injector development work for Teva and certain manufacturing readiness activities under the Actavis license agreement.

Research and Development

The majority of research and development (“R&D”) expenses consist of external costs for studies and analysis activities, design work and prototype device development. R&D expenses were $4,318,011 and $11,786,224 in the three and nine-month periods ended September 30, 2013, respectively, compared to $3,900,475 and $9,260,422 in the same periods of the prior year. The increase in the third quarter of 2013 compared to 2012 was primarily due to increases in expenses related to development of our Vibex^® QST for testosterone replacement therapy of approximately $400,000 and payroll costs of approximately $600,000, partially offset by a decrease in expenses related to development of our OTREXUP™ auto injector product for delivery of methotrexate for the treatment of rheumatoid arthritis of approximately $800,000. In the first nine months of 2013, expenses related to our Vibex^® QST project increased by approximately $1,712,000 to $2,032,000 and payroll costs increased by approximately $1,570,000 to $4,725,000 due to employee additions. Expenses related to OTREXUP™ development decreased by approximately $1,614,000 to $2,963,000 in the first nine months of 2013 compared to 2012 due to a clinical study in process in 2012. The remaining increase in R&D expenses in the first nine months of 2013 compared to 2012 consisted of an increase in other direct project costs of approximately $300,000 and an increase in other indirect R&D expenses of approximately $560,000.

Sales and Marketing

Sales and marketing expenses totaled $2,576,247 and $4,615,736 for the three and nine-month periods ended September 30, 2013, respectively, compared to $237,067 and $527,953 in the same prior-year periods. The increase in the first nine months of 2013 compared to the first nine months of 2012 was primarily due to expenses of approximately $3,200,000 related to OTREXUP™ market research, product branding and pre-commercialization activities, and an increase of approximately $800,000 in employee related expenses due to sales and marketing personnel added in the last 12 months. We expect sales and marketing expenses to continue to increase, primarily in connection with OTREXUP™ marketing and pre-commercialization activities which we anticipate could reach $7.0 million for the year.

Business Development

Business development expenses totaled $142,017 and $486,732 for the three and nine months ended September 30, 2013 and 2012, respectively, compared to $219,953 and $784,661 in the same prior-year periods. The decrease for the first nine months was primarily due to a decrease in legal expenses of approximately $120,000 and a decrease in stock compensation expense of $90,000 related to a one time stock grant in 2012.

General and Administrative

General and administrative expenses totaled $1,836,127 and $5,375,610 in the three and nine-month periods ended September 30, 2013, respectively, compared to $1,551,147 and $5,089,744 in the same periods of the prior year. The increase in the quarter was mainly due to an increase in payroll related expenses. The increase in the first nine months of 2013 compared to 2012 was mainly due to an increase in payroll related and patent expenses of approximately $600,000 and $130,000, respectively. These increases were partially offset by reductions primarily in professional fees of $350,000 and a one-time insurance refund of approximately $100,000.

Liquidity and Capital Resources

At September 30, 2013, our cash and investments totaled $70,013,819, which consisted of cash and cash equivalents of $42,960,486, and short-term investments of $27,053,333. All investments are U.S. Treasury bills or U.S. Treasury notes which we intend to hold to maturity. In the fourth quarter of 2012, we sold 14,259,868 shares of common stock at a price of $4.00 per share in a public offering. The sales of common stock resulted in net proceeds of $53,328,188 after deducting offering expenses of $3,711,284. Proceeds from this offering are being used for development and commercialization of OTREXUP™, development of the Company’s proprietary VIBEX^® QST product for male testosterone deficiency and general corporate purposes. We believe that the combination of our current cash and investments balances and projected product sales, product development, license revenues, milestone payments and royalties will provide us with sufficient funds to support operations. We do not currently have any bank credit lines.

Cash Flows

Net Cash Used in Operating Activities

Operating cash inflows are generated primarily from product sales, license and development fees and royalties. Operating cash outflows consist principally of expenditures for manufacturing costs, general and administrative costs, research and development projects including clinical studies, and sales, marketing and business development activities. Net cash used in operating activities was $13,294,027 and $7,976,861 for the nine months ended September 30, 2013 and 2012, respectively. The increase in cash used was driven primarily by an increase in net loss to $14,871,661 for the first nine months of 2013 from $6,415,705 for the first nine months of 2012. In the first nine months of 2013, cash used in operating activities was also affected by noncash expenses totaling $1,822,288 and changes in operating assets and liabilities that decreased cash by $244,654. In the first nine months of 2012, cash used in operating activities resulted from the net loss of $6,415,705, noncash expenses totaling $1,642,255 and changes in operating assets and liabilities which decreased cash by $3,203,411, most of which resulted from the decrease in deferred revenue of $4,143,463 related mainly to recognition of revenue previously deferred in connection with a non-recurring FDA approval milestone payment of $2,500,000 received under our license agreement with Actavis.

Net Cash Provided by (Used in) Investing Activities

Net cash provided by investing activities was $3,501,713 in the first nine months of 2013 compared to net cash used of $8,786,501 in the first nine months of 2012. Cash used for purchases of equipment, molds, furniture and fixtures in the nine-month periods ended September 30, 2013 and 2012 was $2,184,568 and $2,425,454, respectively, primarily related to OTREXUP™ commercial molds and assembly equipment. At September 30, 2013 and 2012, costs of $437,504 and $358,828, respectively, related primarily to OTREXUP™ commercial molds and equipment were recorded in the consolidated balance sheet in equipment, molds, furniture and fixtures and in accounts payable. For purposes of the consolidated statement of cash flows these costs were treated as non-cash investing activities

and therefore were not included in cash used in investing activities. Additions to patent rights were $195,558 in 2013 compared to $283,871 in 2012. In the first nine months of 2013 we used cash of $9,118,161 to purchase investment securities and received proceeds of $15,000,000 from the maturities of investment securities. In the first nine months of 2012 we used cash of $15,077,176 to purchase investment securities and received proceeds of $9,000,000 from the maturities of investment securities. The investment securities are U.S. Treasury bills or U.S. Treasury notes that are classified as held-to-maturity because we have the positive intent and ability to hold the securities to maturity.

Net Cash Provided by Financing Activities

Net cash provided by financing activities in the first nine months of 2013 and 2012 was $652,282 and $9,572,807, respectively. In the first nine months of 2013 we received proceeds of $261,799 and $494,812 from the exercise of 234,541 warrants and 707,285 options, respectively. In the first nine months of 2012 we received proceeds of $8,962,270 and $639,453 from the exercise of 5,231,135 warrants and 1,034,636 options, respectively. In the first nine months of 2013 and 2012, total payments for employees’ income and employment tax obligations related to net share settlement of equity awards was $104,329 and $28,916, respectively.

Research and Development Programs

Our current research and development activities are primarily related to OTREXUP™, Vibex^® QST and device development projects.

OTREXUP™. OTREXUP™ is being developed for subcutaneous administration of methotrexate to enhance the treatment of rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis. On October 14, 2013 we announced the approval of OTREXUP™ (methotrexate) injection by the FDA. OTREXUP™ is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. OTREXUP™ is indicated for adults with severe active rheumatoid arthritis who have had an insufficient therapeutic response to or are intolerant of an adequate trial of first line therapy including full dose non-steroidal anti-inflammatory agents, or children with active polyarticular juvenile idiopathic arthritis. The FDA also approved adult use of OTREXUP™ for symptomatic control of severe recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy.

In November 2012, we announced positive results from an open-label, randomized, crossover study comparing the systemic availability of OTREXUP™ to oral methotrexate in adult patients with rheumatoid arthritis. This study was designed to compare the relative systemic availability of methotrexate following oral administration to subcutaneous (SC) self-administered methotrexate using the Medi-Jet™ device. Patients were assigned to one of four dose levels of methotrexate, 10 mg, 15 mg, 20 mg, and 25 mg. Results showed that the systemic availability of methotrexate following oral dosing plateaus above 15 mg. Following administration of methotrexate with Medi-Jet™, the systemic availability increased proportionally at every dose, which will extend the range of exposure compared to patients receiving oral therapy.

In September 2012, we announced positive results from an actual human use study in 101 RA patients. The results of this study showed that self-administration of MTX using the Medi-Jet™ device is safe and well tolerated. Following standardized training by site personnel and review of written instructions, all 101 patients performed the self-administration successfully. In addition, the Medi-Jet™ device functioned correctly and as intended for each and every administration thereby demonstrating reliability and robustness. Results of the Ease of Use Questionnaire indicated that 98% of patients found the Medi-Jet™ device easy to use and 100% of patients found the instructions and training to be clear and easy to follow.

As of September 30, 2013, we have incurred external expenses of approximately $13,100,000 in connection with our OTREXUP™ development program, of which approximately $2,900,000 was incurred in 2013. We have also incurred costs for molds and assembly equipment of approximately $5,000,000, of which $2,400,000 was incurred in 2013, that has been capitalized and included in equipment, molds, furniture and fixtures at September 30, 2013. We anticipate total spending on this program for development and capital equipment could approach $7,000,000 in 2013 and we expect sales and marketing expense in 2013 will be approximately $7,000,000.

Vibex^® QST. We are developing Vibex^® QST for testosterone replacement therapy for men suffering from symptomatic testosterone deficiency and announced on September 16, 2013 that the first patients have been dosed in a clinical study evaluating testosterone administered weekly by subcutaneous injection via the Vibex^® QST auto injector device. Up to 45 patients will be enrolled in the study at approximately eight investigative sites in the United States. We incurred total external costs of approximately $3,000,000 in connection with the Vibex^® QST program, of which approximately $2,050,000 was recognized as expense in 2013. We anticipate spending on this program for development will increase to approximately $3,000,000 in 2013.

Device Development Projects. We are also engaged in research and development activities related to our Vibex^® disposable pressure-assisted auto injectors and our disposable pen injectors. We have signed license agreements with Teva for our Vibex^® system for use with epinephrine and sumatriptan and for our pen injector device for two undisclosed products. Our pressure-assisted auto injectors are designed to deliver drugs by injection from single-dose prefilled syringes. The auto injectors are in the advanced commercial stage of development. The disposable pen injector device is designed to deliver drugs by injection through needles from multi-dose cartridges. The disposable pen is in the stage of development where devices are being evaluated in user studies and stability programs. Our development programs consist of the determination of the device design, development of prototype tooling, production of prototype devices for testing and clinical studies, performance of clinical studies, and development of commercial tooling and assembly.

As of September 30, 2013, excluding costs related to OTREXUP™ and Vibex^® QST, we have incurred total external costs of approximately $14,000,000 in connection with research and development activities associated with our auto and pen injectors, of which approximately $2,400,000 was incurred in 2013. Approximately $11,100,000 of the total costs of $14,000,000 was initially deferred, of which approximately $10,800,000 has been recognized as cost of sales and $300,000 remains deferred as of September 30, 2013. This remaining deferred balance will be recognized as cost of sales over the same period as the related deferred revenue will be recognized.

The development timelines of the auto and pen injectors related to the Teva products are controlled by Teva. We expect development related to the Teva products to continue in 2013, but the timing and extent of near-term future development will be dependent on certain decisions made by Teva. Although development work payments and certain upfront and milestone payments have been received from Teva, there have been limited commercial sales from the auto injector or pen injector programs, timelines have been extended and there can be no assurance that there ever will be significant commercial sales or future milestone payments under these agreements.

Other research and development costs. In addition to the OTREXUP™ project, Vibex^® QST project and the Teva related device development projects, we incur direct costs in connection with other research and development projects related to our technologies and indirect costs that include salaries, administrative and other overhead costs of managing our research and development projects. Total other research and development costs were approximately $6,200,000 for the nine months ended September 30, 2013.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, including any arrangements with any structured finance, special purpose or variable interest entities.

Critical Accounting Policies

We have identified certain of our significant accounting policies that we consider particularly important to the portrayal of our results of operations and financial position and which may require the application of a higher level of judgment by management and, as a result, are subject to an inherent level of uncertainty. These policies are characterized as “critical accounting policies” and address revenue recognition and valuation of long-lived and intangible assets and goodwill, as more fully described under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2012.

Recently Issued Accounting Pronouncements

In July 2013, the FASB issued Accounting Standards Update 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists” (“ASU 2013-11”). ASU 2013-11 amends accounting guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or tax credit carryforward exists. This new guidance requires entities, if certain criteria are met, to present an unrecognized tax benefit, or portion of an unrecognized tax benefit, in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward when such items exist in the same taxing jurisdiction. The adoption of ASU 2013-11 is expected to reduce diversity in practice by providing guidance on the presentation of unrecognized tax benefits. The provisions of ASU 2013-11 are effective for fiscal years and interim periods beginning after December 15, 2013. We do not expect the adoption of this update to have a material effect on our consolidated financial statements.

Item 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our primary market risk exposure is foreign exchange rate fluctuations of the Swiss Franc to the U.S. dollar as the financial position and operating results of our subsidiaries in Switzerland are translated into U.S. dollars for consolidation. Our exposure to foreign exchange rate fluctuations also arises from transferring funds to our Swiss subsidiaries in Swiss Francs. In addition, we have exposure to exchange rate fluctuations between the Euro and the U.S. dollar in connection with a licensing agreement with Ferring, under which certain products sold to Ferring and royalties are denominated in Euros. Most of our product sales, including a portion of our product sales to Ferring, and our development and licensing fees and royalties are denominated in U.S. dollars, thereby significantly mitigating the risk of exchange rate fluctuations on trade receivables. We do not currently use derivative financial instruments to hedge against exchange rate risk. The effect of foreign exchange rate fluctuations on our financial results for the period ended September 30, 2013 was not material.

We also have limited exposure to market risk due to interest income sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because a significant portion of our investments are in debt securities issued by the U.S. government and institutional money market funds. The primary objective of our investment activities is to preserve principal. To minimize market risk, we have in the past and, to the extent possible, will continue in the future, to hold debt securities to maturity at which time the debt security will be redeemed at its stated or face value. Due to the nature of our marketable securities, we believe that we are not exposed to any material market interest rate risk related to our investment portfolio.

Item 4.

CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. The evaluation was performed to determine whether the Company’s disclosure controls and procedures have been designed and are functioning effectively to provide reasonable assurance that the information required to be disclosed by the Company in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and is accumulated and communicated to management, including the Company’s principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on such evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures as of the end of the period covered by this report are effective.

Internal Control over Financial Reporting

There have not been any changes in the Company’s internal control over financial reporting during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

PART II—OTHER INFORMATION

Item 1A.

RISK FACTORS

In addition to the other information contained in this report, you should carefully consider the risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2012, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

Item 6.

EXHIBITS

(a)	Exhibit Index


Exhibit No.		Description

31.1		Certificate of the Chief Executive Officer of Antares Pharma, Inc. required by Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.

31.2		Certificate of the Chief Financial Officer of Antares Pharma, Inc. required by Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.

32.1		Certificate of the Chief Executive Officer of Antares Pharma, Inc. required by Rule 13a-14(b) under the Securities Exchange Act of 1934, as amended.

32.2		Certificate of the Chief Financial Officer of Antares Pharma, Inc. required by Rule 13a-14(b) under the Securities Exchange Act of 1934, as amended.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


						ANTARES PHARMA, INC.

November 6, 2013						/s/ Paul K. Wotton

						Dr. Paul K. Wotton
						President and Chief Executive Officer

November 6, 2013						/s/ Robert F. Apple

						Robert F. Apple
						Executive Vice President and Chief Financial Officer

EX-31.1 2 d600897dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATIONS

I, Dr. Paul K. Wotton, certify that:

1.	I have reviewed this report on Form 10-Q for the fiscal quarter ended September 30, 2013 of Antares Pharma, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 6, 2013

/s/ Paul K. Wotton

Dr. Paul K. Wotton

President and Chief Executive Officer

EX-31.2 3 d600897dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATIONS

I, Robert F. Apple, certify that:

1.	I have reviewed this report on Form 10-Q for the fiscal quarter ended September 30, 2013 of Antares Pharma, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 6, 2013

/s/ Robert F. Apple

Robert F. Apple

Executive Vice President and Chief Financial Officer

EX-32.1 4 d600897dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

ANTARES PHARMA, INC.

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. 1350)

The undersigned, Dr. Paul K. Wotton, the Chief Executive Officer of Antares Pharma, Inc. (the “Company”), has executed this Certification in connection with the filing with the Securities and Exchange Commission of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2013 (the “Report”).

The undersigned hereby certifies that:

The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

IN WITNESS WHEREOF, the undersigned has executed this Certification as of the 6th day of November, 2013.

/s/ Paul K. Wotton

Dr. Paul K. Wotton

President and Chief Executive Officer

EX-32.2 5 d600897dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

ANTARES PHARMA, INC.

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. 1350)

The undersigned, Robert F. Apple, the Chief Financial Officer of Antares Pharma, Inc. (the “Company”), has executed this Certification in connection with the filing with the Securities and Exchange Commission of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2013 (the “Report”).

The undersigned hereby certifies that:

The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

IN WITNESS WHEREOF, the undersigned has executed this Certification as of the 6th day of November, 2013.

/s/ Robert F. Apple

Robert F. Apple

Executive Vice President and Chief Financial Officer

EX-101.INS 6 atrs-20130930.xml XBRL INSTANCE DOCUMENT 127613404

12159902

127230176

6234160

127230176

1.80

7814380

389363

15000000

1781428

3000000

1.38

150000000

0.01

4863980

4689615

10187565

-662178

73868480

240919182

-167660826

633970

84930641

11062161

874596

1272302

76542618

1095355

61241

84930641

42960486

27053333

3405395

1804695

1217720

16696929

1001195

317514

17703665

566000

27070089

6013707

1.08

212618

2517935

19357932

125949024

1.49

7814561

3000000

150000000

0.01

2916700

2864507

7938223

-665345

86550592

238745612

-152789165

2157016

95526610

8976018

1037795

1259490

12015906

77659232

1095355

49361

95526610

52097064

21112623

2228650

1002703

1123652

12016530

463033

755159

21116952

3583104

ATRS ANTARES PHARMA, INC. false Accelerated Filer 2013 10-Q 2013-09-30 0001016169 --12-31 Q3

0.007

<div> Revenues by product type:   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="55%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Injection devices and supplies </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,100,253</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,600,400</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,882,973</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,505,344</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Transdermal products </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">407,571</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,085,517</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,990,617</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,569,057</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

0.625

3.49

<div> Significant customers comprising 10% or more of total revenue are as follows:   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="55%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Teva </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,004,531</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,797,761</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,196,559</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,966,246</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Ferring </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,047,750</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">783,757</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,511,332</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,444,510</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Actavis (Watson) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">202,813</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,171,633</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,301,929</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,859,488</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

P6Y4M24D

P6Y

4.01

30153

126581018

<div> The table below discloses the basic and diluted loss per common share.   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="51%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Net loss </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6,359,957</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(3,534,239</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(14,871,661</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6,415,705</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Basic and diluted weighted average common shares outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">127,162,064</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">108,961,792</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">126,581,018</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">105,735,855</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Basic and diluted net loss per common share </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.05</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.03</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.12</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.06</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left">3.</td> <td valign="top" align="left">Stockholders’ Equity</td> </tr> </table> Stock Options The Company records compensation expense associated with share based awards granted to employees at the fair value of the award on the date of grant. The expense is recognized over the period during which an employee is required to provide services in exchange for the award. The Company’s 2008 Equity Compensation Plan (the “Plan”) allows for the grants of options, restricted stock, stock units, stock appreciation rights and/or performance awards to officers, directors, consultants and employees. Under the Plan, the maximum number of shares authorized for issuance is 15,000,000 and the maximum number of shares of stock that may be granted to any one participant during a calendar year is 1,000,000 shares. Options to purchase shares of common stock are granted at exercise prices not less than 100% of the fair market value on the dates of grant. The term of the options range from ten to eleven years and they vest in varying periods. As of September 30, 2013, the Plan had 389,363 shares available for grant. Stock option exercises are satisfied through the issuance of new shares. A summary of stock option activity under the Plan as of September 30, 2013, and the changes during the nine months then ended is as follows:   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="59%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Exercise Price ($)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Remaining Contractual Term (Years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Aggregate Intrinsic Value ($)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,814,561</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.49</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">904,380</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.01</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(707,285</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.72</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,379,554</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(197,276</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.49</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at September 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,814,380</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.80</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,703,665</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Exercisable at September 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,234,160</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.38</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,696,929</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   Total recognized compensation expense for stock options was approximately $982,000 and $799,000 for the first nine months of 2013 and 2012, respectively, and was approximately $401,000 and $295,000 for the three month periods ended September 30, 2013 and 2012, respectively. As of September 30, 2013, there was approximately $2,517,935 of total unrecognized compensation cost related to nonvested outstanding stock options that is expected to be recognized over a weighted average period of approximately 2.0 years. The per share weighted average fair value of options granted during the first nine months of 2013 and 2012 was estimated as $2.27 and $1.63 on the date of grant using the Black-Scholes option pricing model based on the assumptions noted in the table below. Expected volatilities are based on the historical volatility of the Company’s stock price. The weighted average expected life is based on both historical and anticipated employee behavior.   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="86%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.7</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.7</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Annualized volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">62.5</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">61.0</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Weighted average expected life, in years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> Stock Awards The employment agreements with certain members of executive management include stock-based incentives under which the executives could be awarded shares of common stock upon the occurrence of various triggering events. There were no shares awarded under these agreements in the first nine months of 2013 and 35,000 shares were awarded in the first nine months of 2012. At times, the Company makes discretionary grants of its common stock to members of management and other employees in lieu of cash bonus awards or in recognition of special achievements. Discretionary grants of common stock totaled 60,000 in the first nine months of 2012 at a weighted average fair value of $2.59. Expense is recognized on a straight line basis over the vesting period and is based on the fair value of the stock on the grant date. The fair value of each stock award is determined based on the number of shares granted and the market price of the Company’s common stock on the date of grant. Expense recognized in connection with performance and discretionary stock awards was approximately $8,700 and $288,000 in the first nine months of 2013 and 2012, respectively, and was $0 and $13,000 in the three month periods ended September 30, 2013 and 2012, respectively. A portion of the discretionary stock grants vested in the first nine months of 2013 and 2012. Some of these grants were net-share settled such that the Company withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld were 30,153 and 11,165 in 2013 and 2012, respectively, and were based on the value of the shares on their vesting date as determined by the Company’s closing stock price. Total payments for the employees’ tax obligations to the taxing authorities were $104,329 and $28,916 in 2013 and 2012, respectively, and are reflected as a financing activity within the Consolidated Statements of Cash Flows. These net-share settlements had the effect of share repurchases by the Company as they reduced the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company. In addition to the shares granted to members of management and employees, at times directors receive a portion of their annual compensation in shares of Company common stock. Expense is recognized on a straight line basis over the one year period that the compensation is earned. Expense recognized for stock-based compensation to directors was $470,000 and $377,200 in the nine month periods ended September 30, 2013 and 2012, respectively, and was $204,000 and $182,800 in the three month periods ended September 30, 2013 and 2012, respectively.   As of September 30, 2013, a total of 212,618 shares granted to directors were unvested. As of September 30, 2013, there was approximately $566,000 of total unrecognized compensation cost related to nonvested stock awards that is expected to be recognized over a weighted average period of approximately 8 months. The weighted average fair value of the shares granted in the first nine months of 2013 and 2012 was $4.01 and $3.25 per share, respectively. Long Term Incentive Program The Company’s Board of Directors has approved a long term incentive program for the benefit of the Company’s senior executives. Pursuant to the long term incentive program, the Company’s senior executives have been awarded stock options and performance stock units with a value targeted at the median level of the Company’s peer group. In 2013, the program was modified such that the value of the annual award for each senior executive was delivered one-third in the form of performance stock units, one-third in the form of shares of restricted stock and one-third in the form of stock options. In prior years, two thirds of the value for each senior executive was delivered in the form of stock options and one third of the value was delivered in the form of performance stock units. The stock options have a ten-year term, have an exercise price equal to the closing price of the Company’s common stock on the date of grant, vest in quarterly installments over three years, and were otherwise granted on the same standard terms and conditions as other stock options granted pursuant to the Plan. The restricted stock vests in three equal annual installments. Expense recognized in connection with the restricted stock in the three and nine-month periods ended September 30, 2013 was $46,000 and $73,000, respectively. The performance stock unit awards made to the senior executives will be vested and convert into actual shares of the Company’s common stock based on the Company’s attainment of certain performance goals over a performance period of three years. No expense has been recognized in connection with the performance stock unit awards as the defined performance goals are not yet considered probable of achievement. The performance stock unit awards, restricted stock and stock options granted under the long term incentive program are summarized in the following table:   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="55%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Performance Stock Units</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Restricted Stock</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Stock Options</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom" nowrap="nowrap"> Grant Date </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> Fair Value on Grant Date</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> Fair Value on Grant Date</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Number of Options</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Exercise Price</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> May 17, 2011 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">182,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.66</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">317,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.66</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> May 17, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">470,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.94</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> July 6, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">137,715</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.26</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">178,731</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.26</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> May 22, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">185,185</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.96</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">185,185</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.96</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">327,381</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.96</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> Warrants In the first nine months of 2013, 234,541 warrants were exercised resulting in proceeds to the Company of $261,799. In the first nine months of 2012, the Company received proceeds of $8,962,270 from the exercise of 3,731,135 warrants. Warrants to purchase a total of 1,781,428 shares of common stock were outstanding at September 30, 2013, at a weighted average exercise price of $1.08. </div>

4.01

0.000

-13294027

-0.12

0.72

904380

P8M

P5Y8M12D

707285

<div> A summary of stock option activity under the Plan as of September 30, 2013, and the changes during the nine months then ended is as follows:   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="59%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Exercise Price ($)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Remaining Contractual Term (Years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Aggregate Intrinsic Value ($)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,814,561</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.49</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">904,380</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.01</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(707,285</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.72</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,379,554</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(197,276</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.49</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at September 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,814,380</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.80</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,703,665</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Exercisable at September 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,234,160</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.38</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,696,929</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">6.</td> <td align="left" valign="top">License Agreements</td> </tr> </table> Daewoong Development and License Agreement In January 2012, the Company entered into a licensing agreement with Daewoong Pharmaceuticals (“Daewoong”) under which Daewoong will commercialize the Company’s oxybutynin gel 3% product, once approved in South Korea. The agreement terms include an upfront payment, development and sales-based milestone payments and escalating royalties based on product sales in South Korea. Because the Company has no development responsibilities, the upfront and each milestone payment will be recognized as revenue when received. Royalties will be recognized as revenue when earned. The term of the agreement ends on the later of fifteen years following launch of the product or the expiration date of the last to expire patent. The Company recognized revenue of $442,859 in the nine months ended September 30, 2012 in connection with upfront and milestone payments.   Pfizer License Agreement In December 2011, the Company licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. Pfizer assumed full cost and responsibility for all clinical development, manufacturing, and commercialization of the product in the licensed territory, which also includes certain non-exclusive territories outside of North America. The Company received an upfront payment, and will receive development milestones and sales based milestones, as well as royalties on net sales for three years post launch in the U.S. Because the Company has no development responsibilities, the upfront and each milestone payment will be recognized as revenue when received. Royalties will be recognized as revenue when earned. The Company recognized revenue of $750,000 in the nine months ended September 30, 2012, which was earned when Pfizer achieved a development milestone related to this undisclosed Consumer Healthcare product. Actavis License and Commercialization Agreement In July 2011, the Company entered into an exclusive licensing agreement with Actavis to commercialize, in the U.S. and Canada, the Company’s topical oxybutynin gel 3% product, which was subsequently approved by the FDA in December 2011. Under this agreement the Company received payments for certain manufacturing start-up activities and delivery of launch quantities, and has received and is entitled to receive future royalties on both the Company’s oxybutynin gel 3% product and Actavis’ oxybutynin gel product Gelnique® 10%, and will potentially receive sales based milestone payments. The milestone payment based on the achievement of regulatory approval was subject to reimbursement to Actavis if launch quantities were not delivered within a certain defined time period. The term of the agreement ends on the later of April 2024 or the expiration date of the last to expire patent. The Company received a milestone payment from Actavis in December 2011 upon FDA approval, which was recorded as deferred revenue. This milestone payment was recognized as revenue in March of 2012, as launch quantities were delivered within the defined time period and the potential reimbursement liability was eliminated. In the nine months ended September 30, 2012, the Company recognized revenue of $5,859,488 in connection with product sales, development activities, and the milestone payment. In the nine months ended September 30, 2013, the Company recognized revenue of $1,301,929 in connection with product sales and royalties. Product sales to Actavis ended in the first quarter of 2013, as Actavis assumed all manufacturing of Gelnique 3% in 2013 as contracted. </div>

<div> Revenues by customer location are summarized as follows:   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="54%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> United States of America </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,390,966</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,881,106</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,063,929</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,083,259</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Europe </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,047,748</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">787,368</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,585,655</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,448,121</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">69,110</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,443</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">224,006</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">543,021</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,507,824</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,685,917</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,873,590</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,074,401</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

1000000

0.10

197276

9595808

<div> <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="86%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.7</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.7</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Annualized volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">62.5</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">61.0</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Weighted average expected life, in years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> </div>

15873590

349833

-14868494

2681202

7361163

437504

10052458

31478

207238

11844

3167

-440051

-14903139

195558

9118161

104329

1176745

-14871661

804009

2932692

2184568

15000000

1946548

1992959

5375610

652282

6519468

-1676365

261799

2379554

1534100

-9136578

4615736

3501713

1387543

8512427

11786224

288188

486732

22264302

3454

2 234541 1.00 2 756611 <div> The performance stock unit awards, restricted stock and stock options granted under the long term incentive program are summarized in the following table:   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="55%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Performance Stock Units</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Restricted Stock</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Stock Options</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom" nowrap="nowrap"> Grant Date </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> Fair Value on Grant Date</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> Fair Value on Grant Date</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Number of Options</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Exercise Price</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> May 17, 2011 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">182,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.66</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">317,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.66</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> May 17, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">470,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.94</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> July 6, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">137,715</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.26</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">178,731</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.26</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> May 22, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">185,185</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.96</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">185,185</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.96</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">327,381</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.96</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div> 45 8

224006

13063929

2585655

13882973

1990617

470000

P11Y P10Y P3Y 1301929

2511332

1301929

11196559

73000

P3Y

185185

3.96

2.27

P2Y

982000

1.66

317000

2.94

470000

3.96

327381

4.26

178731

182000

1.66

185185

3.96

137715

4.26

8700

P10Y 2011-05-17 2012-05-17 2013-05-22 2012-07-06

0.007

0.610

P5Y

3.25

11165

105735855

0.000

-7976861

-0.06

12765470

17074401

663796

-6509653

6329967

9255970

358828

7758463

-8895

812196

27322

-93948

-423856

-6406810

283871

15077176

28916

-484020

-6415705

2736

2173775

2425454

9000000

404423

2747424

5089744

9572807

5071007

-4143463

8962270

1464225

-7198030

527953

-8786501

321607

7818431

9260422

178030

784661

15662780

-7475

3731135 9601723

543021

13083259

3448121

9505344

7569057

377200

442859

750000

5859488

3444510

5859488

5966246

1.63

799000

35000

60000

2.59

288000

P15Y

108961792

-0.03

5685917

-3522739

2606482

2389428

2052398

-15025

77284

11500

-3519214

-3534239

949753

1622640

1551147

1673849

237067

3296489

3900475

219953

5908642

17443

4881106

787368

3600400

2085517

182800

783757

1171633

2797761

295000

13000

127162064

-0.05

5507824

-6338346

1299328

2503222

3047091

9223

69231

21611

-6369180

-6359957

1092174

1095542

1836127

1909060

2576247

3004602

4318011

142017

8872402

69110

4390966

1047748

5100253

407571

204000

P2Y

1047750

202813

4004531

46000

401000

0001016169 atrs:DiscretionarySharesMember 2013-07-01 2013-09-30 0001016169 us-gaap:EmployeeStockOptionMember 2013-07-01 2013-09-30 0001016169 us-gaap:RestrictedStockMember 2013-07-01 2013-09-30 0001016169 atrs:TevaMember 2013-07-01 2013-09-30 0001016169 atrs:ActavisMember 2013-07-01 2013-09-30 0001016169 atrs:FerringMember 2013-07-01 2013-09-30 0001016169 us-gaap:MaximumMemberus-gaap:OtherLongTermInvestmentsMember 2013-07-01 2013-09-30 0001016169 us-gaap:DirectorMember 2013-07-01 2013-09-30 0001016169 atrs:TransdermalGelProductsMember 2013-07-01 2013-09-30 0001016169 atrs:InjectionDevicesAndSuppliesMember 2013-07-01 2013-09-30 0001016169 us-gaap:EuropeMember 2013-07-01 2013-09-30 0001016169 country:US 2013-07-01 2013-09-30 0001016169 atrs:OtherCountriesMember 2013-07-01 2013-09-30 0001016169 2013-07-01 2013-09-30 0001016169 atrs:DiscretionarySharesMember 2012-07-01 2012-09-30 0001016169 us-gaap:EmployeeStockOptionMember 2012-07-01 2012-09-30 0001016169 atrs:TevaMember 2012-07-01 2012-09-30 0001016169 atrs:ActavisMember 2012-07-01 2012-09-30 0001016169 atrs:FerringMember 2012-07-01 2012-09-30 0001016169 us-gaap:DirectorMember 2012-07-01 2012-09-30 0001016169 atrs:TransdermalGelProductsMember 2012-07-01 2012-09-30 0001016169 atrs:InjectionDevicesAndSuppliesMember 2012-07-01 2012-09-30 0001016169 us-gaap:EuropeMember 2012-07-01 2012-09-30 0001016169 country:US 2012-07-01 2012-09-30 0001016169 atrs:OtherCountriesMember 2012-07-01 2012-09-30 0001016169 2012-07-01 2012-09-30 0001016169 atrs:DaewoongDevelopmentAndLicenseAgreementMember 2012-01-01 2012-01-31 0001016169 atrs:DiscretionarySharesMember 2012-01-01 2012-09-30 0001016169 us-gaap:PerformanceSharesMember 2012-01-01 2012-09-30 0001016169 us-gaap:EmployeeStockOptionMember 2012-01-01 2012-09-30 0001016169 atrs:TevaMember 2012-01-01 2012-09-30 0001016169 atrs:ActavisMember 2012-01-01 2012-09-30 0001016169 atrs:FerringMember 2012-01-01 2012-09-30 0001016169 atrs:ActavisLicenseAndCommercializationAgreementMember 2012-01-01 2012-09-30 0001016169 atrs:PfizerLicenseAgreementMember 2012-01-01 2012-09-30 0001016169 atrs:DaewoongDevelopmentAndLicenseAgreementMember 2012-01-01 2012-09-30 0001016169 us-gaap:DirectorMember 2012-01-01 2012-09-30 0001016169 atrs:TransdermalGelProductsMember 2012-01-01 2012-09-30 0001016169 atrs:InjectionDevicesAndSuppliesMember 2012-01-01 2012-09-30 0001016169 us-gaap:EuropeMember 2012-01-01 2012-09-30 0001016169 country:US 2012-01-01 2012-09-30 0001016169 atrs:OtherCountriesMember 2012-01-01 2012-09-30 0001016169 2012-01-01 2012-09-30 0001016169 atrs:SharesGrantedOnJulySixTwoThousandAndTwelveMemberatrs:LongTermIncentiveProgramMember 2013-01-01 2013-09-30 0001016169 atrs:SharesGrantedOnMayTwentyTwoTwoThousandThirteenMemberatrs:LongTermIncentiveProgramMember 2013-01-01 2013-09-30 0001016169 atrs:SharesGrantedOnMaySeventeenTwoThousandTwelveMemberatrs:LongTermIncentiveProgramMember 2013-01-01 2013-09-30 0001016169 atrs:SharesGrantedOnMaySeventeenTwoThousandElevenMemberatrs:LongTermIncentiveProgramMember 2013-01-01 2013-09-30 0001016169 atrs:LongTermIncentiveProgramMember 2013-01-01 2013-09-30 0001016169 atrs:DiscretionarySharesMember 2013-01-01 2013-09-30 0001016169 atrs:SharesGrantedOnJulySixTwoThousandAndTwelveMemberus-gaap:PerformanceSharesMemberatrs:LongTermIncentiveProgramMember 2013-01-01 2013-09-30 0001016169 atrs:SharesGrantedOnMayTwentyTwoTwoThousandThirteenMemberus-gaap:PerformanceSharesMemberatrs:LongTermIncentiveProgramMember 2013-01-01 2013-09-30 0001016169 atrs:SharesGrantedOnMaySeventeenTwoThousandTwelveMemberus-gaap:PerformanceSharesMemberatrs:LongTermIncentiveProgramMember 2013-01-01 2013-09-30 0001016169 atrs:SharesGrantedOnMaySeventeenTwoThousandElevenMemberus-gaap:PerformanceSharesMemberatrs:LongTermIncentiveProgramMember 2013-01-01 2013-09-30 0001016169 us-gaap:PerformanceSharesMember 2013-01-01 2013-09-30 0001016169 atrs:SharesGrantedOnJulySixTwoThousandAndTwelveMemberus-gaap:EmployeeStockOptionMemberatrs:LongTermIncentiveProgramMember 2013-01-01 2013-09-30 0001016169 atrs:SharesGrantedOnMayTwentyTwoTwoThousandThirteenMemberus-gaap:EmployeeStockOptionMemberatrs:LongTermIncentiveProgramMember 2013-01-01 2013-09-30 0001016169 atrs:SharesGrantedOnMaySeventeenTwoThousandTwelveMemberus-gaap:EmployeeStockOptionMemberatrs:LongTermIncentiveProgramMember 2013-01-01 2013-09-30 0001016169 atrs:SharesGrantedOnMaySeventeenTwoThousandElevenMemberus-gaap:EmployeeStockOptionMemberatrs:LongTermIncentiveProgramMember 2013-01-01 2013-09-30 0001016169 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-09-30 0001016169 atrs:SharesGrantedOnJulySixTwoThousandAndTwelveMemberus-gaap:RestrictedStockMemberatrs:LongTermIncentiveProgramMember 2013-01-01 2013-09-30 0001016169 atrs:SharesGrantedOnMayTwentyTwoTwoThousandThirteenMemberus-gaap:RestrictedStockMemberatrs:LongTermIncentiveProgramMember 2013-01-01 2013-09-30 0001016169 atrs:SharesGrantedOnMaySeventeenTwoThousandTwelveMemberus-gaap:RestrictedStockMemberatrs:LongTermIncentiveProgramMember 2013-01-01 2013-09-30 0001016169 atrs:SharesGrantedOnMaySeventeenTwoThousandElevenMemberus-gaap:RestrictedStockMemberatrs:LongTermIncentiveProgramMember 2013-01-01 2013-09-30 0001016169 us-gaap:RestrictedStockMemberatrs:LongTermIncentiveProgramMember 2013-01-01 2013-09-30 0001016169 us-gaap:RestrictedStockMember 2013-01-01 2013-09-30 0001016169 atrs:TevaMember 2013-01-01 2013-09-30 0001016169 atrs:ActavisMember 2013-01-01 2013-09-30 0001016169 atrs:FerringMember 2013-01-01 2013-09-30 0001016169 atrs:ActavisLicenseAndCommercializationAgreementMember 2013-01-01 2013-09-30 0001016169 atrs:PfizerLicenseAgreementMember 2013-01-01 2013-09-30 0001016169 us-gaap:MinimumMember 2013-01-01 2013-09-30 0001016169 us-gaap:MaximumMember 2013-01-01 2013-09-30 0001016169 us-gaap:DirectorMember 2013-01-01 2013-09-30 0001016169 atrs:TransdermalGelProductsMember 2013-01-01 2013-09-30 0001016169 atrs:InjectionDevicesAndSuppliesMember 2013-01-01 2013-09-30 0001016169 us-gaap:EuropeMember 2013-01-01 2013-09-30 0001016169 country:US 2013-01-01 2013-09-30 0001016169 atrs:OtherCountriesMember 2013-01-01 2013-09-30 0001016169 2013-01-01 2013-09-30 0001016169 2012-12-31 0001016169 2011-12-31 0001016169 us-gaap:EmployeeStockOptionMember 2013-09-30 0001016169 us-gaap:DirectorMember 2013-09-30 0001016169 2013-09-30 0001016169 2012-09-30 0001016169 2013-11-06 shares iso4217:USD iso4217:USD shares atrs:Segment pure atrs:Customer atrs:Facility atrs:Patient atrs:site

EX-101.SCH 7 atrs-20130930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - CONSOLIDATED BALANCE SHEETS link:calculationLink link:presentationLink link:definitionLink 104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:calculationLink link:presentationLink link:definitionLink 106 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:calculationLink link:presentationLink link:definitionLink 107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Description of Business link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Net Loss Per Share link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Industry Segment and Operations by Geographic Areas link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - License Agreements link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Net Loss Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Industry Segment and Operations by Geographic Areas (Tables) link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Description of Business - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Stockholders' Equity - Assumptions Used in Fair Value Measurement of Options Granted (Detail) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Stockholder's Equity - Schedule of Performance Stock Unit Awards and Stock Option Granted Under Long Term Incentive Program (Detail) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Net Loss Per Share - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Net Loss Per Share - Basic and Diluted Loss Per Common Share (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Industry Segment and Operations by Geographic Areas - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Industry Segment and Operations by Geographic Areas - Summary of Revenues by Customer Location (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Industry Segment and Operations by Geographic Areas - Summary of Revenues by Product Type (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Industry Segment and Operations by Geographic Areas - Summary of Significant Customers Comprising 10% or More of Total Revenue (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - License Agreements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 atrs-20130930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 atrs-20130930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 atrs-20130930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable Current Accounts payable Accounts Receivable Net Current Accounts receivable, net Accrued Liabilities Current Accrued expenses and other liabilities Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated other comprehensive loss Actavis License And Commercialization Agreement [Member] Actavis License And Commercialization Agreement [Member] Actavis License And Commercialization Agreement [Member] Actavis (Watson) [Member] Actavis [Member] Actavis (Watson) [Member] Additional Paid In Capital Common Stock Additional paid-in capital Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Allocated Share Based Compensation Expense Recognized stock-based compensation expense Amendment Flag Amendment Flag Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Dilutive stock options and warrants excluded from dilutive loss per share Assets Total Assets Assets [Abstract] Assets Assets Current Total current assets Assets Current [Abstract] Current Assets: Award Date [Axis] Award Date [Axis] Award Date [Domain] Award Date [Domain] Award Type [Axis] Award Type [Axis] Basis Of Accounting Basis of Presentation Business Development Business development Capital Expenditures Incurred But Not Yet Paid Purchases of equipment, molds, furniture and fixtures recorded in accounts payable and accrued expenses Cash And Cash Equivalents At Carrying Value End of period Beginning of period Cash and cash equivalents Cash And Cash Equivalents At Carrying Value [Abstract] Cash and cash equivalents: Cash And Cash Equivalents Period Increase Decrease Net decrease in cash and cash equivalents Class Of Warrant Or Right Outstanding Warrant of common stock outstanding Class of warrant or right weighted average exercise price of warrants or rights. Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Warrant exercises price at end Common Stock Par Or Stated Value Per Share Common Stock, par value Common Stock Shares Authorized Common Stock, shares authorized Common Stock Shares Issued Common Stock, shares issued Common Stock Shares Outstanding Common Stock, shares outstanding Common Stock Value Outstanding Common Stock: $0.01 par; authorized 150,000,000 shares; 127,230,176 and 125,949,024 issued and outstanding at September 30, 2013 and December 31, 2012, respectively Comprehensive Income Net Of Tax Comprehensive loss Concentration Risk Percentage 1 Total revenue Contract Revenue Cost Cost of development revenue Contracts Revenue Development revenue Cost Of Goods Sold Cost of product sales Cost Of Revenue Total cost of revenue Cost Of Revenue [Abstract] Cost of revenue: Current Fiscal Year End Date Current Fiscal Year End Date Daewoong Development And License Agreement [Member] Daewoong Development And License Agreement [Member] Daewoong Development And License Agreement [Member] Deferred Compensation Arrangement With Individual Share Based Payments By Type Of Deferred Compensation [Axis] Type of Deferred Compensation [Axis] Deferred Costs Current Deferred costs Deferred Revenue Arrangement By Type [Table] Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Domain] Deferred Revenue [Domain] Deferred Revenue Current Deferred revenue Deferred Revenue Disclosure [Abstract] Deferred Revenue Disclosure [Abstract] Deferred Revenue Disclosure [Text Block] License Agreements Deferred Revenue Noncurrent Deferred revenue - long term Depreciation Depletion And Amortization Depreciation and amortization Description of business. Description Of Business [Abstract] Description Of Business [Abstract] Director [Member] Director [Member] Discretionary Shares [Member] Discretionary Shares [Member] Discretionary Shares [Member] Document and entity information. Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share Basic And Diluted Basic and diluted net loss per common share Earnings Per Share [Text Block] Net Loss Per Share Effect Of Exchange Rate On Cash And Cash Equivalents Effect of exchange rate changes on cash and cash equivalents Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Unrecognized compensation cost related to nonvested outstanding stock awards Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1 Weighted average period expected to be recognized Employee Stock Option [Member] Stock Options [Member] Entity Central Index Key Entity Central Index Key Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Entity Wide Information Revenue From External Customer [Line Items] Revenue from External Customer [Line Items] Entity Wide Portfolio Carrying Amount, Major Customer [Line Items] Entity Wide Portfolio Carrying Amount Major Customer [Line Items] Entity Wide Portfolio Carrying Amount, Major Customer [Line Items] Equity [Abstract] Equity [Abstract] Europe [Member] Europe [Member] Ferring [Member] Ferring [Member] Ferring [Member] Finite Lived Intangible Assets Net Patent rights, net General And Administrative Expense General and administrative Goodwill Goodwill Grant Date Grant Date Grant Date Gross Profit Gross profit Held To Maturity Securities Debt Maturities After One Through Five Years Fair Value Fair value of long-term investments held to maturity Held To Maturity Securities Debt Maturities Within One Year Fair Value Fair value of short-term investments held to maturity Income Statement [Abstract] Income Statement [Abstract] Increase Decrease In Accounts Payable Accounts payable Increase Decrease In Accounts Receivable Accounts receivable Increase Decrease In Accrued Liabilities And Other Operating Liabilities Accrued expenses and other current liabilities Increase Decrease In Deferred Revenue Deferred revenue Increase Decrease In Inventories Inventories Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase Decrease In Other Operating Assets Other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid expenses and other current assets Increase Decrease In Prepaid Expenses Other Deferred costs Injection Devices And Supplies [Member] Injection Devices And Supplies [Member] Injection Devices And Supplies [Member] Inventory Net Inventories, net Investment maturity term. Investment Maturity Term Investment maturity term Liabilities Total liabilities Liabilities And Stockholders Equity Total Liabilities and Stockholders' Equity Liabilities And Stockholders Equity [Abstract] Liabilities and Stockholders' Equity Liabilities Current Total current liabilities Liabilities Current [Abstract] Current Liabilities: Licenses Revenue Licensing revenue Long term incentive program. Long Term Incentive Program [Member] Long Term Incentive Program [Member] Long Term Investments Carrying value of long-term investments held to maturity Long-term investments Major Customers [Axis] Customer [Axis] Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Minimum percentage of fair market value on the date of grant used to establish stock option exercise price. Minimum Percentage Of Exercise Price Over Market Price Of Granted Date Minimum percentage of exercise price Name Of Major Customer [Domain] Customer [Domain] Nature Of Operations Description of Business Net Cash Provided By Used In Financing Activities Net cash provided by financing activities Net Cash Provided By Used In Financing Activities [Abstract] Cash flows from financing activities: Net Cash Provided By Used In Investing Activities [Abstract] Cash flows from investing activities: Net Cash Provided By Used In Investing Activities Continuing Operations Net cash provided by (used in) investing activities Net Cash Provided By Used In Operating Activities Net cash used in operating activities Net Cash Provided By Used In Operating Activities [Abstract] Cash flows from operating activities: Net Income Loss Net loss Net loss Noncash Investing And Financing Items [Abstract] Noncash investing activities: Number of facility locations. Number Of Facility Locations Number of facility locations Number Of Investigative Sites Number Of Investigative Sites Number of investigative sites Number Of Operating Segments Number of operating segment Number Of Patients Enrolled In Study Number Of Patients Enrolled In Study Number of patients enrolled in the study Number of primary customers. Number Of Primary Customers Number of primary customers Operating Cash Flows Direct Method [Abstract] Operating Cash Flows, Direct Method [Abstract] Operating Expenses Total operating expenses Operating Expenses [Abstract] Operating expenses: Operating Income Loss Operating loss Organization Consolidation And Presentation Of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Other Assets Noncurrent Other assets Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent Foreign currency translation adjustment Other Countries. Other Countries [Member] Other [Member] Other Long Term Investments [Member] Other Long-term Investments [Member] Other Nonoperating Income Expense Other income (expense) Payments Related To Tax Withholding For Share Based Compensation Payments for the employees' minimum statutory income tax obligation Taxes paid related to net share settlement of equity awards Payments To Acquire Intangible Assets Additions to patent rights Payments To Acquire Investments Purchases of investment securities Payments To Acquire Property Plant And Equipment Purchases of equipment, molds, furniture and fixtures Performance Shares [Member] Performance Stock Units [Member] Period for receiving royalty. Period For Receiving Royalty Period for receiving royalties Pfizer License Agreement [Member] Pfizer License Agreement [Member] Pfizer License Agreement [Member] Preferred Stock Par Or Stated Value Per Share Preferred Stock, par value Preferred Stock Shares Authorized Preferred Stock, shares authorized Preferred Stock Shares Outstanding Preferred Stock, shares outstanding Preferred Stock Value Outstanding Preferred Stock: $0.01 par, authorized 3,000,000 shares, none outstanding Prepaid Expense And Other Assets Current Prepaid expenses and other current assets Proceeds From Exercise Of Warrants And Stock Options Proceeds From Exercise Of Warrants And Stock Options Proceeds from exercise of stock options and warrants Proceeds From Sale Maturity And Collection Of Shortterm Investments Proceeds from maturities of investment securities Proceeds From Warrant Exercises Proceeds from warrant exercised Product Or Service [Axis] Products and Services [Axis] Products And Services [Domain] Products and Services [Domain] Property Plant And Equipment Net Equipment, molds, furniture and fixtures, net Range [Axis] Range [Axis] Range [Member] Range [Domain] Recognition Of Deferred Revenue Recognition of deferred revenue Research And Development Expense Research and development Restricted Stock [Member] Restricted Stock [Member] Retained Earnings Accumulated Deficit Accumulated deficit Revenue Recognition [Abstract] Revenue Recognition [Abstract] Revenue recognized in connection with manufacturing start up activities. Revenue Recognized In Connection With Manufacturing Start Up Activities Revenue recognized Total revenue received and recognized under a licensing agreement. Revenue Recognized Under Licensing Agreement Revenue recognized under licensing agreement Revenues Total revenues by product type Revenue from major customers Total revenue Total revenues by customer location Revenues [Abstract] Revenue: Revenues From External Customers And Long Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Royalty Revenue Royalties Sales Revenue Goods Net Product sales Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Basic and Diluted Loss Per Common Share Schedule Of Entity Wide Information Revenue From External Customers By Products And Services [Table] Revenue from External Customers by Products and Services [Table] Schedule Of Entity Wide Information Revenue From External Customers By Products And Services [Text Block] Summary of Revenues by Product Type Schedule Of Entity Wide Revenue By Major Customers By Reporting Segments [Table] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Schedule Of Fair Value Of Separate Accounts By Major Category Of Investment [Axis] Schedule of Fair Value of Separate Accounts by Major Category of Investment [Axis] Schedule Of Fair Value Of Separate Accounts By Major Category Of Investment Category [Domain] Schedule of Fair Value of Separate Accounts by Major Category of Investment, Category [Domain] Schedule Of Fair Value Of Separate Accounts By Major Category Of Investment [Line Items] Schedule of Fair Value of Separate Accounts by Major Category of Investment [Line Items] Schedule Of Fair Value Of Separate Accounts By Major Category Of Investment [Table] Schedule of Fair Value of Separate Accounts by Major Category of Investment [Table] Schedule Of Revenue By Major Customers By Reporting Segments Table [Text Block] Summary of Significant Customers Comprising 10% or More of Total Revenue Schedule Of Revenue From External Customers Attributed To Foreign Countries By Geographic Area [Text Block] Summary of Revenues by Customer Location Schedule Of Revenues From External Customers And Long Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Tabular disclosure of share based compensation award performance based units and restricted stock units and stock options granted activity Schedule Of Share Based Compensation Award Performance Based Units And Restricted Stock Units And Stock Options Granted Activity Table [Text Block] Schedule of Performance Stock Unit Awards and Stock Option Granted Under Long Term Incentive Program Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Assumptions Used in Fair Value Measurement of Options Granted Schedule Of Stock Options Roll Forward Table [Text Block] Summary of Stock Option Activity Segment Geographical [Domain] Geographical [Domain] Segment Reporting [Abstract] Segment Reporting [Abstract] Segment Reporting Disclosure [Text Block] Industry Segment and Operations by Geographic Areas Segments Geographical Areas [Abstract] Segments, Geographical Areas [Abstract] Selling And Marketing Expense Sales and marketing Share Based Compensation Stock-based compensation expense Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period 1 Options granted under long term incentive program vesting period Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Stock Units Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value Fair Value on Grant Date Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number Stock grants unvested Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Weighted average fair value of shares granted Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Expected dividend yield Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term 1 Weighted average expected life, in years Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Annualized volatility EX-101.PRE 11 atrs-20130930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R17.htm IDEA: XBRL DOCUMENT

Basis of Presentation - Additional Information (Detail) (USD $)			3 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013 Other Long-term Investments [Member] Maximum [Member]
Schedule of Fair Value of Separate Accounts by Major Category of Investment [Line Items]
Investment maturity term			2 years
Fair value of short-term investments held to maturity	$ 27,070,089	$ 21,116,952
Carrying value of short-term investments held to maturity	27,053,333	21,112,623
Fair value of long-term investments held to maturity	0	12,016,530
Carrying value of long-term investments held to maturity	$ 0	$ 12,015,906

EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0"M[M-FQ@$``/L2```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F%U/PC`4AN]-_`]+;\W6 MM2JB87#AQZ62B#^@K@>VL+5-6Q#^O=WXB"$((9)X;EA@[7D?>O%D>WN#15U% M<["NU"HC+$E)!"K7LE23C'R,7N(NB9P72HI**\C($AP9]"\O>J.E`1>%W/%#J\@)JX1)M0(4[8VUKX<-7.Z%&Y%,Q`.*TKBK@$'H MWH3FSN\!ZWUOX6AL*2$:"NM?11TPZ**B7]I./[6>)H>'[*'4XW&9@]3YK`XG MD#AC04A7`/BZ2MIK4HM2;;@/Y+>+'6TO[,P@S?]K!Y_(P9%P7"/AN$'"<8N$ MHX.$XPX)1Q<)QST2#I9B`<%B5(9%J0R+4QD6J3(L5F58M,JP>)5A$2O#8E:. MQ:P70T]EEP("_+=VU#"G!W@Y^Q#'*&B&%IM7"AK+)Q^"ILVIMD=FS`(K"]A MV\?LZS6VB:'H.3UPIUB!IDJ2(/=DT[:ZZG\#``#__P,`4$L#!!0`!@`(```` M(0"U53`C]0```$P"```+``@"7W)E;',O+G)E;',@H@0"**```@`````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````C)+/3L,P#,;O2+Q#Y/OJ;D@(H:6[3$B[(50>P"3N'[6-HR1` M]_:$`X)*8]O1]N?//UO>[N9I5!\<8B].P[HH0;$S8GO7:GBMGU8/H&(B9VD4 MQQJ.'&%7W=YL7WBDE)MBU_NHLHN+&KJ4_"-B-!U/%`OQ['*ED3!1RF%HT9,9 MJ&74"T\U<%J"`=[!ZH^^CSYLK$SO+=N5# M9@NIS]NHFD++28,5\YS3$$X4UD^&'!Q0]47P```/__`P!02P,$%``&``@````A`&+@ M!5.R`0``PA$``!H`"`%X;"]?_?'KIX\_^Q[6Y7Y_K1YF^M-N'*%?+#NKVOM`XQJ'*E#IGH MM[P\GLQ'$;&0U\'`F!D-C$DXW.0`R0[.F-G!&<4.=Z[(5"%PNZ%1Q*PZ0BH-Q>K(.*TS)5"V&A!/B3-]&?(5UL4VBX-8>4'.Y$D7D";FJ`Y`;9?1]I_)#;HR/IT<>#2HX/AR;^9NFM MUO?ZIXWDQ9^7U1<```#__P,`4$L#!!0`!@`(````(0"(@-/U&P,``'H)```/ M````>&PO=V]R:V)O;VLN>&ULE%9=;^(P$'P_Z?Y#E/=K/J"?*E104A6)`E*X M]M%R$T.L)G;.=H[R[[L))2PD1>U3<,Q.9LO6>I]9\IS:7HV=Z9:UM, M1#+F8M6S_RX>_ES9EC94Q#25@O7L#=/V7?_WK]NU5&^O4KY9`"!TSTZ,R6\< M1T<)RZ@^DSD3L+.4*J,&EFKEZ%PQ&NN$,9.ECN^Z%TY&N;"W"#?J.QARN>01 M&\FHR)@P6Q#%4FJ`ODYXKNW^[9*G['G;D47S?$HSX/V>VE9*M0EB;ECR[KEO?>V1\E9C=38!W$'ZE(#RG MNEJB:F^G"(&3(H$PW&S(6&S5YQ*.L%1]#)UYMJ5N./Q0X]@KB6.4^]DTG$W& MH\$B&)'A8#*8W@%[ZE,@E&1:: M"Z8U(N%?H_K+8Q9#JKDN*^>*:;!^Y7A4W0%WU3U<'5>'1D9OB4QCB`4)_A5@ M#UR+37%]7#MEADRDUF3.%`D3JA@NQ6;PW./:L8@+;=2&A&Q5!K:RYRQGJD$? MV\%K&',"H1>:D<%*,82\./7SB)#&(8;1SCP.C>]]1P9*NC/E$D3.4]'VQ, MK^',-GVW7*2@,'5K'.^`SW<\2L(BRRC81RXQS@&?AE];^6A=9%7X$$XYD&M] M8'$T#-MPPBAA<9$R@D>JC^,#BR.<%N_LY2&8#\Z2W_!Q"TYYA%&5J1'&P5GR M&UX^;43@4!]8]T"@'SH:2-1`/DX7+(X4.LT(TKT'PAG;OGBKO<^WX&D@(+$' MPAGS&YYNSILZ%9]8]./O*TT[U$'@_1S2-X,.AO)1OWLI@SNZSJ?\!``#_ M_P,`4$L#!!0`!@`(````(0#2\%#LH@8``%09```8````>&PO=V]R:W-H965T M&ULE)G;;N-&#(;O"_0=#-_'UHSF&,19K`[;%FB!HNCA6K'E M1%C;,B1EL_OVY6AD:4CO)LI-',N?*?XDAT.-[SY\/1X67\JFK>K39LE6T7)1 MGK;UKCH];I;__/WIQBP7;5><=L6A/I6;Y;>R77ZX__FGNY>Z^=P^E66W``NG M=K-\ZKKS[7K=;I_*8]&NZG-Y@D_V=7,L.GC;/*[;SS53?%P`-U?F2BV%]O]FROSQVK;U&V][U9@;NT= MO=9LUW8-EN[O=A4H<&%?-.5^L_S(;G,NENO[NSY`_U;E2QO\OVB?ZI=?FFKW M>W4J(=J0)Y>!A[K^[-#?=NX2?'E]]>U/?0;^;!:[SWP.AF9Z\K:!Z>/=59TQ?U=4[\LH(!!?GLNW')@MV#Y$F0?DC'L/XHZ MA-L9^>BL;)9ZN8"`ME`J7^Z5NEM_@>QN!R3Y#J(QDEX0ETMG-KMDTH@Y'L&B%&\FLB,(+D M0/G-E^-@*/;`>V6Q;XE'H!Q'@1(3Z9M$]B:1OT8@>>#(?'D.WBPA=J/O.L+. M)QXQ?2'&D="1)763A@2/)(\M35](L`@0(0F2AXC6T@@5CXX@?;"PYNMS,-%' MO$\\HGI]C%L;<^):&A)<14H84GP9)@SC$2'RD%`QW$9-"Q;)4^^1YV`BC]PX M\8B7IRR/B?PT_%QK;L08==\VPL]YI'E,HI.'`"AG=FI62!@TM/EY5,$]?3D+#":DE,9"'`(?$0'ZP^1P33,53F2"!U;E`*6O_K/=+! M1!WQ/?&(5R=EI`TG1(H(9:1E4T7YU(4$DT;'TI+%G2-$1UJ(:"H0)-"^1Z"# M<=<,XN;3YQ%8]6/GF2+;$^F;1/8FD;]&('D,1JKY">QIDL&I[+W`@1D*U$8V M4B3Z*4:4CHT@FTN&$"69%<&VUM\H1PB4"C38J1*P2+?#SZY2YN1 MGAE7H92"+*%T,#,@BG,E2!PRC%C+K21QR!'"M=`B6!!8I)L$YHOT<1#-'B#;,B*!=8Y%N')@OT@\/2"1Q M+V&>\2*YC&+.KS*)D-A80;?*#%G1L6(LV,:'<@VM6"ZE#48.+-+-!/-%^@D" MK(\=Q9!"2YAG7NLZ;R/9VTC^*H)%NLE@OD@_1X29-%/#'M9D.&M`!9F($21U MCW[0H(>*ME#2M#]G"&%,&UBY9`O*$6-A-!)!S6"5;DJ8K]+/%$@E*<:$A7,' MEUIQ0993BI%81\',U8$1W^!01,'J%S@T*0QO"P!Y#`IDC&QKF;C55"Q;HAH7Y`OUH@022 M^DD8&C\,M`O:$E.,2,D837.&$!EKJ1A9]SE&(F-AT!GSC$6ZB6&^2#]?()%D MC$F89_Q:,T9S<;U[A`@,:4;1731#5J`U*Q%3,SEBX%!%<1UT0"23OVO?.KE3N:I)'<.1D8_[@/:9304T@`4LS$,A;PR(]3G6&&":-9V%A\;\60$M!_ MHQ\I=5-#L"[=V5H,1?SZ@Q;WLP9:G\339&!L?P!P$ZT"#X:J]48F@"0\HQ88 M;;$4B*;%@]-)!IZ9(OU0$XJDSWD)G"U/&SYT6:8XG&/@G*48@BZIF*9/Q!F& MN)*P\ABI(G>4'=PN@FU5&DDSZP^K_0'JL6P>R[0\'-K%MGYV!]$QY&.\.AZ2 M?^3N8)%<3]@M''=>7\_@4+V_OAZ_`&?:Y^*Q_*-H'JM3NSB4>[A5M-(P#S7^ M5-R_Z>IS?YS[4'=PFMW_^P2_7I1PD!JM`-[7=7=YXXY+Q]]#[O\'``#__P,` M4$L#!!0`!@`(````(0#"K^TE#@0``!`/```9````>&PO=V]R:W-H965T?SBU^=@G[/Y^E$6VCNM>--6AW3@E4TTC\IU[]N?_UE:4+A76]1(.=3GE&8Y;= M2EHU0J2F1=K`^ODEO_*'6IDMD2O3^NUV_9*Q\@H2A[S(F\]65-?*;/WM7+$Z M/13@^X,X:?;0;G^,Y,L\JQEGIV8%VFW:!_?.:HZ2N93?>L/)?`9%.2HA8G0C,Z$2( MM;("E[C>O(HA5M0:C-,FW6YJ=M<@:^"9_)IB#I(U**,S!S[%.GJO_V<5/*+( M"ZI$NJ]K,)U#?-ZWMA-LC'?8TZQC=F/&\V5D_T!P!U$W?@P\=8D\)7D0&#ZP MU/N"W1KZ^GFD'LM'&)?_>.Y.#(!V[\>2G[L?$YYB.!XCBD@R)@8BDAU;MH-A MLB&-IVWA).`&+FPGE'WL!.,,&%\$$[0YZ;JF'UB.3.PEP@O5: M[A!AU>%3MWU'=H*!!?2[H$9PEHAGB62*D/QYLK]EF8J3YC)5,%,^9XEXEDBF M",DG'';+XXBP&DS0##U/R52)"`)"3(6(AP2Q3<\.+>6%3Q0D ML"WWB4@.L7H97`W39PW"JD/EN-L)9BJ"LT0\2R13A.0OE/TMRU2<-)>I@IGR M.4O$LT0R14@^"5P4RP/9TFHDU5SM()&LQ'1\7[WN]Q+BPZ$YN-JZRQW7%>E" MQ'(#UW.5DRN11&S'"8CU//YDDU@(+,Y6(LH&^>JPY==MUT%3<9Q'XGDDF41D MEU@Q#%PNRUDBZ@RXA/LK8EP(=-"D6Z$S@<3S*LDD(KO%LF'@=OH$@@9@?`2- M$E=`HA[P0CA"Y:#O.Q4!$+C'E:R()<"R'.C$9`GL1'`A7KP MDM9GNJ=%P;6,W;")L.$*Z$?[!N?%PO)4&=^1-13-X_$8&R(<-_H)T(]<6U@I[@4>;*AXN]%AV-^-&P:]L5'%@#G4C[]0*=)X5RW%P!?&*L>?S` M!_2][/8_````__\#`%!+`P04``8`"````"$`Z_Z8/(`"```J!@``&0```'AL M+W=O MU;M*=]+I=!_/CEG`*L;(=IKVW]\:)S1I6BE]`6S&,[NSNUYX-#6SO0%>#H=4RR9Q/&6*RXX&AKDYAT-7E11P MJ\5&0><"B8&6.XS?-K*W>S8ESJ%3W#QL^@NA58\4:]E*]SR04J+$_+[NM.'K M%O-^2C(N]MS#XH1>26&TU96+D(Z%0$]SOF)7#)F6BU)B!MYV8J`JZ"J9WTPI M6RX&?_Y*V-J#;V(;O?UJ9/E==H!F8YE\`=9:/WCH?>FW\#`[.7TW%."G(254 M?-.Z7WK[#63=.*QVC@GYO.;E\RU8@88B333)/9/0+0:`3Z*D[PPTA#\-[ZTL M75/0=!KELSA-$$[68-V=])24B(UU6OT+H&1'%4@F.Q)\[TB2/,HF^>SR#!86 M(AH2O.6.+Q=&;PDV#6K:GOL63.;(O,\LQ#'F^EZJF*,G67F6@LXHP2PLEN=Q MF6;Y@CVBIV*'N0D8?(Z89$0PC&8,"<,X#.EMD_?*'NR5O>D^E)NP<2@S>5LF M_8B,!Q_)A(U#F32;OBV4?43(@[$]#ER:Q"^\(<6`P>?HY(O71TYBJ869#2RLP-7R! MMK5$Z(V?QP1/C;OC5;%*AVD??^"H]KR&']S4LK.DA0J/QM$,LS5AV,/"Z7X8 MF+5V.*3#9X-W,F#;Q1&"*ZW=?N&OD_&67_X'``#__P,`4$L#!!0`!@`(```` M(0!W$7=L/@,``%<)```9````>&PO=V]R:W-H965TDV:9.F:1_/#CB)5<#(=IKVW^\:!Q+#VJ9[ M"<$<'\XY]]IF?OM4E=8CX8*R.K61X]D6J7-6T'J7VK]^WM_$MB4DK@M2]G,7%?D>U)AX;"&U/!DRWB%)=SRG2L: M3G#13JI*U_>\R*TPK6W-,./7<+#MEN8D8_FA(K74))R46()^L:>-Z-BJ_!JZ M"O.'0W.3LZH!B@TMJ7QN26VKRF=?=C7C>%."[R.'BBEG)0B`7ZNBJC,@$/S47H^TD/O4#B(GG'H!`KBU(4+>4T5I M6_E!2%;]T2!THM(D_HDD`/6GY[[CQR$*HW>P3$XL<#VSO%<*B&[]P/5,^]2#P!W[\/528Z`A>X>A*7_U)B)[$[%^#6'X`R'7^U/@U(;P>NWQ(/NEAL1M*]Y$09@D MX;#9#$@0!A,_2,P(,@.")O$41=&P`0U,-$&PK,])&AYA>5UZ5$LM@%WQ]=94 MDTROB6>J7&I(U'I%/FCTO6BP^%8&QHN3"$V'+9$9&#\*8^2A0:YK`^.%TR", MPQ?L1O]C5TTR[<:#HBPU)-&E]9R+M-L]8S5\'IAQ98/G:+`RX$A3$L[\43]? M5U,?6'H3K0C?D14I2V'E[*`.HP!T]:/].7GGJ[UE,+Y$,]CQQN,9G*OMN-M/ M@'.MP3OR#?,=K855DBV\RG.F4`ZN3T9](UG3;ND;)N%$:__NX0.&P%[J.0#> M,B:[&[5C]I]$B[\```#__P,`4$L#!!0`!@`(````(0!@G#M]BP(``.H%```9 M````>&PO=V]R:W-H965T,-4+IHRPS^^/S^,,3*6-CFM5<,S_,8-?IQ__##;*[TQ%><6`:$Q M&:ZL;:>$&%9Q24V@6M[`FT)I22TL=4E,JSG-NT.R)G$8#HFDHL&>,-7W,%11 M",:?%-M*WE@/T;RF%OR;2K3F1)/L'IRD>K-M'YB2+2#6HA;VK8-B)-GTI6R4 MINL:XCY$`\I.[&YQ@Y>":65480/`$6_T-N8)F1`@S6>Y@`A`M5(;)WW)W18<)C>GG[L"?-4H MYP7=UO:;VG_FHJPL5#N%@%Q.Q%0-!N`72>$Z`Q)"#]W_ M7N2VRG`R#-)1F$0@1VMN[+-P2(S8UE@E?WE1=$1Y2'R$).#^^#X.XG$:IVH43R-#]3IP8*GUV<32YNGKI-8,S3=K?W-E?O:>X\`:0XDWZ MV?*M)[DN^8K7M4%,;=W70)6$`XD(I>UJX'NR_TO/?```` M__\#`%!+`P04``8`"````"$`HC]^0JL&``#X(P``&0```'AL+W=OA/.QT/&< MM_[6AT@/]_L"9B#;[M3Y8><^!G>?DMCU'^Y5@_XM\M?&^-EI3M7KKW6Q_[VX MY-!M\$DZ\%15SU+Z=2]_!8/]T>@ORH$_:V>?']*7<_M7]?I;7AQ/+=@=PXSD MQ.[V/S[G308=A3!>J,K(JC,4`%^=LI!+`SJ2?E??7XM]>]JY(O'B]4H$('>> M\J;]4LB0KI.]-&U5_H>B0!;5!0EU$/BN@P2Q%X7Q>L.(XF-%:H*?TS9]N*^K M5P=6#>1LKJE<@\$=1)8SBZ`FK*.;Z]Q4H3P9Y%%&V;EKUX'A#?CS[4&$JWO_ M&_0TTYI/J(&OG2;H%#Y4TY4$99@E33?YEEF*96;9*5G*)_R%F2:<3B.&:6XS M7TXG!X%[QB3"1'3QL0+41(8F[A2#B8*$/U$IWKDPNZY](NP;B)E1DR@#MJM( M;'H/!HG!8'YB*::)^Y9B8M1L5>+(6_5U#=(FP[2\CLM!-#WM.&H8'8<5:DZ< M5X$<9/,<-8P*Y"7!V&_+JTV*AW,/-GUOL?6HB;'UJV3.\NTP+V_F^B7L#!GA9QB@"-V8GE31!(]7`5 M3IB`HLZ$[9P)!'U,$Z88V&?0)J"(,_]W@3!`RBU?>[2(4P1AH<4$!)RY#"=, M0-'-A"CH6S1[@01;D@'M`@/`<$&[A1F#@'AFU"HU#3WEN9&7N(Y(/"2&?_#"1+:_5>C M2`6BGQOZKT4,_\-WD5"-LEV.M(A3!&CX)`REFG1@[#^*S.1"](>&P4:4=Q]O M2#]%P=$2&%-P/OT$!QGK`#EHHD@(>B`-461V8>:*&!(.\JX(:I1U'2`/.440 M(EHX,$7"$0=0I#D@UNM@K@$$A);B_\.8.8P(Z8^*'V7HYBE0@Z%V)"LTZ$0O"0&81B+GED(_I@43%!3]&L?S@$`19PL2 M##*+0-)9U@&*&$5$A(C+1B@UV0FC=:!%9O)9(R+"0DMZ/.TMKP,5DKD.(D)! MG@5J%.F"Z*\XN`ZTR.Q"OU0&9Z*(X)!9!&)Q>1VHT,->S!4!A9IDM!@AU:0# MXW6`(K,#\^N`,-&2'EEH60\/HS$5YRP@3&06@6RTK`,4 MF;V8*X*0T6+$!!''ZP!%]G-!1(!HR8V,LRP"%-G.!3&A(*_U:A39!8*>BK6( MT?J8L)!9!#)QV7\5FL6!F!!QV0.E)AT8_8]`B]!_$:QGGP_$$FG&\TI+;JFF MN>E=F0IY.Q?./Q^(P1XS,[/UI$O5P3P/\[NM]V+'X^A>G6C^P.\=W%-C_D?:7TL+HUS MS@\P=.6MH;X:W]S`#VUU56\_/%4MO'&A?CS!&S8YO$.P\D!\J*KV]D&^&]*] ML_/P/P```/__`P!02P,$%``&``@````A`(<&M&Z>`P``8PP``!D```!X;"]W M;W)K&ULG)==CYLX%(;O5^I_0-PWF`_S$26I)H'9 MK=255E6[O2;@)&@`(^Q,9O[]'N.$8-.%M#>3X'G.:[\^Q^9D]>FM*HU7TK*" MUFO37B#3('5&\Z(^KLWOWYX_AJ;!>%KG:4EKLC;?"3,_;3[\L;K0]H6=".$& M*-1L;9XX;Y:6Q;(3J5*VH`VIX3\'VE8IA\?V:+&F)6G>!56EY2#D6U5:U*94 M6+:/:-##HOF+%,<3AW1C<"2,+?/WF+`,=A1D%@X6 M2ADM80'PUZ@*41JP(^E;]WDI_T_J^!1B#P)E;49F`:$,\C/Z\;%WLIZA3W-KLQVS/B!BNQNB-A!H1O? M!NZZMAJ2W`B1/K#4^X+=&OKZ>:9NRQ>P6/YMWJT<`.W>CZ/.NQL3?J@B\1C1 M1)(Q,1!1[+BJ'9$F%\IXVI8(`F[@PL587>16,MZ`T8C=+!'/$LD4H?B$A3R> M-@&O3=C$/DLN]C5_D@F[FL08!:&CU>5.(?P01[96EO&0L'$8N#A"ZC2)@@0H M\#QTKU3%(1RNH2@87TNZ%GL9'Q9L39"#G;58ML-"=='R$-:.<9# MPG;#T(D"3209(A%&V/7N!T,Q*)J8P1MBVJ"`=8/:O;B5S%0"9XEXEDBF",5? MI/I[[$"*H+E"E3MZJ$`!_=+KWN! M[Q3"02'&H]M50>PH0KZ.B-Y.;+><)\!^A/#]]I,F9>\F6YN*M$>R(V7)C(R> M15_FPFGJ1_N>\BQQ3C5A\`+5Z3'LG?:7LL:F:4Y`!3 MH44`=V0KFT3YP&G3-5I[RJ&YZ[Z>H)DGT.&@!<`'2OGM04S0_SS8_`<``/__ M`P!02P,$%``&``@````A`+-?J!\0!```%`\``!D```!X;"]W;W)K&ULC)==CZ,V%(;O*_4_(.XW8,!\1$E60V#:E;92577;:P). M@@8PPF0R\^][C`G!9@O<3(+G\OAUU]V=]J\L2LAK08*%=OKU[:MMX;! MTBLI$[:A-:G@/V?:E$D+C\W%8'5#DJR;5!:&99JN429YI0N%;;-&@Y[/>4HB MFMY*4K5"I"%%TD+\[)K7[*%6IFODRJ1YN]5?4EK6(''*B[S][$1UK4RWWRX5 M;9)3`;X_D).D#^WN82)?YFE#&3VW&Y`S1*!3SX$1&*!TV&4Y..#+KC7DO-=? MT#9&MFX<=MT"_9.3.QM]U]B5WG]K\NQ[7A%8;<@3S\")TC>.?LOX$$PV)K-? MNPS\V6@9.2>WHOV+WG\G^>7:0KHQ..+&MMEG1%@**PHR&PMSI906$`#\U#:B;#V->>2NI;>6$O+?P6$>BDA8O4B,*,7 M0=;&\C'"[K**(2+J#$9)FQQV#;UK4#7P3E8GO`;1%I2Y,P<^11R#U_^S"AZY MR`M7V>N>KL%T!OEY/]@XV!GOL*9ISX13QO5DY/A`^`IRW>@Q\-1%\I3X0?#T M@:7!%ZS6V-?/,_4(G\,\_,=[0S$`VH,?2W[O<4JXOHQ$4T01B:?$2$2R8\MV M>)IL*.-Y6WP2<",7MFO*08:"<48,EHGC(A$M$O$<(?F$0-:GC<-['19QR)+M M*O41"L;O:A)CT_,M1_$G$:Z/`Z24930F$/8]J&UE&6,)\4S/<M:CCO$"2#O'D9G0SS6PV'58/VH"L,"F8N@8M$M$C$(Z0?"(X)]8GLJ/53"J%&/:0J%5D.IZ'E0WQ*"&>;WM8W54E MPL((V;:RM<428CN.@]'S/;))W@>LKE8DN@;YY%#.A;"'YO*XC$3+2#R+R"YY MPS!RN:YFD6@SX`P>3HAI']!#LVZ%S@P2+:O$LXCLEG<-([?S.Q#T_],M:%*X M`A+M@&5:/E(VJ6,O(PB$/.3:"A+)B&VBP%)Z77X9X<'T;0?T%([_[`Z%27'9 M$+UX29H+.9*B8%I*;_PB8<,Q,(P.EYP7B[>HRGB(MM`X3\XD M=7(A?R3-):^85I`SO,K<>'"X-^)6(QY:6G^`N&^^SA/P```/__`P!02P,$%``&``@````A`$XO&)*4`P``D@T``!D` M``!X;"]W;W)K&ULE)=OCZ(Z%,;?;W*_`^']"HB* M&G$SBG`WV4TV-_?/ZPI5FP%*VCK.?/L]I2-+RUSJ^H)(_?5IS]/3]KCY\EJ5 MS@MFG-`Z=H.)[SJXSFE!ZG/L_O-W^GGI.ER@ND`EK7'LOF'N?MG^\6ESH^R9 M7S`6#BC4/'8O0C1KS^/Y!5>(3VB#:_CE1%F%!+RRL\<;AE'1=JI*;^K["Z]" MI':5PIH]HD%/)Y+CA.;7"M="B3!<(@'SYQ?2\+M:E3\B5R'V?&T^Y[1J0.)( M2B+>6E'7J?+UUW--&3J6$/=K,$/Y7;M]&4TY.8@)RG)CJ,>>6M/%#: M;@H"$4C;'89/L?L4K+.5ZVTWK3__$GSCO>\.O]!;QDCQC=08S(9ED@MPI/19 MHE\+V02=O4'OM%V`'\PI\`E=2_$7O?V)R?DB8+7G$)",:UV$9CG8"C(3*9S MJ933$B8`3ZDAN]"_+\( M(30I\B158A?ZP^0YK,K+-ES,-]X+6)F_,SO%P+/'+'1F/]0)="*Y$]);.?3! M;$C-AJS7X$'47>A3/?2/U_`>H81EA/=Q=ZH!M'OA1/ID]T-FL=219(A,=>(P M)$R1=(@8(MF0Z(EHKH2Z*S(A0M@GX^[(3IH[JD%WQPA]_P"3?,2L#(,>8-(/ MF,C7=;)Q1C,)]INY:^PFR4Y@9C]C(B.]=XJ!9Y=5QC;:6XG$2ARL1&HELC%" M\PH.MM_W2G:*787BEBV1Y(L]ET.3=2)[%*'*Q$:B6R M,4*S"D[VOE7C>T["ID6AGM([Q?0M"J.9SNR'C&%C8B4.5B*U$MD8H;D$U\SC M+DG8=,F(;Z>8ODL&L;<2B94X6(ET2$Q7QHIF0^;77#679,79N]C'K,"D(_6$V-0^O0)^9PILV6QLV:6D>!&EE&\_%,E4>J!E:U8H79&>]Q67(G MIU=9WT[!W*ZU*[V?0ED?&>U[*,G;`M;K?H"2N$%G_!VQ,ZFY4^(32/J3"`Y* MIHIJ]2)HTU:H1RJ@&&Z_7N"_#X:ZSY\`?*)4W%]@8*_[-[7]"0``__\#`%!+ M`P04``8`"````"$`LS%<;(4%``#>%0``&````'AL+W=O@TS1[79_5V^S8U,7:?R\Z_]OFUU]6KTW[U!V*HO<@0MVM_4/?GY9!T.6' MHLJZ17,J:OAFU[15UL/'=A]TI[;(ML-#U3$@"(F@RLK:5Q&6[2TQFMVNS(O[ M)G^NBKI70=KBF/6@OSN4I^XC6I7?$J[*VJ?GTUW>5"<(\5@>R_Y]".I[5;[\ ML:^;-GL\PKS?,,ORC]C#ATGXJLS;IFMV_0+"!4KH=,YQ$`<0:;/:EC`#F7:O M+79K_SM>IA3YP68U).C?LGCM1K][W:%Y_:TMMW^4=0'9ACK)"CPVS9-$?VSE MG^#A8/+TPU"!/UMO6^RRYV/_5_/Z>U'N#SV4F\.,Y,26V_?[HLLAHQ!F0;B, ME#='$``_O:J42P,RDKT-_[^6V_ZP]JE8\!!1#+CW6'3]0RE#^E[^W/5-]9^" ML`ZE@A`=A()Z_3U9D(AC+KZ.$BA%PP3OLS[;K-KFU8-5`V-VITRN0;R$R')F MD,D+,X,IR6>^RX>&1X'NH!PO&R)6P0MD,-=(\@EB$^DG1'A&`I!WU@@S'VO\ M/.L?VB0,<_`]HRTZAQWD)PIA(X3;1'J-L*3!.+=+D_#:A]A&6FP/G"@D&G+* M2"P0BYS,IF.$$Q2'2+!S%$L(B8DTBT"(0&LXQ["DA7.D2=B19L*JDBI$9PV'')NE-`#I&`@Y-!NS8BUA MTNIF]Q'YD"/0&3]1B,X=0AA/1*Q:_+CA46?L1#.ZP`2'(3&[4LM3832""17\4A9EWQZMPB_DJ2YO MR7,JF&#%Z+%1S"EWUD%Z%;&S-\LM\-0NJ-E\:OMJA@TM>9(W%>`CM0CV+C*K MPU8VRRKPU"N8,WBB&36XP(0Y_3JU`!9380!;VBRCD*:4=(B&!H, MU`RNU]S8+&+.B1#83-$6.,LNL&KU4)KS(8"9U:RKJAC(\IF9++IKB"UOEF7@ MJ66YQC'%UMVZAC,M"J=/,D!B+$!G$EC?+-?#4-IB3FD0S>F-0"N>WL]5K=6/;(!C>$_"%;4L MO(&VW8*9P"IYFE'J,,)1R(4S@]1BPIA&Y-(9C\RRBX%V]+EVH1F]=T/&8V<& MJ45@1,-P=&*P:DMFN<5`.^IA$JYG-7TP'<+VUICF=(:2'\[8O] M,?4.[OA"(M^TP5]TA4E(*'*Z=^H@/&:QV>&VS%G.053+'Q]71N<@G3G%*'F$ MH1C'.)H(M"`:P2X"@SXW(5OB+/<@4_?@KGMH1DF\@]8K!(K?$S/C[?EL?A*;LQOG.\C. MXO:E;=`S%9+Q+L6^XV%$NX*7K%NG^/>OAYL91E*1KB0-[VB*7ZG$M\O/GQ9; M+IYD3:E"X-#)%-=*]7/7E45-6R(=WM,.9BHN6J)@*-:N[`4EY;"H;=S`\V*W M):S#QF$N+O'@5<4*>L^+34L[94P$;8@"?EFS7KZYM<4E=BT13YO^IN!M#Q8K MUC#U.IABU!;SQW7'!5DU$/>+/R'%F_L]E04D%&R<(-). M!6\``+Y1RW1G0$+(R_"[9:6J4QS&3C3U0A_D:$6E>F#:$J-B(Q5O_QJ1O[,R M)L'.)`3ZW7S@!+/(C^+_N[B&:`CPGBBR7`B^1=`TL*?LB6Y!?P[..K(0\G,Z M,@A)K[G3BX:EH)90C>=E-%VXSY#!8B?)CB6!K^/,2)(AMY[C^?9T_N&T M!06170ZEQ394[-F[9D82#U"A-WQL17Y.8:%!VU^.IL4CM%%",B.9F'R-H$[/ M63CQ-3A:/,(9]79F)!^6[\-I"VIZ#906CZ!".P^9D9CR^9&IWZC$^7F-A:?O MMH.3XWS+:_$(;S+",Y(=7C`-0L^?QK8FMS51,DF\8.]CX277X&GQ""^RM\Z, MY#R>K3F-9RX9`X\)PIM*LP5XP9*-X/9^V**[@:AL<: MW@0H',2>`^**<_4VT)?8^[O%\A\```#__P,`4$L#!!0`!@`(````(0`"%GF- MV"L``-^6```4````>&POZYOT&YAT6 M#`52`$H6=59WX@U:DAVG;4N1Y'3W-/9%B2Q*E9`L=E71-AO[HB_F$>9F@-F` ML1]@'L*/DB>9[_O_M:I6K:JB9,>YZ0!]L,AU_,_'Q6_^_?UT8M[&69ZDLV\? M];>V'YEX-DQ'R>SVVT=OKI]M'CTR>1'-1M$DG<7?/EK&^:-_?_(__NV;/"\, MYL[R;Q_=%<7\#X\?Y\.[>!KE6^D\GN&;<9I-HP)_9K>/\WD61Z/\+HZ+Z>3Q MSO;VP>-IE,P>F6&ZF!78]V`;^RQFR=\7\8E^M'MX].C)-WGRY)OBR6DZ7$SC M66%P#G,V*Y)B:5[,=`.<^YO'Q9-O'G.H#C\VK])9<9=CZ"@>A=]>Q?,ML[O= M,SO;_=WPR]?IVRVS?=#^97F,0>LQS-\&-WF113:+;\-OU<33)&PN5NUS$69(2="-S&A7=XYXE^3":F+_& M46:>`>AY8Y\VH)7;V.EVM_8%?FC`_#J+2&[F:CF]22>-'0?7EU?AAY8&+N/; MA!`'9;R.IHUKK0]>7P\NSZ[,Q7>#RU>#GGGQ^F2K8ZD3D%>&J[\`R;PW?XJ7 MX;CU[>WM_G;_H']P''YULL@R4JO3\[,U7=G9]=79N/-U:E9^SJ<QT7^A\;747XGO#SD/^*_+Y*WT000;)#;U5V:%9M%G$U-,GL;YP49H#$* M4*',R$T6#V,L=3.)>V86%^&V+[#$K$BS),Y;OS^-QS$P.8)4RIN[7&3Q/$I& M)GX/^98#GA1&:7$'?`TM`41RW7#;Z[0`8:T>\]_MY[X`/8#\LN3VKF@?\3Q-1^^228.Y7J:SVWO!>RYW7'4W17-X M;T<$+Y/H)IDD!<#>H(02=?-H2;R%:^#[;`&,M`!]4BT;SBH1F<7`^**Q:ATC MG["0V310@[>&%!ENJHNN6$RX\0[8A;9=-\1XL6P`!%1FB5"&_\&L;6]M]\T\ MRGHF6A3@A^0?@,=N#^*(_S6Y,#?H&>K9I"M8W!,)WJI_]%?M[\N:WKI_-/V= MP]X.U&7_\$`HL;^SWSO>.^YM[^R9),^)'&&$:F<3%09*MHBG-^`-IVEE%(2& M_=0*CAYX-I_'PR)Y&T\:\FXP&H%LTAG8AZRWF4.R*$[;$!<>0$=ZI"[W?"2*0KSE)7;_<>I'6XTFYXYM:AJP[L*\ZK:^C/5V>OH33/GYGS MB[/+P?4+#.A"V^Z#[=2&@KU4P=8B/M+18EB8'/JT00DX9H&/6"12J2<=NT<:QW??S;,7QW:#1_=?0PU"->[N& M)WZ>@>,-MAPWA<7YG%86X>`T3^/,EW$.,WFHAHQWIG";*Z)"I,$TRGX&)S?- MKZ<+@#S&858L\SR>X4@362@:39.96+Z4F^&&>GEX8<$-PG'5'=M$GVK]!+[@ M-#8;%@H-*_!U7+0*SJ=1G@SEK*-DLJ"Y"GM,1AJ<"P:6V*?"N>&QFE/?Q;1L MJ&C@J$:W<6UZOE+I=;/GR?FKB\NS[\Y>7[WX\.20V5!P9EH]--"K=L0'/5=VC!54R!U&70R MN/K./'MY_N?.RYW0`A]/TG>Y&6?IU%1D`S\V>=MAM96GS4V1@JN'*33.)*Z0 MC$^)<+'O%SE0!]7]H*5/8\`4VDNA`BA'4[@`R3_D@Q`VHEXW;R)N`)*B7:X3 M+;F&XT_NHMDMF+%^&#':A58]XZW![J6E6CD9X?*>?Q%^M<*.=8Z!MWDXFUQV M+RC#22%FU8&B2%N!V8L%)!K@":X:BV/V$*9.DPCD>6 M]A`N6F1"<=R]:!:K ML6L9320IX%04$S4$+?H0*(NPVJBQ5"L8VBX27OYL/(:Y+N3Q'J0"?C*,1QC] M-^B&-OH#W7L>8A0/$1L$),2X?^!$P0#=#MG*"R`TV/8I0D2S&?$)B$#U(`S6 MN!']^*XO7T.R\3J_'?>(^,Q(B(!`Y$(9UA]6=1\XP>$%3N-\F"5"/[R(LR;" M85:"$187Z00N$FBI6UT-9H5$C2[@7TXCQ,YFB/=LP!4QO_SS_U(I1;/E+__\ M+Y-F_,".Q@=@(1*Q`1EF`/VMH7L';P24.)>EAO%"O!F1V%C$%'=P&,>,-E+L MS)P1)#Q(%,-6(+-$D^0?LEX\&6\Z"RAFN`8^"YPDL8Z"+:P]J5Q5Q,.[63I) M;WEQ$D^1SNE6F=MX8I6(&[]EKG%1>TL#@6AF"$!GZ8+R\RB_ MX,V:?'$S7"!.'_.,O!PVPE*+?`BO.,-?/]')!G1+*"Q-OLSA-N*0=\F0%#Z< M+$:Q^3&YB=\K[6!C_N<"_Y/_@V[AMX^.MW;W'SU^\LT0@,R`.J`9X7M^DCU# MT%T'72=3@/AU_,Y?/Q_G7OUM[_D3LQ6_"&? M1T,< &'F=OXT=/S"C)YVG.V!/`#QL<4;9-Q+I@70.TB+BD%G9IEO<`&^9) M?OE?_PVF7>BD&?37)-X<9S&12RC+2*+`6UKPOPD*APR:5>.:=`:^9'01^)-X M9N'WCW_3K@3%[J.WT9& M^;ID1L2]88!J:/1E,0*K8PX'98*#O`HM[G^R86-?P^T[^C52@+:\I5@)3R2S.Q/ M;PFAS>L,TG+6R:O_]`I`,VEJ;.0FGMTB-"-&K+6BG"$G@>G*YQ1])7O`#K0V'9@`"FPD^LQ9 M/Q#`94X?_RZ>O&"81!,"E%08748S:;ZK/>5L,FNE]7SE0'-B*;D5:Q`6[3)!,8/;$"[(;)2,X`+US/GUY=E?WES`/@"F M`"F.@;**84E#6S67%A,X@QLH#@B'PY!`F@Y_3V/D>HHL?H^%(9ZI?!7GE$"^ M,GP5CY+-[^."1DE.T[@R]=2^VS+G,W,.LP39F(\?^GM:VU"#2S2;(8$ZQ+9< M/9KCV##VJ'JK&YD-_TATE)U%"17*:2(6GR'1*!1Q"J":@1>GA+U"D^+9Z8!Z M'XBP'V!#A.S:KU]Q.?X9A*5=WRHN!3^PG\I6N M2)0O-XN4YE?/,+@-6V^4\H^0+YQ"](_W\0,/F`#)0^!B)#M'(]CSEM1RT"&S MM)+#,ME=#`NL2)$H!@G>,6H!*D/$\RZ9C."FV$/IX'DZ66)4HC;Z3PLD*QE% M2T9)BK`)K')O#;)LR[:(1D439+ND"&*>(SV(R&O=(!*A\"[-)D@!P[XOH]`V M82P7\K#!C>CQD`@D/O*&%J6:BT`M`N+P$S1CIK8JF1'$73IIL6#3<@\EUDDT MBT9U025LQ-(-%#HLA0#"-;P388F2P(!6Q[<\*+86UP_;X)\J],C;@#AP"WOV M!D(&!H2C+$9+`R=HLL`$.B3^/9RTD1B$ M%4.0A36954G)MTDD!_B]D<75==V+MEI^R[R9DWOW]A%1LFB M$0,2QJ^;#Q65B689#(OH+:3[!FWU.,.)_HQZ1Q"@RDKG6N=?,Z@U@!TP^?AA M1PER1Q>>1-"Z=]2SS^.)%#^:W:_$>N"1?"WO0E7I^R4DVA(!39Z8,EK2O<)C MF`*#(9(:*:Z90B]9K70S@>6$O!OY\GSP5#7P=;6'"/S(DY^EO%1]Y:ZZ0'5< M9N-%[C-`P*8P`(%*N=1O5**$OM.+F?D^FBUH%*&*YW?D*F_PPJCA3"64^G6#'`!0R$48JB[J5*.& M5MJ=ID`BV)QFFS6PWD9Y.DWA=,`<%JU`OSA/F2O$!L*1T"`PG&#F;95QBM*% M:$90&5T:1\A;:LK)"0WGW5]44>4+YUN@9&`Q1QI;+4',>(7D0AS!CDL0'90_ M&G+XBL.C[:5S'Y8`J*Q:'X!?6 M"H$@Q!FJ;T'M*P.<,G?NQ2==A+CI`0W3;)Y*WN>.OE`Z1LF5^B<65N;4<\]X M)O"WM1"-0!'8@]7L@?+L'>#3DZCQ]XCIQ!`TMZQ!"9#[-^5KN99@=X^RM M00S,4R,10QLV'$3QS7219&)(6HM9M(![C/LC'9^#).F4PE\IZ\%R5R;F MVSV@B3DPH:8/ELM&J!ZSP>1;K3F!7,=&K.@#:#5!Q?V@T9#U1U*C7>'R_"A: MSV!)B7DGX$BFWGF2JH1?4<9L"K&=S"!0%I*OD(C$,RA8A,8V?Y!A`WI,<)/Z MV]R"XZ_*_+`,.'.)2=(B1J>4&$[#%.TP)#,Z4<"$#*N'3HM8'3"QK=00H`1M9,8 M[G\;!D6+\F",RE(P`!20-`C!D!PA!IAW\LHT-D@3\(B(.`R=\3(3G)VJFY_A MY-D"B@S2FP,A?7&C&3HO$$4M* MD;<""7!<5?C!C]W22F+>=W(:U$S(4<3/`YW:PB&JS'4AZSPI/51$+I33`HEQ7'GH-]=C;AZC3/CI6L"$`F65+TDM]S/YN;W=W M5[9M$-+.I^_:[_7A31_O[ZS8E6-V>@<[NS*&"&P'5.N],!/M-;W]W>WN'60, MZL^W#QJ<<,4JFJ"Z_IN@,4QK[E<4/?B+0&78(OUP&1D%H4&1U"BLN<:M';E# MO$+!P#\"^8>U:0WC54MXU+#1FAVD<2/PAT:YH`O290Q]XP(9E,4EQ@EKF43Y MQS^H^TGCLH02ORV*8ZR*![N=22XQE M`0K<`.J4-JV43U'\J)'+,@"U$R7/3]T&C0$\`3.08@YOS3 M".&+Q93E)&R.`(($[9A;]780>*Q.E^V!K/Y^V>S!';A@YS)<4,K)?"7CD1&% M,&-P,/E@1"5SG-MA/((@01/6")I2E!!W+C?64U)3"M$3''-;>N=N@*U!YVP[ ML_"%BG`[@V;+BC>5HZ(O*S'9W][^BM#@Y41(JX_D"+RB:4&T1]24UVZB*Z$# MUR!9(@%$:!>>%4USB*VK(!8T81\4H\!OI;1^"PN'\E,Y`)@;R"XMFEZ1*&1) M&;9[=-S;/=AU$(C>1LE$*DF(0GO(*Z^ZKP0"\`WHL%@U%_V)1$&ZN+7&KT,] MP#%#"8T%?2B$!@@T3@$EX-/A7.\/4TX*=YA*V1=Z4(4` MI_H6$/Z&0!`S"M2!]1#_("\VJNX^?OCX(3SP:R'YCQ_23=74W^%*SU53A!\[ MH#1J'C<.M]'6=;0?3OBZB3=D;]!TBIQD.':C?XPU#@_"SX/#MQ!<.,,>4U@' MHN(!,URW2:G&6E4LV5"%D1,-[T"T]2CRVO$1#`\TTI$'U@Z/T=F&/SB3U*\Y M29\'P$+L@9;A&KV$75]VL&G\I667O6T1IKK+SK&(]'(7L#^JQ\3-<$+(LED+ M*#IVOD]J0=ZT'&NGM]\_[!WO[HL,E4;5Q"BAR`L:'R(0L:\&SIW)>;$`(D0P@F:/*P]`GC7$;:SM6TMZI", MKH$PS%*)V5RP;OP[BG`JRA-Y]R-=0(FK2RI"W)^UG:V=0\5N?PLJH M`42Z>HH,V,^;5T,8K#"=K."F9N0`!C]=B,NN`T]K@:`G#4YQE,4SYD*%,,T- M*B'>;9DS!^2WZ02ZQ08VJ6K4K+2+(?#-V@UFN,J!HD:XX(FZ:F*8*2I%8:L) MV4!2B=9),H;GDU<;2=V)MQ/9"]:&&!TD&6VF4H@C;ETXKT3!",TS(^A* MLV393#CL2JR"06MI/LE8H2.1Q3(58^L-7#G.5#II1:?#MD+Q+_WI*@0$PT;K M>06)MKX9G\'=QL"\EB8AWLLUZ*[8$(S8OL"5FB`4$34+;S&W!)6B^Y9/($#1 M8@S,J815R%!ZM[>(_X&B:7WA*1"&ABB'^#^SU"WK=EDX>QE!`^_2-E2VFBEW M5:#:@\H&;ME[YN\TZ`Y^.AB;O?8>/P"R/P-J"*:C78%\2,M+9(=@@('V&FP@ MYCP$>6@A'VC[L>,`<9TF2;P0`+/9X":=`7YR`:S.ZFTG,+DSA]FB>MAZ=PF` M2T(!>$\[3A><#/W30.J!]H_?!Q[ZFRW2N2Y,(?WVCQN`)"^@ECET.%&-`261 M193W2#G"&X%T@N@H/5%)Z()JK`8@Q'S)0JS4M^4@16 MX%DBGB@(E[`GH`&KQ#JEV+Q.BGI]2S(MBOZH=^ALG)VC([%Q[L'\_2;.FC6: M^O(:`:F4E_\BQDPH+P<(&<)C5>+G+FVWM^QH;9('7V_+7+''57$'*)6D@'K%J/$Q+^I$14"?3!&,:G:FZD^B)3 MW5R,*5`KXT,83^EL8P_LZE9V*<00=,(461FYF@"$+T'L*VGT$>X[V"?:[S>( M*?%K-D@ME#-$4R]'*`LY:D2N@BTI$ M8PG(&NAQ?0_8DFD2`FY`13766G][K[>[HV'7M9VCWG'_X$&WIP&&9STF:@#3 M`W$I'0+?>>LD&4NS\$"K_-T5",.6KH%$I?/M&9UN017(=1:0J%Z8X0FAM;)= M3\D8V;ZR91(A;I^&<3#\N<1145,"2N=W#?$GE/].#`2IG1)5]HZ=C%)%Y5X$ MX1TUW^%DHL,I"1?ULA+_P6$P2!,`XB%06U@ZM1AN*)47]2I@'M*2CY/,*U5O M20!@$ZOG<1Q(7K">>T`(W!6(&Z83-,L$YJM"N4"7(UU@1DFR9@:H2?XY.I!! M.@G#62582ISZ`>!811G2%=5&GA(IW=^V%FE`J;HW%<;:'K,*3DGL'L*WQQ^6 M(BL/^+,=U,HU7ML!(Y4[]>%_'U4[_3;J0XRTND,A4@N'`L'Q?2;PU@Z3%_TC MAU./GCQ(49(MK-_[>3[W_L&!W)X*Y[,][IJ^__).]I%->JH^:+A]=7NJA0<(LCZ0&J0`V##0_= MH$`"KX=O`+$&I]9SJ[8,FNL9U8?843M@Q0XUWT-]\7`]+_?N7!TE"A?9 M(#Q]HU&_E1R(K4*WX76T)]PB\8E+XVB`TQ0M!1&3F&BP:+O:/`9^T&*XP$.* M$,?4_GI>!QZ*$P0Q-#=<-YAJ>M_*5#7""5.US(.;"HD@(@*WE44)D(R;T)3` MGB,RION!R8Z[LK:O8T8EO!D_\#-&:E]USO-B^M##@`&L#AQ?(@(`!7*^6#>0GI:BG:FF'YE#^=S!;17E2%J\X9Z958&ZV;864HI8!Q/ M)FK86"^1`5,+;M*YV*:5+>)$M]TAQ^.0,`\QD$S/ZX#3,0LNEO83X4_@"I`, MX\5N(1A--=9E"DA!UZ`<&CJV(HJ'5/A82F=AD[M)J\H&TD*_C_AM;&*1J\J2 M5Z&"WGQH!%G5O6HA3EX[U/?DN$\9RM;KM9.-BTU,(V2`+>X;`@]"!J42-Z!^ M0(3212$.+F;6#;,TQ^+4[7W44G,??)J*"K:GB0.$-5QXS#_X;8K*)HTOP++S M_&C\F^^BRM8E16V9U\@8VM@%E8)8MIY=U8$D?^%*UCI081UBDHT++"_Q!^OQ MZ"7,4$2TY&,O<`!L#19DZHTX?CBD%^UY`'::>7!!09W7'8&7P;>5>D^REI)V ME/!I*6*8!:0+)M'H1C;PHH+XQP]7E)T?/[QA*CY4TI>5%)9AX??/I_UH0;U51@5=DX,LPR8%0@$/_`!P85^:!\O*I*FG5KD"P+T1*XJ*GB*Z.01;84%P?7DC M4AXCC[CA7%Y(@SLN20-B$DZ]SO`B/X":#PU;Z\1"-0+?V>B;[I&TRG5WLX36 M:[DZ9\?B7)"##"#K8VWMA[4Q#!5D<]3&(94`W2\OO#$TUT((O"Z<)7E>G&3A ME]M1!;BC42C`0'9K0NGKJDAIU.45E8BC*!"4IQ?[#N*[+$2$ M'Q]K0(0JD.FHS7*6^&*@\N/>/M*S1RA)XEYP"0\/]GOPC6D=MQ";C&HF@E4^ M>]DY'"^G>80D`M'%D/=0YLH!L&]Y:@<3HJM!F]=,%7_\\$I*4C]^.&,Q1DB= MY2GY^&KXY6L&W'5Z^_OH&P>]W?UC5/H=AE,W=E&=MX?78(\;WZ"M^.BPWSLX M:#QLC>7V4,%TN-VH-=C`R[:M'^XVEM_>ZC>>P.3T1NV!?<9D"4S=BD5`'-KR M7N9.P2S/8_IPN9!;5F]JIM$$T-4EW'>U2?JBTT!X5,T4F)U!]SN1#/;`83 M6_:=?7<(:999/H+!B^^E:50%)HM&%G!WH?=RTJ_)'Z',E M?5'S@]PEK"D.DFT2"/&@[QR$GYZ#>1JOGON'MU`P!1[6;U@B+\JF=1^N^8+A M]98G33W@.>"&Y[G"DX[P<_$(`*RV!605.AY4IJ.OG\33W_Z**3R\8J@I!HGX MV&=2!:ZK@(G6TW##9_H23_CQ8&B;$;4'L5&<]!)4Q#CDH&R$#E>P0#276IHA M>.^F_+*S+NSS:6P4[@.#YS?L_F.'HSN;5(NJ8:OEK.X+]4PH9]W#8O2G2U:6 M>$O0:;G[E>,OQA.&"!'/01*TBF!T-7H%R_2U=38109*WM>`^+^905B`6FYJ` M<&"8Q;[*2R[/^5ZLC=CBS2R8Q)0J92:#0_#>6S0!9X*\,O<>;Y5><1P@"S6. M][32AC71A7R\?Q)Z@G1"W,OM&N!QAY=#,(O:.&#I],%J="7&H'!'\.C*DERV M&)1;>![,OB;\D&DNTDVA2Q]>W3:O5H`U4Y3!@DO`!\863(YQ,B[8X"W1`BNW M"+FJ^9:H=T`#J_)/N'\)RDDH^R0)A77X,3H>)'HG7Q,IM(%4U3LUX-W;71J3 MU_;V$.7>/R8ZN%`53^?+*=#A+:;%#@>'T0`?`PW@NR;GJC_D8@Q'+3,/84I7 M9,AX'EYGYRG=G9![I/!`Z"0U=D4$7+>$3TY`)0OPD?DNQB-_=VA&0'63>\^8 MLEZ5(M[SA&:J*4(@T7N0#TM;^H-5Q.H4:RZ)VR%-SM1#_O,3-*&HB#+XZWAJ MPS6;P8S42TO-%`X]7B`,(;5K)-L:8=O&)G[O>OX])L!O,?B]FYK`\*6&$HBE M#4=!%L,5S.Q;.:7BK[<+NW@%BNDVJZC/:X6ZA(0]'3?PD1Y)BC@^$/];<4/HGAV?%*TY#.B4H[MK'B00%+T%KL MP^2$1Z6>#/9J,Q$>EAJODHO:^-22;,,8=,:$$QLD"URWU)9*]Z4IT:;A%W#A MFH($TE)B^!K^\YE9V85RN=*=4D3ASF*=Q5)A2PD>A920E)Q0GIFI22Z14!UO M)_@:O0([7N_($;+%07&!4L=;'YMO$X&0:Y(R`)Z\5/7&5K(!!=5M?(%:,FNI MULD[3A34I`[CUNCA0]LYPJ7V06[A4^=/4"Y8)D/('"XMZSA45M$E*;;51)">RJ,)($UA/3C8^M\]<*,7\'IY8 MA/FON!#Q6P9-0%P.^"H[U:,KY6UI[ZEQT?B\LO:((B\N3&KP.];%2H7S1Y$" MVN:;7=3B>(I^>H.2H"X-UBUB@B\^P6*M"5__ M>KXIC.`:XDM[1T=M]JV3%,(5@7-4RC_E*%ZG`==/.N_N@\[;[^VB>>,8A5_` M3&B/U\XK4"ZE*`Q1^SR/LKC'96KR8SG>0#N(!.9ES<5#I8@(*0_TLN96@5=9L7#/+U.QJNJJZS&2>;0'DV:B- MEN'B`Z]3X8U]4HO9&2/)&;P"PQ9S%3LXO,VT&,GLM$0R\9.2>&I/;%\$XZ$D MM?Y53R+>Q0#18'A]U&ZU\]D5;1?F)U:*0'Z5>^62[%_0DY%"!>A6^!#-:@$= MYXHO$&*4UETX,O"-B.85U1YA?,T1AG37T29JSZLU\Q2=6'Q:AIM/;8C_I4MP MT+"#<)-,6(C,:YS[R\>P/R-(VWDQCSPOV66P0'P=UMJ)#<4ACZ,AS/!F'?,< MQ[;]+*\#P**?MS_>;3;R?J>4)T-_>SYV: MC5.\*)I,&C$^/GX6+OY,'SAJL*D[=3C^`K8]3,3P8_^,Y^/*P>\.$&K*E0(* MV3;I4RW#H^'BWE#=G59JRQ-PW?-:'H'K'HS'F-@:M2S#VXT4`+E%0M,7X'1` M0_V=>_'1]3M?$K,&);K'-[Q'.\S?7DD;3^,78U_91O&N[]$Z5DI&3[P"W,C^ M1/(R$Y^W6;`O'?SP*OH)%M4)-#I_5Y18J0YA_O:2.:$7_"V`QCF\8>[Y#;'H M0O"N[VB`+?QX]$4:8U/5)>#O7H=@@7.6F\>N(M@JU\&?3F(AO&S5F9*)\0V'`H@%]%8B$X(^[T.IX(RIT)17XLX;^ MZE*24*V>,V=I3^$,:U&:^'W*[A,D_GHE0#A';@N3XFVCG=]KJ9^C`BR<^.:+M,ZJE1&NW6A(5!^+ MD6KM*P`L;OS&VG"!=5?3&W[16'E<>UI$<)IK5TR+A:9%!70'2\;!KWQ7/2[K ML-'##A>D0]C#4N^_"(]EJ5,CO#2@RM+]SUZR+$!Q^&^DSJ'_O1^DLH4&);DT MAML%25*X$U M;.%)1`"Y;B=7TAX.HM8RU\RV(.(/!F*3*8`$!IQVG@FA1O>`0NG]!W9QN,TZ M'G.3!$WXA1[2N0E=VA"^@981EF4P9=]NG9CO.<9IK8'2RH&N3>5K&XAQPJ[> MEJ:<[`HC.[9M5OG0/.? M8M%\*FTX3#H)KOX1-:B2"D2#I;*YI3+7.*3R+H3>^FX[W;RR0J?K7NO]?OM$ M`4=3+?O&OZ@@O4CI!I=&>9<1Z*_K'CMZC7JG%=4EY8,BX#W[@HAZT3UT^FL1 M=D-@=,[Q?_X=\^6MAA"8W9/M?@P1=$TNU8A]H`6%!/:!%3A&E4`06>(]$=*U MW/J!XL?LV584@ZC@*%HVC/5/V?3\N? MH7N*S#UH/`1]XQ;!:L\UGO"IT]PJ#3JY;[_.5U_NF]B"6O.9=V[!5M=2E0MI MA7;M&"7T0_`UIG6`N3&N$ZZ-D9V`;(RL';F=01MS6D`4WM$7/.YGYQE;^#5Q MNE+:A9LYKFU\;KDJ_-P[W#J>SL;S\"'V$U2IT)UA93M<]:7!FSP,Y/8[C8!?M>S.%USV>R9Z[:/V M7W!9`F$'=>@2S>[2X>V445E.#S11/@/\0K8(+;?T,$B(06/=<`:&9^3#?MDT-BFAL;%RJ!LHVLA'/IYQ_3UM!EJ,K, M4`@$:GS4=C1Z%SHM'_MCC4X>A>MI9JCKVR\*;O07<1H>TWZ?S>U:ALV,:3SH&NF'10=J#0"UV= MX>YRS?HK.XS07K)EW*\[A)10]H"`X,J^"Q)=XWR=-W%7+F=@-BBAJSRV'4%9O] M#@PF*XY7"OFJFM5(Q[G>?'D_PL` M``#__P,`4$L#!!0`!@`(````(0"*@.XM+@L``"I?```-````>&POVD:J5N53G&)&[\ MH+:9(5OU?^\YUZ]S`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`!B/ M1I/18&J8\#^KD:='()O3D:[:JP2!(J\2!(J\RB9N/0F5/\\46,-2G*L$@2*O M$@2*O#J67(%AD4^Q5PD"15XE"!1YE0VS)>8JK`TK]BI!H,BK!($BKTH;?.85 M>*K\\O^#>-UO#O4Y2FL`UU>[/T[.S) MS?3TQ7->01DWY<[P9BI.I:&L1":.\,VQV1^;(^,JFT1)4AVX2V\3[%M7ZCX8 M*T`C0RVL`>\:Z#+6O2[[.96.=X.2R0`#\0,:UM]OEL M;7*`T=8VHIP6Y$%]VP?IGQ@,>A\J`&%]"@;L(C$P%,^0L$X`05"/#X5LX!A*<*!#"5 M*A!`@%8(`$Y#5!R3!P-2S2`&*I6@_U0JH<845G(J3VAE7?D%_0U66ESY/8IF M4F\AT"N:X4,#@*-4UI58526&N!TRK:(`/C108$&O*Z?+&]35?&6$D*(+&"I& MH`PT,2(O*DG-!9T5@&9&YA+'(20HL!2IA@!PE$`@CH!3*NHQ*.J!:30HZH(I M!*X//F-.T&C@>DA%&`"/DJRHQ@D#KL]$\FSUE,T?P!9M+D:DT MWC!G%VNGVDL4>[_`)!-OG'-@,=6-=;S1,O4<>N5;;*\?W2U,1;-]I^VJ?JT7 MD!3K&[O!R".LQ53IA\5U7>NB7#H_1V`YGHA6R]FDOG5A?BGRF*VGL!I!@2H M.N5DD5UIN`YW)X=-R6*QY5RYB:WAW1E9O8"DZ#4-5FBXG`)W:]Z0SK,#EL-= M.!_1[V"6G7#I..`B^?8N`AO*5@="5)LN)>'H0*.U]RJ#G#W#8#_(:P*K&:A( M7-7V$13^D9'4C))W]CGPO"NR98Y5VKP-A*WRP270+I30V&^I"B+]X3O&64N2;`L%-DW($73^`'JY MQ:+AZ5R,#G`+;>-Y\/-I;AW@MM?SB:!>ZCFV<5\PZ)) M5CG\PJ$&E06UI*NLLH\S<$N4X()9_.0']G1#L(7F"R"B\JJ_`C,$1OAB4V=955^!,=166!R M5UR5'P$AD66"DJZR*C^"%Z@L"+>NLDH_FEAW*NY'@MQ?'?0C'ZNX#RN"B\JJ M_,C'ZE`P5JFLRH]\K*+)77%5?@2IA"\3ON@JJ_(C7R=,P3I!;:S\R',_$N1^ MMZ+R$6\(1GPFI?(=O",2:G\Q<>W*1C?F93*4R"/ M6&3"%^(6E3X:\NR:@NS.[651=?F`P7Y&!`8\8!`CQB$ MI\J$)+VXSJNV@-O&2D%\/F`W*B+H?KOV[=!.H_A-P[,%I3C>Z2-!<7^,HI(C M7H(!'T4`_0F>^@P/E-:`EXPA/H9Q7[F+F#(7>'H&@AXKT$#K#`T??SAN[((& M6F=B^***XR<1,9_"]:;T$%]+L>L6$?'9"U_=)1\Y/,,X41*1].!NTM@NXX]/ M*4.0F`>\V;"4P9>(["&,Q9V1^?CS`>XM+$C$^3?)'1Q#BP#_RR8E-+(3_U6_ MBYN'(D(>O13N"2^2F,IQ2Q4U$$9?S-CD/,%BYU=V*TQJ+J]!2, M_I?;ZL93QGN*ST5GMZ26\P&@=^FN[(V?/I9?SO3J_9_9TQ8@F/)?_>A]C5(F M8J97[S_C8RP@BV%J#.7FG!N9UXL.CW./W_`0``__\#`%!+`P04``8`"````"$` M^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H96UE,2YX;6SL64]OVS84OP_8 M=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B0-))?1O:XX`!P[IAEP&[[3!L M*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7UVH.(H4,B).5Q MVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ)!%!L#Z6 MF[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK59B7"-/90C",@ M>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<)=(A9VP,^8WXT M)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1+(#LXS+M;K51K;OX`OWU M)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P] M?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[QR7P;8%'1?B0 M1D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF9;@.<8UW5T#Q M*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F8E;$'6!\6,:[ MBV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8=8_Z@DL^4>@> M11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<],9&R;,UM`?H6G'X#0[TJ M=?L>FT1.[P:3?$45*&'=`X+&(_D%,(48SVN2J#[W$W0_0[ M^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5!DJZ4ZDC&O]= MV684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;UKD*_J]#>6U^A M5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C\S210*:D`XD2+N&\:(9+:6L\]/[* MGC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D1$&WUV%6TT*= MF5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K..YB1L;:[]5'F M%N.%BW21#/&8I#[2>B_[J&:+T5';:S76&A[R<=+V)G!4ALZ%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q/M8>\.%V6&"D M,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY2\.D-9PDU0$- MD*"P'ZE0$+(/994FRE)")J(*X,K%BC\@A84-=`YMZ;_=0"*%N MJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV#4UF_US$O#U8 M[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO-3+AP(O+&L-@ MWA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY(%T@[.(+&R0[: M8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4:.[6P8VL[MM+4 MX-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:CP,``%,,```8````>&PO=V]R M:W-H965T&ULE)==;^HX$(;O5]K_$/F^)`Y?IXA0E53=/=*N MM#J?UR8Q8#6)L[8I[;\_,S&$V($JYP9(\OJ=QV./,RP?WLHB>.5*"UDEA(XB M$O`JD[FH=@GY_NWY[A,)M&%5S@I9\82\5G_^L3Q*]:+WG)L`'"J=D+TQ M]2(,=;;G)=,C6?,*GFRE*IF!2[4+=:TXRYM!91'&430+2R8J8AT6:HB'W&Y% MQI]D=BAY9:R)X@4SP*_WHM9GMS(;8E/9:#J/QA3D MP89K\RS0D@3901M9_K0B>K*R)O')!+Z/]GD\'CP8E`T!?)\&TW@H06AGTR3J MB1FV6BIY#&";`J^N&6YZN@#CZ]F`-*#V$<4)F<-Z)43#DKRNHF7X"DG/3HJU M5Z,:-O;A]Q;A5.""0A2X([I,Q M;-&/,X.#0->9]Z1UMX16,>DHIJXB_4CA$())E_!C,A0G!&;?KLC,C;NVBB[9 MW%6D?<6%W2AA.AF*7[),;=VT57;)[5Y'V%3?(9K]#AF*7C/H;W4JF31%, MZ'3BI\P^[Z+?`(-J&IXR%'M@7GVMK:0;F/JET)?<8,,7YN##`<4>VZ7";`U8 MB3$\<8W:H_.VT_JD M&&I/;*[1PCUZG!]TG3Y8J]DTBN:6WQX6`_GLT=[ER_V MJX):C'S*X/V#__8+XTKFEM\,,\NW[!W&+1L?I7$ MEP"V2DZ:;AX]"79^:#-KCD8:SV=T/(DN<[&%8ELVVXF47.UXRHM"!YD\8`M& M86Q[M^TI3\U>^P"ZLYKM^+],[42E@X)O86@TFL,[0=G^SEX863=]SD8:Z,N: MGWMHWCGT#=$(Q%LIS?D"NY+V[\#J%P```/__`P!02P,$%``&``@````A`$DE M2$C6`@``T@<``!D```!X;"]W;W)K&ULE%5=;]L@ M%'V?M/^`>(\_ZZ2)XE1)NFZ5-FF:]O%,,+91C;&`-.V_W\7$;NRT798'Q\#A M<.ZYE^OES9.HT"-3FLLZQ:$78,1J*C->%RG^]?-N:,[-D$OH1-$/>R;"96B M`8H=K[AY;DDQ$G1Q7]12D5T%<3^%5X1VW.W@C%YPJJ26N?&`SG="SV.>^W,? MF%;+C$,$UG:D6)[B=;C8SK"_6K;^_.;LH$_>D2[EX;/BV5=>,S`;TF03L)/R MP4+O,SL%F_VSW7=M`KXKE+&<["OS0QZ^,%Z4!K*=0$`VKD7V?,LT!4.!QHL2 MRT1E!0+@B02WE0&&D*?V_\`S4Z8XGGK)+(A#@*,=T^:.6TJ,Z%X;*?XX4'BD MSI?\(GM(C9G.."8>(;8>PJ0!YO4:( M_%3CZZYW4BS82K%9L-HV;@*X>VW1Z-QSQ/2ZAPR4@$.7*[%@Y M.L$D_<'P%WZ:Q".I_[%A MH!SNP.7*+7BL?.RJPQR5!Q["E$@?"ID-AW>5XOP#MIK'`EW)R->DP MX%=O?QR.,-O7,/,^CH%.N'B7&VC!8WTOO$Z?PW0&]H>ZBGQCT2ER/=2U&,%4 MP;:LJC2B#/(IG)-V0V,;-K&MI,&FFG[6L*WDT$W"#P`YU*:;F![3?\U7OT%``#__P,` M4$L#!!0`!@`(````(0`.[V5H:0@```8P```9````>&PO=V]R:W-H965T\653GXF2_>:[J8][:'^N797.NBWS?#3H>EL%J M%2^/>7F:0X2[>DJ,ZOFYW!6ZVKT=BU,+0>KBD+=V_LUK>6XNT8Z[*>&.>?WM M[?S+KCJ>;8BG\E"V/[N@\]EQ=_?;RZFJ\Z>#U?U#1?GN$KO[81#^6.[JJJF> MVX4-MX2)#C5OE]NEC?1XOR^M`K?LL[IX?IA_47#D8_;7+P+_KV;YXSM\.[7^J M]W\6Y(F1)S)#H!4%R0BS'I2GZ ML``OLMP@6VI]%7&()YD"$_68-28RD=`B83@"Z;03Z:=MFDXWZ&%N%_.6K3C" M*E)@XJXVU7K5_<%(!HC]^QJ&+(66@Q@N"%)JLT>5AK8Q\87J!E&E9)(I,(R, M3"0T$'ZUQA;+<#&0SACKY/4YF.J+<9I28#A](J$]L89RP!2$D%N/&T15DOZ8`I-T.5C' ML2TSG(@,`$ZE%,)P(9#*[5"EO!W=(*IRBT6DP#`B,I'00R+8D,4R0^;6&)!2 M9;L,3:@LM1M%M&[(89QZB!,K(]HCVZXPHL6*7,6@[T/KN*XKCG4Z:_#IPE5@ M*-!ALB'G=NHA5B?$81#MH_AMOE)K:7@/K!2,H54`<3( MR&1$>^1RGD1A0':)0420;-6MZ^.D.B?1D\H?)PI\!Y9(G8&'6(F*"*MU5H*HG6`0P(#@W)+VD"J`?`-914//APB5!`EUA1H1T<;=G5P-0+<: M!A'A9F.?EET)I#0@5H@_33J:--KD%KF[=NHAKU`%L2+UG7F"R;@6@Q@V"-8X M8H/D;`8C-B@A)UKJ(49))B-:1@R+8+6V_FCMRG'*W4X(3($!%LW?/`ZPD!)RHBMHD]0@AA$&&=<)_`2HE' MFIC7$:_4>SKL3QN`_&FSMH:\=T_1(5D@VBGM$2:*8:-@M2->:4)>P<"@O,:# MO(HN)PM$1(\@P9J8;#,"?=2;_I);"D;<4G*[@L\N0,R6S'P@?L%^QNC M@52XRN5^HN=045Y=#OO[E3]K.IKV8'J_YB%F\IF,:!DQ+()5CK@EV3^$X)9X MI^\A5BW$81`M1S$L@M4ZO_+I'ARZ422W@Q[LH:A[B$=:9^:_A(:CPG[GA.Z+ M@,1Z?-R=#?H^2.Q-PHW`"HE#FG;*A&-.B>R;U$-,LC(9T3)B/`*KY1Z3?Z35 M3N4O9-.-HMFD3C\$B-4J(EJ.8CQR:5;KVQ&`TTJLDM",P/V@PR4AMV5I*%LD M&=$R8E@$JQRQ2!.:$;@?H1D!Q"941'0H(H9%L-H1F^0:MY#;$9N4W*H&#M)0 M]$"9C.@KXMYON.W![A+&?PF;-$2&$JLD]DA0-V*+MN32:2AZGDQ&M(P8%L$J M1TS1A,H%)R)4KFR*0A'1,F)8!*F-B#6:=LATHVCCI97K(?@E:33R.U(/,!M9 MHQB;X6EKV!A8Z8@]DO=H!+8&]=\M/6(\Q`C)9$3+B&$1K';$'LE5'($]XJO8 M0ZQ:B,,@6HYB6`2K=:;GTV8PC6\?7PLZI4']ZKQ]0W^Q_\#``#_ M_P,`4$L#!!0`!@`(````(0"Z'6@'(Q@``-2(```8````>&PO=V]R:W-H965T M&ULK)U9<]NXTH;OOZKO/[A\?VQK\Z)*/KWYN7TOY_^__\^ M_-H^__[R?;-Y/2$+3R\?3[^_OOX?SYN[+KM+CC_/NQ<7E^>/=P]-I96'X_!X;VZ]?'^XWX^W]'X^;I]?* MR//FQ]TK^?_R_>'G"UM[O'^/N<>[Y]__^/F?^^WC3S+QV\./A]>_=T9/3Q[O MA\&WI^WSW6\_Z+K_ZO3O[MGV[C]@_O'A_GG[LOWZ>D;FSBM'\9IOSF_.R=*G M#U\>Z`I4MY\\;[Y^//W<&:X'5Z?GGS[L.FC^L/GU4OO]Y.7[]I?W_/`E?GC: M4&_3.*D1^&V[_5U)@R\*4>5SJ.WN1B!_/OFR^7KWQX_7'U1H4(_<_;7[^>OAR^MW^NWF MK'L]Z`PN27_RV^;EU7U0-D]/[O]X>=T^+K1*VZJL=+45JJ&M]"[/!E<7O8XR MTE+Q4E>DG]Q\[^QZ,.A?7E^UU[S2-2F0=O*]?.WVN:\;D MG3W;X3%1OW"S[XN##@UCU<=F6-[9:I>'1_UR7*MJX'>MJE^XZCO[JB,$NWRCJEW>U=E[=Z+MY8WSW>O?IP_/VUPE-QG2I+S_O MU-3>&2IK/&-4=^E^#CDTA=#GY\ZO=Z'\S]IKKK7 MFML&C:T8L4)-3,KL6`)'`E<"3P)?@D""4()(@EB"1()4@DR"7()"@E*"B013 M"682S"582+"48"7!N@;.*4SVL4(Q_F_$BC*C8H5'^9:!"9ZN"`Q6<)6Q!(X$ MK@2>!+X$@02A!)$$L02)!*D$F02Y!(4$I003":82S"282["08"G!2H)U#5B! M0<^5?R,PE)F/I_1O;1+IVY%P6VG4(VTO&MB2T5ZRCQ8@#A`7B`?$!Q(`"8%$ M0&(@"9`42`8D!U(`*8%,@$R!S(#,@2R`+(&L@*SKQ`HB>G#^&T&DS-##C'[L M`P0?15I$ONQ%,HKVDGT4`7&`N$`\(#Z0`$@()`(2`TF`I$`R(#F0`D@)9`)D M"F0&9`YD`60)9`5D72=6%-$:RHJBYIT/+UN4>A4VG9$$_JQ#]%.[U),=7L1^S\&X@!Q@7A`?"`!D!!(!"0& MD@!)@61`]$^-H`X0%P@'A`?2``D!!(!B8$D0%(@&9`<2`&D!#(!,@4R`S('L@"R M!+("LJX3*S94*DYNR+J#,QKK([=DRI`=-IK887,MPF8OVH<-$`>("\0#X@,) M@(1`(B`QD`1("B0#D@,I@)1`)D"F0&9`YD`60)9`5D#6=6*%#25*K+!I?^XI MM1T;FMBQ<2-B8R_:QP80!X@+Q`/B`PF`A$`B(#&0!$@*)`.2`RF`E$`F0*9` M9D#F0!9`ED!60-9U8L6&2EE:P5$E>B)$J740[+IX5;E6>6\TOG3T:(1HCRQ4RN6(L:@R--985*A7OU_WJ+9^[%_8D_U8'330(/;JF^1.OV.K M'*/BT7<9F18]1#XCV[S8<05&Q>9#1L9\9%#+!<6L:FTQ,2IN,65D6LP,:FDQ M9Y75XD!T=&%4W&+):->B'1!DZYB`4'(Q@5?("@A`8Y5AP]$7>5G'J-AUEY'I M+`^1SXA:,5N8ODCV!4;%YD-&QGR$*&;4:CXQ*C:?,C+F,T0Y(\O\0-P:A5&Q M^9)1P[BJC,81-[I.@-0GW0I9XPIHK!)CU;BR4PXBEY'I!@^1S\CJAK[)A^S. M<`*CXA9#1L9\A"AF9)L7V]S$J-A\RLB8SQ#EC"SS`Q'AA5&Q^9)1PR#2@NJ8 M051R<7-6R!I$0&-UI"\'$9#+*M,-'B*?D=4-?9%H"HR*NR%D9,Q'B&)&MGFQ MZ4R,BLVGC(SY#%'.J+=?:12(2D8-(Z9R-/7;KK8T?OW^I0CU*>?.M-3OQLK9`TDH'%'(U/10>0R,EWA(?(9&5L!HI"1L14ABAG19%&; MGL5V,#$J,VIPC1FK3(LY(^-J@:ADU#!J*GM2'[6&T:&/FNR'1R=;3'.WZC,) MZM:C_;2YP(%8?8Q813LKH\*%DK9ULX]!1U>DSR"HHW#Z%$I_<"D>#RYK*+@. M&_>,"]S'/J*`;75W[77.^F*H0A:T-A89RRTNQ4;%+B6(4D2902WF\"V?:YH=EX!-Z?NAS\_]<\N1""&7*>UL8A5K9<;&Q6[ ME"!*$64&M5QQ;E1LOD!46LB.#94C.2(V=$JE'AL54A^5,2,S$&N>44=7I!]& MA1/'7L57X^B*ZN-$IN)`/(U=5EEC,1`K(\\XP>9]1`';JJ:.B[,KL0(*66`U M)J\E,I9KCDM5;%3L4H(H1909U&(^-RHV7VBD9^)N[^J&/DYH[V%+UARZ0BN$ MU.?*K!#Z1RN&G15[Z:>1F'7$2FG$%0_Y6GUNRJBX(QPV3^O$6F2)YX3+%>WX MDY'%*C/+^(@"TZ*:>'KX4.(Z5F,R9B)6M5YQ;%1\Q0FB%%%F4*U?I!.Y4;'Y M`E%I(3MJR'LK:MI7+%TE%^%1H:[YW-1(JPBUN#YFU;59GB!R&1GS'B(?48`H M1!09U.)J;%32D6!2/U4*"*W?:'BE;1G,87Z7!%LQK%%0=K6N\RCU7&N(_M!:SBU:B8PT(N M;VTK8E7KY<;8?,(5J^8OS\1TGW)Y:_,9JUJ;S['Y@BM6O=VYHL^]7UZ*!4+) MHD,^V'%'"]'6N)MN?U)`-6Y2:]L@]621@5//`=75'O8BZ[ MO7Y'SE@N&Z>)Z[!QCU7FT>,S,NT%&NWBF3Y=?M:#647[V-I8Q)9;KS=FE6D_ ML=L?G(DU4;QL[EYLWDJN=\@'._!4QK`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`4:D1;5+G*I=/U?Z/# ME!41.QK5.VR/:EV!'5:I>M5A6_>B(YYJSLYEVI6;Q9"K475]NUR*A\@W%54V MG2R+959@!#P*H67&#C694GKC]L+4D?IDK70D/DN4:LHLG9J+#7M"V3 M5G1T1:3N-NI9%?:FSRY%!XRTZHWC9Z/B#G`THKVCZMG+[ID8,Y?K4"C7 MVH>NU8Z;Z=7GB@8%HC%Y],PU#C5E]ZQ*!1S1LU7FH+ZGI;NN(69%(FG$JC=B M5MNJQVR%=,R*#G.U676\8+I5W@J>:9P'S$<4L*TJ8L4`AEQZJ"6[5X_+%/0P M4Z"1B%>1FQIQQ4-.50>71L67[VBDXU4VTBT^>*!@6M+85< MX5!+=J\>M[?NX=Z:$7ENPN5*7/[(J+B_QH@<1"XB#Y&/*$`4(HH0Q8@21"FB M#%&.J$!4(IH@FB*:(9HC6B!:(EHA6EO(#ANUYSUBBM-;Y/K#8[]KKH>-F'=' MO;W*A`T@!U4N(@^1CRA`%"**$,6($D0IH@Q1CJA`5"*:()HBFB&:(UH@6B): M(5I;R`X;M?<](FRJK;+U9-2(GF"UV48L,4>]O)S&RPT;L M>49&M0\;1`XB%Y&'R$<4(`H118AB1`FB%%&&*$=4("H131!-$&L*E0[41[I%4U-$;D('(1>8A\1`&B M$%&$*$:4($H198AR1`6B$M$$T131#-$2(IN5C(:&3G;V06M[]7F;`!Y*#*1>0A\A$%B$)$$:(8 M48(H190ARA$5B$I$$T131#-$1A\A'%"`*$46(8D0)HA11ABA'5"`J M$4T031'-$,T1+1`M$:T0K2UDQXC*V=9CI#:EO/]S)GV=^:V'CD:UCTVPBN8B M\\R2IYYCK5+'P49U)8X0':/BVC\UMFHJ^4VS,Z-B[^>(%HB6B%:(UAHU M?,9G<%R2>B>W5^(:J>,3$US7\DB,590/,BK966-64:#75,*68U3<6:Y&E`-C MY!E4MR5.>'UCJZ:Z%B=9'!M5LR6N,665=X[5(ZB=&Q2VF&M6N M,3.HI<7_>4U.ROBCJF2\'3'L!:7ELF:KDLH5NC%NU"Y1G;+2J_474MI6A$'V[:W9Z="_DE+%C5ZL&R487W9'5;Z,^J M=L]NQ'IBS68.N63?D\>=70WP[$HC?F1V+F[$,V3$E=YX9&K3M0\[ZXK\R.Q= M777$\L-E26O/>N_RP&]4R?X/N,5J3NR?=<7EABQH=2EJ;$S.)+%1<5`F;-X: M7CE1I:QJ=2(SYFN3GG0B-RIVHF#SK4Z4K&IU8F+,MS@Q-2IV8L;F^5M0KJ]Z M8O$[9TFK!PMCN\6#9:-*AL>*6SP4'FL6''+)OCWI<73,BE;)Q3ZK0OM')GV% MAOUG+J.!KG3((?W(W*NX_QU=D;X1HEK1#CK7<'OJ6E:+%C5ZL&R424[9<5.'>J4 M-9LYY))]I\ICV3?VGGCT.M"(?M16H")!/3(J[MTQ(@>1B\A#Y",*$(6((D0Q MH@11BBA#E",J$)6()HBFB&:(YH@6B):(5HC6%K+#1AZ]OA$V>-Y*[_K>S?DT MTYJPN1'KU)%1F;#95V3DH,I%Y"'R$06(0D01HAA1@BA%E"'*$16(2D031%-$ M,T1S1`M$2T0K1.HU[GIH:82JL*E>RUZ]7OEQ\_QM,]K\^/%R?F@5>]WG`1M]0C M31U"9RU#E9S&RZ8CEZ'*46,)';,,U2%*4TF'2IKJT`G+4&6IL0X=M`Q5LAI+ MZ&!KJ'+\6$*'64-U5-54TJ&2ICITCC5467ZL0\=90Y7LQQ(ZPAJJ`ZJFD@Z5 M--6AD]>A.@O%.K=D[;:QSHA*U%D,UJ&CR:$Z>&PJZ5!)4QTZE1RJTQBL0X>3 M0W4H@R5T(#E4QXU-)1TJ::I#9Y%#=2R#=>A--T/U1?]8,NZ1-?J;XJ:2[E!] MCP*6T)*H$E]`JFH7K!4E-)CTJ: MO*;7P%!)D]?T;A$J:?*:WE]!)4T>T,NIANI]&N@!O:-JJ%ZK@27TJJJA>A%5 M4TF/2IJ\]LEK]>:;ICH#*FGRFM[@025-'MR2![>-)2,J&366T/N[ANKM7.@! MO=N)2IJ\IK<#44F3U_3*&2II\IK>84(E.Z_/]X']\NG#S[MOF^3N^=O#T\O) MC\U76@#1EWC0.OCYX9OZN%'UGU?]Q;6_;5]?MX^4'#D]^;ZY^[)Y5@(2?]UN M7_D_="'GO[;/O[]\WVQ>/_U/`````/__`P!02P,$%``&``@````A`*-R6B0- M`P``"PD``!@```!X;"]W;W)K'6X&2K5NH+E^'X^/C, MV,/Z^JDJK4A^3W[]NKY;$4IK6&2U%S6+RS!2YWGS^ MM#X*^:`*QK0%#+6*2:%U$SF.2@M6466+AM7P)1>RHAI>Y=Y1C60T:P=5I>.[ M;NA4E->D8XCD6SA$GO.4W8CT4+%:=R22E52#?E7P1@UL5?H6NHK*AT-SE8JJ M`8I[7G+]W)(2JTJCNWTM)+TO8=U/WIRF`W?[;94(8Y?),^^\9J!V9`F3,"] M$`\(OKXE@98`A]:N]'GNDB)O["7@;!/%PN@.:>*7W+D9-8Z4%I4?WM M4%[/U;'X/0O<>Y;`]I>!%X0PZ6L#9_U`N/<#9Z$=+-R9=WF@T\EOW;BAFF[6 M4APMJ##0IQJ*]>I%0#;8T&D>C?F?+V`(DFR1)28+8L&*%>3R<>/YJ[7S"`E( M>\SN`F:*2`8$Y@WDC1K!G0_0B"RH$7.)HG=#X$6T;P@:$*8@,.H#!"%+3.!Z M8MILJF#78;Q34#"%)"/$5#G_$)7(`L4!MQ.99FY[T&LR1X@I$PK]U,S+&W`H M-`2W:L8L]A&WK3HS@>/'R^(G519.=>!.\,.%C;OYG;L!F:8B^PA0O9@X4";/LN^%SO@!>E%#]^P[E7M> M*ZMD.2S=;:M5=MVL>]&B`<^A(0D-3:A]+."G@\$!Z-I@?"Z$'E[0X/$W9O,/ M``#__P,`4$L#!!0`!@`(````(0!TX))F3`,``(P*```8````>&PO=V]R:W-H M965T&ULK);;;J,P$(;O5]IW0+XOIY`3"JD2JNY6VI56JSU< M.V""5<#(=IKV[7>&4X.3K1JI-R$,XY_/O\>,5[?/96$],:FXJ"+BV2ZQ6)6( ME%?[B/S^=7^S();2M$II(2H6D1>FR.WZ\Z?54O0<522 MLY(J6]2L@B>9D"75<"OWCJHEHVDSJ"PJ5RN3]\B55#X>ZIM$E#5(['C!]4LC2JPR"1_VE9!T5\"\ MG[V`)KUVSWGI+!U06J]2#C-`VRW)LHALO##V7.*L M5XU!?S@[JI/_ELK%\8ODZ3=>,7`;U@E78"?$(Z8^I!B"P<[9Z/MF!7Y(*V49 M/13ZISA^97R?:UCN*`HR-C^%)4240``_%HEQ](`1^AS?V8CH-9HLYR.R8TO<<-8F5')06Y=\VR^NT6A6_4X%KIQ+8T[D[\>"= M;XV;=./@VHV;S-X:Z+3TC1EW5-/U2HJC!14&>*JF6*]>"&*]"RWRX,O_;`$_ M4&2#*A&9$PLFK&`MG]:>[Z^<)_`_Z7*V%W+&&7&?@`,CF/,!C*B"C+B4 M"+WM`Z_0!G+<9YA`8-0'`*%*1.#WQ+3)V))MF^.=)DW'*?&08E(&'T*)*E`< M<#G!-(S:=DEO80XI)B84^JF9E_=?7VB8W-`,J]A%W+;J#&^&AY?A1U4V&W,T M.\&%"KAR*Z#,F+"+`,N)@X%!.B29]L"F.K4'L?SE!+])UY*ATIBLBXS)S/H: MDDPR[(3&IR-PES;,Y$K+4&@,UD7&8#/#LB')!%N>@_DNU-^56"@SQNHB8ZRY M@34DF5C0S>F[?FHTGT+,W/GY@C?@6>_FEN!_"-_9"_B2$S]IY?!.$&YC" M^8-M$,;!I?@LC&>7XO,P;CJ!";H(X\6E_&48+S'N#`/@+%#3/?M.Y9Y7RBI8 M!G:Y-O9^V9XFVALM:K`1#@1"PR&@^9O#J8]!!W)QZ3,A='^#+QC.D>M_```` M__\#`%!+`P04``8`"````"$`9Q402S@&```Q&0``&````'AL+W=OET>MBOWG[\_WT6NTW;989WMZT.Q\7R[;?%=46;NHC\4!?[.IFRKK\&VS7;;'ILC6_475?BD\+UA667EP MB>&^N8:CWFS*O/A4Y\]5<>B(I"GV68?ZVUUY;$]L57X-794UWYZ/=WE='9'B MJ=R7W<^>U'6J_/[+]E`WV=,>U_T#9):?N/LW9_15F3=U6V^Z!=(M2>CYFN-E MO$2FQX=UB2O0MCM-L5FY'^$^]:6[?'SH#?JW+%[:R<].NZM??FO*]1_EH4"W ML4ZZ`D]U_4U#OZSU1WCQ\NSJSWT%_FR<=;')GO?=7_7+[T6YW758;H4KT@N[ M7__\5+0Y.HHT"Z$T4U[O40#^[U2E;@UT)/O1O[Z4ZVZWODSVU75_\1"`P5D0A#@J^&!,3-)+XAP=>11$0*5/"VE"4MJW?I4]9E MCP]-_>)@ZZ'P]ICI1H9[9#[90XL9#+OD%QJE23YJEI4;N@Y:T6*1OS_&ZF'Y M'>N2&TAR#@$;D9X0NIRH;I"(KDTEOEZYDQ(-UDIT);6TA#Y`[D&:8-][C@BB M`6(I08.N5Z+!V"V3+XZ#@9:T$41.(,RU=`YA24.2ZZ5I\,K%=0^>1..*21I! MHKZ6=R"C$(*`%\S"!!)P6XSZ+76X5:;J=)?YN)7G2ZDO8@:&S$""H(YA(:.` M?AWI',*2&-@2YZ5IL&U@S`TD2-`;**((N,/I%`!AY/G>L#A+&.ZJJ7?SPC28 M"8L'6JHL04@8*%^"-WXQ>68A9""%&%VUI.F09,/C[;+JB^RRGBE("#-7USF$ MI3&V-<[;I\&V?>"QKD\(0_[=`81!*$=[R,`I1$;2$Z/#EC;`/3`U<%Y:P!4ALB0G\<2[8Z/9!O+B_0&)\.%U^R%C08(]*7<>3[-B2U M(4'@AY/I:'(W[ MJ3@YM@YM7R#,T'^19.ZF-@+K*\8FL9W3`_QZ<33N+7%GSA&&Q($?A4HR2`I3 MB"\@\,:A;JM[5VCH>[NS+C8(28SH;@>=N8D#&R!@@@LF&H%+; M&%!>&.(=QK`*6R++ENNZ4IQG#``/&0,BJ;[R((1QNABE5@Y%810@[(+0FW)& M4$`@_7!3#S`RT[8Q((0.(#8!TEF(;>2[DD8_=/.D@3%IC4X"D9&APF_SQ`%>S*2G7KFF-7'@XT@?:FGJ33P&(J(8+K4ERYLK M9;Z2.S`..>,F@4A#H(2(F-^IF")B%8KHTNV%8)ESI4S*#&NC`^N\I*<^N>E/ M9[6QDDB,E:$,1P*[+]\5.^*5V)G4RCAI14H,>(<1LH&:&J*33(@O/Z/JI[[K MIV6/9H^`P&/'@.9V^"S$I%2T,"%!Q[%U2R.+F#0\I'JPI M/GD,IB[T"31;XSF([:#.C4EBZPT=O'G(A&?/9U-$XT?#J5?<_ M[O!/$P6>DWH+!&_JNCN]T:>PPQ\['O\'``#__P,`4$L#!!0`!@`(````(0"= MJ)\D00,``%()```8````>&PO=V]R:W-H965T&ULE%9=;YLP M%'V?M/^`>&_`?`6B)%43TFW2)DW3/IX=OGXUUL6T+B*L<%J\C"?B7" MOE]^_#`_,?XD#H1("Q@JL;`/4M8SQQ'9@9183%A-*EC9,5YB"4.^=T3-"*X;.26FE:T99OP6#K;;T8RD+#N6I)*:A),"2XA?'&@M6K8RNX6NQ/SI M6-]EK*R!8DL+*E\;4MLJL]F7?<4XWA:@^P4%.&NYF\&(OJ099X+MY`3H'!WH M6'/B)`XP+>>//;TI.HO??$@=V^L1I_I56!,R& M-*D$;!E[4M`ON9J"S%[4>3<.KZ".#6E@CY2!6E;65' M(5GY1X/0F4J3>&<2'Z(_KWL3+PY1&+V#)3BSP//"\MY0(.A&#SPO)+>&XFAS M&J]3+/%RSMG)@OH%^:+&ZC2@&3"W)FM+.MO_YSK8K4@>%,O"GMH6&"J@4IZ7 M"9H[SY#=[`Q9C2'1U(2L6XC*I:)-VXD+[8!UTR)4(8&B3A;DK2_KWS731J_` M*OKVO2L]`=R='&\0ZA@1Q28D'4,&))LQHD=BR('RZ\M16?+A0%V7I38!KJ0J\L,'#+O9XD(*5AL1-0=Y% M?I@DX;#F#(@?^H'G)Z8%J0%!03Q%432L0P,3!0@.]\5)0R,I>I>_/DO`]69.B$%;&CJH/^>!]-]NUR`=/W2N#^16:P6TWGD^AI3;S3K&ULG%==;ZM&$'VOU/^`>`^P@,%8 MQE=)H[17:J6JZKU]QK"V5P$6[:[CY-]WEL%\;$QBY\4V]MDS9SXXC-??7JO2 M>J%",EZG-G$\VZ)US@M6[U/[Q[]/=TO;DBJKBZSD-4WM-RKM;YM??UF?N'B6 M!TJ5!0RU3.V#4LW*=65^H%4F'=[0&G[9<5%E"B[%WI6-H%G1'JI*U_>\R*TR M5MO(L!+7?'BM8*200M,P7ZY8$U\LQ6Y=?059EX/C9W.:\:H-BR MDJFWEM2VJGSU?5]SD6U+R/N5A%E^YFXOWM%7+!=<\IUR@,Y%H>]S3MS$!:;- MNF"0@2Z[)>@NM>_)ZL'W;'>S;@OTD]&3''VVY(&??A>L^)/5%*H-?=(=V'+^ MK*'?"_T5'';?G7YJ._"WL`JZRXZE^H>?_J!L?U#0[@5DI!-;%6^/5.904:!Q M_(5FRGD)`N#5JI@>#:A(]MJ^GUBA#JD=1,XB]@("<&M+I7IBFM*V\J-4O/H/ M0:2C0A*_(X'WCL0/G-!?Q,LK6%Q4U";XF*ELLQ;\9,'40$S99'H&R0J8SYFA MCC[7N50A1TURKUE2.[8MR$)"?UXV?A*MW1>H:=YA'A`#KSV&]`@7U/220,98 MTN4BGR-KL(ZLBZZE/.`7XS#^Y3#!+6$T&+HV$N\G<<^+D1$3CC"+'C%)$"#7 M)ZC!J0U9]67SDV7/BY$1L\3"!W&R6(0]8A(9IFT<67<[@+OAXQ+K0Z:"I.=' M!8B)6@4DALF.HIGDHZ](T(>F$@+/,R0@!HM`HBB)$G]0.:D"S.GM5="'3`G# M`&,5$#.>@,";F3[]:##NN\\[H0^9&@*C#(B9:IB9AN0K&O0A4\/0:JP#8A*< M!B><:0.!R;N]!NTI4\`[K]'4J8T*0L<;&C49!*(]Z>8NM*=,!:89="!4X#GQ MS!@0P^RNNR/;4Z8"TQ0Z$"J`)\5<%PP?O%(!FMW8E@)OB(!C0!!TGH-!X+0) MVKUN;P)ZWD0`,2V!(.@L()A3\"5;U`N`>2>08="Z$HR-$9[4X2(:(-,R&,;X ML2>3"XY(AAGK@B,(73GQPF`Y%&@:VW#$3V)?L$)BVA!!$,:^B[W87PXN,0UN M6.$GP2]X(!G\K4L<05UPDL1^/#C$-+CA@9\$OV!^9$BK"XX@#*Y;/EMV6%DG MD_]Q\!9MW/1D2`N#=R`,'OE!2"*SY[CEXA)84;&GO]&RE%;.CWJ#)6#:_;?] M=GWOM_MQ_P,LMTVVIW]E8L]J:95T!T?!Y6#:!:['>*%XTZZ86ZY@K6T_'N!O M#(5%S7,`O.-B^B-G=9RQABVA)*`"WN[_]9`%)'7^U1M[H%R/_R,S* MJDRR2.#QSQ^G8^5[$"=A='ZJ6K5&M1*<=]$^/+\_5?_SE_O'0[62I/YY[Q^C M<_!4_1DDU3^?__VOQ\\H_I8<@B"MD(5S\E0]I.G%J=>3W2$X^4DMN@1G.O,6 MQ2<_I7_C]WIRB0-_GRF=CO5FH]&MG_SP7,TM./$]-J*WMW`7#*/=QRDXI[F1 M.#CZ*?F?',)+PM9.NWO,G?SXV\?ECUUTNI")U_`8IC\SH]7*:>=,W\]1[+\> M:=X_K+:_8]O9/V#^%.[B*(G>TAJ9J^>.XISMNETG2\^/^Y!F():]$@=O3]47 MR_&L;K7^_)@MT'_#X#-1?E>20_0YCL/](CP'M-H4)Q&!URCZ)D2G>X%(N0[: M;A:!35S9!V_^QS'UHL])$+X?4@IWAV8D)N;L?PZ#9$@R1U0V&J6ME])&ET^E]^TBI,Y,K-0IF. MA7*K6^OT&BV+QKK72*LP0LL6>G0LA^M9#;O5NST>+6`Q[YNCQ2DD?I2#WC%+B]-&_.`Q[YLGYXVE)LX] M`1'75;Y"2N[<.4_.'JH%[.Y=V6IQ^H@?7YLGYX^E)M"->=;STI!5FJ&?^L^/ M*I1`L:[0B_(VC" M#!5+.I0!P5)7")$OI9`9M5*DC!J0$1`7R!C(!,@4R`S(',@"R!+("L@:R`;( M%HBG$BUJM!MK4;M^[\O;D)#.@L.+VB]((]N3VL:54YZ485)CJ3E">[OFB-@H MFYT:F?CB5BD,Z3X6A$R5V6+9+M1NZ/5H M6`BI6YQE&P5V5`IQT7*!C(%,@$R!S`HBO9X#691:RCSLKCZ/92G$+JZ`K(%L M@&R!>`7)7-0B)KIQ+61YTU43#QO20[C[UH]H(Z!NX$KQ:M%&5K1RLPP MW5'*51D@&C*B/5?9;XS[DY&4XH5Q$8T131!-$A4IE*`S]WDK!=BRIYG1+UO1#JK1OG)YTO/)\OK,NT>0\/>D$: MB*=E(O94/DHA>FBF2PVO2CWT=*E1(=4DD]*6;4BY+$5))Z4ZAM18CLAK-9%( M432=F+)YW0ECVC.6NNG$7([(3BPDNN'$DLWK3MCZ>JU8ZJ83:SDB.[&1Z(83 M6S:O.D'O5'0G/);ZE1-Z4HI^5TW*K"_IBA<"7]E+BJY9+4$Y:JE>V(:K`_%< M0N2J*G0E5TLI7J]1H=AL9W7*:O:L;K/1-6X?7#:OKA>8'[.4O'6<()H:(S8> M[*[5LXTB-F/%FR/.64J.N$"T-$9L=CL/5L,R\G[%BC='7+.4''&#:&N,V.CT M6IV'CK&S>ZSXJQ'U_!*=N9I?_U#TBD9>3:00QRFSI MX:'+7`O/_W?Y"RO&K62!M*W**)<#\=)$Q/$?MJK"E"9E[A(CMJ5F)=UEZ+71 M92FMX.!65?K%*3;7O4^ZKB MV8]:8G*DE9@2W2PQN50K>P^?M54C\1*/XV7%U'!H83O4R*,\-:*.:`WQC&?3U*Z=&%J6([HM5*%6RA'=$IZA5L@1 MW0Z>H5:&'+AVIF\[_:L.#&Q'=/]H:V@[]$#E"J=)BE8=S\QL1S3L>&)N.Z)M MIQ/U58_!&V4)OTJEHQODW+/D_:7&UOT8I?8.27?@' M^M8HH$=_#?%8_2V*4OY'#%!^O?3\-P```/__`P!02P,$%``&``@````A`)*- MX%*[`P``^PP``!D```!X;"]W;W)K&ULK%?+;NLV M$-T7Z#$VE_KX;=@^$VD/8"+5`4?:P9B;:)2*)`TG'R]YTA*4:BU"`)LK&L MX=&9,S/D:+3Y_ER5P1,5DO%Z&R:3.`QHG?."U>=M^/=?]]]682`5J0M2\IIN MPQT!I63EQ41,&M.$>R M$904^J&JC-(X7D05875H&#+Q'@Y^.K& MNHJ(QVOS+>=5`Q0/K&3J19.&095G/\XU%^2AA+B?DQG)6VY],Z"O6"ZXY"Z`G^(H*`GQ$\M'JX6/YV_.ATZBHQHG8,[HLAN M(_@M@(T%LF1#<)LF&9"UP1L&EX[_RP:D`4GVR+(-EV$`@4HHX=,N3>--]`1I MSRWF,,0D?<2Q16"U0)[3"$GY`HW(@AJQ@BCZT!HZHCU!+<(7!(GZ`D'(L@WA MMY,T+R4'@TFZH+DGTD%\E;"#OD`ELL#F@$M'IE];"WI+IH/X,N&0=&6.'[MV MHR%8JW%5M)98[[J%EQNW."Z^M\L6']&!X+X.:X%+)T^II\>!_"3`T>DF`8]A M.DNQX=BN\>ZCB$Q]9=8"5!UE4T^9`_G*\#77:1!OEP?!?>?&,INZ8W?L6GH% M6'_$$X+[GJRE7X"9%Z8#^6$F\-[HQJDKL(HG'R^`9NI+:TW]$O@'^14U$#?2 MI=/Y9[29%FM>IZ8+)M;4SYM_D%Y1`VTCW7FY^(PVTVU[VJRIG[>E5]/$H0;: ML#=V-J]^NRU7GQ%GNZR>0VSBK*DO;N6+L@:K.#L MIB>=P4H**REVA<'*%%9TOQBLS&!%Q^BMP(BX'^>"!\9\@/-1/+@>\[R?9?M1 MQP=0-";HL,B.BS''R^RH)Q`O@,,J@[XXDHQU=ERC/7(/P.C9D#/]G8@SJV50 MTA.4)=:[1ICAU=PHWD"Y8`#E"H9._?<"'QD4)A_=U4ZG<^2L%EU] M?E.R%X-[2Y1L_XG3_"MM"!0;VJ0:L&'L24&_Y"H$RH_&N0=J#2)?R`)0/UAW+?]6>B%T3M8)@<6 M^'^W%$?;ZJJ48HE7"\[V%LP\$"Y:K.:Q%P/QY;)`/13V08&7:(HL<"R@E<\K M/_07SC/4/SM@UAOI13W"`>6]?*CL4+[J;@!SY+H-E:1L MJ&XK7VLSD)B!5`=&@L+@LB1H\E#2=2D*/))B!A(SD.K`6,KDLA1HZ%"*JL[D MGW/_V&25!%4WY=,(V!:]\?`Y&\B4BO(48]!L5#%]<+JL!+!.WJE?EA M9*C7F&OJWT2DYP@_/,WBD?YHK/^V.:J23!\SPX?&S/1"G+I3UYW-QY!D!/$\ M+YJ;"S;5D,O5&/F`=3_LPVT^5)+IPQ"YUICHZ",,X&?X&$'`AQ_Y!B35D!M\ MJ)U]\,F[S8=*,GQ$[ECD6F,FG0]C+-%CVJ/GNUX4!@8D/::?INYI48T:,?\? M`RK)-.`9!C1&3RA#73(<4P;"N6NL*]C&U2NN=4!OTWH#J@G?DH14E;`RME-; M<`"5ZZ/]Z>`A4!]J([[VXO6E>.+%\,54!X(^`7;S%F_)-\RWM!%610IXE6M/ M805S?1[0#Y*UW7:X81+V\>ZVA&,;@0W"M0%<,":/#^H%_4%P]1<``/__`P!0 M2P,$%``&``@````A`%&ULE%5=;YLP%'V?M/]@^;U\!9(F"JG:5=TF;=(T[>/9,0:L8HQL MIVG__>[%*2UI.I$7P.;XG'NNKZ_75X^J(0_"6*G;G,9!1(EHN2YD6^7T]Z^[ MBTM*K&-MP1K=BIP^"4NO-A\_K/?:W-M:"$>`H;4YK9WK5F%H>2T4LX'N1`M_ M2FT4$.O M)#?:ZM(%0!?Z0-]Z7H;+$)@VZT*"`TP[,:+,Z76\NHEC&F[6?8+^2+&WK[Z) MK?7^LY'%-]D*R#;L$^[`5NM[A'XM<`H6AV]6W_4[\,.00I1LU[B?>O]%R*IV ML-T9.$)CJ^+I5E@.&06:(,F0B>L&`H`G41)+`S+"'OOW7A:NSNEL'F2+:!8# MG&R%=7<2*2GA.^NT^NM!O:.!)#F0P/M`$F=!FF2+RPDLH8^H-WC+'-NLC=X3 MJ!K0M!W#&HQ7P'S:$5A![#6"<[J@!(*UL`T/FR1-UN$#I(X?,#<>`\\!$P^( M$$0'95";KHQ@5,;<8B@W?N*US$L@(YG9.3(('LGXB9%,.COM)SU'",$C(3\Q M%DI/"T')3$\<@D="?F(LE)T6FI\CA."1D)\8"\U/"T%%37>$8#A`KPHL21<# MKZ\.CX&<#D7XCD7LT)/+'\$YAXS73M\Q'(/2=,<]^D@VBXYD#R"O^Y*/D6?HSN?((OI8]J6- M>+<]94Y/I]JW87:X0J[G_24P_(`.WK%*?&>F MDJTEC2AA:10LX`09?P?X@=-=WT>WVD'O[C]KN*L%M*DH`'"IM7L>X"TSW/Z; M?P```/__`P!02P,$%``&``@````A``G(UQIH#P``:$X``!D```!X;"]W;W)K M&ULK)Q;<]LX$H7?MVK_@\OO:Y/4795D*I;$^[UF M=Y\56TE4L2V7I$QF_OTV2#1!X%"(O9.7\>3#0>,0#8(`*.G=;W\^/5[]L3N> M]H?G]]?NC7-]M7N^/SSLG[^\O_[W[_Z_YM=7I_/V^6'[>'C>O;_^:W>Z_NW# M/__Q[L?A^.WT=;<[7U&$Y]/[ZZ_G\\OR]O9T_W7WM#W='%YVSU3R^7!\VI[I MG\7XV[[T%1Z>KSU'&=Z^[3=/U^W$9;'U\0X?/Z\O]^M#_??GW;/YS;( MX/9/_T]?]RXFC/=V_)MS3]OCM^\N_[@]/+Q3BT_YQ?_ZK"7I]]72_C+X\ M'X[;3X]TW7^ZX^T]QV[^`>&?]O?'P^GP^7Q#X6Y;HWC-B]O%+47Z\.YA3U<@ MNOWJN/O\_OJCNZQ'D^O;#^^:#OK/?O?CU/O_J]/7PX_@N'](]\\[ZFW*D\C` MI\/AFY!&#P)1Y5NH[3<9*(]7#[O/V^^/Y_KP(]SMOWP]4[HG=$7BPI8/?ZUW MIWOJ40ISXS4V[@^/9(#^>_6T%T.#>F3[9_/WQ_[A_/7]]6AZ,YDY(Y?D5Y]V MI[._%R&OK^Z_G\Z'I_^V(E>8ZH)X,@C]Y2"CFYGK+$8S"F*I.)(5Z2]7?'OK M8QF$_LH@WHTWG[B3J;@$2^M4VEP[_9457>?&'3L_JS>5]>@>>EN#"UF1_KZI M09>&19LEU<.OO$:7NUC\#S?JOJY_7.Y9EZ[X;5?JSM@Q_<];FZ5^;:_VM1U\ MVP[JYAY9;\_;#^^.AQ]7-/'0L#V];,4TYBY=BL9W1SLHNOOETNU"0UQ$^2C" MO+^F*Z$[X43W^!\?/&?R[O8/NB_OI>8.-:ZN6+%"W#DB[-H$&Q/X)@A,$)H@ M,D%L@L0$J0DR$^0F*$Q0FJ`R0=T#MY2>+D2E$YE9ZR1=UH!L@/A``B`AD`A(#"0! MD@+)@.1`"B`ED`I(W2=:UFCE`5GS)C>$A]=O_$`2]9HT2>(T3RM1?L/3&AZ8(I'N4A-QTX\9S9OJ4L.I$?&EK(!L@/I``2`@D`A(# M28"D0#(@.9`"2`FD`E+WB98F6HQH:;*/%Z'6EJSJK\0\9R%KMHH%<]B/J(`48@H0A0S4NX3A2SN M4U;UW;L+8X6<*16[SQ$5B$I$%:*:4>->SZO8K^'>N9G5SE_W]]_N#O04)]'` MG3:B58C<.;>[/EI0LOT[MT5:N@&M645+IVZQX"Z,A+9S%U)A`?=;0 M?7NYO>!5KL)!E>DJXA:EJ_G<=1W#5,:S,F>1U58QV*!IJQQ4F;8J;K&S-1]Y$\-6S:)+MO2!+';;;QC(?T*U M:-1OSG/A.%=6[*L&!G*GXGMP(TY7Z`[PQLWTYSKCV6QL[+Q\J1&WJVW4=L$M MJI!CJ;5MI%N8S6>CJ>$@YEI6!PFKK)V0*A5W0J8[\";SR71B/-USKF:U4+#* M:J%4*K90Z19&X_'<]8PDUUSMD@5]Y(ESEO[(ZVT$W[!D$E&,F54B?68UION5 M>.WWBIFU4W%';&1%.8U.%S1?Z<](GQ76/@Y>92!4*C80<7@Y"K6XFVAF-_FW9I_@\AGI,(' M"EG"AZQ2X2-$,2,5/E'($CYEE0J?(>3A6LL,F..9'65L,KJ*F65U56FNW(G]'B> M+(PI.>=05EL%JZRV2E99;56&K9E#\[0##TQJ28R92[;TP2R.\VR#^??#"\4: M/&/H[T7:4T%Z5O-T>B=>]HLY2-V?*X6LH[FM.&H^==,,N(VLV$.^BL4M!@I9 MPH<8*T(4JU@JJ4D=WLN41/U7&8C6B#:(?$0!HA!1A"A& ME"!*$66((]:$8_/U<2-2;#5FET!K1!I&/*$`4 M(HH0Q8@21"FB#%&.J$!4(JH0U1K2VWU$`:(0480H9M0[$5=(^0+W*:OZ[O%MAU*Q^QQ1@:A$5"&J M&>$AN2?.&_M/IM[4]_JM>Q/%2'=[D*FE&]!:5AS1>4Z76WS;H53<.SZB`%&( M*$(4,^KG%JRFK+):S92*K>:("D0EH@I1S6@@D>)([.\G4AZL]>=0B=2$N:+- M3'-W6Q?7:ZE2+R",LXV-$G!?^2HRHT"AWA`Q#UU#%6OXG4"D!!PY5I$9)0I9 M&DM5K`MO.Y2`(^Z6]9SC2WM2GP"73P`:/79J6!R7`^J8`LM5;10$#TP<1W'FQACR6<- M/?`OMQ<,MH=C:K62TDK+)V0JI4W`F9;L%=+)RI:2'G:E8+!:NL M%DJE8@N5;F$VF2ZMXP\N2Y4'\&E8BFF2[OGFN907M[>40;1#ZB`%&(*$(4(TH0I8@R1#FB`E&)J$)4:TA/CSC'ZJ>GMZ#] MR;.N/0'3YH@6:7MY0&LZ\!>9ZJDVB'Q$`:(0480H1I0@2A%EB')$!:(2486H MUI">%G$,U4_+3W(A3ZWZ=XU$:H9;>8#6B#:(?$0!HA!1A"A&E"!*$66(:7B:=Q'%"`* M$46(8D:]_9Y"RA>X3UG5=X][>:5B]SFB`E&)J$)4,\(MH%C*:/=8;^I[_5Z^ MB6*D6P2FKS2I#EM)50^M&='FL,LM[N65BGO'1Q0@"A%%B&)&RFJ"*&5DM9HI M%5O-$16(2D05HIK10")I(?(+$BFB&(F4J+>7IPPV*EIMJ*R9J_RU5%W>RRL! M]Y6O(C,*%+(T%JI8PSO>2`DX#(M8I,2)_'Q2'5ZY^IH_9,J[^^840+F"[YGKE"7[&*GK:="B;' M]:#*W`ANI$KNY6G'/)Z,S'T1:ZQK_6"P/7/@AH,JTU7$+;;;4V^VF,VFAJN8 M-597R6![IJMT4&6ZRKA%N9=WZ5$S,3\BF+/(:JL8;-"T50ZJ3%L5M]C:FM`G M3[VQL7FI67/)E3Z.Q7'B&\:Q/'WLK0W%^;%X0/6;\USCDWTKJ1*?&+>-8QE> MK3,WLJ+FXV#]F?S*"=BJ]X(RO*Z=)SO+GYSM]G MB;4W@UAF3L=&8_(F#56"XD*;KE#4J5B"QF'EQ9&CHL?X&:- MU4*A@ELLE$K%%BH.+^<\^KC4>&Y,+^+7;D22Q3O4P1F@'7GM#]JT/];QM#M^ MV:UVCX^GJ_O#=_%C-1./C@L[W/Z2SIWG+,5;9LHSN4>!AMH>T>_[#/"/X^5'ZHD!L^-EW=PX9@/393T= MTM.U#5X:7=G0A=VY"[J"Q4`DVK92+"2QA):$Y&"HY(XF)&#H3IWY.!NT,&*2E:#)6LJB0:OE-Y=4\G0]="'!9;B MI3*Z3J@D&2RA;T4NQ?<4L0Y]S8Y*AK)04QWQ_3>LLW9IC-)'$;&$OA:V%-_\ MPA+Z#M=2?$T+2^@+5^1@J.2.'(CO-6*=%96L!DOHVZOD8.A*Z;N/5#(4C;YL MNA1?2L1VZ#NGRZ0MN>TF%OJ=KY?MEUVV/7[9/Y^N'G>?:6IUFF]P'MM?"FO_ M<9:?LOQT.-,O?-%6F7XHB7[1;4??@G;$;U%\/AS._`]J^K;[C;@/_P,``/__ M`P!02P,$%``&``@````A`"H=_X#$!P``E2,``!D```!X;"]W;W)K&ULK)K;)^`9M#P!4R%0X&8W.LV=UK!TQP M#6#*=B8S;[\MVY(L_81)LG,3DX_6KY9:IY:Y__+C=*Q\#^(DC,[]JE%K5"O! M>1OMPO-SO_KW5_NO;K62I/YYYQ^C<]"O_@R2ZI>'/_^X?XWB;\DA"-(**9R3 M?O60IA>K7D^VA^#D)[7H$ISIFWT4G_R4_HV?Z\DE#OQ=5NATK)N-1J=^\L-S M-5>PXO=H1/M]N`U&T?;E%)S37"0.CGY*_B>'\))PM=/V/7(G/_[V_5>G90>[GR4.]OWJHV%MC':U_G"?==`_8?":E#Y7DD/T.HG#G1>> M`^IMBA.+P%,4?6.FSHXA*ER'TG86@55IT[]XO0I:9)_0L/.E] MV)%.H4'/0H/:]@5(O3\=",,&@29)^S#AYMA4(OSTC*D MGVB(P6/*/GR^*30B3O;A\S$Q[K@3].'S3>'CPY`#Y)=-J>>S M+9N\(S_U'^[CZ+5"*R+-I^3BL_75L)@@G[;Y)!,3^:UY3'./J3PRF7Z5FD53 M-*'%Y_N#V6S?U[_3@K$M;`9H8Z@60V[!IC23'>E@K`-;!Q,=3'7@Z&"F`U<' MG@[F.ECH8*F#E0[6.MB40)W"(V)$T?T=,6(R+$:\=P<\(").A;:XT:8R> MJ49@D-NPM4_,+&U>#86)B!*0,1`;R`3(%(@#9`;$!>(!F0-9`%D"60%9`]F4 MB1(T6OA_1]"8#"V6]!`!,9L=+6J%$?DBC/2H"1,1-2!C(#:0"9`I$`?(#(@+ MQ`,R![(`L@2R`K(&LBD3)6IT"%.B=OTXR;D#F0!9`ED!60-9!-F2@=3P?B M#W0\LU8[/B=-4XYX0>1Z9+0:ZGHT*HS*VX?1:ZE&8V'$%RT;R`3(%(@#9%80 MZ;4+Q!.E2NWH:=O@7!AQ%Q=`ED!60-9`-@7)7%0B1OFN$K$\GZFQ]#\]A-MO M@XCV`3IH7]E'FI2WY-D,$U$#F9-R((&,"D);F=AJC)ZV[8^%$>\2&\@$R!2( M`V16D%+4@'BBU`T7Y\*(N[@`L@2R`K(&LBD(1HU=,/S_L&4J:MPXDEG/4*)2 M)\`4+*R:[3R9;1A-;?I)`]Y-ME3F:()H*@MF:7+#T([\CC3@,C.4<1%YLF"A MK/D\EP9<>8$R2T0K6?"ZSVMIP)4WBHPR1PV6Z)8O':Y,1KKTX[,Q,]?"FJ?* M[,)"S+5N5XW0D)>C42>,<*V]:M753HCCPLJDC%!J]30KFUN1=]*JK5E-9(V\ MKZ82E0KJ3CA<7G5":_:,6]UTPI4U?RJA,]M>\7W.JF$TM9(W=B M)=$-)]9K3FRXU5M.J(.2M)1!R78.L\,NJS^P<[!+3VWK*%"S[$5/ MY,9%0;.5K5.&>6=TS$9'.RO87+[<7R`_X592?HK(T6IL M='L=XTZ_MYCQ@C=K=+F5K-%#--=J-#OMKM$PM'&_X`5OUKCD5K+&%:*U5F.C M?==LTWL$?7P5X7BK1G5\L8N)#RQZQ3U&2QP=!^P2B,:66=[+!"K-%MS+"JNN MT!IS+8ELCJ3\!-&4(UG0033C2&JYB#R.I-8XQRU`JD;%7:TD\Z,6]UTPN56/3%\O7<%52>T0]&" M6]UT8LFMI!.K=SFQY@55)[0%>L.MWG)"':OLAD8?JT9;)CE?H\M;24[Y7%5< M])0':XZ4)4:@FTM,;M7,WA%G2=28O?RE,5U"=H%*\A-$4RSH()IA01>1AP7G MB!98<(EHA077B-@[=KE*YV'+WYGGK]U.0?P<#(/C,:ELHQ?V/MPT:.L66+RL M?\RR)(T/V$M\-@UT;EKTLN(*;UIT(8[\L64]DJ/XQ:!ET5WL%=ZVZ%[P"N]8 M=&V%W.M:E+5?X3V+\D+DFZY%V2'RD=&PQI1)X#>41UDL5<)O*`^R6*J#WU`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`#]._!X[T)#>J1 MVW]VG[_OOVY_?#RL-2HGI\>UB,P/OJPVV^3>2!X>W/W:;->/R]PHLE*Y2-6* MT">+U"K-DY-ZHWGZ>I6:5:%/JQ*]782:VUT/?5J1T[>+-*P(??+UO+HO3FU= M^GS_5=#=N;L*^F0'*E']N&'&)#`.9[8:?99#QCF3D MWN%SE$C!0!/IAI:(OS]5:\1;M-C"S.%&MJU!1X-$ M@ZX&J0:9!CT-^AH,-!AJ,-)@K,%$@ZD&,PTN-)AKL-#@4H.E!E<:7&MPXX`C M"I,B5BBV_T2L&!D3*SS*YPR6YCEL]BICGQ35J%21$M0#I`$B!=("F0#$@/2!_(`,@0R`C(&,@$R!3( M#,@%D#F0!9!+($L@5T"N@=RXQ`LB6D/_1!`9&5K,Z*,(D&I-+33GUHA\*8QT M%!4F110!Z0!)@'2!I$`R(#T@?2`#($,@(R!C(!,@4R`S(!=`YD`60"Z!+(%< M`;D&U,S3"%$5=K`^D`28!T M@:1`,B`]('T@`R!#(",@8R`3(%,@,R`70.9`%D`N@2R!7`&Y!G+C$B\V:'OK MQ4:^UZV8\WLX3$Q%/TQR4J\6FY@6D#:0#I`$2!=("B0#T@/2!S(`,@0R`C(& M,@$R!3(#<@%D#F0!Y!+($L@5D&L@-R[Q8H*.+%Y,A`/!6/N!8$F>+#)GEA:0 M-I`.D`1(%T@*)`/2`](',@`R!#(",@8R`3(%,G.)U_$F.^L>/,,=;ZS]CL]) MS;D#"^),W75U"&U;(W?EC^IJ>]`IC'A^3PIM)ET@:5'+;;_F+QU98<1"/1#J M%\054A'0*(_8Y`:$ND+2HY71'71U5LL*(I7L@U`%$4N/0&@,9%+4XX(FHS MJA6K;0=1PDAFA"ZBE)$?%6KSGXD5]T*/DS*&#,KM_'N7(&;46HC8C MJ=A!E#"2KN@B2AF)5H:HQTBT^H@&C.AH*$>WNCJZ#<6*+WO$2.3'B":,Q-4I MHAFCDE&C:/)&K61TZ%N!8GB,N9HL+:)%52[P1"WY+9,:,Q5IUA8KV`:)%7=# MQZ+J\2Y]?]J,ZB<-M3@D;$/!M5^\B^(IHHRUJKOVHHH>JAX;!!OKBW+`I8%8 M\?4.$8T0C04%Y"=BQ?)31#,/^9.PR6>XM_0+P6'3'Q*+YR;A1<->I=&7D3E1 M6Y*6M3)SBUAA<%AY.=1T6+Z^&ZRSXWJMJ79_"6O3)+)?N\M6HITBRK@Y.5:!V.,ZP<;Z;!6\W(%8\>`-$8T0C04%KG@B5BP_133SD!\;)I_QAMBP MZ0\W-G)DOMZ3D3E1>YZ6>:3B%1-'8<57T[$5S9>JCKQ:C1.V\L;B1.V,NN($ MRZ>(,M;*IX[CRJG:`?78P&M,QWE?E!W'M=5`K-BE(:(1HK&@@/Q$K%A^:I&= MB:NUTS-ZSL3??9H8.RU/,.9&EEO2$Y?WX@\@"^90K2HN9M&@FGEK)HF1EO,9TS/1%V7%< M6PW$BCMTB&B$:"PH(#\1*Y:?(IIYR(\:D[MQH^:%1MSPR%%5ONMMF0=& M3,30APRI[IDV6S6+4.L@2AB)?!=1BBA#U$/4%Q1P=2!6W,M#1"-$8T$!^8E8 ML?P4TM*+O1 MDAV'M=DW!^X..EUQ@7LPM8CVR(PRMN+=J)K#>EP>;*O/5L'+'6#S0ZZ8-]^H MJ.E^Q.7!YL=L%6Q^@LU/N6+>V]$I/1S9:*@-PHR-]OG@QQWY$(R[^?KGOD.J M>PPR,NH8E"-O4BE0X%9JFR,1:=5V3YON8J.#*+'(D>\B2K%BAJB'%?N"`JX. M4&N(:"1:',9C00'Y"6I-$L1*N%ES@NVPE2T_*2-K+N+W\&!-5:GI6X3K! MQOIL%;S>`5M)^T.__9.*VA.-N$JP^3%;!9N?L)4T/^7F\^Z.&HVSQEE5[=YF M7&^?#W[@46#\@5FE:F14Y.7(N>U;UNJ%K8JUHAZB,:(!HB&B$:(YH@FB*:(;I` M-$>T0'2):(GH"M$UHAL/^;.'28VZ>^'P@<;DTO0L89%,\J]99Q;?M?\W#[CKKK!(5L`66P47BK:UJE%].0$VU(:W(U9\ZR6( MNHA21!FBGD5T;H)9R"2XW"!Y7X?9-)ES&*9=[:X/W0XKD-,5B%FK9:$5L=6M#&K.BSATN"`=:5Q'K`44<9:><2J`>QQZ;Z6 M_%XU)^TW]&I^,/=Z-45V(K MBS5>F-^^/=SJ[Z4'FSVI-+2KG;!7:'XL-]VP; M40=1@JB+*$64(>HAZB,:(!HB&B$:(YH@FB*:(;I`-$>T0'2):(GH"M$UHAL/ M^0%&-_<;;EMSPAG)RMM"U$;4090@ZB)*$66(>HCZ MB`:(AHA&B,:()HBFB&:(+A#-$2T072):(KI"=(WHQD-^C/R1K(5),>@%"K,6 M;$5GCV+-HA=1^&M6VUKY68M3M2'MB!6O;`FB+J(448:H9U&>M=CM0ON"`MX/ M1,NQTD]P#<6*O1\A&B.:()HBFEGD>'\AR/%+]_U@:T8U%)1DC2LSXZ]\+BYY-S3AYCYT"?3/IG2&;ZF#;8BOOL*`[J\U6=.AQ MPEEI=<2*.RNQJ"ZS:E>0JZ5NC52T'*NF3B6)%;?88R0/WO8%.5KZ&@=LY5UC M4YU@AF+%+8XL(6+RURKG$I*-#BE6BY5BH1<"U6W.(-(WSHN68R;FXBP-D:OOY1]9V*G\^R MB.X8]J+%2'JZ;1&]G,J](A69';%BK02UNHA2J>C(Z]LV$RN6[Z%6']%`*KKR MZC`U%"N6'Z'6&-%$*KKR:J*8BA7+SU#K`M%<*KKR*IH68L7REZBU1'0E%5UY MM29SQ$U8=*@]#(KO<2V:K:2?U>K&;4M M5NQVQR+ZMMQ(1TUZ!YVJE;#)OA1=GK82;:?C].R3EEHU5;XXXQ;SE&%4T0G= M'AL$7>J7-J9=&H@5=\J0Y;T5L:ERKR.V"CHQ%OE`OTS$BIV8LGS0B1E;!9VX M$/F`$W.Q8B<6+)^'1RTZA?"X9).@!TO1#GAP56JEP^.:6]P7'C=LL,\E__8T MR?$WW)XVE^[>GCFB5G>W9W2L_\M8R^S`7DXHBQ7W?\A=MMK7*[O[.!4K=B)[E1,]KAATHL]602<&8L5.#%_EQ(@K!IT8LU70B8E8 ML1/35SDQXXI!)R[8*NC$7*S8B04[D3_^5#>WI)JR+[E6T(,E6P4]N"JUPGLR MCW#[S4>UPM]Z0Q5QNY'/&2&1V?J36\5;.5Z$-N+7W3 MM,6*^[]C$2^9M=/32&T_$C8)]FQ7M`,>I*56NO\S;C&?$^N5JKK<'AL$7>J7 M-J8[92!6W"E#EO>&5T]4([8*.C$6^4"_3,2*G9BR?-")&5L%G;@0^8`3<[%B M)Q8LS\\\-T_U:Z(NV23HP5*T`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`Z12LKJ4'8\-HE"5)LU M8_.>"2R@1VMC\[!K60E=*.WYL82>`:4Z927TE1>Y5J9&7R?1\)25C)JQ>9T& M-C-NQN:E&E@P:<;371)7S6:3LWA:-I?1*W!B\X*;$J4HHI*RVY;>W4$E9:WW MFK%YNPB*]9NQ><<(%@R:,;U5JX2?Q?16IA)._IKW_9251%12YB^]RH1*REI/ MFK%YLPJ*=9NQ>;\*%J3-F-XY5L+/8GI!50DG?\WKC\I*(BHI\Y=>XT(E9:V? M-V/S5AD4:S5C\VX9+&@W8WK]6@D_B^E=726<_#5O@RHKB:BDS%]ZA0V5[%H_ M*L*._F+$S]OOJ^'M\_?[I\W!P^H;K;_TC#!E=)[SOSF1_[*U_V_QRWI+?RN" M=LOTSG3ZVR`K>F3IN$+&W];K+?]"3AT5?VWDT_\$````__\#`%!+`P04``8` M"````"$`7(M;6)4/```!4```&0```'AL+W=O/IX[=P,KJ]V3W>'^_W3 MMX_7__[=_]?L^NITWC[=;Q\.3[N/UW_O3M>_??KG/S[\/!S_.'W?[GNZ^[QZWIYO#\^Z)KGP]'!^W9_KG\=OMZ?FXV][7A1X?;MW! M8'+[N-T_73<6O.-K;!R^?MW?[5:'NQ^/NZ=S8^2X>]B>R?_3]_WSB:T]WKW& MW./V^,>/YW_='1Z?R<27_[D`T^]5Q]_7C]6?'JX;CZ]M/ M'^H&^L]^]_/4^?^KT_?#S^"XOT_W3SMJ;8J3B,"7P^$/(8WN!:+"MU#:KR-0 M'*_N=U^W/Q[.U>%GN-M_^WZF<(_ICL2->?=_KW:G.VI1,G/CUF[<'1[(`?KO MU>->=`UJD>U?]=^?^_OS]X_7P\G->#H8.B2_^K([G?V],'E]=??C=#X\_K<1 M.<*IUH@KC=!?:<2=O+KP4!8>M86=F]EX/)K,IJ_W@)3U;=!?Z<'T[4;(Y]H( MC0UIY!V>S*41^OM^3QSJ!TU85).^PQ>'VU;\C_1F=C-U!O/A&]K6H<@TSE`# MO;]AG"F;H?]YOS,4G,:9]T3IMNG]]6!:;<_;3Q^.AY]7-$-1_SX];\5\YW@. M6>9AU'3Z=F!=&E\$*M-[PDS3%&[+&60%9`UD!\(`&0 M$$@$)`:2`$F!9$`V0'(@!9`22-4E6L/3WO@-#2_4>L,W9-CI\2U14Y,S&N@K MR4J*NBN).S"6FW4KXOG+!Q(`"8%$0&))E-=)2RQ>IZVACFAN;&VR5L1>;X#D M0`H@)9!*DMIK+8AT-M6"V)G!SM_W=W\L#K1*T#:\9U0-Z533G'6$$3VV#>G& M%LA*$EKHVH7(F1N;@G4KXB;Q@01`0B`1D%B23B"!I&TIBXM9*V(7-T!R(`60 M$D@E"49-)`7^_[#55O2X,5)GHJ5"G4:`42E5E-^JC[H#9Z@/V[42<#/YRC*C M0"%+9:&R)2MS]]%E#SEVN+^BMS^RX8:_*]"KB&J57LYGC MF`?3F#56KY+>^DROTEZ5Z57&-39>.B26WI'%GF'-W3D)DU!1U(>)`NG0<-N=:X#Z399L*OJZ M)*RR-D*J5-P(F>Z!.YZ-)V-C/=]P,:L+.:NL+A1*Q2Z4N@O#T6CFN$:0*RYV MR06]YXGL2;?GO6N#)+)5Q@Z)D3ZS&@O9DE4OS*S2_+SM[VM94$ZCDSG-5_I$ MZ[/"VL;!JQP(E8HC$;%Y.0E,1R-C1Q"SPNI`HDQ;QD.J5.Q`QN8;!UQW1$\C M]2;8L,3J0:YL6SPHE(H]*-E\X\%X-!Q@7VPBYU[R0.^+(B?4[8LO+.L4N9+1!6CVKP>5Y%?ZL;U?7.,S%)UP]V@D4)+\4!8S$1T MJK^\"*U8I75+E>.6-:GL=S8TK>L"FK6SFKK&X5K+*Z51IN M30F<6B3I;9_[]\$S]KS>CT#V+-/D^&C0\G2ZO7)^H.MY:V.LA'\X%"%O,AVHH0QCS=UPYYX\TLBKW]>+NS4AT_E+:W9^G2R$/.64-&RV4Y?QA9S MJ33<%"M$:T0^H@!1B"A"%"-*$*6(,D0;1#FB`E&)J-*0'DB1(^P.W!=V%TU* M41N@$M%TT0;'-1-!2Y%+$"%L7D%J7FH`M$:5CRA`%"**$,6($D0IH@S1!E&. MJ$!4(JHTI(=')`.[X>EL$EZ(5)-&U"+5H.[3)@?0"M$:D8\H0!0BBA#%B!)$ M*:(,T091CJA`5"*J-*2%A0Y8>ECLL:CE]2S'<]."D=IV+A&M$*T1^8@"1"&B M"%&,*$&4(LH0;1#EB`I$):)*0WHL:%>A#9$78B'D1BP:U'UN(8YFI"*D)C5, M";&JNR[A4RFEXNC[B`)$(:((43*[=177YLI03<5KY$M)-B%"ADJ2Q4MOH?[D1*P)9C99E1HI"E MLE39NO#82@G8\D999I0K9*FL4+;Z[ZQ4`K9<*2%>;Q)1'7W M-Y22J+L([2O;(>LZ1FYBR2K:^;2JGJE=VM)4D`N1MFAQ$BTP=@8#=VPD/'W6 MT(IRN;[@55Z%O2K3JXAK;+P:3@8#RH+J1ZJ8-5:ODM[ZS.&4]JI,KS*NL?'* M&*7I7I5LDU-F[-QX,Q/3_0&ZMBS26O]'XL\B9O MZ,5!"I%Z@NM6YCGG@E2KQ1.UROUHI%0_!M41T4Z+3C@;3\=3(_?A< MRKK]"5AE]2!4*O8@TCV@]Q#'8TC6<3&K"PFKK"ZD2L4N9+H+SGP^F)@N;+B8 MU86<5587"J5B%TK=A>EX,A^,C91EQ<4NN:#W/)'QZO:\9L?TYJ2,^.U.L]2J MGN6.C#ZR8!6MI6W_@SXJ+0W;17.EBG%#K!'YB`)$(:((48PH090BRA!M$.6( M"D0EHDI#>B#-[-H+2V&;1.,F75"ZM`ZAGI0QGH0ME8H+KA"M$?F(`D0AH@A1 MC"A!E"+*$&T0Y8@*1"6B2D-Z>$3B"L?9*UX`IB=IEA$+JL;EA=&39/ZTC:0$JGW*Y8N MH!6B-2(?48`H1!0ABA$EB%)$&:(-HAQ1@:A$5&E(BP4]8GE++&JY?KB3J',D M7RJD5AS"3ZB`)$(:((4<)1>DU=;61:0M366>Z-?2EDS*4.IC-!X:AQ>?-=9#6_`JK\)>E>E5 MQ#4V>09W.I].)X97,6NL7B6]]9G#*>U5F5YE7*-,RCBTU(S-EW8W++*ZE?=6 M:+I5]*I,MTJNL7%K3.^"NR/C\%*QYI)7>C\6Z;PW]&.9_>LD988-$C-JVT-= MQWC7=BE5+R1EE(J'X%HBF92I7R4>&SD[GXO1=-JZ`/N?@%5=1T$5*A6[$.DN M3&?TB0ACF,99[H$[=ISAT'@W=L/%K"[DK+*Z4"@5NU#J M+E`J<$1972,=R,4NN:#WO+>E`VGY@QE4(GT&-=ZL7W)!;6XTA]]*J?B.UQ+) MZ=(=N#/SY0V?)=;6#)1M2_<,E8H]B-@\3T)39S(TELB8-587$F7?1"XRCF3&]B`\)B=XA'IKVS@!- MSVN^%=1\WN1Q=_RV6^X>'DY7=XY.[9*C'SF)('V_JX9]'WF=Z.0XK7HR\JEXTS`K& M7M5[VW37?7;H'.B)DQG60`<+NM)W$W1L(V_[KM#>VEO3)@^MT4;8$WM=O$*[ M5D]L3/$*;3')@[XK"_)@T>L!G=V]9>^5%5T1)VBLATY[=*7O?NAX[8EC&)9) MZ$K2>X5>=_#$"PA8AIZ?TY6^^Z&W$ZA?]%VA1\C>FIYEHC5ZWNN)1[IXA1[. M>EGO%7J22A[TE5F0!XM>#Y9T1;RW@/6LZ$K4>Z?T4@-=Z2M#;Y%XXFT#M);0 ME:3W2CKSRK[!E\Z]LF_P5S1:^_C*&7CBAZ)8-_WDTQ._ZL0K]/M,3_P$$Z_0 MCRD]\7M)O+*8>8N^^I>?3S8N3)S$MJ?MM. M"O0!MN?MMUVV/7[;/YVN'G9?:6(>U`GD8_,)M^8?9_G6])?#F3Z]1@&UL(*($`2B@``$````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````G)%12\,P%(7?!?]#R7N;IH,A MI*;S&YZX)-&G*CW?Z]6=?5#7T2\A+.N5_./:D6.],F7^!1=[8F M+,M)`E9V2MNF)L_K97I#$@S"*M%V%FJR!R0+?GU525?*SL.C[QSXH`&32+)8 M2E>3;0BNI!3E%HS`+#IL%#>=-R+$JV^H$_)#-$"+/)]3`T$H$00]`%,W$Q[Y[]VV"N*WH;ZU2 M^4QW4EYF=W=KY>$%SF;I8RE^7Q=%&7!XGFKZ,DUSO,):,8` M_R:>`'S(??GG_!L``/__`P!02P,$%``&``@````A`);:8H6J`@``/P@``!`` M"`%D;V-0&UL(*($`2B@``$````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````G%;?3]LP$'Z?M/^ARCND%#9-*`T*;1!(I8F4P!XMDUQ: MB\3.?$Y%]]?ODJR_AF'0-\=WW_F[^^[L>%0G]3:@TT>\7)EC@^8J M:_GA8[JNB;#O!75=BHP;RM*_%YE6J`HS"%\R*#UWW^@1NP2R1@NS]H>>N__I M)1DO84*!_8*7")Z[V_!N@;=%B[G0Z'LK<[F"S"@]0/&;RC9R!D\[6%VF>^S6$2S9-H M=C<-TG#*KH-9,)^$++D-PS3YK#^+^?\A24HGW8?S-&'1#8OB\+.0273_:4A@ MSV4*F&E1MPW(5,&N&Q02\$#A;9VN.0ILO6(-2(/2M:V52&)4]KQ494X#S,)? M#8E@]9N#83.%R&+0+%ER3;V[/:[MPE[3.YDWU(%KEL"BG=!.VXC&_&T&,QIH MB<""A09H,?:4+$19RI^H_ZQ$7O-]S_M]VF?6$][0@P5Y+HRP0JRR_`4H:878 MTNY/4)+3S;.M_$X#&R1IJHJ3+*KX,"1`;*JNW3X,2>CBSIL2F'UZ+9KL4F'6 M4RR0MHA9UU=3*^1]+4='8,Z/P%P<@?EFQ;R>CVW'\/*@:@#ZD5W!OSW-W+[__!P``__\#`%!+`0(M`!0`!@`(````(0"M[M-FQ@$``/L2 M```3``````````````````````!;0V]N=&5N=%]4>7!E&UL4$L!`BT` M%``&``@````A`+55,"/U````3`(```L`````````````````_P,``%]R96QS M+RYR96QS4$L!`BT`%``&``@````A`&+@!5.R`0``PA$``!H````````````` M````)0<``'AL+U]R96QS+W=O@D```\`````````````````%PH``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`'<1=VP^`P``5PD``!D`````````````````,QL``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`(<&M&Z> M`P``8PP``!D`````````````````3"@``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+,Q7&R%!0``WA4``!@````` M````````````,S0``'AL+W=O&PO&PO&UL4$L!`BT`%``&``@````A`#2% M)UZ/`P``4PP``!@`````````````````%7L``'AL+W=O&UL4$L!`BT`%``&``@` M```A``[O96AI"```!C```!D`````````````````YX$``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT` M%``&``@````A`*-R6B0-`P``"PD``!@`````````````````X*(``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`)VHGR1! M`P``4@D``!@`````````````````$[```'AL+W=O&UL4$L!`BT`%``&``@````A M`*(L\)<]"````B4``!D`````````````````G;<``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`%&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A``(92#DP$P``LF0``!D````````````` M````(N(``'AL+W=O&PO=V]R:W-H965T M&UL4$L%!@`````E`"4`]0D``)T+`0`````` ` endXML 14 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8 CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) 3 Months Ended 9 Months Ended Sep. 30, 2013 Sep. 30, 2012 Sep. 30, 2013 Sep. 30, 2012 Revenue: Product sales $ 3,047,091 $ 2,052,398 $ 10,052,458 $ 7,758,463 Development revenue 1,299,328 2,606,482 2,681,202 6,329,967 Licensing revenue 69,231 77,284 207,238 812,196 Royalties 1,092,174 949,753 2,932,692 2,173,775 Total revenue 5,507,824 5,685,917 15,873,590 17,074,401 Cost of revenue: Cost of product sales 1,909,060 1,673,849 6,519,468 5,071,007 Cost of development revenue 1,095,542 1,622,640 1,992,959 2,747,424 Total cost of revenue 3,004,602 3,296,489 8,512,427 7,818,431 Gross profit 2,503,222 2,389,428 7,361,163 9,255,970 Operating expenses: Research and development 4,318,011 3,900,475 11,786,224 9,260,422 Sales and marketing 2,576,247 237,067 4,615,736 527,953 Business development 142,017 219,953 486,732 784,661 General and administrative 1,836,127 1,551,147 5,375,610 5,089,744 Total operating expenses 8,872,402 5,908,642 22,264,302 15,662,780 Operating loss (6,369,180) (3,519,214) (14,903,139) (6,406,810) Other income (expense) 9,223 (15,025) 31,478 (8,895) Net loss $ (6,359,957) $ (3,534,239) $ (14,871,661) $ (6,415,705) Basic and diluted net loss per common share $ (0.05) $ (0.03) $ (0.12) $ (0.06) Basic and diluted weighted average common shares outstanding 127,162,064 108,961,792 126,581,018 105,735,855 X - Definition Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 2 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.6) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_BusinessDevelopment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Costs incurred and are directly related to generating contract revenues. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_ContractRevenueCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_ContractsRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Total costs related to goods produced and sold during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 2 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_CostOfGoodsSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 2 -Article 5 + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_CostOfRevenueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + References No definition available. + Details Name: us-gaap_EarningsPerShareBasicAndDiluted Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1,2) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_LicensesRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + References No definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The net result for the period of deducting operating expenses from operating revenues. + References No definition available. + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 9 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details Name: us-gaap_RoyaltyRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details Name: us-gaap_SalesRevenueGoodsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. + References No definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). + References No definition available. + Details Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 15 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8 Net Loss Per Share 9 Months Ended Sep. 30, 2013 Earnings Per Share [Abstract] Net Loss Per Share 4. Net Loss Per Share Basic loss per common share is computed by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per common share reflects the potential dilution from the exercise or conversion of securities into common stock. Potentially dilutive stock options and warrants excluded from dilutive loss per share because their effect was anti-dilutive totaled 9,595,808 and 12,765,470 at September 30, 2013 and 2012, respectively. The table below discloses the basic and diluted loss per common share. Three Months Ended September 30, Nine Months Ended September 30, 2013 2012 2013 2012 Net loss $ (6,359,957 ) $ (3,534,239 ) $ (14,871,661 ) $ (6,415,705 ) Basic and diluted weighted average common shares outstanding 127,162,064 108,961,792 126,581,018 105,735,855 Basic and diluted net loss per common share $ (0.05 ) $ (0.03 ) $ (0.12 ) $ (0.06 ) X - Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 52 -URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.21) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 16 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 17 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8 Industry Segment and Operations by Geographic Areas - Additional Information (Detail) 9 Months Ended Sep. 30, 2013 Segment Segment Reporting [Abstract] Number of operating segment 1 Total revenue 10.00% X - Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13537-108611 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13531-108611 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + References No definition available. + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8 Stockholders' Equity - Additional Information (Detail) (USD $) 3 Months Ended 9 Months Ended Sep. 30, 2013 Sep. 30, 2012 Sep. 30, 2013 Sep. 30, 2012 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based compensation arrangement by share-based payment award, number of shares authorized 15,000,000 15,000,000 Maximum number of shares of stock granted to one participant 1,000,000 Minimum percentage of exercise price 100.00% Shares available for grant under the plan 389,363 389,363 Unrecognized compensation cost related to nonvested outstanding stock awards $ 566,000 $ 566,000 Weighted average period expected to be recognized 8 months Weighted average fair value of shares granted $ 4.01 $ 3.25 Shares withheld to meet employees' minimum statutory income tax obligation 30,153 11,165 Payments for the employees' minimum statutory income tax obligation 104,329 28,916 Warrants exercised 234,541 3,731,135 Proceeds from warrant exercised 261,799 8,962,270 Warrant of common stock outstanding 1,781,428 1,781,428 Warrant exercises price at end $ 1.08 $ 1.08 Director [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Recognized stock-based compensation expense 204,000 182,800 470,000 377,200 Stock grants unvested 212,618 212,618 Long Term Incentive Program [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Contractual term of options granted 10 years Stock Options [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Recognized stock-based compensation expense 401,000 295,000 982,000 799,000 Unrecognized compensation cost related to nonvested outstanding stock awards 2,517,935 2,517,935 Weighted average period expected to be recognized 2 years Per share weighted average fair value of options granted $ 2.27 $ 1.63 Discretionary Shares [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Recognized stock-based compensation expense 0 13,000 8,700 288,000 Share based payment discretionary awards shares granted 60,000 Weighted average fair value of shares granted $ 2.59 Performance Stock Units [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share based payment performance awards shares granted 0 35,000 Restricted Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Recognized stock-based compensation expense $ 46,000 $ 73,000 Restricted Stock [Member] | Long Term Incentive Program [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Options granted under long term incentive program vesting period 3 years Minimum [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Contractual term of options granted 10 years Maximum [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Contractual term of options granted 11 years X - Definition Class of warrant or right weighted average exercise price of warrants or rights. + References No definition available. + Details Name: atrs_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights Namespace Prefix: atrs_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - Definition Minimum percentage of fair market value on the date of grant used to establish stock option exercise price. + References No definition available. + Details Name: atrs_MinimumPercentageOfExercisePriceOverMarketPriceOfGrantedDate Namespace Prefix: atrs_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - Definition Share Based Compensation Arrangement By Share Based Payment Award Options Grants Contractual Term + References No definition available. + Details Name: atrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsContractualTerm Namespace Prefix: atrs_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Definition Warrants exercised during period number. + References No definition available. + Details Name: atrs_WarrantsExercisedDuringPeriodNumber Namespace Prefix: atrs_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.F) -URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section F + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Number of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph i -Article 4 + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Unrecognized cost of unvested share-based compensation awards. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Definition Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585 + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The cash inflow associated with the amount received from holders exercising their stock warrants. + References No definition available. + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i)-(ii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The highest quantity of shares an employee can purchase under the plan per period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Net number of non-option equity instruments granted to participants. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - Definition For net-share settlement of share-based awards when the employer settles employees' income tax withholding obligations, this element represents the number of shares the employees use to repay the employer. + References No definition available. + Details Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 19 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8 Industry Segment and Operations by Geographic Areas - Summary of Significant Customers Comprising 10% or More of Total Revenue (Detail) (USD $) 3 Months Ended 9 Months Ended Sep. 30, 2013 Sep. 30, 2012 Sep. 30, 2013 Sep. 30, 2012 Entity Wide Portfolio Carrying Amount, Major Customer [Line Items] Revenue from major customers $ 5,507,824 $ 5,685,917 $ 15,873,590 $ 17,074,401 Teva [Member] Entity Wide Portfolio Carrying Amount, Major Customer [Line Items] Revenue from major customers 4,004,531 2,797,761 11,196,559 5,966,246 Ferring [Member] Entity Wide Portfolio Carrying Amount, Major Customer [Line Items] Revenue from major customers 1,047,750 783,757 2,511,332 3,444,510 Actavis (Watson) [Member] Entity Wide Portfolio Carrying Amount, Major Customer [Line Items] Revenue from major customers $ 202,813 $ 1,171,633 $ 1,301,929 $ 5,859,488 X - Details Name: atrs_EntityWidePortfolioCarryingAmountMajorCustomerLineItems Namespace Prefix: atrs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 20 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8 Industry Segment and Operations by Geographic Areas - Summary of Revenues by Product Type (Detail) (USD $) 3 Months Ended 9 Months Ended Sep. 30, 2013 Sep. 30, 2012 Sep. 30, 2013 Sep. 30, 2012 Revenue from External Customer [Line Items] Total revenues by product type $ 5,507,824 $ 5,685,917 $ 15,873,590 $ 17,074,401 Injection Devices And Supplies [Member] Revenue from External Customer [Line Items] Total revenues by product type 5,100,253 3,600,400 13,882,973 9,505,344 Transdermal Gel Products [Member] Revenue from External Customer [Line Items] Total revenues by product type $ 407,571 $ 2,085,517 $ 1,990,617 $ 7,569,057 X - Details Name: us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 21 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8 Industry Segment and Operations by Geographic Areas - Summary of Revenues by Customer Location (Detail) (USD $) 3 Months Ended 9 Months Ended Sep. 30, 2013 Sep. 30, 2012 Sep. 30, 2013 Sep. 30, 2012 Revenues from External Customers and Long-Lived Assets [Line Items] Total revenues by customer location $ 5,507,824 $ 5,685,917 $ 15,873,590 $ 17,074,401 United States of America [Member] Revenues from External Customers and Long-Lived Assets [Line Items] Total revenues by customer location 4,390,966 4,881,106 13,063,929 13,083,259 Europe [Member] Revenues from External Customers and Long-Lived Assets [Line Items] Total revenues by customer location 1,047,748 787,368 2,585,655 3,448,121 Other [Member] Revenues from External Customers and Long-Lived Assets [Line Items] Total revenues by customer location $ 69,110 $ 17,443 $ 224,006 $ 543,021 X - Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8 CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) 9 Months Ended Sep. 30, 2013 Sep. 30, 2012 Cash flows from operating activities: Net loss $ (14,871,661) $ (6,415,705) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 288,188 178,030 Stock-based compensation expense 1,534,100 1,464,225 Changes in operating assets and liabilities: Accounts receivable (1,176,745) 484,020 Inventories (804,009) (2,736) Prepaid expenses and other current assets (349,833) (663,796) Deferred costs 440,051 423,856 Other assets (11,844) (27,322) Accounts payable 1,387,543 321,607 Accrued expenses and other current liabilities 1,946,548 404,423 Deferred revenue (1,676,365) (4,143,463) Net cash used in operating activities (13,294,027) (7,976,861) Cash flows from investing activities: Purchases of equipment, molds, furniture and fixtures (2,184,568) (2,425,454) Additions to patent rights (195,558) (283,871) Proceeds from maturities of investment securities 15,000,000 9,000,000 Purchases of investment securities (9,118,161) (15,077,176) Net cash provided by (used in) investing activities 3,501,713 (8,786,501) Cash flows from financing activities: Proceeds from exercise of stock options and warrants 756,611 9,601,723 Taxes paid related to net share settlement of equity awards (104,329) (28,916) Net cash provided by financing activities 652,282 9,572,807 Effect of exchange rate changes on cash and cash equivalents 3,454 (7,475) Net decrease in cash and cash equivalents (9,136,578) (7,198,030) Cash and cash equivalents: Beginning of period 52,097,064 19,357,932 End of period 42,960,486 12,159,902 Noncash investing activities: Purchases of equipment, molds, furniture and fixtures recorded in accounts payable and accrued expenses $ 437,504 $ 358,828 X - Definition Proceeds From Exercise Of Warrants And Stock Options + References No definition available. + Details Name: atrs_ProceedsFromExerciseOfWarrantsAndStockOptions Namespace Prefix: atrs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Future cash outflow to pay for purchases of fixed assets that have occurred. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586 + Details Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 230 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906 + Details Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 230 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906 + Details Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The increase (decrease) during the reporting period in the aggregate amount of accrued expenses and other operating obligations not separately disclosed in the statement of cash flows. + References No definition available. + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInPrepaidExpensesOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585 + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The cash outflow associated with the purchase of all investments (debt, security, other) during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details Name: us-gaap_PaymentsToAcquireInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 + Details Name: us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 23 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8 Basis of Presentation 9 Months Ended Sep. 30, 2013 Accounting Policies [Abstract] Basis of Presentation 2. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of the Securities and Exchange Commission’s Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The accompanying consolidated financial statements and notes should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2012. Operating results for the nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. Investments All short-term and long-term investments are U.S. Treasury bills or U.S. Treasury notes that are classified as held-to-maturity because the Company has the positive intent and ability to hold the securities to maturity. The securities are carried at their amortized cost. The fair value of all securities is determined by quoted market prices. All long-term investments mature in less than two years. At September 30, 2013 the short-term investments had a fair value of $27,070,089 and a carrying value of $27,053,333. At December 31, 2012 the short-term investments had a fair value of $21,116,952 and a carrying value of $21,112,623 and the long-term investments had a fair value of $12,016,530 and a carrying value of $12,015,906. X - Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + References No definition available. + Details Name: us-gaap_BasisOfAccounting Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 24 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8 Industry Segment and Operations by Geographic Areas 9 Months Ended Sep. 30, 2013 Segment Reporting [Abstract] Industry Segment and Operations by Geographic Areas 5. Industry Segment and Operations by Geographic Areas The Company has one operating segment, drug delivery, which includes the development of injection devices and injection based pharmaceutical products as well as transdermal gel products. Revenues by customer location are summarized as follows: Three Months Ended September 30, Nine Months Ended September 30, 2013 2012 2013 2012 United States of America $ 4,390,966 $ 4,881,106 $ 13,063,929 $ 13,083,259 Europe 1,047,748 787,368 2,585,655 3,448,121 Other 69,110 17,443 224,006 543,021 $ 5,507,824 $ 5,685,917 $ 15,873,590 $ 17,074,401 Revenues by product type: Three Months Ended September 30, Nine Months Ended September 30, 2013 2012 2013 2012 Injection devices and supplies $ 5,100,253 $ 3,600,400 $ 13,882,973 $ 9,505,344 Transdermal products 407,571 2,085,517 1,990,617 7,569,057 Significant customers comprising 10% or more of total revenue are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2013 2012 2013 2012 Teva $ 4,004,531 $ 2,797,761 $ 11,196,559 $ 5,966,246 Ferring 1,047,750 783,757 2,511,332 3,444,510 Actavis (Watson) 202,813 1,171,633 1,301,929 5,859,488 X - Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 25 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8 Stockholders' Equity 9 Months Ended Sep. 30, 2013 Equity [Abstract] Stockholders' Equity 3. Stockholders’ Equity Stock Options The Company records compensation expense associated with share based awards granted to employees at the fair value of the award on the date of grant. The expense is recognized over the period during which an employee is required to provide services in exchange for the award. The Company’s 2008 Equity Compensation Plan (the “Plan”) allows for the grants of options, restricted stock, stock units, stock appreciation rights and/or performance awards to officers, directors, consultants and employees. Under the Plan, the maximum number of shares authorized for issuance is 15,000,000 and the maximum number of shares of stock that may be granted to any one participant during a calendar year is 1,000,000 shares. Options to purchase shares of common stock are granted at exercise prices not less than 100% of the fair market value on the dates of grant. The term of the options range from ten to eleven years and they vest in varying periods. As of September 30, 2013, the Plan had 389,363 shares available for grant. Stock option exercises are satisfied through the issuance of new shares. A summary of stock option activity under the Plan as of September 30, 2013, and the changes during the nine months then ended is as follows: Number of Shares Weighted Average Exercise Price ($) Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value ($) Outstanding at December 31, 2012 7,814,561 1.49 Granted 904,380 4.01 Exercised (707,285 ) 0.72 2,379,554 Cancelled (197,276 ) 3.49 Outstanding at September 30, 2013 7,814,380 1.80 6.4 17,703,665 Exercisable at September 30, 2013 6,234,160 1.38 5.7 16,696,929 Total recognized compensation expense for stock options was approximately $982,000 and $799,000 for the first nine months of 2013 and 2012, respectively, and was approximately $401,000 and $295,000 for the three month periods ended September 30, 2013 and 2012, respectively. As of September 30, 2013, there was approximately $2,517,935 of total unrecognized compensation cost related to nonvested outstanding stock options that is expected to be recognized over a weighted average period of approximately 2.0 years. The per share weighted average fair value of options granted during the first nine months of 2013 and 2012 was estimated as $2.27 and $1.63 on the date of grant using the Black-Scholes option pricing model based on the assumptions noted in the table below. Expected volatilities are based on the historical volatility of the Company’s stock price. The weighted average expected life is based on both historical and anticipated employee behavior. September 30, 2013 2012 Risk-free interest rate 0.7 % 0.7 % Annualized volatility 62.5 % 61.0 % Weighted average expected life, in years 6.0 5.0 Expected dividend yield 0.0 % 0.0 % Stock Awards The employment agreements with certain members of executive management include stock-based incentives under which the executives could be awarded shares of common stock upon the occurrence of various triggering events. There were no shares awarded under these agreements in the first nine months of 2013 and 35,000 shares were awarded in the first nine months of 2012. At times, the Company makes discretionary grants of its common stock to members of management and other employees in lieu of cash bonus awards or in recognition of special achievements. Discretionary grants of common stock totaled 60,000 in the first nine months of 2012 at a weighted average fair value of $2.59. Expense is recognized on a straight line basis over the vesting period and is based on the fair value of the stock on the grant date. The fair value of each stock award is determined based on the number of shares granted and the market price of the Company’s common stock on the date of grant. Expense recognized in connection with performance and discretionary stock awards was approximately $8,700 and $288,000 in the first nine months of 2013 and 2012, respectively, and was $0 and $13,000 in the three month periods ended September 30, 2013 and 2012, respectively. A portion of the discretionary stock grants vested in the first nine months of 2013 and 2012. Some of these grants were net-share settled such that the Company withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld were 30,153 and 11,165 in 2013 and 2012, respectively, and were based on the value of the shares on their vesting date as determined by the Company’s closing stock price. Total payments for the employees’ tax obligations to the taxing authorities were $104,329 and $28,916 in 2013 and 2012, respectively, and are reflected as a financing activity within the Consolidated Statements of Cash Flows. These net-share settlements had the effect of share repurchases by the Company as they reduced the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company. In addition to the shares granted to members of management and employees, at times directors receive a portion of their annual compensation in shares of Company common stock. Expense is recognized on a straight line basis over the one year period that the compensation is earned. Expense recognized for stock-based compensation to directors was $470,000 and $377,200 in the nine month periods ended September 30, 2013 and 2012, respectively, and was $204,000 and $182,800 in the three month periods ended September 30, 2013 and 2012, respectively. As of September 30, 2013, a total of 212,618 shares granted to directors were unvested. As of September 30, 2013, there was approximately $566,000 of total unrecognized compensation cost related to nonvested stock awards that is expected to be recognized over a weighted average period of approximately 8 months. The weighted average fair value of the shares granted in the first nine months of 2013 and 2012 was $4.01 and $3.25 per share, respectively. Long Term Incentive Program The Company’s Board of Directors has approved a long term incentive program for the benefit of the Company’s senior executives. Pursuant to the long term incentive program, the Company’s senior executives have been awarded stock options and performance stock units with a value targeted at the median level of the Company’s peer group. In 2013, the program was modified such that the value of the annual award for each senior executive was delivered one-third in the form of performance stock units, one-third in the form of shares of restricted stock and one-third in the form of stock options. In prior years, two thirds of the value for each senior executive was delivered in the form of stock options and one third of the value was delivered in the form of performance stock units. The stock options have a ten-year term, have an exercise price equal to the closing price of the Company’s common stock on the date of grant, vest in quarterly installments over three years, and were otherwise granted on the same standard terms and conditions as other stock options granted pursuant to the Plan. The restricted stock vests in three equal annual installments. Expense recognized in connection with the restricted stock in the three and nine-month periods ended September 30, 2013 was $46,000 and $73,000, respectively. The performance stock unit awards made to the senior executives will be vested and convert into actual shares of the Company’s common stock based on the Company’s attainment of certain performance goals over a performance period of three years. No expense has been recognized in connection with the performance stock unit awards as the defined performance goals are not yet considered probable of achievement. The performance stock unit awards, restricted stock and stock options granted under the long term incentive program are summarized in the following table: Performance Stock Units Restricted Stock Stock Options Grant Date Number of Shares Fair Value on Grant Date Number of Shares Fair Value on Grant Date Number of Options Exercise Price May 17, 2011 182,000 $ 1.66 — — 317,000 $ 1.66 May 17, 2012 — — — — 470,000 $ 2.94 July 6, 2012 137,715 $ 4.26 — — 178,731 $ 4.26 May 22, 2013 185,185 $ 3.96 185,185 $ 3.96 327,381 $ 3.96 Warrants In the first nine months of 2013, 234,541 warrants were exercised resulting in proceeds to the Company of $261,799. In the first nine months of 2012, the Company received proceeds of $8,962,270 from the exercise of 3,731,135 warrants. Warrants to purchase a total of 1,781,428 shares of common stock were outstanding at September 30, 2013, at a weighted average exercise price of $1.08. X - Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Article 4 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section C Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(d),(e)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Preferred Stock -URI http://asc.fasb.org/extlink&oid=6521494 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644 Reference 17: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644 Reference 18: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph d -Article 4 Reference 19: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 26 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8 License Agreements - Additional Information (Detail) (USD $) 1 Months Ended 9 Months Ended Jan. 31, 2012 Daewoong Development And License Agreement [Member] Sep. 30, 2012 Daewoong Development And License Agreement [Member] Sep. 30, 2013 Actavis License And Commercialization Agreement [Member] Sep. 30, 2012 Actavis License And Commercialization Agreement [Member] Sep. 30, 2013 Pfizer License Agreement [Member] Sep. 30, 2012 Pfizer License Agreement [Member] Deferred Revenue Arrangement [Line Items] Revenue recognized under licensing agreement $ 442,859 Term of the agreement 15 years Period for receiving royalties 3 years Recognition of deferred revenue 750,000 Revenue recognized $ 1,301,929 $ 5,859,488 X - Definition Period for receiving royalty. + References No definition available. + Details Name: atrs_PeriodForReceivingRoyalty Namespace Prefix: atrs_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Definition Revenue recognized in connection with manufacturing start up activities. + References No definition available. + Details Name: atrs_RevenueRecognizedInConnectionWithManufacturingStartUpActivities Namespace Prefix: atrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Total revenue received and recognized under a licensing agreement. + References No definition available. + Details Name: atrs_RevenueRecognizedUnderLicensingAgreement Namespace Prefix: atrs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Term of the agreement. + References No definition available. + Details Name: atrs_TermOfAgreements Namespace Prefix: atrs_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DeferredRevenueArrangementLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A -Subsection 1 + Details Name: us-gaap_RecognitionOfDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration EXCEL 27 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`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`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D)A#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/E-T;V-K:&]L9&5R5]O9CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T M;V-K:&]L9&5R#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-T;V-K:&]L9&5R#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/DYE=%],;W-S7U!E#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DYE=%],;W-S7U!E#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/DEN9'5S=')Y7U-E9VUE;G1?86YD7T]P97)A=&EO;C(\+W@Z3F%M93X- M"B`@("`\>#I7;W)K5]396=M96YT M7V%N9%]/<&5R871I;VXS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I3='EL97-H965T($A2 M968],T0B5V]R:W-H965T3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]F-34Q,6(Q,5\R.&(Y7S0Y83!?8F$V85\W M9&$V864R-C-A.3(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C4U M,3%B,3%?,CAB.5\T.6$P7V)A-F%?-V1A-F%E,C8S83DR+U=O'0O:'1M;#L@8VAA2!);F9O'0^)SQS<&%N/CPO'0^)S$P+5$\'0^ M)V9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)S(P,3,\'0^)T%44E,\"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)RTM,3(M,S$\2!#;VUM;VX@4W1O8VLL(%-H M87)E'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]F-34Q,6(Q,5\R.&(Y7S0Y83!?8F$V85\W9&$V864R-C-A M.3(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C4U,3%B,3%?,CAB M.5\T.6$P7V)A-F%?-V1A-F%E,C8S83DR+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO'!E;G-E'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D(#,L,#`P+#`P,"!S:&%R97,L M(&YO;F4@;W5T3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S3PO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO M'!E;G-E'0^)SQS<&%N/CPO'!E;G-E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-34Q,6(Q,5\R.&(Y M7S0Y83!?8F$V85\W9&$V864R-C-A.3(-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO9C4U,3%B,3%?,CAB.5\T.6$P7V)A-F%?-V1A-F%E,C8S83DR M+U=O'0O M:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E'!E;G-E'0^)SQS<&%N/CPO'1U'0^)SQS<&%N/CPO M&5R8VES92!O9B!S=&]C:R!O<'1I;VYS(&%N9"!W87)R86YT M2!A=V%R9',\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]F-34Q,6(Q,5\R.&(Y7S0Y83!?8F$V85\W9&$V864R-C-A.3(-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C4U,3%B,3%?,CAB.5\T.6$P7V)A M-F%?-V1A-F%E,C8S83DR+U=O'0O:'1M;#L@8VAA'0^)SQD:78^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!3 M13H@8V]L;&%P6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!-05)'24XM3$5& M5#H@-"4[($9/3E0M4TE:13H@,3!P="<^#0H@06YT87)E#(P,4,[ M06YT87)E#(P,40[*2!I2!H87,@9&5V96QO M<&5D(&)O=&@@28C>#(P,3D[6QE/3-$)T9/3E0M4TE:13H@ M.#4E.R!615)424-!3"U!3$E'3CH@=&]P)SXF(WA!13L\+W-U<#X@8G)A;F0@ M:$=(#0H@;6%R:V5T960@:6X@=&AE(%4N4RX@5&AE($-O;7!A;GDF(W@R,#$Y M.W,@;F5E9&QE+69R964@:6YJ96-T:6]N#0H@9&5V:6-E(&ES(&UA6QE/3-$)T9/3E0M4TE:13H@ M.#4E.R!615)424-!3"U!3$E'3CH@=&]P)SXF(WA!13L\+W-U<#X@,B!6:7-I M;VX@86YD#0H@6F]M86IE=#QS=7`@$%%.SPO0T*(&ES(&1E=F5L M;W!I;F<@:71S(&]W;B!D28C>#(P,3D[2!C;VUB M:6YA=&EO;B!P$$P.S$T+"`R,#$S('1H92!#;VUP86YY#0H@86YN;W5N8V5D M('1H92!A<'!R;W9A;"!O9B!/5%)%6%50)B-X,C$R,CL@*&UE=&AO=')E>&%T M92D@:6YJ96-T:6]N#0H@8GD@=&AE(%4N4RX@1F]O9"!A;F0@1')U9R!!9&UI M;FES=')A=&EO;B`H)B-X,C`Q0SM&1$$F(W@R,#%$.RDN#0H@3U1215A54"8C M>#(Q,C([(&ES('1H92!F:7)S="!&1$$@87!P&%T90T*(&9O2!S96QF+6%D;6EN:7-T M2UT;RUU#(Q,C([)B-X03`[ M(&ES(&EN9&EC871E9`T*(&9O6%R=&EC=6QA#QS=7`@$%%.SPO#(P,40[*2!F;W(@=&5S=&]S M=&5R;VYE(')E<&QA8V5M96YT('1H97)A<'D@9F]R(&UE;@T*('-U9F9E6QE/3-$)T9/3E0M4TE:13H@.#4E.R!615)424-! M3"U!3$E'3CH@=&]P)SXF(WA!13L\+W-U<#X@45-4(&%U=&\-"B!I;FIE8W1O M2!E:6=H="!I;G9E2!A;FYO=6YC960@=VET:"!!8W1A=FES#0H@ M*&9O#(Q M,C([+"!T:&4@0V]M<&%N>28C>#(P,3D[6YI M;B!G96P@<')O9'5C="!F;W(@=&AE('1R96%T;65N="!O9B!O=F5R86-T:79E M(&)L861D97(-"B`H)B-X,C`Q0SM/04(F(W@R,#%$.RDN(%1H92!#;VUP86YY M(&AA6QE/3-$)T9/3E0M4TE:13H@.#4E.R!615)424-!3"U!3$E' M3CH@=&]P)SXF(WA!13L\+W-U<#X@*&5S=')A9&EO;"!G96PI#0H@8W5R6UP=&]M6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!-05)'24XM3$5& M5#H@-"4[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A;GD@:&%S('1W M;R!F86-I;&ET:65S(&EN('1H92!5+E,N(%1H92!087)E;G1E7-T96US+B!4:&4- M"B!#;VUP86YY)B-X,C`Q.3MS(&-O2P@=VAE28C>#(P,3D[2!A;F0@8V]M;65R8VEA;"!D979E;&]P;65N="!O9B!T:&4@0V]M M<&%N>28C>#(P,3D['0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA6EN9R!U;F%U9&ET960@8V]N&-H86YG92!#;VUM:7-S:6]N)B-X,C`Q.3MS(%)E9W5L871I M;VX@4RU8+@T*($%C8V]R9&EN9VQY+"!T:&5Y(&1O(&YO="!I;F-L=61E(&%L M;"!O9B!T:&4@:6YF;W)M871I;VX@86YD#0H@9F]O=&YO=&5S(')E<75I2!F;W(@82!F86ER('!R97-E;G1A=&EO;@T*(&AA=F4@8F5E;B!I;F-L=61E M9"X@5&AE(&%C8V]M<&%N>6EN9R!C;VYS;VQI9&%T960@9FEN86YC:6%L#0H@ M65A2!B92!E>'!E8W1E9"!F;W(@=&AE('EE87(@96YD:6YG($1E8V5M M8F5R)B-X03`[,S$L#0H@,C`Q,RX\+W`^#0H@/'`@3I4:6UEF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M)SX-"B!!;&P@2!N M;W1E2X@5&AE('-E8W5R:71I97,@87)E(&-A0T*('%U;W1E9"!M87)K970@<')I8V5S+B!! M;&P@;&]N9RUT97)M(&EN=F5S=&UE;G1S(&UA='5R92!I;B!L97-S('1H86X- M"B!T=V\@>65A$$P.S,P+"`R,#$S('1H92!S M:&]R="UT97)M(&EN=F5S=&UE;G1S#0H@:&%D(&$@9F%I6EN9R!V86QU92!O9@T*("0R-RPP-3,L M,S,S+B!!="!$96-E;6)E$$P.S,Q+"`R,#$R('1H92!S:&]R="UT97)M M(&EN=F5S=&UE;G1S#0H@:&%D(&$@9F%I6EN9R!V86QU92!O9B`D,C$L,3$R+#8R,PT*(&%N9"!T M:&4@;&]N9RUT97)M(&EN=F5S=&UE;G1S(&AA9"!A(&9A:7(@=F%L=64@;V8@ M)#$R+#`Q-BPU,S`@86YD(&$-"B!C87)R>6EN9R!V86QU92!O9B`D,3(L,#$U M+#DP-BX\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]F-34Q,6(Q,5\R.&(Y7S0Y83!?8F$V85\W9&$V864R M-C-A.3(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C4U,3%B,3%? M,CAB.5\T.6$P7V)A-F%?-V1A-F%E,C8S83DR+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R MF5D(&]V97(@=&AE('!E M28C>#(P,3D[2!#;VUP96YS871I;VX@4&QA;B`H=&AE M#0H@)B-X,C`Q0SM0;&%N)B-X,C`Q1#LI(&%L;&]W&EM=6T@;G5M8F5R(&]F('-H87)E M2!B90T*(&=R86YT960@=&\@86YY(&]N92!P M87)T:6-I<&%N="!D=7)I;F<@82!C86QE;F1A6EN9R!P97)I;V1S+B!!6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE$$P.S,Q+"`R,#$R/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C$N-#D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CDP-"PS.#`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE&5R8VES960\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-S`W M+#(X-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XH,3DW+#(W-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C8N-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$W M+#$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C8L,C,T+#$V,#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$N,S@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+C<\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-BPV.38L.3(Y/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/5%1/33H@,'!X.R!& M3TY4+5-)6D4Z(#%P>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU43U`Z(#!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4)/5%1/33H@,'!T.R!-05)'24XM3$5&5#H@-"4[($9/3E0M4TE: M13H@,3!P="<^#0H@5&]T86P@&EM871E;'D@)#0P,2PP,#`@86YD#0H@)#(Y-2PP,#`@9F]R('1H92!T M:')E92!M;VYT:"!P97)I;V1S(&5N9&5D(%-E<'1E;6)E$$P.S,P+"`R M,#$S#0H@86YD(#(P,3(L(')E2X@07,@;V8@4V5P=&5M8F5R M)B-X03`[,S`L(#(P,3,L('1H97)E('=A&EM871E;'D@)#(L M-3$W+#DS-2!O9B!T;W1A;"!U;G)E8V]G;FEZ960@8V]M<&5NF5D(&]V M97(@82!W96EG:'1E9"!A=F5R86=E('!E6QE/3-$)TU!4D=)3BU43U`Z M(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G/@T* M("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$ M8V5N=&5R/CQB/E-E<'1E;6)E$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N-SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/"]T6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%=E M:6=H=&5D(&%V97)A9V4@97AP96-T960@;&EF92P@:6X@>65A$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+C`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE'!E8W1E9"!D:79I9&5N9"!Y:65L9#PO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C`N,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$2!M86ME28C>#(P,3D[F5D(&EN(&-O;FYE M8W1I;VX@=VET:"!P97)F;W)M86YC92!A;F0@9&ES8W)E=&EO;F%R>2!S=&]C M:PT*(&%W87)D2`D."PW,#`@86YD("0R.#@L M,#`P(&EN('1H92!F:7)S="!N:6YE#0H@;6]N=&AS(&]F(#(P,3,@86YD(#(P M,3(L(')E2P@86YD('=A$$P M.S,P+"`R,#$S(&%N9"`R,#$R+`T*(')E2X\+W`^#0H@/'`@ M6UE;G0@=&%X97,L(&%N9"!R96UI='1E9"!T:&4@8V%S:`T* M('1O('1H92!A<'!R;W!R:6%T92!T87AI;F<@875T:&]R:71I97,N(%1H92!T M;W1A;"!S:&%R97,@=VET:&AE;&0-"B!W97)E(#,P+#$U,R!A;F0@,3$L,38U M(&EN(#(P,3,@86YD(#(P,3(L(')E2P@86YD('=E&EN9PT*(&%U=&AO2!T:&4@0V]M<&%N>2!A2X\+W`^#0H@/'`@65E2!C;VUM;VX@F5D(&]N(&$@65A'!E;G-E(')E8V]G;FEZ960@9F]R('-T;V-K+6)A M2X\+W`^#0H@/'`@$$P.S,P+"`R,#$S+"!T M:&5R92!W87,-"B!A<'!R;WAI;6%T96QY("0U-C8L,#`P(&]F('1O=&%L('5N M2`X(&UO;G1H2X\+W`^#0H@/'`@ M28C>#(P,3D[&5C=71I=F4@=V%S(&1E;&EV M97)E9"!I;B!T:&4@9F]R;2!O9@T*('-T;V-K(&]P=&EO;G,@86YD(&]N92!T M:&ER9"!O9B!T:&4@=F%L=64@=V%S(&1E;&EV97)E9"!I;B!T:&4@9F]R;0T* M(&]F('!E$$P.S,P+"`R,#$S('=A&5C=71I=F5S('=I;&P@8F4-"B!V97-T960@ M86YD(&-O;G9E65A MF5D(&EN(&-O;FYE M8W1I;VX@=VET:"!T:&4@<&5R9F]R;6%N8V4-"B!S=&]C:R!U;FET(&%W87)D MF5D(&EN('1H M92!F;VQL;W=I;F<@=&%B;&4Z/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU4 M3U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/E)E$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R M/CQB/E-T;V-K($]P=&EO;G,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED.R!724142#H@ M,S@N.#5P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3 M25I%.B`X<'0G/@T*(#QB/D=R86YT($1A=&4\+V(^/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG M;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.V]N/&)R("\^ M#0H@1W)A;G0@1&%T93PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P M.V]N/&)R("\^#0H@1W)A;G0@1&%T93PO8CX\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.V]F/&)R("\^#0H@3W!T:6]N$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($UA M>2`Q-RP@,C`Q,3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X M,BPP,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$N-C8\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$2`V+"`R,#$R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ.#4L,3@U M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+CDV/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X-2PQ.#4\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C,N.38\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T M.R!-05)'24XM3$5&5#H@-"4[($9/3E0M4TE:13H@,3!P="<^#0H@26X@=&AE M(&9I&5R8VES960-"B!R97-U;'1I;F<@:6X@<')O8V5E9',@=&\@=&AE M($-O;7!A;GD@;V8@)#(V,2PW.3DN($EN('1H92!F:7)S="!N:6YE#0H@;6]N M=&AS(&]F(#(P,3(L('1H92!#;VUP86YY(')E8V5I=F5D('!R;V-E961S(&]F M("0X+#DV,BPR-S`@9G)O;0T*('1H92!E>&5R8VES92!O9B`S+#&5R8VES92!P'1087)T M7V8U-3$Q8C$Q7S(X8CE?-#EA,%]B839A7S=D839A93(V,V$Y,@T*0V]N=&5N M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]F-34Q,6(Q,5\R.&(Y7S0Y83!?8F$V M85\W9&$V864R-C-A.3(O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQD:78^ M#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P2!D:79I9&EN9R!N970@;&]S2!T:&4@=V5I9VAT960M879E2X@5&AE#0H@=&%B M;&4@8F5L;W<@9&ES8VQO#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#%P M>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T], M3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!&3TY4+5-)6D4Z(#$P<'0G(&)O$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P M,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4 M.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($YE="!L;W-S/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@V+#,U.2PY-3<\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z M(#$P<'0G/@T*($)A6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,"XP-3PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C$R/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,"XP M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M*28C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-34Q,6(Q,5\R.&(Y M7S0Y83!?8F$V85\W9&$V864R-C-A.3(-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO9C4U,3%B,3%?,CAB.5\T.6$P7V)A-F%?-V1A-F%E,C8S83DR M+U=O'0O M:'1M;#L@8VAA'0^ M)SQD:78^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L M;&%P6QE/3-$)TU!4D=)3BU4 M3U`Z(#9P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+4)/5%1/33H@,'!T.R!-05)'24XM3$5&5#H@-"4[($9/3E0M4TE:13H@,3!P M="<^#0H@5&AE($-O;7!A;GD@:&%S(&]N92!O<&5R871I;F<@2P@=VAI8V@-"B!I;F-L=61EF5D(&%S(&9O;&QO=W,Z/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z M(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G/@T* M("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/E1H6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\ M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P M,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%5N:71E9"!3 M=&%T97,@;V8@06UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L.#@Q M+#$P-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L-#0X+#$R,3PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV.2PQ,3`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C(R-"PP,#8\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$"<^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT6QE M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XU+#4P-RPX,C0\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$U M+#@W,RPU.3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L M93X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($U!4D=) M3BU,1494.B`T)3L@1D].5"U325I%.B`Q,'!T)SX-"B!2979E;G5E2!P M6QE/3-$)TU!4D=)3BU43U`Z(#!P M=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G/@T*("8C M>$$P.SPO<#X-"B`\=&%B;&4@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0V(&%L:6=N/3-$8V5N=&5R/CQB/DYI;F4@36]N=&AS($5N9&5D/"]B/CQB M$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5& M5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1R86YS9&5R;6%L('!R;V1U M8W1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#`X-2PU,3<\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L M;&%P$$P M.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C(L-SDW+#$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L-#0T+#4Q,#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(P M,BPX,3,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L M,S`Q+#DR.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU M+#@U.2PT.#@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQD M:78^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313I#3TQ,05!3 M13L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P M="<@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P M('=I9'1H/3-$,3`P)3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-"4@=F%L:6=N M/3-$=&]P(&%L:6=N/3-$;&5F=#X\8CXV+CPO8CX\+W1D/@T*(#QT9"!A;&EG M;CTS1&QE9G0@=F%L:6=N/3-$=&]P/CQB/DQI8V5NF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N)SX-"B!);B!*86YU87)Y(#(P,3(L('1H92!#;VUP86YY(&5N=&5R960@ M:6YT;R!A(&QI8V5N#(P,40[*2!U;F1E M28C>#(P,3D['EB=71Y;FEN(&=E;"`S)0T*('!R;V1U8W0L(&]N M8V4@87!P6%L=&EE6UE;G0@=VEL;"!B92!R96-O9VYI>F5D(&%S(')E M=F5N=64-"B!W:&5N(')E8V5I=F5D+B!2;WEA;'1I97,@=VEL;"!B92!R96-O M9VYI>F5D(&%S(')E=F5N=64@=VAE;B!E87)N960N#0H@5&AE('1E$$P.S,P M+"`R,#$R(&EN(&-O;FYE8W1I;VX@=VET:`T*('5P9G)O;G0@86YD(&UI;&5S M=&]N92!P87EM96YTF4Z,7!X M.VUA#MM87)G:6XM8F]T=&]M.C!P>#X-"B`F(WA!,#L\ M+W`^#0H@/'`@3I4:6UEF5R($EN8RXF(W@R,#$Y.W,-"B!#;VYS=6UEF5R(&%SF%T:6]N(&]F('1H92!P&-L=7-I=F4@=&5R6UE;G0@=VEL;"!B92!R M96-O9VYI>F5D(&%S(')E=F5N=64-"B!W:&5N(')E8V5I=F5D+B!2;WEA;'1I M97,@=VEL;"!B92!R96-O9VYI>F5D(&%S(')E=F5N=64@=VAE;B!E87)N960N M#0H@5&AE($-O;7!A;GD@$$P.S,P M+"`R,#$R+"!W:&EC:"!W87,@96%R;F5D('=H96X@4&9I>F5R(&%C:&EE=F5D M(&$-"B!D979E;&]P;65N="!M:6QE3I4:6UEF4Z,3!P=#L@ M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!);B!*=6QY(#(P,3$L M('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A;B!E>&-L=7-I=F4@;&EC96YS M:6YG#0H@86=R965M96YT('=I=&@@06-T879I6YI;B!G96P@,R4@<')O9'5C="P@=VAI8V@@ M=V%S#0H@6YI;B!G96P@,R4@<')O9'5C="!A;F0-"B!!8W1A=FES)B-X,C`Q.3L@ M;WAY8G5T>6YI;B!G96P@<')O9'5C="!'96QN:7%U93QS=7`@6UE;G1S+B!4:&4@;6EL97-T;VYE#0H@<&%Y M;65N="!B87-E9"!O;B!T:&4@86-H:65V96UE;G0@;V8@2!A M<'!R;W9A;"!W87,@'!I'!IF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX- M"B!4:&4@0V]M<&%N>2!R96-E:79E9"!A(&UI;&5S=&]N92!P87EM96YT(&9R M;VT@06-T879I6UE;G0@=V%S(')E8V]G;FEZ960@87,@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2`H5&%B;&5S*3QB2!;06)S=')A8W1=/"]S=')O;F<^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)SQD:78^#0H@/'`@6QE/3-$)T)/4D1%4BU#3TQ,05!313H@ M8V]L;&%P$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE$$P.S,Q+"`R,#$R M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$N-#D\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDP-"PS.#`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE&5R8VES960\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XH-S`W+#(X-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XH,3DW+#(W-CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N-#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$W+#$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L,C,T+#$V,#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C$N,S@\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XU+C<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-BPV M.38L.3(Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T'0^)SQD:78^#0H@/'1A8FQE('-T>6QE/3-$)T)/ M4D1%4BU#3TQ,05!313H@8V]L;&%P$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XP+C<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N-SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4 M+5-)6D4Z(#$P<'0G/@T*($%N;G5A;&EZ960@=F]L871I;&ET>3PO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8R+C4\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C8Q+C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4N,#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C`N,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/"]T'0^)SQD:78^#0H@/'`@6QE/3-$)T)/4D1%4BU#3TQ, M05!313H@8V]L;&%P$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.U5N:71S/"]B/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A M<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO M=W)A<"!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E&5R8VES M93QB6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ M.#(L,#`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+C8V/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C,Q-RPP,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$N-C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1% M6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($UA>2`Q M-RP@,C`Q,CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0W M,"PP,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(N.30\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($IU M;'D@-BP@,C`Q,CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S M-RPW,34\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0N,C8\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C,N.38\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P M$$P.TUO;G1H$$P.T5N M9&5D/"]B/CQB$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/DYI;F4@36]N=&AS($5N9&5D/"]B M/CQB$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XQ,C"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/B@P+C`U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,"XP,SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C`V/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT"<^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/"]T86)L93X-"B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M2!'96]G'0^ M)SQS<&%N/CPO2!O9B!2979E;G5E2!#=7-T;VUE'0^)SQD:78^#0H@/'`@2!C=7-T;VUE6QE/3-$ M)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$S+#`V,RPY,CD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$S+#`X,RPR-3D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($5U M$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,#0W+#$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW.#$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L-3@U+#8U M-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#0T."PQ M,C$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G M/@T*($]T:&5R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$W+#0T M,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,C0L,#`V M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4T,RPP,C$\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L-C@U+#DQ-SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XQ-2PX-S,L-3DP/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$W+#`W-"PT,#$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@'0^)SQD:78^#0H@/'`@7!E.CPO<#X-"B`\<"!S='EL93TS1"=-05)' M24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,G!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU# M3TQ,05!313H@8V]L;&%P6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/E1H6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$ M8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($EN M:F5C=&EO;B!D979I8V5S(&%N9"!S=7!P;&EE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C,L-C`P+#0P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C0P-RPU-S$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C$L.3DP+#8Q-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XW+#4V.2PP-3<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T2!O9B!3:6=N:69I8V%N="!#=7-T;VUE6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%2 M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G/@T*("8C>$$P.SPO M<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L M:6=N/3-$8V5N=&5R/CQB/E1H$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$ M8V5N=&5R/CQB/DYI;F4@36]N=&AS($5N9&5D/&)R("\^#0H@4V5P=&5M8F5R M(#,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5& M5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($9E$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#`T-RPW-3`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#$W,2PV M,S,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L.#4Y M+#0X.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F M-34Q,6(Q,5\R.&(Y7S0Y83!?8F$V85\W9&$V864R-C-A.3(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C4U,3%B,3%?,CAB.5\T.6$P7V)A-F%? M-V1A-F%E,C8S83DR+U=O'0O:'1M;#L@8VAA3QB3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]F-34Q,6(Q,5\R.&(Y7S0Y83!?8F$V85\W M9&$V864R-C-A.3(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C4U M,3%B,3%?,CAB.5\T.6$P7V)A-F%?-V1A-F%E,C8S83DR+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`M($%D9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I;"D@ M*%531"`D*3QB6UE;G0@07=A M'0^)SQS<&%N/CPOF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XQ-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO MF5D(&-O;7!E;G-A=&EO;B!C;W-T(')E;&%T960@=&\@;F]N=F5S=&5D M(&]U='-T86YD:6YG('-T;V-K(&%W87)D'0^)SQS<&%N/CPO'0^)S@@;6]N=&AS/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO2!I;F-O;64@=&%X(&]B;&EG871I;VX\+W1D/@T*("`@("`@("`\=&0@ M8VQA65E"!O8FQI M9V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES97,@ M<')I8V4@870@96YD/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD M(#$N,#@\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE M;G0@07=A'0^)SQS<&%N/CPOF5D('-T;V-K+6)A'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XR,#0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0@07=A'0^ M)SQS<&%N/CPOF5D('-T;V-K+6)A'!E M;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,#$L,#`P/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!3:&%R97,@6TUE;6)E'0^)SQS<&%N/CPO6UE;G0@07=A'0^)SQS<&%N/CPOF5D('-T;V-K+6)A'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N M/CPO6UE;G0@<&5R9F]R;6%N8V4@87=A'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO6UE;G0@ M07=A'0^)SQS<&%N/CPOF5D('-T;V-K+6)A'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#0V+#`P,#QS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0@07=A'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO&EM=6T@6TUE;6)E'0^)SQS<&%N/CPO6UE;G0@07=A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M65A M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F M-34Q,6(Q,5\R.&(Y7S0Y83!?8F$V85\W9&$V864R-C-A.3(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C4U,3%B,3%?,CAB.5\T.6$P7V)A-F%? M-V1A-F%E,C8S83DR+U=O'0O:'1M;#L@8VAA2!.;W1E(%M!8G-T M'0^ M)S8@>65A&5R8VES92!0&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA&5R8VES92!0&5R8VES92!03X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F M-34Q,6(Q,5\R.&(Y7S0Y83!?8F$V85\W9&$V864R-C-A.3(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C4U,3%B,3%?,CAB.5\T.6$P7V)A-F%? M-V1A-F%E,C8S83DR+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPOF5D('9O;&%T:6QI='D\+W1D/@T*("`@("`@("`\=&0@ M8VQA'!E8W1E9"!L:69E+"!I;B!Y96%R'0^)S8@>65A6EE;&0\+W1D/@T*("`@("`@("`\=&0@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`M(%-C:&5D=6QE(&]F(%!E2!3:&%R92UB87-E9"!0 M87EM96YT($%W87)D(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO2!3:&%R92UB87-E9"!087EM96YT M($%W87)D(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO'0^36%Y(#$W+`T*"0DR,#$Q/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2`Q-RP@ M,C`Q,B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)SQS<&%N/CPO2`Q M-RP-"@D),C`Q,CQS<&%N/CPO6UE;G0@07=A6UE;G0@07=A6UE;G0@ M07=A6UE;G0@07=A'0^)R9N M8G-P.R9N8G-P.SQS<&%N/CPO2`V+"`R,#$R M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO M2!3:&%R92UB87-E9"!087EM M96YT($%W87)D(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO'0^)R9N8G-P M.R9N8G-P.SQS<&%N/CPO6UE;G0@07=A'0^)R9N8G-P.R9N8G-P.SQS<&%N M/CPO6UE;G0@ M07=A'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO6UE;G0@07=A'0^)SQS<&%N/CPO&5R M8VES92!02`V+"`R,#$R(%M-96UB97)=/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!3:&%R92UB87-E9"!087EM96YT($%W M87)D(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO2`R,BP@,C`Q,R!;365M M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M&5R8VES92!03X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]F-34Q,6(Q,5\R.&(Y7S0Y83!?8F$V85\W9&$V864R-C-A M.3(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C4U,3%B,3%?,CAB M.5\T.6$P7V)A-F%?-V1A-F%E,C8S83DR+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!'96]G'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`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`@("`\=&%B;&4@8VQA2!396=M96YT(&%N9"!/<&5R M871I;VYS(&)Y($=E;V=R87!H:6,@07)E87,@+2!3=6UM87)Y(&]F(%-I9VYI M9FEC86YT($-U'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO2!7:61E(%!O6EN9R!! M;6]U;G0L($UA:F]R($-U'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D M('5N9&5R(&QI8V5N'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC XML 28 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 86 156 1 false 24 0 false 9 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.antarespharma.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.antarespharma.com/taxonomy/role/StatementOfFinancialPositionClassified CONSOLIDATED BALANCE SHEETS false false R3.htm 104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.antarespharma.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.antarespharma.com/taxonomy/role/StatementOfIncome CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 106 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.antarespharma.com/taxonomy/role/StatementOfOtherComprehensiveIncome CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS false false R6.htm 107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.antarespharma.com/taxonomy/role/StatementOfCashFlowsDirect CONSOLIDATED STATEMENTS OF CASH FLOWS false false R7.htm 108 - Disclosure - Description of Business Sheet http://www.antarespharma.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations Description of Business false false R8.htm 109 - Disclosure - Basis of Presentation Sheet http://www.antarespharma.com/taxonomy/role/NotesToFinancialStatementsBasisOfAccounting Basis of Presentation false false R9.htm 110 - Disclosure - Stockholders' Equity Sheet http://www.antarespharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Stockholders' Equity false false R10.htm 111 - Disclosure - Net Loss Per Share Sheet http://www.antarespharma.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Net Loss Per Share false false R11.htm 112 - Disclosure - Industry Segment and Operations by Geographic Areas Sheet http://www.antarespharma.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Industry Segment and Operations by Geographic Areas false false R12.htm 113 - Disclosure - License Agreements Sheet http://www.antarespharma.com/taxonomy/role/NotesToFinancialStatementsDeferredRevenueDisclosureTextBlock License Agreements false false R13.htm 114 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.antarespharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables Stockholders' Equity (Tables) false false R14.htm 115 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.antarespharma.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Net Loss Per Share (Tables) false false R15.htm 116 - Disclosure - Industry Segment and Operations by Geographic Areas (Tables) Sheet http://www.antarespharma.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables Industry Segment and Operations by Geographic Areas (Tables) false false R16.htm 117 - Disclosure - Description of Business - Additional Information (Detail) Sheet http://www.antarespharma.com/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformation Description of Business - Additional Information (Detail) false false R17.htm 118 - Disclosure - Basis of Presentation - Additional Information (Detail) Sheet http://www.antarespharma.com/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation Basis of Presentation - Additional Information (Detail) false false R18.htm 119 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.antarespharma.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation Stockholders' Equity - Additional Information (Detail) false false R19.htm 120 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail) Sheet http://www.antarespharma.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivity Stockholders' Equity - Summary of Stock Option Activity (Detail) false false R20.htm 121 - Disclosure - Stockholders' Equity - Assumptions Used in Fair Value Measurement of Options Granted (Detail) Sheet http://www.antarespharma.com/taxonomy/role/DisclosureStockholdersEquityAssumptionsUsedInFairValueMeasurementOfOptionsGranted Stockholders' Equity - Assumptions Used in Fair Value Measurement of Options Granted (Detail) false false R21.htm 122 - Disclosure - Stockholder's Equity - Schedule of Performance Stock Unit Awards and Stock Option Granted Under Long Term Incentive Program (Detail) Sheet http://www.antarespharma.com/taxonomy/role/DisclosureStockholdersEquityScheduleOfPerformanceStockUnitAwardsAndStockOptionGrantedUnderLongTermIncentiveProgram Stockholder's Equity - Schedule of Performance Stock Unit Awards and Stock Option Granted Under Long Term Incentive Program (Detail) false false R22.htm 123 - Disclosure - Net Loss Per Share - Additional Information (Detail) Sheet http://www.antarespharma.com/taxonomy/role/DisclosureNetLossPerShareAdditionalInformation Net Loss Per Share - Additional Information (Detail) false false R23.htm 124 - Disclosure - Net Loss Per Share - Basic and Diluted Loss Per Common Share (Detail) Sheet http://www.antarespharma.com/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedLossPerCommonShare Net Loss Per Share - Basic and Diluted Loss Per Common Share (Detail) false false R24.htm 125 - Disclosure - Industry Segment and Operations by Geographic Areas - Additional Information (Detail) Sheet http://www.antarespharma.com/taxonomy/role/DisclosureIndustrySegmentAndOperationsByGeographicAreasAdditionalInformation Industry Segment and Operations by Geographic Areas - Additional Information (Detail) false false R25.htm 126 - Disclosure - Industry Segment and Operations by Geographic Areas - Summary of Revenues by Customer Location (Detail) Sheet http://www.antarespharma.com/taxonomy/role/DisclosureIndustrySegmentAndOperationsByGeographicAreasSummaryOfRevenuesByCustomerLocation Industry Segment and Operations by Geographic Areas - Summary of Revenues by Customer Location (Detail) false false R26.htm 127 - Disclosure - Industry Segment and Operations by Geographic Areas - Summary of Revenues by Product Type (Detail) Sheet http://www.antarespharma.com/taxonomy/role/DisclosureIndustrySegmentAndOperationsByGeographicAreasSummaryOfRevenuesByProductType Industry Segment and Operations by Geographic Areas - Summary of Revenues by Product Type (Detail) false false R27.htm 128 - Disclosure - Industry Segment and Operations by Geographic Areas - Summary of Significant Customers Comprising 10% or More of Total Revenue (Detail) Sheet http://www.antarespharma.com/taxonomy/role/DisclosureIndustrySegmentAndOperationsByGeographicAreasSummaryOfSignificantCustomersComprising10OrMoreOfTotalRevenue Industry Segment and Operations by Geographic Areas - Summary of Significant Customers Comprising 10% or More of Total Revenue (Detail) false false R28.htm 129 - Disclosure - License Agreements - Additional Information (Detail) Sheet http://www.antarespharma.com/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformation License Agreements - Additional Information (Detail) false false All Reports Book All Reports Process Flow-Through: 103 - Statement - CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Sep. 30, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 106 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Process Flow-Through: 107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS atrs-20130930.xml atrs-20130930.xsd atrs-20130930_cal.xml atrs-20130930_def.xml atrs-20130930_lab.xml atrs-20130930_pre.xml true true XML 29 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8 CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) Sep. 30, 2013 Dec. 31, 2012 Statement Of Financial Position [Abstract] Preferred Stock, par value $ 0.01 $ 0.01 Preferred Stock, shares authorized 3,000,000 3,000,000 Preferred Stock, shares outstanding 0 0 Common Stock, par value $ 0.01 $ 0.01 Common Stock, shares authorized 150,000,000 150,000,000 Common Stock, shares issued 127,230,176 125,949,024 Common Stock, shares outstanding 127,230,176 125,949,024 X - Definition Face amount or stated value per share of common stock. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - Definition The maximum number of common shares permitted to be issued by an entity's charter and bylaws. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - Definition The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 30 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8 Net Loss Per Share (Tables) 9 Months Ended Sep. 30, 2013 Earnings Per Share [Abstract] Basic and Diluted Loss Per Common Share The table below discloses the basic and diluted loss per common share. Three Months Ended September 30, Nine Months Ended September 30, 2013 2012 2013 2012 Net loss $ (6,359,957 ) $ (3,534,239 ) $ (14,871,661 ) $ (6,415,705 ) Basic and diluted weighted average common shares outstanding 127,162,064 108,961,792 126,581,018 105,735,855 Basic and diluted net loss per common share $ (0.05 ) $ (0.03 ) $ (0.12 ) $ (0.06 ) X - Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 31 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8 CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $) 3 Months Ended 9 Months Ended Sep. 30, 2013 Sep. 30, 2012 Sep. 30, 2013 Sep. 30, 2012 Statement Of Income And Comprehensive Income [Abstract] Net loss $ (6,359,957) $ (3,534,239) $ (14,871,661) $ (6,415,705) Foreign currency translation adjustment 21,611 11,500 3,167 (93,948) Comprehensive loss $ (6,338,346) $ (3,522,739) $ (14,868,494) $ (6,509,653) X - Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Comprehensive Income -URI http://asc.fasb.org/extlink&oid=16317811 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e557-108580 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684 + Details Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8 CONSOLIDATED BALANCE SHEETS (USD $) Sep. 30, 2013 Dec. 31, 2012 Current Assets: Cash and cash equivalents $ 42,960,486 $ 52,097,064 Short-term investments 27,053,333 21,112,623 Accounts receivable, net 3,405,395 2,228,650 Inventories, net 1,804,695 1,002,703 Deferred costs 317,514 755,159 Prepaid expenses and other current assets 1,001,195 463,033 Total current assets 76,542,618 77,659,232 Equipment, molds, furniture and fixtures, net 6,013,707 3,583,104 Patent rights, net 1,217,720 1,123,652 Goodwill 1,095,355 1,095,355 Long-term investments 0 12,015,906 Other assets 61,241 49,361 Total Assets 84,930,641 95,526,610 Current Liabilities: Accounts payable 4,689,615 2,864,507 Accrued expenses and other liabilities 4,863,980 2,916,700 Deferred revenue 633,970 2,157,016 Total current liabilities 10,187,565 7,938,223 Deferred revenue - long term 874,596 1,037,795 Total liabilities 11,062,161 8,976,018 Stockholders' Equity: Preferred Stock: $0.01 par, authorized 3,000,000 shares, none outstanding 0 0 Common Stock: $0.01 par; authorized 150,000,000 shares; 127,230,176 and 125,949,024 issued and outstanding at September 30, 2013 and December 31, 2012, respectively 1,272,302 1,259,490 Additional paid-in capital 240,919,182 238,745,612 Accumulated deficit (167,660,826) (152,789,165) Accumulated other comprehensive loss (662,178) (665,345) Total Stockholders' Equity 73,868,480 86,550,592 Total Liabilities and Stockholders' Equity $ 84,930,641 $ 95,526,610 X - Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3-4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a(1) -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669686-108580 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e637-108580 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e681-108580 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.30(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.18) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 18 -Article 5 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.9) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 9 -Article 5 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 + Details Name: us-gaap_CommonStockValueOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_DeferredCostsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details Name: us-gaap_DeferredRevenueCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details Name: us-gaap_DeferredRevenueNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 35 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.32) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 25 -Article 7 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 32 -Article 5 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 21 -Article 5 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_LongTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.17) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 17 -Article 5 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 + Details Name: us-gaap_PreferredStockValueOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 8 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 7 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.2) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Subparagraph g -Article 7 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8 Net Loss Per Share - Basic and Diluted Loss Per Common Share (Detail) (USD $) 3 Months Ended 9 Months Ended Sep. 30, 2013 Sep. 30, 2012 Sep. 30, 2013 Sep. 30, 2012 Earnings Per Share [Abstract] Net loss $ (6,359,957) $ (3,534,239) $ (14,871,661) $ (6,415,705) Basic and diluted weighted average common shares outstanding 127,162,064 108,961,792 126,581,018 105,735,855 Basic and diluted net loss per common share $ (0.05) $ (0.03) $ (0.12) $ (0.06) X - Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + References No definition available. + Details Name: us-gaap_EarningsPerShareBasicAndDiluted Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). + References No definition available. + Details Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 34 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8 Stockholders' Equity (Tables) 9 Months Ended Sep. 30, 2013 Equity [Abstract] Summary of Stock Option Activity A summary of stock option activity under the Plan as of September 30, 2013, and the changes during the nine months then ended is as follows: Number of Shares Weighted Average Exercise Price ($) Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value ($) Outstanding at December 31, 2012 7,814,561 1.49 Granted 904,380 4.01 Exercised (707,285 ) 0.72 2,379,554 Cancelled (197,276 ) 3.49 Outstanding at September 30, 2013 7,814,380 1.80 6.4 17,703,665 Exercisable at September 30, 2013 6,234,160 1.38 5.7 16,696,929 Assumptions Used in Fair Value Measurement of Options Granted September 30, 2013 2012 Risk-free interest rate 0.7 % 0.7 % Annualized volatility 62.5 % 61.0 % Weighted average expected life, in years 6.0 5.0 Expected dividend yield 0.0 % 0.0 % Schedule of Performance Stock Unit Awards and Stock Option Granted Under Long Term Incentive Program The performance stock unit awards, restricted stock and stock options granted under the long term incentive program are summarized in the following table: Performance Stock Units Restricted Stock Stock Options Grant Date Number of Shares Fair Value on Grant Date Number of Shares Fair Value on Grant Date Number of Options Exercise Price May 17, 2011 182,000 $ 1.66 — — 317,000 $ 1.66 May 17, 2012 — — — — 470,000 $ 2.94 July 6, 2012 137,715 $ 4.26 — — 178,731 $ 4.26 May 22, 2013 185,185 $ 3.96 185,185 $ 3.96 327,381 $ 3.96 X - Definition Tabular disclosure of share based compensation award performance based units and restricted stock units and stock options granted activity + References No definition available. + Details Name: atrs_ScheduleOfShareBasedCompensationAwardPerformanceBasedUnitsAndRestrictedStockUnitsAndStockOptionsGrantedActivityTableTextBlock Namespace Prefix: atrs_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of the change in stock options. + References No definition available. + Details Name: us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration ZIP 35 0001193125-13-430417-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-13-430417-xbrl.zip M4$L#!!0````(`'6*9D.!-)/?M64``.QS!``1`!P`871RE)]P'I2=7@+``$$)0X```0Y`0``[%U?TZ2<;QS9O8E18QB#+^`DWD^_+7`2;)/$26SB M))Z'R3%(J'^M5G>KU9)^_OOU*%(N19J%2?RYA?=02Q%Q/PG">/"Y- ?65&2MOW_YRW_]_-^:IG2[2CN)8Q%%8JK\WA>12/U<*(>Q MK-$7\+(_&8DX5Y5S/Q.!DL3*[T[WJT+VL*(,\WQ\L+]_=76UEZ;!S6?V^LEH M7]&TFR9^*ZD[4!2V1X#"RJMN,HF#`X56'KFI\',HK@1`QX%"$*8:QAIB/:0? MZ/H!L?Y5+9V,IVDX&.;*7_M_@\+(T&0-I;O7W:L`^TDY3>(,2H_&?CQ5["A2 MNK)6IG1%)M)+$>S-/GI]GD8*\#3./K9#Q)0E;K^=A75?AJ)X__=O M7T_[0S'RM44$("D#WQ_?UKSPL_.BWNS%?M$/"&L4WU0)Q%U#!469Z.\-DLM] M>%%3W,_3>9;Z<>ZG(AL/_73D%S(C*R%.486H?#H662U5Q9N:=B0I03Y/V8P! MQG[Y#*JE\0@3_=EC^Q#"9&&_=L* M,`0?KY/$VD*]29[>*_)\']ZV8+`J2C%>6E%OM1C+WKK/@&8-X=?VP7\*"(73@Q7F83T%E MC9+X-$_Z?YX.Y7@YGN2%,@<%K_23.!?7>5?2*9+H[,0S*34T^`]3C+1?$0CR MV6FO?8;.)`*,X2>,KDD)87MGY,QH?<'$9)CJ2/]Y?S4$)=J9 MCCEP_6QHQX'\X_W_)+ST(S`\F9V[?II.H?1O?C013P1-9+?-@9[IR[-_GK:K MR-$2;M3&R&'(T9C=09KN\8YF6Y1H-C8YM5R76XY[AA$B9X1+[-C@')&?]Y\$ M9X$#:^SM)>"K]79';SMMRS$TY*"VIEO(UASN=C3';-O$Z'2P2YTS?$9)T=V$ M(FRR"N:5.[MX[4B?0EIE$6>%U;?3U(\'0GHR8.9= MB[0?9OYY)(XFHW.1-L0?[B!*=`MKK$UMD`K/T"P3$L='I4/?Q?2U16!#=,$?R!F(B1.P-P^59LN,ZRB3<_&(CU;9B!98E^; MZ-QU&=4L2PXAT]8U^(TTXGHFO#&I[?)R"$F;LF>MZR;;F(.9;G,L2EIQ2Q];HZW M1/A"5P=!*,VW'YWX87`8N_XXS/VHHMNW#RAM?2$ZXIACJQ*,?1S)0]:H4-;K M=/+7/I+U!T)-B]3/(^V*W`]C$7A^&L/+K#(2VN(B[(?;I[-25UR*>+*])@B<*T8I-RL]7$_ZO1;(CH.WH*3`UEHZM,)T7&N/ M:F'<"WKK\!$Y%\<(3`^KQ_>@>!XE<7]+)91@Z#A3-SB[5T+OJ+]WZK/]6M:Z M6;D@M1.=AQ7MUR0>]$0Z.BQ6U^4$>?LD%),Y.U)#\H*#D&4BWUK_%KK+9(9. M&*YZ>E62Y]'\DB3!51A%6P<$RR4SQ`UJ5/ST&VKG,13>:XEQBQ4&!B^-85)5 M\[6$UTG;]H'1Z\Q62>SF,QP:4'LP`R:<(9CIORB[X728I/FV:T`Y?3"10>&_ M:O1SF?+Z:$97]`4P0Z[/BWQ;]:)1#G23J%`EL'3:X8 M6TAG56A5@N>A=$*@0WR%*3Y,"<%H#T+`/=-!6P@.HR+/R#1)Q48_C*%F<>/\ M\2C^^>-1?&@K#>,L[!<#'3?'*\JPV3:,CD8MQ]1TY+F:;9BZ1@BBCLL\OSY[*"*5;<3419-:J^,0[,,]H;C:-D*L2I M2"_#OJAO%?QKZ<:(H&@@ZR5E)/3VO>S'HR3_0P"+^LD@7LN"Z\J,)H9G.Y;; MUDR'.S*U0=5'7; MJ\]QX>^:"%G\J6J]'N&B+D_&(LVG)Y$/\AP'X0J,^H>2C3X;9L-BN\UJG0RBDAJ^<126]J#UD_[Z\+[YHL1!D$EAO6 MTF*G6E98V=[0CV>:\W;`OR3Y\HP3`ZS>-?RQN/'T=*U5=!J9Y;01/!^Q:HPU M6VU*H`)KN@EKDR.8:)9ZE$T:X@7'9"5(I M&G*;A]&X<=E$B`AC0O$&-\$4/"N"X\`Q>+XUFV#($O`UION0V288@^L<$;UV M1>"Q'4]KV:^Q:91X-92;WZ^Q8:#O;[_&,L,VEC:*9WH3[^F+T9:/ME_CN6*Z MTGZ-&S[+E&ZCNHR\X?T::TT"W_1`?FD2^/H2CS>MF[Y1T;5)]?=GW%O.,&0(,IMIAA((-79H6-YQTW`%0F#E"9!,?P MMN0=-S"0MRCON($^+O*.#6):8'HJ@_A5\HX;L$!9'4-*O+[HTG'C>`T[H- MP;U*XG$#NJ8(I2)L<%11-AO-/]X\*)E_;#+P?*H1\?7G'S?0.\WF'S<`"+PU MG5/60/YQ`V#T.NO55/YQ`]JO]<4@B)N(Z2]:6%I#_G$#KHCTN3`FC+Q6_O'F M,8*\$D)@6HB6(QL;S3_>/#2CR`,D)JKT7D/YQPTH&AEMAE:84;%G3\D_?IVD MV!J-QC;QC@PSXE-;;! M;,+-#P1<6B_&JQIB*[,)-R\-O/6%&A8TK5?E_K%L0GEP;B_UY2SN=#HZ3YXP M&2`FG4L,?,XYOD4"FMWKGI9'^,Y1LG@V<5<,PBR7.7U'_N@)LK@>.D'4[*.> MW?5.E9-_V-UOMJH<'KE[U:.'YPF$]\&C@>2ZYW(?$D_Q&Z';=M`FT=C=D. MT73=Q9KC4E.S.]AFB,O4,ZND^P($2Y2$SI&RR.!.&(G4]7,Q`.>A:?Z"DP8^ MV>Q"@$`I:*DR=XZX.\IO+@SHA%G?CXJQ#$^>X&>OA\O2C8:/E`3?0],RT;WI M>'URO"*EQ1D\VJ_SE$I"ELD[$6F8!%X2S]-U1_;,2M\)R[H9OB+E(,+P9:)1 M7))]'UWWC;VR5UYE]('N^+5V[%5HFK?L-X=O'H^EOI$F1PR>.$%?)/W6L,\^ M]>BYH]QKVZ;A:?!]4].9QS6.J*M9M*-SS!RB$WLV7N\,^KUT+X0>RJ==,8:) M/)1J`S>B))NDH@?8G.A)*YJ/])'';!`OBVOP#P?\-+X*'E3X/\$U`K?^5RXJUD^53>E.`<=]M>5W./OWZU3TZ]`Z`PBOQQ M)CXIG>.C'GSPV^'7/PZ47C@2F7(DKI1N,O+CV=O3PW]!%8S&P/CS)`U$6OA2 M8%&B;.SWBPMJ9K_'?A#<_+X*@WSXN063Z!];5<+2ZH]`N?2C5)?%S^4_C#WYS_WSFX?[>?#`%^_]#*B+";@44V76HXH?!\JL M\^45,^=3^.(O(AFD_G@8]A4[%7[V4,O[<\CVBPZH/!C?=,8WN_O+X9'6.SXY M4-@X?ZP+9L6=XU[O^-N!@F2-V;.O7J=WH.@_+O?3K-W>4-Q>E3/T,R6)A9+< MR+>2EY%_IUF4@ M5#">E8&X*U-V\_B563A;>Y+RH("NRY.12!48Y>751C*=+)N,1GZ940AH+F!D M)5?9P6K$5TF9(Z]*#;FCYB=_-/[TP[6-/BU]?VL&/"=WH[G^5=3W?-=UHT_,J-$]OQ'EEF;4J0Z462M'N_"!Z!/Q" MC8?KS@^_FQ']0YG5J^!QKF1)%`:M)0[#^(2A!0]8W=BY-5J]82J$\@W\BV&F M@-G8IR+(OF=(G5%T_D^N'44QEO$K)UPRQTI#W27](3? MF7P^"IA\-,"['GYE+3)SZP:`(`&_[@?7];Q.YQ[%(J=0=3YLS_N]IQT>M;TC M\)XU+$8KNN"ENWU7?MG?_J=<@PR48H=#)F<:=G&=H+_D[ZY5#FKJ_L]*GM'L M9W%S:5%-5RE'*F=LI>IQ#%5$:,J)_P#`;:H M2HP-`UZ/8ML6->9-Y/I@XTKK:35J.EM%NJF:NO76A/NEP$W+5"G[<+"):EB& MR@SCHP&GJJY;*B;X+2BU[?76BF2?-Z?E&%_T MI;`-'=RV5]5N,V4QOEXA9M4`0Q=UXFS*7ZS"W,WWKV?S_9HN>*J"VVB#3Q>1 M'?]V_-OQ[ZWPKXG)\,J]!F\NDCBOT>XW*Q+W=JRL]Y2VGAFC,%0#F:I%]%1R;._[4N\:&:IE4-?CK3`K>`(-,%9FZJJ.=1_DD`T'!0`3)Y#P2 M39FDY[>XG39]Q\$=!W<33L7@'2916DSF4QBZ' M7&+"\Q,++8NHW/PH'\2O&^ M$BE[E=VA-SM#&]=@+\W&T)&I&N:&8^?;!YNHR#)4XY66G5XSU4KE'*GLXP$' M,6=<1<:&@6]C$/,4H(478=^7QYG--HK+,R]&XS3,Y'9[C'Y4DE09):F0^UIR M>:.`^:EPY"'# M\GQC$6?%>;QVFOKQ0,A/.=.[(B?^5#ZRK_PTN+V/Q,ZRR6A&U/TTW$Y/GQNN8QHXV8 MB]H.Q>4!WV@/56\/WSC\!6[WAR*81.+XHCQQ_WL80.F+)!T5[<[R]SMI,O*N MX1NQ'[DW*V#.]&2V:B]O7A5ID8^T_J/2==QYV>Q[>RPK8QVQZMX"RV_.PV_/P?H5[MW:T"'BW.OC>`>]6 M!W=['MY.8&*WYV&UP--NS\,61]BW19?M]CR\W0CK;L_#1P.^'7L>:F+JFPK: M;C`2+Z^1[^?7P/[*C>QG8Y&>99*\K-HA M9*E#VD3GKLNH9EG4A@ZQ=0U^(XVXG@EO3&J[_,Q`J+BDEN[I_`E=LF8.S?+'DPQUGBCZ3V[).H,M!&`J!>>C+JVY!&_GI((PU:/"@N*ET]KLT M!P>H\DA2>"!7C.:Y_&"7W'J,0Z'X_7YYU:N4N$GL3X+B)B60O2(64=S]?A'& M?MP/P:_,Y`5+Y;W,0_]2;CX[%R+^#WO7_Z,VDNQ_7VG^!^LI)R62X;`-!MY* M3X)A)B][NTDNF>SMO5].'M-`;XS-NNV98?_Z5U7=[2]@F`P+#$PL[28![.[J MZNJJ3U=W50'<9`M8%UC*E1J,Q_`\@VE)9L:4A2#Z0;#$7]#?.:9'I(Q#`XN8 M0]N+``B$M[%H[*9B3C"D&)X!J\/G.4T76'(VLT^T?Z=^L24>BB1.?5F:-XD, M6*!S`Y<./3:($^Z#=%LM:`-CZ^"-S\Q/8YYPY0FX>O!GN/JQ'NZ<"X'3*ZTM MK+?^C\+XQ*9I('O^W/BM>8'76G#\,+9@:6*32V,<@?U.=&%<$*U`][9".+P] MB:($'H;N8_9'RI&GM\L"PXKLJN`L#Z&-1WF(,QXPL)!5$]LTWNE&H@4/D31X M':3&DTK0I`%XX]_![$M)>(W"P@61!X^&."2^/FNM16RRJ\79!6G$S)5S&+T@"X MRH`^CR06WO\]#:4;2(L.O*U*()?G>Q"&,!!#7CDPX`4M4O^@42#7ELR+#88' M`-#("`:)#OX50 M06$4,L-W3$D;S8CL)YEY"4SI$KG`%'98HQ\)JR0?&L)>MU1: M+J@OJW8D@4$43N4G MGE-,L_>E^1DD&XN%I[`@;CF802.*H97R#U*$:?KP+3_P0"=-N"PB/6/!&`;5 M`(6".@QGU_=2P=1J+I;TQL^+2'`2#U2IJI*Y=TOH$77E+()5(L5&Y$H1?M#- MRY58^(TH\F#%(SD)OLMQ!-X<;^?\249%)/(M6NMWB&)1.%&A%-H!DSIFR"58 M!6-94?V/-$(1A5GYRA+4@2#G3>)P-4N)1AR9`8J2&$8Z[3XBZ<97DZT+"OE3 MF+M"TZ24QEI=94-X96.NXQ9LX_N2D<0)4D_Z&7B3GNHXIN,X1,)F[;`+!99I M6:[9[]B;*%#/V*9K.S@Q(4WP!A96]@'OMJ"/CM.2?4`K%;W04QVSWW+7=<3Z MCG,-^)9Q\7N:R@\3I2W1DN\+&%M]RW$&+=@A#`:C1OL2-@R]Z\MVHW?9'5SU M.E>6?=7?"1@?,_#],6Q<`L0%H+P1&UN/8>-O@]@C)OR8T\8(A6*8"EC.0NP# M'1>O-+F'O7`U`"P"5M/X"/N^N6<"-O*;QFM<-3DNN/QQ#2J,?I3:N_B0:JKX MT!O4=5YH`$A!F[*@<8N[X.P-J=<+-@9>#U,@)4H%=I@`5A4SOA`28JWT*P='O<`# M#`$F-C`'M()85Z+^,"=0CQI5%7XWC;VYV`)(CB@Q*VS0E*(EBV#@(KWUT\0+ M&?(%60I#`^)3X<,^(J;-C#Z2S+B_-,02IFX.K)EQ?Y;M)'[EM^P!QRG21>GL M0MW@Z`"5OUY]NGEW.?BY,?CYW=OW_VUD>UAE(NH\!*..N]' M3G(#Q-E8$,Y7SY%`Y3"<>!F`W0]1ZG@BLHXJNLD/=!'50B/8.LG=+(4)-J9Q M=(\?`+M'@+1?%Y?I[.W_EI.80\$<`?&]',".Y-2.Q1X M6FS(U)%=:RT)8_AK^64=`U8B!/GVT^6GU9>)1\TJ$N#A%0J(!T@9-:9Z`9R( M?R(Z(I12`(OES0_@KCGNU[)$-:5%7WJVR,*PVG-I&JP6_$-2@&X'Y;<@E?M_H/?VS73#5NI!&9.#]*%Z M^,V4NUO@3WUDP4@!<194H%G5FHH0NJB=0=OIYKIN)= M$:49:.>,&H:\+SZ+$P\ZAUU9,%96$^<$9$];48Z[^JDWE1*@3)J3@0 MN1_"YJF?%'W[?]):G3'H3]%Q&G;O'-#:'P`/5;:-%KMPK8UYZ87AK"C M\IGLVUL`^0#=D>:*P1NOBY2_*6F:VV6NIJZC:$SC&<&L&`.E0N7.;,6&C08E MZX/.T:J.N71'3'@L$@->4I2R<1DK%A4@QC&3JY@9 M\8P![D@B#JR+DQGZ.="]8_@S'HP!B],[.&/R\444+#UT3B,D-'Y/[UC($02/ M>;3P$H"`A59H&YYW3()#7<<,P('/@1<(D05H']QGK^O`^R@.QK`O9,J,2(!" M!]52]53-&=DR#Q%!=`>OCHTO"*LD,"&./P!"%9Q.")1^1:50W)PPZ8122PKT MX*47>F-O*Z2@F66`A[E8;ZY2M@H&%@1":13M^X@,V@8A!-=F@'S8,4H%`+O; M5'KFIV!ZI5-$HLEBOU+2HC1!MS9UIB>;@#OLM"36*CR1>?4*,\&5,2JHOP.@ M^W^FW/_Z&9;1BJXIK=M_?KXIXTYR##.`?`B5$"_';!$`_B3=CJ6.&DP=%1)OWN)GM(666D5^X1T0<8IX^WY`V*N)6:0";QI<%"FZ[DP_['FP/>?+#.$(KI*5>#M=#9$$J M]0'0>P+8R*`S:>7LXU-Y1B!XLN$$[F3@!5*VYGB@%5;"$05)(E6LXLQ1S!'V MLA@X($/.5W=2;U!'#,"T![G0V5+H;%.MW,"#IF=H1-^R(.1_I,QP_E9&$1LM MO?*>X&GCPQ*4RS($?L.(LK'H(Q@PD8;@-`&*Q>'7%?A@,RY9V M'>@6U%NFSK3!T('X:0AM*Q>#_@[^PT,\>!JXEAF(;.SP=GGT)8T+<_:3%Z8( MHS(69F21ZB5A18R=V8EU"HV1Q^ZC"+Y?W347",:C-OT8K8=54\.%YK(I<4.& M,H#BSZ"=L8E_1,#X+5LQFJLH3B91P".IL)4O!L7K*F!H-?:\<7R-C7I@^LGK M]@;-S\J$R(T?P$A/6^#B)%3)%.+4:(S^=(:X2"&&.T]$\TCND4EGX]901,## M1*TEPKA%E8%'9T8$\_'4RQ>T&?:W'[,/9_ZKAHT\C:.8+J"B,`< MOO,+#T/F`0SCL$6A#R)*/$`%`*H2"5>!\A0ZPJ,P`DQHPO+UH<[W*X5HN]\J MV]A+:!>S@(C*8:IVH$F@(`C3/,5KM[*?S3PBV[=1?A2#X..>9H8;JF@RP=T8 M-J7X:(R*FU?:\%]F2U!R6)X0%MA\=0^\,DD4?H+=((-=^_T,)7'+`3PNP;+G M&6QUS`IN5KH!4FAF`X$5Y,GYI9G3F$'Z%>B.1Q0O5SSLJYO<35-.9EPYL!_= MS'[#B=GZD=BFP'MU77.X_,7[/8H+-S6SG`DJAX*X0>G9?X2]ZUX/AIV.VQA= MNJU&N]NU&L-19]APAIW+7F]D=3JMWDE%V-<)N>N$W'77S]MU';M<)^3>:Q1^ MG9#[5.*3ZX#LES[@>H;KD/LZ(?=YQEW7";E?^(#KA-QU0N[3%^Z_'%M=)^3^ MK@9>)^2N$W)+,%XGY/Z^!EXGY#Z>PGM2\I!=#YXJ M^!QY"-WKCVRK;U\UKH9=T#;N9;_1'PTO&[`2+D>V<]6VVXX\9P>3V7%6F/W$497Y MLL+&]RF>KGR8T*L%+81AOOX@'(]XD*H,(WOGS+J*N!QV>KVNU6W8[7X.><+NMZ_95KSWJ6O^!]D$'6[;;Z5DMJYA;:R"X,6H=@5(G^9K M\;4#W[35C4@\EK5[?(,Q5!*.4(?A,&J"2ZET/WIT@NOO%ZFF4O'BKH?2B3 MMWAX^3Z7J`ZR"]?Y&3(NP;YY^=/_;_3&W5U MA.],SD_N(/^9AGGL"QKU;)[1;+YTE_][EA"`7@.S)WI^_=HUG4[?[.]^N/?F MT-[:OS(ZQ^PX;=-V=G9HG_3HK+;9PX.*W:^7G/3P7+-M=A9',N./#[C5 M,_NN97;[SWT5X6@S[)J=GF6VK`.?R)W,@%N@Z1P\AMQ9V^WASL6Z=V[S@(^@ M)U;5I\*YY&?,0>Z#`KD5T_!4I7;0#H\A6#77:J[57#L4UU[ZYG4=1(9J.ULX M#Y(`Q$O@*;[>Q6,C+@N^CA(WD#:,T/L#MJX[=Z7:Z2BT3-E7(L9UCJ3Z9&R*Z]84`KSO:[DCI,;,6A`9N_R\,*N,*9XZ9;) M7*SS11`M&28^4]D]2[5G*(J+A=)434Q M!WL2,MDJ&E\H>20*@4^#R=8VD2O%@$ MI*L#)B]-9E%,TD)E!H5(J88A)0ZU.B8H?/P_2^6]L2'\%XVQ4&0-FB@(.JX< M3#B[H!S/?(&IQJ1$4M&F@(5C+Y9EV$`:+=WUA;K9*II:,Y"`IC%(HV"%[K7C M0W(Z9EG?E`J6J1*DJHH6U8W+BF09J.KU:J/UITINJ648*H:.=5G!PM*C"E+J M524/1BS7">8!3ACEA6FZP@L5;+4C%&>D'E`MU1!,S-A ME_I.:"E=*5$H=6`H*Q52)NLZ_]VNM[#[3[^%O25EWKZ^K[L^:M?U[=1'+OK) M0)RC^EQ.D2PN^CAXX$-]J#M8P8@ M[WG@K_,\26[.2(0ZS>4L/?TS6A-?RMP5O-P?/DX&[A ML_NJM;`YBNB`@951X@7%J-+*J%>,,2L&8`GCWL,(*8QXC![XW$M8L#1>]7MV M%D[XJMOOTP<=5SGAL4B*$58R5`O1-[V`]W0IU!)+#_$[:%"&:D%/J_VT6Y;N M!UIX9?<[I9X2S&4O.]$1=RJ,:\L.`$=32<7V8+T\5"]FU4S!`I9=L^]T*(R0 MV)V&FQCN1P+#&6,6>"JN,HS".RKP4\P6NC(9%)3)!4V7+]^#1F[96K2PMYZ1 M5`4/`VUENNTFQF92/.-I1`/>R$AG&:&X/HYR7+7FC`X2S6*C-TEB60Y)Z(#K MQ(PQAOZ]LIMV5PN!YW]M?/9G48!!I3)N$:-3)1WS M:,P"%36N6O+R^EL8OXI1A_*'0N&8IJ%+*'ZFAJ*5840RO#7]?8G(E8P"A MKE.AAEG7J7B2>_H3%U\;$\2J'-F)N2)B%3-X5A>!F/,,5L<;.:7G`7G%S_2.I#".Q6Q/M3X=G&& M6[VC)I.D`NFGF$M2NKJP7+OA30'A4^%VF3'29W'B@;&8T\:IO1 M,>B%GBP(#Q;%#U),TXAC;4@W&WP'/\&C0N4^D\D>I4\O:P>35Z;!&%W`E&L0 M7MR022]=9.GO(M]/XYBI9'!W7LRC5!@)"-J4488TS'&7"'(,D@<6_@@CU?#% M#UE/64XV3)>9#UXY,[U0C/&PJY18$S`6^U<`OONG,8M7U2E70QB$2&(/AP$L#V7M=I'G M8L6S&NGA5P6>+,+.DG)<,DK_\CYP,E&:@Z`&EJQM$A5L8WCB=;88A' M:O`6J<%"1E15[:0H=M3#198IM>(,L&=V]4FCW>NM22')()VS5![P;#IH?*6: MM!S5HCHRVNE(,>^-N%$X4CP)$1\8BRC6VH!F`C22)Z[JT/B"SFT#[M,!$5A9)'Y5 MU9+^3;P'5.[X6\SF/*'S5DPG*A6OHH2D%984+@YX@P*P9#)>/*U3N67I,+@P M,API-$$\`B&R.I*=EF5:;@>9_[@,LT(V:K5`RXI&P0#Z"96*U%=R%=/Q=5&3 M+(N3L:(*@DCD)]'ZR!!'A+K/6TJCKX_DJR<&&%.8"J%Y)_F%,Y)S3#+EE86) M;>R^7O=FWW+7^;*RVB1G\'PT9I-`;FE0GX`8AZ!^:&IT/EFDR#?,A929E\U4LF0-$BT%.A9 MEXIW3.F2@2!X2"*,[.*'G)'<')R&YGH'9G@\EDA&RQ:"N;!3Q1MHR/(PI,JDUI MLQ6@P&E7(E$F`BR2%\.RS3LK])/=X)'[B-41`+_R\9,A;'?SU."OG&[7M',+ M6[2MNYC#\O*\^"$WOS:L[ZQ7JV>;O;S7C3;X8FO"YTW7>KY5DL_Y=M^EI"JY!+!RKB5%U*^JN7HSJN2_/]%Z]&%]?6VS:2 MK-\7R'\@C!E@!B"U;-Z9[`E`4E+6LY/$)Y<=S)-!2RV;>VA20U).O+_^5'7S MKHMC61?*YKQ,+*F;7=75=6E6U?=[#(8%6\""FL[O*H2+)`8^W';PHF:E;^/& M#)%C!K%P(?4W101RAYLNA$@D^DDP37DE@[@:2&;I]5S1B,Z"TNJN3KFB4<`0 M-ZK+FX%PL4BP+7]66+?R<P1T4'.3*XC:> M!@RQH!D<-(X9M\AY((R,Y]'Q$E?9H9K2$/Z9,+M+)7#UDNI@QASH88ETF"1' M^5@[IC+^%5)(H9.8O[%^9)WYC!?@2<<<)P-OD+[A_L,XY$;ANS'J6Y2NI;/Y MO/)VJY M3F<;RW6]?XM$^XAQ,F7T<=9.XHB[J0P^@H>2[?-6&(AYZ\PCH`7GYI)0(17Y MA2HL%*6&2'N^"<8-FU)+#V?U*.]&: MV];5DE58]UM_2DNG?TF]?0O"D$/3Y)Y!O@NPJ[COB%/#.I;7CNSZ"+=Y(=N( MJ5<.\#.\V&=A!MZ7\GO^%D'7L1^FA?M1_Z+R/&K2-Q`^Q$R)\3U$(\1T]^:K MM1P3J@8XM,Q&'F/"`9^Q2']YB3Z[W<]@'1D+%J(TF#)-`"KZBEV2H)-4W1T/ MB@3M%7M77N2)*Q5D2UT4!Z+"=D'SAR*ZT@!R, MV<*`[AX/VK(A>W==PJ]RO%SC_M']H_N\\CWGE>PD.<>R/\<3[\\L_7 M@FH-+/WARXOUZV.,8^@#PK!(":^8N;?LJYW4"+08^7C(JQHPSE'PK3K!H[H@ MC/V@QJ1_8WA>XUG4XME:L7D1?&O+5I,W>%7=BU0O4GM25WNQ?2?&I$W@>QUS M"CI>OQ>(R:[0R'[M_CY:(?%>$#\TN$,][7_:DMJ!L34^P;%(?>H.5Y>? MVM;KZ/GQ?/FA@N[J-4!?7?2@<3L]>,[^J/?\Z/G1\V-;?N3)E:=&]I:F41G8 M)P'5UMU(\+=%>"\8)VHLB6J*)MDS($1GA%T;*'TD^,+5>\^/E@8P+=%43PZD MN;,:X/E%@HKR%!R&HUYSZB+9'A?YQ$1;'=@OSKCU.]QU4I]\4:F8HFJ]%/.T M_QWN=..8/_R$5:*SI76G%NG\@>XH8!Y53=0U(GS+">!%"47M!&;@\QI?3'D. ML(XDGE`Z+8NJB[)4UF;#(*)IVX/EI[YJ%:4IS2XF>67LM)H=I[-$VU!$Q92% M61)C>0BK=RZ*.N`7*GI_(E'U[AE=E M-"!.7VVL0Q#7="%I%:"PI_]$!K*U7%OW]VEPAW_^X^^+5+KV_?EKEO5V$X=3 MFJ2COQ9!=O\ASBAV40GC=)'0+_1[YH;PF[K73!"@>*[G0.)ZEX"<_>NF/V?@:K^$1G_W-& MX_#R8F2JJB[!?T0ELO2_LBP;EY^_#"\54[U$1LFV*E_*9RQYGXT*TEA3B'GY M]?/PS+W59)I?*V5NL=JSQ]'#,>>2NK'LNYM.P+!JGZN)>-%`; MYOW3/F$MTM/W`DX+K7->7>*\*GNJ/;3&DCX:CH#SLB'9Q-:DD:$/9<.3AZY* M+LFE>O96'L#S'L'WIY+?Y/8'FF$CA8LDQE],W?NO,.UY]!$DS$<]YO"V#`'K M9[5#$:YS3U[BGCPDLFO(KF0X8UG21O98;;E>L`]HIV]A8IR8N1GX`"ODY!8@L6!Q,G`NZ%BXS50A_C#'NN;EDF,25%\^`, M6Y8AN>,QB)-ARF-M9&E#$^0(G@>\D`=$J?CP`#T[5H;%D7X>^I`=3%/9H3Y\ M%']VI!)7JN)W29SNXC0O,_S\PWB)Y;8KJXIF$LPT[]>R].,W`X M_J3`EZ(HD#]Q'">?JI9O9'NFMYBJZ"/'M;RA9+JV*VG:".18(;IDJJXVMA7- M,108CQR]L-[7%,)!J5TAPUV;%MS7!C/9?A"_]-Z3Y1A2XH/2_IF MPU;ZPSOCT&AH$-R6"PP4:A!Y\[\$7< MVZDJS<:M[OK[V6*,5M5UAG26-?-P-1Z\/)QMRV9<.PWX,\+OJ+-A_WCN_*9I MMP-0VVMDS1P/(402L(=*$4&R)EP!J_*>,P?KZIXW.L9`,@*B<<2K1E\Q7=NXJH4BJBRK)AUZN_-9Z:-F+6HE<(K_\>"(6_UUHPS%'T#6,]S'CY M]APBS2C#+IY3',;ZV4$(W@K`$[8`K(%/B]Z?=++(^ZJQHOAFKZJ+8M;P/I_W MKBHBKW>.**\BZ'?6J7;*GUZ,J6@HFOU=T8F_P+9BK)E6WA*--7>$YTGEN**[ MJ"WJMBY:LI6WT2"*:!JZ"`'-`W#.:Z'<>(>!&J`6:WH(ZZ2RZ/[PNJ'"ZN_8/N/:AGOV75L M]?<(VZTT37"MRJ:_:XP]X9,$4UB4%T*P8HBZ14296"^$8!DTG:J+EK[G MO,N-:F_Y=FX]P0?0$VWUF?NY[)ZQ>>_"Z[$06KP677B1NYS/"-[,XRE;8G.+Z;ZVYP'&/L3O;!AWR8$_QQBY8 M]D_LDJ?0\ZWG M6\^W7?BF2WEHRU4\:[,46XFDF`-USI`5APL$Q>;)I[RG+/NRE7"]B\3]7>IGZ[GC0VB MJ=)8';F2YBBJY*BN+.F*IPYMQ70UTUV7^GDEEB->4W?*U:9%^5(C0$#@>$P*>D+AD?9+IW- M?GPZVP9`E5U]WC_ZH(_NTWP>R)A8W3#[@;2L8_1G/P9SBG**%B/RZHK6IYNZ M:@N__/3K@?G5';32XU2-RB8=QQ=\^34ARUKHFH=NV7N@8C%;BB] M\G@.:WX._LHF=5+>!YZ<0OG%E$U1V;ZQWT&2A9]*)+81Z15)]X51$573%G7] M)/JD=T7W>`@^&X:GJ'N(#;K'W$_^0%=TC]I'0,]DS<\M(^7YY&#N[*SW"V^G5<0'BXI=SZ%'D4HX[!'C(X!GNKR$B)`8Q M3L#).X[[JQZG6\`)B9`^V+K1STMA$3%$PS9$6]GS76[O_G;7A/;N;^^\]1P\ M30X^NA+ND:5H.&-5&HX,3=*&NBZY MZMB0+'D\U#7BDK$[W*KK?_&/-P+:6FGFWP;A_>LEEYU]F0;_I:]75A[5*XW: ME4@_V/*_UN6_'G"L[]5O/-3ROSYR*8@II_D]F-`HI8)SG5".+K-IVA]M^7_K M)]=!),'37K,BN_QO?E!>R[6/<'FOK9_?""@G4A!-80FOL:BNR?*-^U/G*T/Y M&_KT6QQ'U\(01#.,YT@7JYM;HI:1\0`RX".)V7+QYY'PFQ\ML%QP&8N/Y>AC M'1\V\/>%D)'!WHH4A,`,WX+L1BA)O[CQDUM_0A=9,/'#5/@E5QPPN5+O]U>+[#X*(N&: MAH+Z,TPT3^+I8I*)0AQ-*&(L)/$=HT7X'"]@R?^*$^JS=OT5.2`.R2T"%C"L M`9C$CX3%?):@(SWGP"6B,&WM;NJ'-)48N(D`K*9I%D>T^#G#=X`?T138P="Y MA"2^]T,&C,#'Q%&Q5CY5>XDP@UN!&I2;<^.GX`HW5H-`!*!(@ZL@9,@+;#=A M>$$"6X@_N5E>)N?V%6(_%)@W6+J9_JO03U%>0939#Y!V!*'@(E"#GRS(*&A`_$E-4T1+ MMW%K.$OK^)F\V'7]/8F"P\`F10@2`8O"$]/:E66YV8#^4#OF\^]O:GJ"6-7? MI9[X$>"'54I'/H(&O9C!N*3C^K(HF,&M)4V%R34D"`,(64[+>309-)35*U8$ MEBY`KPG_I'"*;B8(NN(N0+/2-!6^1@%((POL;3EY4*@*FJJ(`:F59G(L)O&'I*RD%6$(`D9:`P'^($M(P#*P%E/2A6 M[".^(@*M+)@"3K,<&J6A7>[9!#[^(@PBU/5U320"JZ/%#.OH:W-^ M/EL'.,@50,E&\/2"+$[NQ=(^@%&)"P6=@MN39#Z,BN)(*FDLAP5YV]5@RKC) MR(4I2H*_K,*=7:7R&1(-*KK\5S!)7>^6IS>M#(+0,@B@C'T$U(5)?)2!R@H` M&[#K%Q_%L7I`[+G2$^;(_US;Y=SY.OC\W&S"`]K7U&410YB<`4NZ]]6FW@5* M+CL,!(@_EB^A$/?)34#9QJ_;55@+FJ0IQSF&LU,_9\59AL&UTYP+]`8EWE3; MAU>USB3S[X"60M>B''A+Y[.;&OBW17B_0OLVW=6:TJL\5U0@I<_!/->"#SE$ M5>ELBO7CQKGC1_[4%U_];;T?"J0S5;CDCU;>:"F+,$^ZN$KI7PM8"]!3>J@Y MV-=XZ.`2&M;FQ^1IC\S_FG<.PE=.\$KX[]V.81LO5-$S0L`NP=C_)I,6\ M:$T2Y!JT,'=X^KGR@Z%_+1#"B^LP_-$-TRFEUF;M1A!4+`OY4`+4L8I)8Q/RZ M#)AS;3;BQP[&XZ<"D7^NC!+&.C4XM8+LE5:H6 M.%VL_I&.D+IN];6UPP0_$5&5";Z->W#U;(FE5H4`@G^)EHU]73O[>4,HONY9 MD(!7"_N>Y``K8(O(?4R;(DN,)>OE_B<0SB>!UY\0([ M6-#4O7]'X^O$G\-1&2YF=R`>.\ZM'@^S8]O5.03%HQ-\:&3,HQ/<[_"1M4C'2QOQ MY1*&N!E$P2F[$N'O0I;#I3WG2&T)B:")JBV+MK%U6X,GY=0>@U[+(B+9'@;B MQ.@EJB@;ZOY3@3M%L*6*BG[,W.?3*U%9)/%\2TBDW-UN@LQOC=]VJE0KBB;*I^>=/KFH3P.W[:C:[03+U5Y02ZR>?SW_>OYU MEG^'"(9_>-?"SD/TZJ(NFZ*E//L^3EOSQX`PSR;/OM!_VSLN7;1,5=3M$VBC M<1P&F:)L:J*V[X[\S\VC?$Y%U#T'>P[V'#QU#CZA%<+.DTI;V:N(>>AB;C\F M`-,H92F63I(@G"MF%;OWU4\N>**Q@[T8WOO?@]O%+<=9_#CCV(D7-!G=SL/X MGM*#H0][QMB5AY8J68JG2YIB&Y)M$E5R+$\V7&OD&;)]22[)V5O"][G&Y7T1 MW^2QAZ7FF(*,LW\*TO^#7^('_C4E.V#3?)'0.I.49:SBL3'4',V0B$Q&DC9V M/RQHIL*F3D.*[%TW_E`:GQ9]/"=R1&>9,/D-X9#;`@)SV/.`)T!^&K M-9`AVU1,8P=*`NF0;C(@COZF4X6"2L#&'UGE:Y35`OXX$7&GOMQ MUD83=VY1(1R,E\:(>$0;JY(^M%U)(^Y(21,>*29NNV;LE6 MQO#JG=XXG7YVZN9DXM5E2VPI5UN&G/TF MG$`"Z9'([--&'Y6(@"ZA-,/BB(#5V*>9D.0XS2>5FB!OWXSUYWVOMLOT/:_L M02>*%G[(2@KO8FS*A17")R?+AC+8.J_L)(39((.M7Q@<0)J[JZW_H,A#+)B] MHPF$\-C$@&)5M!`&,][8A#47.CV1WUX@#K?L71"J[YO0YZ701X5\0P@=3&DT M%>X#&IX>9J>\)X77%;'>%WU/:4"\@_NBYEU4V=+@Z5=Q01IK"C$OOWX>UN_C MEB^:/%>W+).8DJ)YCJ19EB&YX[$AV88IC[61I0U-ZF=OB6Z9JF[7[GZ+ M]3:I.(\F"06V#"G__WETD="Y'TR+KAEXYJ*4.M&492D#[))?6V5M5LV%(1?%VM+6O^F_G";W!KF)W M,,$DOJ4?:/9Q]L7_?M"-)XX\],9$DAV\AO5D(CD>L217-FU/'>OJ6/%@XY6S MMQ+1+,/2;*U^Z[^6AJ7W&JRO2IK+2@=%&RB$$421E<9;C<:RFT2]2^(TO4CB M6;"+6_-=TT/DL[>F:A!BU`2WMN36!OGS(/-#)K?3XB7#9(&R["ZR#W'V)\TN M0,`[>#Y5@F`/8?RK7X7Q],4A+F+.\O>3^J*IM?>B:Q: M>Y,ZIHD^Q%$\IPGK(\T/;*ZJND@G:EZBF34J-]/0I#?O2]EAE:."RI%-1:T1 MV%KT0R:5\>-CP8S.FE#41818FK;)A*ZB984$K[`Y14(#GN]H.#=#Q( M]AW]?_:NK+=M9$N_#S#_(?!SZ*E]Z<$8X*8[N>ATC"3=C7D*U#*=:%J1,EJ" M^/[Z.:=(V11%2Y1$EAE;P.T;6[*H^DZ=.DN=+3\CO40,S&Q!M%)%=T*^QU"/ M]GW>G_KC#$3`G^/EER^S"4;Q08[49ZWTD!*,HUDD.+/;A#@4WCY1%XY&F$(" MS\4.JB[/HG\$4:ASM=)"[A)SVU`VP8-BZ+=XL[EGJJDJ'X&-9>_;3CP>TZ+; M?__V$62:(:"N[*YM+$&H7":YYJIW_36"!1C!EC-E2W[WYJ+W".AK[.0Q7]Y= M3X;3)=@W*;R:]]_OWUY2.)0,#&&I=FFH1Q%5*#&?C;+L9H$);^C^O1UB?]OE M'7PBGDTF>=-=O*`$FPZ[7/=V M4>F]7EJRE*&](Y049H^,/P!I_YQL1>7$EN9:JG'J]!\:6.H^'BR]PK##.=1/=_0ZF MSYOI8#P=3C&/,WP8H]`_$<%`5RC)F&$;BKXAH"I?+\#C=3=E'\`:[.%F:P2+ MI]N4>7ICU?M$7*5!>0^WE'(TWY167.TT4RM('E>$?PXQH7Y9C*#WR\:,Z#3A M\2!((@T;*U(6&`G?I9F18<1C24FN43#I1(I!P$W$0Z$"2-@U!J$3!&>!2K5"06#@.65"#9N`;O M7K174]&$&DWHW\.3A14HD@NZOXJI&@E:?$'K"OY!N_,[&%U@3.74J9[+'L)F M8&$'EH(X*<<-#@%5V>]L,D$U,KUY.YS_G:&MU&/[`*2I4%1J7JX[>A1!(],@ MMZ@W-"E:5N/I"EXK[$)\M,APN!">D-'>YQZ>'G259$AL*O&/WY5U\U&H9+C:&F)->;(-G$OIZ26IZP MW<,M!NTMC-*\Y.G4K/R1>-0Z9M5'8'@!QI@2O)QGL[7R36#I[6TV@M.;_AA] M0\BV3F$%6-EL/`9238KB<+WY9%Y%?SV%)\[O[XOX6,*^? MM>]B*B(DT2FQ040&8*Z'`QY$DIA@0&&7(Y5P1D5>D`K;NW/1)5R%QW-OC=\D M;DY7;I[EG_=6EMS0AT.`N*>T0-D`0@GPV_$4FP(\U,@C*^0?!#*-LG??LWEN MK.6_WOX#'PX/Q0F#[;#XP*?":8...B8 MK^^>OGZY_%4%8Q76_%U'Y?DQL9$PH5-Z*0@+%@#9'@B]./\'G9P5C?LZIBV.LLWP,ZF0V M_9R/4AV[1B`X/_;;'+O*?,4A?/_^;^4Q?.LACFX4'PYD='E&+W@D'R7DF)E\ M.YH./-:G@#U=BX3S5Y^_^MP.H^-V&,47N+X$)?7YL!BG)!]^=;K3+=!?QX:G M[1/R8#R\RFGQDL`[Q*\*&ZE=Y-V?R+JJOJJEL(]R__GJSS?)Q__^Y14WET;N MM[8>7Y\CG#,S7R7K3A8/Q.RL:+25UB850NZV:I,TMU)JXZT7T_&9'6 M%S45TK@[N9X9!3UOE/)V>/>*ZM>O&*&T6[W?03,%:MAK8+!&'^[1Z*5C6^1? M_GPS7T_=X>+SP)WBZ'69WH< M2P^AR0M2C>S2=CR;[;E[@O]<3>Y>J9]465*N7VOZTPT9/Y+9Q24[>X(O7+R? MZ5&1`-J\UKSCZ8$O2`(\/T^0,:?<^,^GW(Q\#?^]$-;FE_;%*;?S#O<=ZLD7 ME4R_YN:EJ*?N=[AQO^NG3]:NJW^!;\72F'0ZQQXP-V^F'Y:KF[L6\N6+)^]M MSS)0"8UC$^@HPKQO>'C$K0R8M2J-6:0H&>1YW]A\J\G::U`6):F?73./#^-E M*_5<"WA.2^CHQ96I@-M>6>P.,+"WA#22"6E!U22,@XL"/1D^J@V(9JI2"4V8%("K"C6012&.B`A M'9`X0MXF.0NZW3*&6YDK`[W9W*P9N'+5 MU(GM3IRB7:P;8ZV&DX]8L7,\\93@>+XY%36U44T*"%T/[&M*_V=M:70!L/<$ MY,RB@#R&@"PG(/%%P+R@=3";Y_U"Q]//1:_&$X@`C<'[!KOJ;#H^LL82DD#OS%[/,4"]/>3`'X-.\I MB&UBWPZGJULD`Y;R?E@.Y\O?OYW>(&V-V!IM&Z-@X@?TG)F#*BD`,8A:$ MJ5'!((R`*6@L%4^0)JQ0]]1I^S8PMZYS-+42]AZDJ#RJ;G5@8L&X'`0A0UMU MP.`G971`$\)!J$<)TR+7INV`_J6$.7X71#Q:X;SG5"X4_P)Y:BGTRLD75-,'XL MQK],QY/_NH!59EL;HJE)K;&#($Z5!:M614&D3!A(#M^F0`<+&N=*5UR\^H^G M(=QZ1F68CZAT;V+Y`Y9-_'%*%\,C*5N2!Y^^9?-/;5-:/AFE.R8D>.V<=L:B M[`6S:)6RW;(H>[8L2I74EA_<2J@IX83KU6DD_*\%S78@Y5[DR=C:T,=.QL,& MLQ.V%_M_75KE?W/WDOD9GE8KM)2F,WW"7ZP^V2)LM^J$MZE.GHJIY[)56G:^/7;9':791^R M^??Q**M?RV\S%S',6,1D$%@"V\!9:@13S,)VY,0'W_V:E3Q3O_"?YD;D<>[>=R/2E*K` MTM:P[J]$%J>I3K$<&F/D%U*?C<&V?-.M>@S MN+U1.`Q4D_WM_4\BTG,]1TU=XS;.$<-SA!4VYW/4PDZU>XX8GJ-J7/Y\CIKN MCC]'FJ$CK0]VI,_GR,,=EML;U$>P,$//Y^C@W6GL6K=QC-QD,:R`.1^CTS>J MW5/$W=!>;33OU2EZ[`O`?J\CH/GTO@-J'DYMKFG!AT\!RK@.1)B:P M,B5!8F7(;&B2F/%[_[(-O;^7$#_K/2N2_RD\'%Y M?O#EPCDJ]_!QF]W=:N_2$^'UBL];T?%B]'%9_5Q!N=_G!5Q!/+U=?\J+T?+_X>S+/L#7:XSQ;+ M]P<2!BNH*-L['7-[5SF)N4W,()!ID@)=B`I`THH@53(A*B9)Q.DG5ZQ"+@EI M(R&K*?P.J8WZ`+MX_#&;P&-PP&7?Z$V1WHJV<5W8G``U%/]K_Q?^=<@7H@8Y M*,%MD]#'$1/SV62UTJH39+ZL[3]"J8X+D,AZ%TYMD/%D=&$]K3)DC9[G#\[&-!Y&:2U/NNW(< M-`^:*QE_']]DTYN^Z2V>VPE=ZZTR_$UJ_Y8M<>C\]7R&?W$3W?V^P`/_#F36 M$`MDC^MYL%\HMC"2&K2^N+@*M-7*J%+0O#FD2M;Z<#Z%MQ<@[-84;OD`'J,4 MFAY(D%0!L%+I6F4/GLIEQW0YOL$WL'M7-EK-'8'2'Z/)"FB(([Z1'5=+QXWO M;JO/#K_.5M.E-^FM4AI3,>"!3%!3TB@-PE`S<`##4"9X=0CTI`O)":5$"T$*9V0^F8*;Z:C>092)!J2)![0@(3(^S&A01A3$T1$VY@/)!\PO%<`(QZ,&6*5+/4/VP&A MBC6_Q%H4K-)#S@:`BF-?0EW&M[GL35`N_PG4PNVX#4G5-AZ*!2],2EL65J4E M5S9H^&V\'$XCN([@VBZ'K0@;JU_TVR9V>F_]=+9;HX*R5 MU/5L[MY8+N?COU:N=?''V3589:W8GFVK8#CW@>56F,J!\$62AN9=<1KSRY_N MR%C;;K@9/UH@I&#8W!@./T\!H;HKZ#!ZCC#@2@/0/?BV`L;ZZK=:WU$#+Q,)='` M!FHGYGL0]7#?9Q.,WW^<^;M8;9L4C./F6UI#AT/1[9-TX6B$7OLB[PB*,K*' M]%`HY8P@C.R2H]T!E\6%-GR[GHRG"[!ML$0U+>O MGNVWIK(:3B033`HI=HCJ1Q%5*#&?C;+L9H$7C.C\O1UBG]WE'7PBQFD0H_RZ M\<,7L.>6V?QKS]48^'J6D,W:Z1,@-A#@\U5V\^MX^!>&W^'@K&_J[NVBTGN] M-&(IN[@21(`=NT>\'P"T_M*N.(G80::'(L2@?!1:,+%];U=:>>7J+IL"^@G0 M(KSY.IZ.%\NY&S32X]L0>7$EB;%:E'#N@=$H-#<83X?34=]#@+/KKLD^@"78P]W6N-F:;F1\55:]3\2M(Q%/H/R;2C".%BH5?.,F M)>^9@1G28\'@1)I$-,MF&!D?!=P+(RC'@L*2FR2XU5 MC.E']%P50I-,-DJ2_:DD#6$VO94`EZ*G5Q(40W6,JK): MVXNC3G?WUZ.U%U?:4"/*;39(5,8GP*\8=_M57?<9=+Y4-J=X$R2;V:+483[/% MHD2C/NZP0`X6JIP"5[/R1R(AZVA)'X%A0QRI%(.-K(F#K%=>2>*[OF.LM M7:^AK0TJF&M.*5\/3FV`H3R?K&26KS_Q[G;]C,KMYJEG4EDBGV#:ZA9H+]-6"S6BV4GU[ENS$G^?WF3S M/-L+_;[/\RP[Q1Y\&'U)K!%',8$T*E0)?)?E6*%KHSB(4L4"QGD:I]J*E#Y, MQQ0"5.VC@R`?`5?E^_N>\^]N6[JLW)H`>C@9F@X)9?E9V(Q8[<+T---"ZZC3 M_;10QR,2.`2,\;Y,"ZU2PM.TT+6&$Y(2#ZK`U[30W,A:[[`O6)U/"W6*6UIP M$H7:!ZO=9JJ=%1$_R029O%;JVJP7W>LWB\5J\^8A+P%_G\&'QUA=Z_[,/?_@+M2U!*UVA&I& M4#N@B6"A`D-(2S"08Q68,,)F`N`@)!&-TO!ALHZJ3#TX"N@SZ][0I"-78\'; M?#>PA3LT)U"8,4>+9&<>8_N2=[?WKM(!AQ[K_A$VO%SC M!Q[IY!6MS.2ZE5EU>7X[4%C6<0,*5C2@,%91;4N1K38:4+36!^`Q,G36!H#= MMP$HV7$'M0$XW/1O`+*5#<=T.@7^"]U[D]5*G?;IL)K4B+E>2P&7C&ENR_'G MSLNT?6T;X&.**&%8&5[K5=J^X+C*2&ZL*!;,E.(7.XN3>UJ3E)2*DHE[4,7(T742OB#B4&&E.7BZ M#-`R>%6T(V MTNX.R)$]*4_4&TA7NFLWLOV[3!/UADMA`)`8)5B-55*?)'KB+8?'W#CG0%,M M!&\_:%N+J?O,.'?_"MM)*=D;LFT-5-=Y<7EVB=%<=1!=KV+RE167A]X4"$;2 M02K$(Z@Z3XHK+CP,6%K>D^*V,7O)BG_F8VN@ M.D_BR;4!U51Q#_K`5PY/'I#35FNU-Z>XZP/I*2W$'4CX[>2T$#_TZ#PFN\Z6 M/Y4";&7#,;`IB39L M;^5!BX'-4V`UN6"G>?]IS@TO)V9Z"VQVOVVHB9FU?*.+<5>!S>[AN,"F!,5< MKA/N-+#I`1-X+T1HL&">+K#I`26VXF+EKE(>PYK=P^,75PK<>/HQ+BFX0J\FJ>):W8/$>.:EEBBB/>XIH?]P[BFU(H) MWX'-[K%A8),0H0CS']CTL'/8":*E?J(X2AFRE\`F=W$4C$^?4LOU MT(=\W;$.!Z\$QZ/)JLA(_5`2,L1^9FS/V!Y7&@;_ M[[;5NZL8;=VXOVW7'IJM]F:@TC`4G:G=JXZB9Z[KL0;H0.JC\)EK61_OK(JD M;/*GWUTV*8H+XYT![P>23_RS..\[H&-*V%^^-24S\OEJ&@3S:TU;+I>??&)] MFG@+[?[I'_[Z7,NKNL$[HZZ6/I:*\LE$>E#=U7?FV/2:K.8.M6C0)S*+I$UG M(K#LN9^O-K4@MJ./HCFY75'_ZD9V6CWJ6TPF7359O('=CP5TM8-R;[K:^H>3 M(FI;9>S.Y2[VS&N*'$1B`_N-J*Q*E0^0>".57MU\D7#/-_T:U_&J$&UGOM35 M,L*[6@+J+-1B"X5`;3///IL[7D1()MED*<')G@82N)W$'>6"MC4D4I):W_SA ML?O0#[P987ZFI1R1A5E*6/&@'!:L6RLP%[1D7=F6:PB+UP-A(L%1N7B]'I%0 M$MY7D>EHNR_KFRLZ"V='L.7^A2$ODQTZ9##>9#L:C(=D;C).8GV>Q5T4:Q&_ M-/%8-!BG<9?MEY-K+/[UW,EH^U2[4Z)9L;G>D\$B?Y8NG,+C-G`@W@ MD_LCSBC<(^*./-,@G'.!90L.9*?SE(0X#'@-B&<>B3=AYGQ*K=T&]$LHCL(M M)3+`PO@R+%\:7@?#"T!],:ACZNP2`&/H#31%#?Z"Y M8>@/#BT,_4&DIU;H3X':>?,((25U>^=LU3PB!&R;03MA8X\[5JY% MRLP-8_+@R&%0'B`MC,H#`X9A>3#`A&/0:=?T=DU-7KG]@L3@UHZ`*W95Q_.$YWY"^6+%DZ440 MQ-E2V!AQNA0V.)PO!80+)TQ!XE-NQO3/5T]])Z=+W:BM=!DJ;KWPBQV=MTV- M5K.IJ`\M0_ZB5C+Z'4_.//*Q74#L@?MWZ$1#NAHMO='4"WW3M44F_R5Q%L=Z MFI,]OVQ*JXS[]S\-IJG;D&;`>C8CN1_^+A(.XF!\4$Q:KG0GO26J;D'XN(C; M]['-_[^YVRF/BA:YGR>7BNJZT6QU%!WXY-#1OAEQC72#2&AIJJBC*64!(<>F MJU!/P>AIM6DT54TODD]/AR*Z)90RJZ?8FEZ6EE8[;56GLMZOI5\<<1&U%+B6 MJJF6J`X?J0ZX\`\N-KGP#UW-=W8[9UJ;B.T:3`-!1Q>M!*WDJ)6@FXTV@C9R MQ$;0R4<;01O!?4A`N8E]2.A&GK=A.WVK%#9M,$T$'4FT$[23'':"KB1:"5K) M42M!9Q*M!*T$TR,`)B<.,D2'\KR-VVEG+6+#!M,\T)E$&T$;.6(CZ$BBA:"% MO&DAZ$2BA:"%[%N(PB:!JGCAJGC!NG=IU##-(T!:F.81&#!,\P@&&*9Y+`=C M3/-X,3R-1KVUZM1K'5736'T5]+9'G7WJTEE8-A\A)E6KZPU%>\-#I,Q5"4EA M:DV@V#"UYD40Q-2:L#%B:DW8X#"U)B!4#P!T!2J' MNKPBN*;)=*+\3YS0M[YV[C+KZI59+[K,N`KX%!P;LRL>![J^BK!0J3DHO,RJ MI)O>:O:+YJSK_*-29:Y7>,M?-4XI<^C2N,"^7-NU*&UL550)``-]P'I2?=G[^Z?OO/O^EVS7&8^.:48IM&Z^,;R:V,4C5SHS;@C]/=G)/`_#/FO9)KZXX#@:V@*5SX[0_ M..L.!MW^QVG_P_F'#^>GG_Z=I&;+%2?SA6O\S?P[$/=_[,H6QOAD?)+`^%=C MPJ@`:F>)Z,H8VK8QEJV$,<8"\Q=LG82=VB%<`R1*Q44G@?#MF=LGC,][,,Q9 M+R+L?/^=$1"?OPF2:O!Z%I$/>M_N[R;F`CNH2ZAP$353#65G>4T'GSY]ZOF_ M!M2"G`N_ESMF^E*JP*"AI)"?NA%95W[5'9QVSP8G;\+J_"0'_,R9C<=X9O@\ MG+NK);[H".(L;=P)OUMP/+OH()<+7_+]3V=]V?Z':V9Z#J8`U;JA+G%7MW3& MN.-SW3%DOT_CVQ3["(@Y%LL%`C)?A]Q0(7N2O%?88V]??L?0\K>)"THGQQC- MOA`*3XD@^Y$)(H>XLI$09$:PM1O[%?M^3R"/P/".#V.+`=P%=HF)[,-#NP4; MY^"]`83=')R]$2#GTN9PO,!4D!=\((:5'1\Q77A&/3W9OS;'][ M,WQ-A&DSX7%\C87)R5(JX&AVZ0E"L1!#R_)5$MG[FY]=1CH@ODLDB!C-'H%' M:01E][6@JSS.`;%-7&;^OF"V!9["S7\]L.VU0*LZ3*W()I[C(+X:S?R?1KX: M#4V7O,!OAP=8.%J]3U`(S_''$T_@.-[2+XCP7Y#MX7N,9)/0E@4D7SF@W'5I M/3P;]6H`N'"69V.89)C[6@?NH$_V1(D[?$7<$D-J)9Y8R-83A4[N&)U/,7?` MY`/G8/L?.9MSY-2@._7P>4#9/F#WC@D![$T`(*[%:%0:HSY,TAR;(.5K8GL@ MVO`G6/P=1GV"`^,K'^^`6&^IY0F7KR9X+J!X@I:@Q_(H_#P7:53A9\&R0K,D>69[A0&URVF M)"O:)30AQ'U6*B*HQPF]'M@+A93M@[IUZ&;>$"N)X49/YC=@&TU0MV@PEAG M:)K,`Q^%S@^-:7.`NB%MNG&2-E:G*7YS+VV@.334Z@,W1@13]&SC@^OQML/7 M+8X;Q"EHWMK#JTT#U`-I@UC/$RX;KG8%#Y;),5XR+HW*>\SN"D,V`'9-,[KR MP'6+X!K/,.?8"KV9=WCP%48,09OQKJ'<-$R!!UI,+9G?";Z5@QYN\R<8OY=A MX!VXJKBGXW,"O("T4N/;,BQB/*T3X?#^5MT,B6=_O\X3W3E"RY[4E1ZV71%] MXVM/MS\(M^U^"+_^+?0XQ"-:2D3$NJ57:$D@4@QS7:YO3//!E3?4@D<([`H5S\&/^O@JF0,I&AU< MRJW)(;7D'^FUOR#;#[;=*\3Y"A9]?\]`P7VUMEI0Q3KI,S'R7%E^8OFQ;CZ6 M@A8Z$$0.R!4394J42ZJ3Y]!IJL9UAK@!?#\P:F[#>H)>!_?@@A$7W\$"`S89 M5'9.P!<(#`NL,PH()8UTX/C*F/5*;%O!\?IG';S=4GC2T/=*+=$4B0X>$XZ4 M@L4DA68.HPW45,*HG.W\9IJQ%-NYAOBW\;[T"Q:N'^.J&,ZAU,&Q[T"')JG, M(N?3ZN#ZD8>+PS;.1TDC33B6X.7?O"W];1AJ)41R8-RM9I9R2;7P M7'7=*EJI$OFY(4^SCK@9=0C_W4C.I8O90XJ>D+O#LK# M,548:C`.+/L'*O[9[W>,5RP/#?B?X=.2$\8!RT7GM&-X`IACRR`KT%1TQ1,_ M!ONO8P!;%@W$<#\=`]PX:%@#&_2/`5BNOQ9C'!P#1H6'%Z,\;1O*C&>4!%LQ MT1;/S]8]X@+P^>M\C/68'G3Q7DZ,^>R(,*?S(S'&#T>$,3\C&V/]\8BP5HK^ M8N@?VP,])TN66G9STCKQ>G0\.`M2WC'<%GG_55.+BF>=1-VB,&`7U&4)JE@0 M+0H0=A%$'M4:_&F+5BYU*CK/+ M2K6I7+C='\_I%B4&JN&N4LH3PV]10%D-?I5L>`R_13%FQ:>_;Y%=L3>91Z:K6HRY'I1NL5A-?*&JU- M2IT"PU2)JGBII)46)%P>IK6+I`3R"-#_%IJ&DD9XJ$X'! M797;50GGH!A&<1L]*(*+!I0,AS]KX8VMD.VNB@U;ADA+K0NRUX;5]P[4M5*Y MI%IXQC;T.0=%O$?\=YRP8RK.U0VT1H&Y#E$Z[9'Q[5JY(U,!9DZ`T,H:I1R7 M*YW/B"Q6*W<52]!EGK.B[JK;;(RYCEZJIB7/:VEEZK4<:HF[T\I]4Z6/G)ZH MA0Y2*TO1*@$O6EM;69Q6"75N3JV556J5X):F.%JY95@03J;`)Q>Q5A;+5@2: MHPJ*3=&&+\G9."]EKW+CEU;66!;!W$Q(M[*TL@CB1BZPE86410BS.8']JB@U M;X`I[VK7<=M?Q/ MX2RT_N,%M>&1L!_EQ5/P@^MR\NRYLFYIRH+=WJ)LZKOQH#EO4JK62?.2T:%6 MKH%;0GYGA=QOS=5LL+.OJ&C,532/&"1GP8.3E^#B:QS\51GN;;K0<]4(**-) M_.<)_[=QJ'5#1VK6_\*K6"^\C9"P'?\G(5OC\H*+\%50M>HZ2>>EMTT"!\P<'D M%'LRJT:H!]\E;__?!G/53ALDA]BD[/B<\SKX,V>BO)0(K?S#\&/LU_%/&029 MOQ)W(8O_0880J4:O)Y('CQUI'(IBA)V[TXE]RH8FN/?R?2CI"TM*0*K;-01- MV95&A4T:@4%Y=4Y51.H.ML.W>66\_$9>[6-B;(DOG#DW;YB;1.#1[%?$Y1O9 M,F]IRSZ%'3K0=&W9FD.YG74OWQSGK48S_X8-M])-6OOTJ.>2 ML"TL8)E]TY*VW"&QE4G=5EZJ6UF64).`*OMTK;SRH":AY3KZK3Q#NZ^`MLMK MMO*<[?;!GA30+DMO*^_7V$T\^_OVBCLX&EZ(=5@ZCV<:W;6M-=O[KE"NEC^S6M(#5V;(46^TF@VB9W*TL4]Q-,Z7K?IEK& M_411;0M:40-YU/:C9+M3<33L#R:2:GN,BO.0?TQ99?8E%0F-NP=TD8C2#14#(%PD'=<$"=HPL8D(]R_0O(=I"TW"LSP!R5>9V(U>Z]PT*!-S@2W/QJ#HF/N* M0LV`[(D2=_B*N)7)28=PGH`E'K]LPP3$Y$7F&><<.4W`"J98)A(`EA\]-G9" M9/B49L>4Y^.)[8&8PY_"FTDE01-XOJ66)UR^"M]T+Q?R=;+K!>3288`);GNE.@:_VPIF0.24S8L(XT3,2 M_G$F`C['?-`?\7O&P>1-F8OLR+5J`-KPK.YPSK&_A#1MZCPP%XLI6]\HNSX& M)1[D#@"62]XZY]U`+D.7+HS/Y"77#61R4=UFYJE)]P'I2=7@+``$$)0X```0Y`0``[5WK;^.X$?]> MX/X'UP6*%JCC)+MW[0:7%LYCMRF2.+"=>_3+@I%H6[<2Z9)2$M]?WR$E6Y*C MMRE3LM,/VXO-Q\R/Y'!F.#/^\5^OCMUYQHQ;E)QW3XZ.NQU,#&I:9';>?1SW M!N/+FYONO_[YW1]^_&.OUQF-.E>4$&S;>-GYQ<`V9LC%G0EZI80ZR\X5GEK$ M?TZ*33F;ONXJS??WEY.6+,7(UX9%"G MW^GU5K/]Y--UUOGAZ!1(BWPSHAXQSSH?(A]=,HSDQ"90=-8Y/3[YT#LYZ1W_ M,#G^>/;QX]GII_]&6]/%DEFSN=OYB_%7:'S\?4_TZ(R.1D<1%O_<&5/"H;6S M0&39&=AV9R1Z\L7D4#&H'['8`4,+/NQ$.7Y^8?439K`_3?.BO&G:_ M^T/';WSVRJU8AY?/KTJ2^_C;8& M.DQWW3Q*UO=]_TN_-;?.N)SSEAH2TP+L=%);B+]ZJV8]\5'OY+3WX>3HE9O= M?XH)?V34QB,\[4B*S]SE`I]WN>4L;-P-/ILS/#WO(I=QN4['GSX[CZ"9&/H+&#//%'$$SN>/<8/?V1?-^YHC] M;>D=0<^O8Q>VJ)AC./UL$5A3"]D/E,MSY>,/`#!%1>C MQ`3N'+N6@6SUK-V`0'3PU@P$PR@G;PB<,R&A&)YCPJUGK(C@U(&5LW")^/RS M35_XE<6PX6Y-^>9X6Q-\97'#IMQC^`IS@UD+L0&'TPN/6P1S/C!-N261O;WX MJ3*30OXN$+?XQ2X]N>P!+BV`"4KRS;`VB#K^#R=RB1#13SES^?0EYOB.EQERW'>":.(4P[7`C# M51S%B^47+#;,8@[T@`E9SUVN@`)=>*Q%^P@_8^)A:'$)O4$/9"OS<*?H%*&G M05B!.#(]PYW`Y+IABI*B':&Q-2-@O!G`_FKYN+0U+%!T9R?'0W9'&=P)$^HB M.^!!#X"5*%6([ZT%-QO'@QG#4HNH1T(5G$6-Z7=/7CM!W2R]5>-$VW`[3?"K>V%#&]6L%I^X M,1!,T).-E>_CLM/7#<5KWLHC;-RVG'[3IBPXUT@-3"8<[)3T33Y%GN^6H>]M]-[12 M!UFD,JE^[SHIE3/T'.P\85:2S%C7&FF/\^)M M/D8S'#),3.$8]3\50ZE[-?6G[\?GKY^F@D^AC:8N_K2IG]3@!5`_(:F/D_I) MVWQ]U$11I9=$[;06?A>41`%9H!O$:+&%$Y"R1/DKI>84\2FR&TZ`O- MJ(]MEZ\^D;I2[_@D"%+Y4_#QUW]CVYS0.^%`$.\6V!#_;V%07I[C]QB+SL^7.+0+$"XK5P)$R M9#D,WNK'XI.O-^09 MH98FTQMOHH%+>-PF099*=TTD''R-$9GCP:J7MBO![;=1E0AIMT7@*OYYJ MH3%\45]+Q.%TC!=(!.L&3F)^L;Q#OU%V"1_-J'CG"/=GQO90,G0;,5E]=A48 MN;6@LS').TZ%)FGI*0,M&M^`S5#740O';R,ZTM-9$S+^V%I0F5/F%E//$INN M:0Z-L0&+4X^8L1HQ\`E5<1@&(TP9=9)T@]6,-/EB[E!F8B;S2>!_W?=TV['XT`17?@6W0XXB@FB:@R!A&D`2W'W92H_<>4DRM&&IAUR](/V1U8'-&PU)Y78+ M%(P5>L?'P2[S7V3.A#L2F^==ETD/5?`A)2Y^=:]MZ>D][W+_Q79/MV8B_)F> ML7`KGNSM@@=#U'Y7@\J MB8_^=6`3,ZI57J:^3JA=7],/9,2B#-`X+8J&SE?7HBF+&EPF`UL.CLU5WA`V MQ;,_K*XDZ?I5_&>:IZA@9QVN()G8)G(Q,KSM\38ZJ)21*,/ISXB)G+LAD]4O MAIXK2E&8,I(]D?#<;DH>:!-G^1F+?[$Y>,8,S?#U*T@$B^,'9AEXW98'C3>! M5S:LCK5:Q5!&=_A`T#63YHK0.F\`_6?+])`='H@'M/23")9BIPVGB<.D[]&Z M9]6"I`SQ#LRNG85-EQB/,7N&,Y$L M<.^IO$+A&,FT7IDR%?W^DG+WGKJ_8G>$#3HCUN_A];8!?WWS[15Z#QCT#O,S M9<%'HMW)KB%-)D(KSF$V>>8A3V^OY+RG9:^G'_J<'N\!/*E4@AJ=2V6LC9(5 M#H:$$R#6"S2'X32N.X`^<8?8-^P&JD10W.`*M-:D]=]J/!VXKR[Z$;:%(CZA M$_0JE`)A;8`F"$(A64]U*V%H6YPS8,,$=:SN/VR:4ULJS?P)%D01&P3,#[>&"2^R5TH^&3; M\?4$H.30G$:R_.,?M."N$)G\*X-2-4RY\[4*/1!4_J%Y?. M*:U#'5.V:EI]*5I./K0<@2 MKP_;>1XK#:6%9^&!N>'&V)R*M'15KB;WKRGQ`BQ>+AT'2J!]BC.8FE,6M!I1E92L>VS MHW"P*.3YDJ))X&5LK@9BU[2MIR"MM@D,;9]4&X\K67-TVMP4J(IIPJ?M28]0 M]/2;'=G?JCR'&A#9N('+YCOL*2JU7QT!SA\.'.<4:S]`YZ,V=-*SH94]K29G M;FV-\3ZG0M>#O?KGN59D4#<+S/R7]E;D52L%54'H<2NRKM6#5M.[:2LRKYMU MKG-?Y;7G;6O#M&A.K/X*3[H0JC$;37N]G?T#-25)+43Z'P>&],Y#44*H/[U# MK2Q&<8WJ27/=FS6A6C$&(43LW?[1%A!V*J;0:M7IR9XC9 MNT&DZJ"_22\*03XT"ZGRJ(EY;B&.AV)'%8^L";$Y-',H.TC=*`X=YOKNU?-(!_?6?DE24+F2YFO#>KM.W8\=]U&6XEA04%FGLYFJ]90JBFUJQV% MF]^+`>]IR=#U@\W&]!M?OIO2448WPOP)7%ZH`7X#M M:OI]QK9YI>7VHNC+>VFY+6*\,FMXU#!3(Q%K=@F`G6E MTU9^E"'YCVU`YP'(IM;YCO-=+V8G#?B]*J.PL M`Z#-.>D[R@!H<\;X#I.2&IPH7E^P>,$B&#ICEN^Q>POW#X@"N1,&IFGYM-T0 M*1O$'_HCJS>HA/UJ&;`UKRS;@X,9?`4KYU`B&^BG&,QY#P3'4-1+\;#.,1@)I[N'H<4E]*:.B&,W(ASM.);58W21 M_:O#L29*7D:E;GU)/0(W1TKT97H[/7&7_IJEAEH&7^ND322=7\/F9G!,5CM+ M)$\(:7P+0M@<<(Y=_D;53.&E]'!Z(TM+DETLG+32H%IP\"50*'*0G1W,E-J^ MU=3K^DDQ%RS_38HRGGF/C:$:?^X:4EDN?^."/3;J#C[\^CC<(C'RQ M:X?OME(LVUR[U\&M_W"MB`^?)7L%K M5&"TPG]?A*ED#;@5KO,B[&4HVOH]T\4B[W+OU=@Y3`=%_SDL%+:AAMTJ47IM M-J(?]PQ5.*BWVLZP.\;-EXHAK(J`NZ6K),[^JCZ?$,K\AOV%#NO:P*.@L MD^^]Q<+.--/S.VG)\O0WQI`%Q:DS%/+$IAIIE@CZI/!,2RB]?:NIUV3'-=G+ M$RJN925$*".C0!=S@*B<2XE\FC!$.%QN#K*_8'LU5[IHRFR_:QMWZ[LBV$L4Z:TY;4NF2^Z%NS8$"^AU;;!\ MBS..+$=X`>(`CEX@A4L;FF5'5F-6XF>4842&W^[*9%0A MK?.LQ=)KN(>VH6J<&_0F6M`L3+^GHGQER%?]AE(AHW!+/MMB$N9>A*&%%)%Y M^GT8*CG;T`[;8-@69V[#;&BW)5M1C8B>V*1SW2:K]19L;<+Q8,:PGW.0$>RL MQN)S].AB?9O%59ISH4S/9G&44P&\0,?F\9-I1!?JNH<\ ME?81I,BTZ(]<8^L9;KL172+;728)L/3&:FB96K\+VZ:H/,ULK\>#LOZA\#!9 M;>6O3?.J9'11@FHP6/B[YC?DDA+B/\6(JB9WB'A39+CR9Q3'H#.XCXO@ET>L M-]X@)4/6PY?_>QQR-PBK>;4?"C&0UE>19XU41N))'N`W.@2H(O!4-;?`45.$T0]'0[C]0 MSW(QC4"_?W9'Y[JLRJ&_`D@QQW5Q0ZSX#=DRGW9]$+3%W5W&T@M_`+>4+ZD- MI7\KP5#!'=B&NIA/Z&>+("(6<)U+Q.\12'HL?@QR M%0NEJW!&.HVB7@D'5&4@.W MQS5B!#;%NKQ-@[%.);6IV`;O:^OWMG;LZ'RBFXKWQNU4!NX?^X*8)\0Q_/%_ M4$L#!!0````(`'6*9D-[BJ.Q@D0``,^O`P`5`!P`871R&UL550)``-]P'I2?K:V9*A\B=?>D,^6VW5G7.FV7[:2336UUT20D'R[?'_WP<'+^ M<'%]??2O;__ZEV_^X^0$W-^#RR@,81#`-_"3"P.(G!B"1^!Z-W MH]$[>_Z_V=+1^@WYR^<8_-W]!RD\&)_0&N#^]/XTX]Y_@8/CZA(+3""W/B)KAF2AX]->_`%[X MW2OVW&>X6?3*T3E^Q=_0M5?@-B@)X#Q>`V?`N?EO#]T?8 M7ZT#>)1\]XS@HMR*`*$S6O\LA$OR+#VJ84XU6!.JX6_)UPQG1X"6_.'^6NK0 M/">+5SKC1@;T'Q2G.3/A:PQ##WK"4%J](EQ,.HLT$TK%1FY.8$!C'J%2QYFL MA8.?F,`-/EDZSOJ,0O$,!C$6WS!PG@RL),A_2[[^I=%/BN#_'Y M$XZ1X\9"&_/Q_9%"A;.M_;1*S@,$<;1!+FP4$OYX&EKQ)7BBE58!J4+3#PQ/ M?G@X`K[W_LCWOMB3V7`XGGR9V[/Y=/;%^F(=?9O*`D(8^$6(^[]ON!W=NA:3 MO`1O#N^?WX0-%*"4M"?Z0NM!_H19]@K$:+TJK&&!'F1VJ:)I-!X,"1U)Q@,CK M!U7V=C%/&+05=PQ"6.J;;N)4X:^,/M*(&"(1VI"NIN\\^8$?DY:NED&2\GKI M4VZ$+1^=5_L0;2=%+ MM":FJ4)T9-LI_80"P#2`G`K`=0"JA#5IMPLZ=F.,F0<+AET,!J>IFPM&0*0; M9FL;N!>A1S2O(')])_!_ M9Z-,YTL$X8JDD^_AZ@FB`@A:"NF8JUY$PD>D,UV=6*B(TIEMS>PO0XY2I@(D M.@!1`G:T@*T:\`M7=)C1C;+DI2$05N\"(&J)A=QV-0R>T_3("S6=[1+7+ M=%:;JLRFH298L@93RR(M82['_/VS$^,H_(?9)-+&C5R&,,_\-B[8C9^$3MY6 M<[(UWSIZ,?`\GW+#">XO@@$0NX7,`$&^KB=^NP77!X382>^"%PN5BC?7EEA.:Z[VKQ M,4.Y?V]P3%LE_!C=0QH"GXVPI6\5C]&%@Y_O4/3B>]#[\/8#AL2'VS5=$^"' M2Y(Z_!FA&DF'`A$/OX=E!\`-=TT1'6LAK"NNR7_$!81E\ MU2KK3%A*%BE29#2P9V+B3,@%3#!@DD%6-$AD&THDW?O-4@.%]S+T?R?.8MIH MG_!5;V[6<2AW7!OU&Z$X1V;UP+6G)X;NZ3)Z.?.@SYE)/A0)2;[Z].[O&FBUHU2U<;'FHVG"'%$=T/IZV;&?^;::^8?&N!08%,;E'AII M2,+8]_Q@0UHV^`#=#6+MV]6K&VQ($_B1N$)YM>$C0;>+*P>%I"7$=Q`QYIVO MZ(RW++MU(EMG,]2%P:HOD-9D(CK*&;4@U0N$8D`U@XQJ.DLFE`.B/6G=N'Y# M+9GVT#&>7XJPL6:.=&ZI>#X/_M5!R*%]8RC"2(D)MH%F/632M0.8&F"T&>R2 M@[E6LK.'8B0U80QC+,,;_U%GQ1N,RM/.M3O:L"\'4P[]$M]-X#]94,H6:'A^O"$/^SIDXUK>ATW\*8I_ MAC%=>BIYC,K5-3)%U2;E_;V3<4(?L6XZ*QH(V8`(!T0Z(.+92FLSQ#J(]XQM M=\369X=N:R;-#?QMXS/D'H-5%'CX&"PV*&3ZV&SOPG_EX:'+()''USHZA5,X M6$FGL&G:)(&;LB'+ZD:!-T-U_$SW3)$_5^3IO3@!77MY'E\X"+V1-OA')]C( MEBBJU=5*<@6#E"=:[=E0,!P_\YUT]$-&,CB/@9`-F/"#T'L-D1]Y5Z%73?&N M?1]1WZ_H804+P$TXH'O+ M82K9;$9MD'3RZ50U2+W-I3437,UD]"VW-IPZ&EJC^:!QCC4^6W:X4%13UNB$ M6BMP-^:N\0FXFX(DK[N)>1_&\%#(L(X@\OM4FYH)H-:`G,-0*@` M0H>9-1X'BP);`D)WS7E);<#VF/YAFM]JC-VH M\)%T[%V^ISU9?U[MJC86*@(TQSR5('5RM$FIIL^0_A]ZYR\0.4MX]4J/6<'P M#ODNW);%2>'B%&AG8G4?H]*!S:I'?LP'L^&4'[["J4JP^U7`&`%^_/S71#5P MN&X`$^5@3;5GZN!M)7RJ]\P6[3&K26]"-4AT`Z$<,.V9.GA;Z4#;`2H/BM$> MMURF%$#""9(<\E58.AZBY8R9#G/0]F2:K@)LI$N3'O!QYZ!;]!#3S;7LO4GL M!I(UK@HU=79LZLU1?FV>B@G\[+DU@(BE/.:"DV&#[1X\0QV<5'LY6$(FS#UT*CTT0"H9`B5D*@U++TATC?%&G4!):9/DX28H+\>: M3H9RXG!9/2%-"\?DA/&EGADC2QYIE43)A*(7)%$8L:JJ8I(N+09OAN/93,X9 M\V-47;DH9T]?!J<4<%C)H_T&I3HG$^M'-N+23@TS5"J:H=JKF8P'94SB;T)] M(M)>#N[PZ!WXS\'IP*)O0O_,=-V`-1X<#P;LOX1I_P26/3VVAX-C:SIA4S26 M/3Z>C^;'`WN4-&+\JH[4-CH@\D"8PXZU!:0JNS.2E;J$;O*MQ;ZUCP%1LH;T M-#H8O/6$RS(:2*A<^FP,,;EX04'-=1Y5-?0R66:&\EK+X2CM1^Y>RG'H^SAJ MYU,[\G"RZZ'IFS844%<@3F4DS!"'>!G&B$UNW/OXUSN(Z!?.$EK2!UI112MU MY'8H#Y0-Q5%Y.6F`B@.I/&"9:@8[24F]/"FJ5SZZ9&BG]&!"0"(%4#'&2+&7/TF?$+.)_\P>H)XP M0P:J`B%*0V"2!S@QIN:I;8L98(#0K=[OF`SR\,<"_V:AW\H1?M1B/_%>!$\9 MV'-.FT$Z)KVU[Z+(PP]1(!^8SI?2BO.<:N6L.)O8`N:8O2PP$8#*,(7S]H[D MTOL:1=Z&M%K8"0SO$2O'3A[GNTZ;@WE=-L^6T0[QANEO;LW&>8`?-(O7OQ&W M]2%[BER"\%XD\1+`["*['^D[L:)NETUI65,X;[I59#"Q!J5X-[\S9F^WL$/T,'787L1*3"8ZHLJNG*`YE^U?DS MHF&4@#\Y;9"+`E06H-M5J33]=R%TXI?=QB\=ER34`4S\L4O2/KS1`^)N%Z5BY,<0'EJKQI[T@5U1WG8V M%(,L0E+^!K.,28#:!%*C>";OH]8KLH$+2NR^7:/(4R.FY;!:9R,F'S%R8(8\180TIJ3MI'>HQ:S0.LKFN`(Y4&*2]-']BS`FG$ MT%BV`19MZR],N.$VM#O'[3K'C\%3O>>ZJ:>$XC(NU@>N7^2\\4-X'<-57:>\ MJF8OB+DU1_TZ;'',4R4M?Z&"`9/<.TZV\[F6D;4^FV?C#FS5N)@/6+^86#QU M71D%VXJ]X*&P1OV2!W%F;24D>0/1@[?+CCRN)V&-Q^8Y6`2L&@5ST>H?`RLO M@U&JVAL6-KQLQ9X57^WDJ#1ZFTSG7I=SL0\7S33!JCK]#%])4S!.;;2D4-@< MR1J.+XQ'$UDOLQ=C)GMXE:=-#]8$50.K@A\]&SNY]+$;1'B#ZE8,U=C$'4`]-):KEX](#KGV* M0K=)QR]3WARS4B.4#P0@724)H5)AO>!02]]*.X'@!`1T,0^Q8=4C$NUBKH([ MA7B8HLIW.M_W#5"K8 MBF7KQK*"3?&K8Y?M'9?9I50UCNKCFCI8\[13#%,W"W4A=I&_ID)O%Q^2V^TD M;UD*%;0OQ:VR1A%,D[%%7CCXTMM4'%VG])0(U'PLGZ0D(KMTP;ZDD,[&-*=9>37&;)YL2!3U#:TG M[\`-6]D-;0E#[%6TT%O_)R[BHTFTL+:FS*9)8I`F,_M MP2AIQK*BQ+F,AO:*=.*59<:KFB:L$]?L5J[I:;GJB)2V6I6AZ(;5"7](3_@J MC/WX[3I<1&C%5SI7]5=5ZFGGNH)1BB@:6_8@N8Q$2&6O09#)!7XJ6''H`U\^ M.-AWR5OWI1]L8NG=7G6U#+*G8(KZ9C\Q)5J",R:3#;$D4OO!I7U<993B?M$1 M08^+`"&,V:4-8$V<%W=NRV[<-$4P"4:K>%86JC[0K6[MK+R\08HU7S.'@9\)D^N?JMXW_X@1T^;'LT381H9-2#>Q21.%H,!LENZ>X=+K81<@'5`&X M#0&5S5HR]B&CQ1#U#A4'.Q.':`&@B`.B<>"?,2"-FTO#0%M`]@%6QT,;;UL` M/T?EIE$UPN[5.HC>('R`Z,5W87I^5?:NM$RK+C0^7#Z=.:-0SFA3"Y+;-$4IH#$EMPA>+G#V[;V`&X0X`>D MY\JP`Z.)48!8!5*S#&6E7D29I;`?0K2M33OD:<38^?((!O22=1!'(-Q&.7O? M(6:71CK,1*,I[=!LS^6_@SZ_/U6R%#.(*/F*EI/=*Z?9B#]#6BWU3/E%?3R9 M:LRUZ40X`AES35VMU^-GPC+S9^@OGVF@G1>(Z!6$:QX^^$KOC.4Y^8ET."O; MLC]\^JW,'UIRLOQQ&DW4M-V]96OU*Q?&R\N;2']%(U19,9K-9\5,Q3H>7)CA MM?/=N,=(G_7*["I<9<"5DK`T$H>?4>9K^2X@O2\NN`X]^/H_\*UDIK2\G*8Y MYE+EZO.U<]%F\]68B1S`!`$B2?^\\_X.V4T=TC$770DF,2DM]UT;VM/;V/GJ M]Y+;VW7(SI."SRSQ;)IL:*SJKD3X* MZ"QPJ2Y(NHCUT0\@NG!BN(R0O!')E])*G9QJ]7P['N>XPJ0`(<84-=K[8C?R M11_R2^&3A_JNT[JP?0^7/ET9$L:?G%79XKO28EK1G=>M#HEAOG^4B@%4CBE\ M[^&-WXB5^&WEM9L9\]CV8V>B3'"[SD;AU]4J>8>@$%QL<1RN( M;FI.8F\O3^=K=ULCE;=_6]8H1S:J*[<_3)RO1-4!H0\(A3TXSUU/C!B%12P6 M[6*A[85_7ZKD!@3V"F\GFW=3$^XB%"^BP(\N'(3>2'?R?!5MPOA[Y]\1JB/^ M7J)T;_%M::?J58'CD3T8\FV_6=YO=0&A#'!MQX#ITTC[LJRH+S([&5$:&>V! MJ=Y#K"4Z]N%PHV6_\9[Y9+L%>9]@&^E"_;8A]M;M=\@7TMG9R6E675EI#[=3 MH*R^^?T,[=VPE=W0UI4HA4RN?[#KKA%L;U"TAM43:=DB.G&=T:L\GS0:BU:( MU38]/];6!5O1!6UX+H%)#LU%1SOIP'Z$")%&07Z.5+Z`[LYF3KOR;=,S:SS@ M73R`!,(4HF`BP1$IIDFIT,_ M&4?NG)ANC49T218^IMO83+9#:B#,MDP*\3#!IN]@")$3T!.&O14QD78#8V+D MU2M=DB6[H;:NED8^U9BB"K3I:)`0*A'(C\W.B02)3#.$ZM)1.^LH.S8[)](D MLQ0!F:662F2,<"N*O*]^('V@XF>=;$ET*J/%FB7[.D5-0^!O8[==9[` MD`-OUK-.WE:^HW-])<<6%7[4_9:RU:S:0;:F0RL9Y&9U#W];&1+Z,SMJ5K5-#DL@5\MLF(W5H'GFF4XPBL$O-,IH>.N9=- M+5T^@_ZFI<]^_.R'Q`%V+F@GN4@BLG<)J-Q.Y?WF$S%>WB3K<)TL[?#S8_\0 MB::#2)5D%_P7.>`EF;6E]/+W.JC5'M4<[FL^F60TP4$#+!=0B$5)"(-<:F#KUEO-HZ MMI8[II%,:H@LT$HA)OTBV#UTH?_2BF.9JKV@66J/*O;&(W$#=#734LG=DFW. MW0WADIZJU(YN;;T>Y2B'*CTTS[I=F*H1KQ"=WG`/;:!M,9M5\IDI!1C*;6&=ZP59Q]O<>-:Z' MBI=H>UEH()^EQFP>/F)Q26Y:!T%U5(SFB!9TJLT?3>/=C]QR"1>0/"\OV52E M#+!B/:/9H6",$D16\Z\L)OT@ MV'5(+"+:FK3,V3I&B94Q1+FW.,V,Z.R2*B.Q/WWCUFZ.N)^5+IEC4@GTJEE4 MC$,_&+1M02^E!"*+<<8]6D>/4M)",_FU<(&WJ MW7+$2B,X$OB6LF!:-*[>0W@OVX4MQR+506.QG"UED*U\5U+AXQDF^[M.QDOJ MIB=TSB(6)5VU`8>BT(P#@_-ZRA@G,FFN!X=H'NXOBA-"^&K.\:)4FYG54)E/3A:MJM\#O\) M=WC3R`>(CXW'L[X/Y]/I@+XSQ!ONFU\RO;VET2+5G1A(I[NFVUYRF2`32H9$ M)M;2?GW-CCJV'95OI-'LK=O36R.[;Y01F>_*48N2G4&;SL==Q&<#E!XQ.@!? M]2JO0*R=O'PB>]O>%O_.#KB5.5_KV_EYO:0\)E8\U33RL3)B5F+[".,CGX6X M3YH?XWAF*#*@LUBNEELVL#%!>=TTP)75?S4]E/7WQZGXDY?58U%6!JS^/KFR M-K(X+,G@4AB+A`&P,0`UEQ59JA#J4+RRK].T6[2K]62W*+TQ;235 M-0V%,F.H>2G7Y)"+(5ZB@X]XB)X>V-Q&_-?L]':N+>J+UNM-#0(T?R_(!%2H M=6CT=[6`EZ+#7L7AOT@\M@`D:2\5H$LM+ M]X-X[U:]GR(N96T>3;!:I/&45'2;4RM\X7^4!!!=BM^N_CAGMU`U>1C:#( M7]!KRGV][K"6>>HO4?B,Y]`^(RM#?+#F?1P]Q]Y1O#S;\(;I>6NY.:ISH[.M M,\L69K%`D!T%DHG$AX]AF8:GL'6ZYN2N88D@%PDRF3;7877ZZ?;QT\A4MQKB M\BEOA>!8&>ERL_+C M[3_^1#\$"?H0"G;P#F6/7[WX3YC2'_?D$'GHB^Y(Z"7/]-Q&'V.5/YM7B\V& MSGRP_G;*]>$O@ST^*?5(M+#/A1"D+Q#X2`M^X)G<*7!.(/E40!FJ]W0(DA>0 MX!4]$)U(-33,[`8G;*GAB11S<2R1SU4?N-L#IA$0'0#K!%0I^\T>9'IMW2QA M+DZNN+^5>XJU:1H=Q)-/XO0.K(W\X)MW1):4DO`/T=$+JE35_+S!O$%HA&I* MN5RLL]E2+`J#LGI--I5G*:70XU_E>U#BD:G\HK&S%7,->1#L8"4]Q\BF;(][ M%(JF13@/&D5'5;MRMUG-'08++`,#XRK%%A9Z>9,=]I7LXH#F*&CP>7=.@A`F M5F<%Q7VIC`&N\U8Z/TS?>\G+?1R]!C[TWUU^2_!%F)^"T`MW^+R'71J\RJKD M6P@P"19EJ]3O9V3?IT@VP,(!DP[>70"6CS=4YQK`586=:JR!0K!B(=CA$)Q8 M")XN8)^[[DE=-X;%UEV[A-%VX1LW=ANJOSH(&B666]?JKF:SCIBV7DLV<%2R MI484D?TA^I$`#"TNPJT6G75'0#>H6R]2$YA*5Q0+L<1CQK>D6RM@612Z M<>.V6_HO$S1*'+=,=.>S[6S;$<]C3?]U186;_O,0/L;T7P$!W:`^AO2?WE'Y M)4HDHW'A&;-`O2I6/K]B-5]=,9A=(8H%6(-51Q]( MZ'H'KX"UXJ,5'")/$&5<,_O0SR<(/Z?PV#CB*K]O$K^J1BD70,Y7+%^FHHN? MS*%?F$HGXNV/J8,$P"T&8'PS:&U[<@F,K0*FI8STVQF7I=[M/WD[O&7\\@6_ MRYG;:GC8=`&HT!+5:CMGMEG,:'4GE44K.JDT<&#B#-=C:G++*;AUMP=,&LC% M62BAU.2:V]1BUNHB&Y&4%SW*0Z$5UAF5/'MX@^Q#D-;FG)J>M@7LNBF*_<1U MY\YZ6T(V@D!)'"#R[""[KU^.';_4L-W7N0JX@Y)SB<@YH^@6`ZH&;T$TK.37 MF4GY-_@#?)9M31<_;S)_%AFAO`EN50?,=?*)2;.4&VMQK@*8ZX120J59S82; M^EPI\Y6&0^N0>(_D8\D?0^3)`<],/:1GOWJJCVJ#IA9'*T1P8HY"YFA`MZ8E(F>-#J(-$*R-I+(0Z>6& M.#AZ\27?6B]MM^JSUMB@8HCB"++>;&>+ZA?PB0#779'K-ZU\-Y5PM^O+Q>R[ M1>RL@I1=QM?4!?+G;$"/*5?L:HL9^E<594R&G77/?JX43IJ^?H]"B4/&\5'M M1EPHE'P?1:]7'8UJS]M$07OB935$=32,9XSIY5UE6&'0L+ILV=C9I!@9SPC1 M6,W#>](&/MH7EBPVRUHV-GA]C_)0T=&?5=D?V^4RDG[$!<`(2F?NXF1V$2'0*?_'`;^O>HS=D,PMT^*R7P#@_H-Y#,KC8-*5IDFX27#H.5R7S# M=KL5U8*27E*74]1,UN.9;G!5;G]L,QXZMQJZFTKLO&KLHDZQ,T8>.I%8HAMM M36.%H/#-Z;=)`M,$US=)[POB/VN20'@&*!_AL-QFDX]$#*!RP%60)63W]LF] M^N01.59A)NM/)=@(_;8&@_?1\13#%WS#QBNDR<.G*(;!QJ.]8U--"E+U\-+IK,1H27JYY&R@R5I/^)>M6/Y''>-GKIE3^EU-*J>&AV4 M&SMF;1251\@:PM!7452>R23W?9@M>3!/(5.&O6_SE M6]"&/Z0!T0>(0E#4:`>]1N+CEN*S1T'`9;[P>#I$%PB3OX!C=I=`@KY"SJCS M7QC^4Q3`Z.E`]J?H#M&6ABB$S]ASZT%R%J0FQ?N)/BM.7N"#..M':01"F(*$ M])L$INF!3)J3VQ;^[XSW%7H_O-BW.M_9EUF*Y-DKVC9I]3&ZW:$&B>%G]#4= M/@=/!TAG=ANZE?@]"T0I-$9]R7RUJ3`B8L),*+A*S58>;&-:D[\$O+>^'Y`] MLABS)V0!0FDTP\(/+)NEBN831@U!2#.C0A M$W0#CBA12V[`_AR'`;EM!M?([(.?^-_C0FMC1Y=B5QY+*TB&,?JZ.GHH$B1' MED]&BYXVB5&^"UED[FQDD7*QY(N\X4J)C=+)Y%D6X?@-.R'=R+;K5++I5ORTEU>IQL@](FO;?GM.7*$;LX2NU?>TE:P"L M6J+Z);==LL-.J\#+OE.O(L<`MEYN\D&64#\]J9]VP";JDV*0<>,S%G#=G=,D M]4*\3-JBL8MO6897P135CK=R%JX47P69XP%85T>E"(ODGMJ$&*=G-F&L&B+[ M(".C:EN,U5ZR!K&J)%,8Q<#\ M9C:;X?\R_-V`,`KA.%$HZKIB$'+#:`F#N!XJ*YZ\#?W"GLGWTIVZ*F^:16.3 M.:I]=;O<+G-(DFJQ3"I9=BSM['UOM=%.@/&Y MUS;6J4[>+]P-.Y&4R0=8`6`:\(Y7IH.@D0Z5F1K#\[/#1<`9500:YG"'"X-; M"@.Y,0^R,$1[D!#/(RJ9\-2/3*N]>=XNH+]._+8.I9V4X6KE@W>`7[T4%XM= MD'WO\>',.WH2R0/*Y-*TO.=).)!UEV@TQ>ALIG(!T'JYXJ$?JP-,'X']52-F MA%SG<$6*ZEF)F2AQR.%(505CK6?L#YQR-M,OT+:Y(^,U1G0JY%![Q1+ZJW8H M7^WNK+GPSN3E@_P(H-O+10XVLZ$Y'\`MSU,W=T,1U+B!L80E_[Q+[^('&+\& M.WC[,Y!@J/ZH6>S4]"L7ZSGN/,<,ED+64ZD<\`>69*L(L:]3;L$IFK]FDA*) M7P8A(NQ=%6CPHV`1$B15SD+Y(3IZ@7"3K?!Y\^"H&Z%\$=0FW[7".M-MJ3-1 M<79ATM,]&58D[AE&B[CC<2`CB(@EW/"+[;]!\?2OY!6SZ!':H7QJ_6;EY``2 M;C/!)ZY9@Y`>'PF*/BIN)KG!.Z,M@ZJQ5U9P)0^3#6A]1ZTB2\VN?S<(FERI M\O+X@@TQY%6K>5G_ELXVQ* M/=?JQJ6N#A1[[PC2'4X'J?5@R_7*W^$N>@X#.@?V(5M[_PY?87@652E+7S'9 MRR5V*&_RGJVSLI*"-#Q3S.2!3*`E'.ART:VZ&.V!SUR,Q2X:0XI"-RQ!IRDP M=K"40.3S"\JI/B!3#A')JN1'QD M6W(2?P_X5X%VD:30"9;%?=8L=NH&*,_;;.>K'#.9 MF*Q:P7(2UMLKM[57!E$B[EX5=`B"8`<5*\-L)7#5;*`HV&BN7WZ>L M%0%KXI2\+%A',($P2N",)Y3*3#?&:L#'C@PCDTLXM[)U\6=5: M9A#C7V'\%`W0%(Z@9[&F`(18!#=;&/[BY1=Z%+VV28]J,T!6[G.OZE8^,<== ME#^B[-^OWLN5(N_\;0P=6F'BQO[-X\P0NJ$2M5#H'=XSIKX-?7PMVQ>%3X\3N@4="O<08_:;2@9*S]D$N44M^ONVFC1^--PDEFQ*]1Y"?BW1W< M1PWV;IY^Y8^#%3N^ATAA/1P0.?8V+^M,Q;XO=-L*`G8O MT#\?X-V>K4FPPY5BP>&,[\4C5]/#G^D[9,V?HA;M*,TDCKJ9J/II MLG;<;$V=*<(EQGFA2G[0,2#::,DDU0>(0O`'5@F(3DO)H(D($>32$'B%$'R) M$AJC]]'Q&(7B,Z&-8;H?/$JP[Q%6R\P0ID%Z^3WPX>>07*J"IY`R`N,FK^\N MG`V=Q*WF+J=1EQU6T>>`\FZNS9S'.<00@"T!!5/RP5_TC?KN`@2;IHE1]DG) M4H#K\]R7;[B)=^" M!]_A*8I37'L%G^DMEBVSO[:2+7-;2W.5=SJOY@TLQI@+,11172:M7#M@ZL>7 MQ0T9.K<4NBLO85JJA.L&_ZY=O&P25T?D-5%4E\:P2T:?O""F9\?O'^#)B[T4 MWNYVT1F9R+Q`OWJ.XLO=_GK>H^3X$2VBK=!1=WO5YVYFJSH?8;WL;H8]8*H! MTUW@IDP]?NQJ@-6C4XQ'KT9)A>A%O.@]U:(7*4;//#_U!R.?H'JVS109BOU. M>EJ?9B438JVRYO_-=VCQ6T&%+=I':C%M.I$!P?RSJICM-V4R2] MIG(S??(G1'6MJZW<^9KSU=@[2[->I68GD/H3MI'4LFD'JTY"LU_MUM<#M1FO M/K(GQ&&MIFZZ>78'<;0Z\U0VG4:).Z]+FA/(^SW<[%G";7F-)F&=]S`FA;(H>N2!W\*`U,)6#NAFORY>`?XKOH@4<3`]ZN\BG>4:@4&F M3_:SZJWJ3?>K[7RSSLX+])[.!R\&?I#L#E%RIA-`"2%&BNA=$?H>@?7I:G_V MT!F;FITRF)]0GY`3ZJ]_HC]'U!'P3#UA9ZM>S)X[.*%V:C&^D=8I6)T]1`PD M27CM_H#KG^C/F?D@LY^=Z'JQ/I4ZM5:K#:?%9KG&GK99MI6MT`)Y`V1G5N*/ MIT<8'\%G]'Z(3\W#NSX0AH[6CG`Z5XV<% MV'0I_;INY!WD6R^$SYL$J\@(Y16`Q9PE`U04*,JRO:%!BW<$9,I>&4-64W! M"S\:8T#+AWPZLS%15'C3(H8XYJC?&KJ9B>!T%3N&!%"SSP1FGT/_C#KEA16# MDAFVNQ.,/9H*/]7JINP>;:G>@65`%(7.(B:3XJ!*XJPVE$G>,X]'L3'*GR,; MISRX)>5$D`@=RS"GR=WB>)?RH'>@VAL@.\PP$/RJ'_U8O_A)@7 M*E>6UUI=^()1J(FL4.UTF]4JQQB111:V)RIO(__X.$PSS>Q@'D>^T:O^.*JRCL9O=R@<= MS99S.8:+57KR6D?Z_\P.0`T!SI@XP$`L"7/<54J3LFLS<>U%BFLO@KSVXD1K M+\!K%K4343D^9ND'T&8^ZM$RDV*QC_]W#M++YQ!E]J3^+[E+7V#\^.*%Q?*0 MY'-(/=3=N]NJGP+[M?1)>09H,9_I8D9J(BC8"(B1`%M9+BY(\"WI]T(6&#%S M#MD.UWR,%AI.DB`[8E\+>79IG+=,K+_#X/D%E^&]PMA[AN2/'[P4YH=*6$9' MLWUOD)H;G5:^=70YUY;5=N-NP'P!F3/T"8#=*=29O6V*U]N>9`PH'HT3%F+Z M[S`@*'.6C1%#K:W?UI#R+2+'"D'_V_GX!&/C:*OJ?Q-#0L4IY0*BS<(PY>>& M`FKI6^/R/@U1R->?ZU[TT0=4NG ME6]P6\Z69HF<.O)OG[L/V9YD/,C#ZF5AW>-8OK)S+LE>X7S._&V.$QV)S,PX MTJ4#3&JA_1R[JAIZRWBF,"ZK.J/+#9K78Z.+[ MPNQ`<7\?,P\P^\!WP93!B/E[D+@37L[#X[/P7`)XF"8#MX6X%F9MU336&/.I MV;.G-I[A4P2D)1C#*#3-D8-XH9P\S==%/8.P;]0D%YS4=:YT@S4!\\E.8TS>?;\ M'B1_?HHA_!RB#@^3U!1W/X!"P^\51K&MIB?##2%#;-I"CS2],UB_T%3X'TOK2\#]!=+;;:9A5' M<)VBV;BY>=P:3FUN.+2Y(6ZCY[(:^+20U1?[]R5V-?VK]S,XGH^TSB`['BZY MA_''X^D07:#VQ*U1WQ2XJ\D)Y9-?9OHV)&0V995+^:F2"5X!!\RPB7&=UC@3 M"F11"FF4KFO4^%_7XB84W30"$>*ZDQ>GP2XXH5].DO!4\:V%!Y7::U+T^"W* MEM)K2^W9N:&ZNWRSPBD09*,7ZH?VS+0E?<@H=KPCIXI(<@[LB!E2;Z"O66)V M=O\I"V#Q5'^/GDK^!FI[E,&MA1S5FFI:[%@B^MMS^A+%>*)8>R\7Z9D$%PJ, M5]XI,]>7)-:2PZLY4R,^'5&M?167+S0I?Q4GA><8+Q(NO*EGDYXTK.,GQ@9< MZ^%#60M.F09?O>"`CU7^%,6$V0?N^C5U$R3%J@_*%6_.6E]Z6.-&9A4^%IWF MA],FR5Y1OG(EHK<\,B@KI"E@=B!*^H(^F9&TMT![(AP/P7[$=6]B& M\2Y(L"^?\77`81+LR#J.]KK"9H53J"ML]$)UCFM;/O:I1UWA75X;D]L$!AR@KI44D?0W^0TD*]H5Z0VICGYQ@^XTU$U0`5M-P`Y)'M8Q@'A[66^D*U M)II4]#X*R84#9^\PR.:^'I9,\^M-R MN5L2QS'FQ79(9J`I@5;-/.'<&N8G\3U&J7,$A.K$XH36WD:*ORN=-;U)H_G--?=.^!_@'RYN;6F2*J?HG@/@_0< MP]IQW)H[/4_3A"B38[YRG?72<74S9,&SQ) M<#A,F_4D`-5),.BE.-"MFBF@F?>,GYK_A.ZV&O>EH,U]JKTW[][B;RD"[$'[%)R0D).8_Y.?9CR#' MMLPFPY'S&SRB+=L!VBH&0T11%#0EHG3\H;:.*,..AFB+J>:3)@NYK]C>,.RGQ3WPS1+[#\ M%3A%?M,4H(?4B]/QAFC9'*)W\#D(P[^1#U%G;AM.3>@0:P M-[D+1^R?J#+='6@K1!=+)K0+IX-[ZC=?\YAWAAPC[US7AZ:)J3!\B M'>Q7GC%8;EIL5$_DGQWT_]@>@`P"V"*`30)_4*/&>MG#T/&EE\+20X]IC&0! M&4U2VP.AK3+8KN&?%JV)=OD,,1FCUXA)4&$7SY2+P1;+%L6'#20IVWMH8XYF M0/H2G_9(^1%XP,PAMZ:+AS,TZ2H#D[E&Q0=%LSID32+7U3_E2=+UH< MU:Y(T]P-D&^4J(=L%R6JGL9.RH$81"M9=VG*2=*UM(S1"%.WL&!*)*WNEO)* MD+MIL3E1D9^;:['?!#4/U!IT9F+X`.G8[&.KPRJ-7)*=4I,9M]I3J=8AJV7[ MZ3LQ@-T`=1?^[_EP>0A^/OZ('E^B<^*%_FWH/_Z`AU?X%7(J);O)L++/OX6! MBO!8K)?+36$+?[Y=$-R%`"L!2`M`:@#30V:%J2;P!]4US)0P;V`!-\V=D.PUE?O\@!?$0-`&!;4 M?SS@7RKSEHH4R\RE8*):!W5FL^UF.1.1%](#$0$)CE<+1B M,.TQJ9(8#H:S)B3FC([$6C"!B,94`VB0R%HF8"I2QDED[4=:9[9<+>=.!R(; M4QJF/1SMB6QTJ9CVF$B(;'S96`LF:$EDIC(RI"=,+UAQ0?=+$&-SVE"9@AS[ M9-9LI&)?=5;+]78NHS.JBH*W!.!,W6@837=,))QF-R9M:4UW8'C$YKJ$V.9C M)#9U9I!0FV(0K2WI)/=>X'^*XD?OY^]!^O(2'7#5*OH%?YI0-B?<5I3I19:6 M]JE./J^V,[<$>JR&W(6+%(&")O([T8J*Q>6.(>-2O`[W!Q8.#SY((W"$,`7P M>#I$%PB3OX!C$`;'\Q$D:#0[H_Y^`4&XBXX0I"B&T=,A>!9&R>BT?4>XU.;? MN\3<#D=$<8H+U#^'KS!)R?*`L"]Q'C6*\;I^Y4/SYYL@>G%\P?23G\^48+F_D!-1@ZMDD&,303`.THN]!<:^#>GF+5GSTBZ#B,%4 M9@A!`*PP`&)DLBSX*XR>8^_T$NR\P^W/0$@#PN=-N`N\PWV4!&2!_2DA M&[Z:VE3VJ@T$2>Q1OAUWE7\6YV"ZVX-<+F""40_,1-M&EBZOW;+740>OC6-/ MH?-R8=@4,\N(_$P^*&Y#DEC'\`7EUL$KS'ZK#$XE*79PJF*::A[ESI(HLZ."I&DXJD]8/'ZI1QM7(\@%B'P*AW\@>4#HF!4<.P;`"$R MQX=$20=N!J4H3M;P^3E)SM#_<(Z#\)ENYJ%KD]\A8H]@ET*?/$;V_DAO2^LF MS#1R6UNHG*FYLV(F"J@B0#6Q[8[9(OA5679+%=TE:?-&L^%CJ&DQ@C=@CPZ>B!_K)PU(KPDO+V@L=`" MUSK5:8[9:K51I832;77R4W"Z1Z/%Y=T#!X5_,\`X#O_IW.V5L2X.H);Z9EPU M<+>_?8XAY-7J\)\Q79=<-4#U9M_58KZ@)<>/V6V^Z0L$'I/S5[.5Q+V\<'(O M[O;@*L-"W6\O-UQA8UBKXQ4A(*_1Y3JL"7ROGGC+0.&OY@''5*MN1=DZLX7# ML/;J62K6[VJW8\;N)F!U,]Y5,MX0EJH=NH"BDG,AP$G26O4R6OK4%4K:]+P:L0ONZP3N#NK\_1Z__X,*"(1O^H`AG]ZA^/ ML8=WA#Q'K?S<`OII2U7[D;-DB1_8ZH.^;!4L_\UTU\X?N]<*.@?LS MWT,]'S:Q%R8^^F[R#K_"PWT<^>==FD@^=63/&__XD1BCFIEO9LYVFWT.7<4! M)`\P@;8^D;1YY]CSKN%#2IN+;F<7S7QN*<#L^@'6%!4KJ2=2<+?_`/7'=1$[EE!R22363Y)U7+NJ--;-_W]%8TK=_"P.Z<.^EJ`.C3GY[A'&PLSM35^\$N+=6W-22!O[N MQ>3HUWS=JKB\Q;VA7ODUTTFA@DW*IS:YSGQ)"0M"(MGP M0I5V7YV2K[G8RNHVE6PA7]3NK\MO6VMY8@L MN$KQG9<$N]O0_Q`9L/:#2C&- M[1%IBI4L#%^08/0S^@G]`U?WH1_^'U!+`P04````"`!UBF9#1\/K*"HB``#" M:P(`%0`<`&%TE)U>`L` M`00E#@``!#D!``#M75F3XSAR?M^(_0]R;83#CG!U'3T[=G=,[X:ZCG;95:4* M23TSZY<.%`E)F*$(+4BJ2_/K#?`0#Q$@2(("!>FE#PI'YH"/2@ZP.?-C=X1.[OK\"#_S%@?]H#^NG7 MS^/'P?6[J\%@X?NKCQ<7W[]_?T>(G;3YSL++B\'Y>=+?SQ%E'P<_OKNFQ&5^ M&>/`M3\.WF<^W1`8=6Q3FCX.KB^OWI]?79U?_CB]_.'C#S]\O/[P?]G2>+4A M:+[P!_]F_3LM?/G7B?,.D_D%[>;]15+P[,]_&D2%/[YY*%?A^_ND M^-7%KT^/$VL!E^`"` M6X+][SPI=LX^G5]=G[^_>O?FV6=_8QW^1+`#QW`V"&GXZ&]6\-.9AY8K!Y[% MWQ8$SCZ=`9]X(?*7']Y?LOI_N<56L&2SR+7O7!_YFP=WALDRI/ILP-K].G[( MD0]H83KS5@M`BX5SR(]GY`4K?B%L\:(MO6-:\]N$3GK(^AC-[I%+1PD!YP5[ MB'5QXP#/0S,$[6;D2[:]3T9>*,$-!Z-&!_X"^L@"CGK6'N@FMX2M&8B;44[> MB').V)Y#X`*Z'EI#101S&U;.P@WP%O<._N[=(@(MOS7EQ?9:$WR+/,O!7D#@ M+?0L@E9L`HYFGP,/N=#SAK8=3DG@M-]^FO2DD+_/P$/>:)8]G#OA3KH?A;Q- M?&S]OL".326%NW\&=&_OA#79;CKE;!(LEX!L1K/PIU$XC8:6C];T-_4,"GOK M=@0]+UB&_7E?J>#XX-X#1'X&3@"?(&!5XKTL*O*%4"Z;'JWJR>AV!E`1S@X< M2!<9).&LH^)@6.RKB_SA=T!L;^C:F1&+R?KJTD8>L3N?0K*D6SZEG.[]+P3/ M"5AV,'>ZH5,AML_0?\2>1\F;4`9A)YN&5!_=\<2V8XNB?(N<@$(;_T0/_R5V MPP**^:ON3R&O#ZX=>#[93."<+4/:[6C%E%&V%#]OOD`V858+2@]5"KLYRQ50 MH`N/[=8^AFOH!I"6N*&UJ1Q($O5PK^C(T-,CK.AV9`>6/Z6=ZX8I2XIVA"9H M[E+ES:+L)\/GA;H&HH+N_.IR1)XPH6?"%/O`B7G0`V`C2A7B^XCHR>;!X9S` M4(KH9H>2[$6-ZO>,?>A-\5:EWZINWC/P`P9F.C#-&*O50]=,Q;K.T+)P0&44 M=ZZ:I]T.NF9I5XQC9=/I-(5O_F>'EE'-JGS'O8%@"EX=J'P>U^V^:SCN`''I MS-M*>)W-`'Y'VECL9H2KNNM\@D?'Y!BN,&&;RCY6MT27/6"[HQ4MW7'7$-S" M&20$VK$TLX>!E^@Q9GJ5L1BR6\,<][0P=&UFX(F^LE[5W?Z$!%`2*#FY7AVF M=V"2!SWN-+P+\Z#U;H[7%S9$%VP"9#\LONFDXVB')5IR?W1 M&"'#GY#EY?9'7Z3Q<\G*:.%=4A/-^AO:(6&*G`W?_A=N2L@J+[.:+[4OVL9PCM@6Y_K/8%DV M%TN+=4_=E``V1I/-\A4[)63E?]_2DSWXAR1/&R!6TA#]Y\ZIGW=(B4M%GG[$BHP"6K>X`)5(UZY!(;4^52O M@V%)5A-A0BGX='9]-@@\RAQ>1;:9PX*G(-^D^%R?\!&<;2E.[T\X">64%*D? M3DA52)XI5G\]855R+J7X_'C"AR]5I##]YPDF@4)+4)5/0NA;)?[HH6BKW8;^4=/]NK./-@/<:HA)XYW,`5I&B!QW? M2[X4-;[X\[?XCOK2*)AY( M0"I4,<,IKHCY8!@Z=V#;/)9WYCU&,1[,I>./S5*L5+9QN?2Y> M`+(?W!NP0CYP,EL:C[GJBEKX\3SH%\W'A1_UT<6Y..`4TD=GQ5K-E=%.I12H MQ;(ZJ&8Q(E2Z8'\Q]XDU<$*O)_\&$+*ALD+HO,WA0JZN%J[2%1\2P3>DR]30 MP4%R$WR#O:JI7UI4)\WQ[;4GS3$X]. MV3FBDE:TP=!3G,-"124=?'S!V/Z.G.)5R,[/.FA[<.E(T[8W?$1S1730F!%3 M.21F2VBF,(EDR7GN59-=7JV/O%0(`-+5-?,FWL-[HAGMDB&/?A]DL#1X:PT] M/W0$XQ%>4E('Q:'J&!\75:=E>5D=5+\D9JXZ@F%%)4U\K*A^>_>V"F,57#L# ML7C!RM34PQ%>0>)O7AP0&3OI)KABTYM_W@JKZ.!A#'V`7&@G_LH92PL5&)&% M>)Q(5-3!SV2!B2^W+946U4*SP.Y;<29(5=7#DZ27*M5D>!?+`B+?S%!^S/`KD\:E2V5.$S'(FD$9G@=R'@`1'Y\\"(GG+ ML3^WB)[C52[[I_`T<%0^H#U'`B"Q.T0*E%F>RK5ARMO-4UC,L.5*"TC$I)MAV=.DO64XSLE4U-S`%84 M?CX,_`6=(7^D@\GG9*=&+SAX\+Q`GOJX="\HKQ7]IC*)G"I7[9J+0K*R?KXD MET9%I;[P4=>7OA\S;6\NPP>D7LNN/M/MIFKPVUWEIIM15>+&4;I/]C".I4)F MM9IJ"FL-GFBIFFH14P1:(AZ;;Q=3!!AG8^O:-J9=$8]?S]4@ZB6OQ]["-71P M&)#"D>S*2NI1Y=QP0B4WC-CC45Q64B?%WO:Q,B&Y7OZEL'W3ZM'YR$)-O`EV M^*I]OI0^2JL@S9;13F6%[E1>5@?5Q?>%"F]R&$L)=0"9YQ@Z:S)?1DA&&GV/98JYCMO-)ZLF6$3QQ6 M;-#%4CHH?89^>JW#H3-?1DLNC.@%17<>+Q@>I;OE>D%MQ6\*"NI M+5/*,Y6$\_2(M^2*2GJR6WB0*DDLBBXC%(O9$-?1PT7T"C"7X/AGG;15+,B= M8EIHQ1O@L"3XHB.D4$B+<1\XVR,LE.#Y^61*BVJA&3JTS3E=-$^`_`XS>R^/ MIE^:U)PWV[VWW9U(_WVI*S2MO$]=\0@UW06L!CB<^67J^QD- M$,I9'=KE@C!J60ETQE8I(PT@2:%RF%=B_3LT;4PDIDN3`]3T0MH$H=$=HE MB#`,H6X_*K7^FNX&*8/,KI>.Z7Z.,JCLW(R; M[LLH`TKQJL?T*%XI3+;7B.TB=`\J@)(7\R+!^-)M5*3YSHZW`L8R,S].Y4`6)[7LRFW]UWMH@7+RW[OX._>+2*00J5A#TXGMS?%8VAAUT)A4N]TDYEB1N<+ MP6M$^?Z\^>JQYSNVNO>0+IEUE)*JXO'?+KK2\W9PF.0G-#K8R`]8%%B4&=;^ M'/C/V/\']%DZ()Y()EO]]"[RP7#U[;J_?%5%I-1JHS]/`6 M1G_78I+3A)ZWF.FI8Z'PS*'_=F`LAPR73-;X(_S.X4VJJI8(H]F,GFJCV=V; MM0#N'([IP3=RRX>"PUNM)C3%P^0FSX-;2+;+8:RZ7K^X21_\J,U0IFIO>"HD M^DW>6MA*&M6/2K=NMA]8%'+Y2C-;K-.YK(%^\]=L7O?-VG88-X;L;2@*9KHP7'N[(3[X<%DY&-+U MM<:?%RS63]!?8%LVE%Y<64LZ3[`)[=%C&*;7GN(I>/L%^0N6+IH2?(^WWM8P MO..@(HK($M.X.9V\3_'0^F=`1Z3X)'<%D_QZ/>$F\X*K+"-IE5[PP'U/7I8C M?@/U^`,^\4*J+S^\OPQI9E_8>_<6A+9W3_#R[@T2"WEP-/L%$`*8"3E^H62T M*I,P&C2@)^%O2B'SJWP"?L`N%<-+3\>!X7TQ"R[`Q/>+#P>7#U*+%K5X:=39 M`:OV-PWWU5W><.9?Q9*QX)ON;[HOM'FSTG37U48W?FV>A'_?P*]H%=ZK37Q` M_!.:X>5P!L\&7D$1GG>NW6\TZUNR\V^FR]P]-8NG^A#AZ,(YD\N/"\7\-[_&+YNS,J;U9@F9#)BE;3'=O4!JEL'I"*%L<\M@>NJGSF9K M*89U3O[CFZAMG8S:Y8TZV-.JYN7&D<7XJ@&MFYLGTZ-YU6!?1]BDW+B:S89RY:YF;84Y6@*);%V^9:. M$$VAQ<7T[/C-T:P7LFMZ#OWF.-8+63<]Y[YJ'+D..J:GY6^Q39;Y%D.]J@D>`L]BZ!59%Q+DA,/;1M%5#ZX,TR;".\N5+A+EW=7'CPA44&) M"W>2'?T>6.QF=O/(ZO+:$-LTWGSB7, M%$NW[XD?V!L12;PJ:NDB:`G(YB;P?+RDJTY(4+&LCDU,?@UL[V_YO)IJ$VL# M$F^BFFK#:H%5V19CJF&J!4PEI\+^THCKE@[8`R$>VWLR(]5>-E`3E//?T+&G M.+DFG$"+_4UUW%OXZL=?F<8[HX"/7#A=$!S,%_=TKO\#`N+=`T1$*<]4M:XC M7$F.=N:O@EQ*/*-8#1R<)I6<^>E=94+%%))EV8G/*:GEP77LSJ=2(7%E)750 M_`3>T#)8/D&V^W%HS9?1$HQ-YL"-`\INZ)Z,'62#.-@LNUG1[3O2\("SS3E: M^>RYDK:UI>PNF4C"P:RHI.6):69V&[XA[EO=V]^U42>$-%M"2[BJM8!VX$`F MO,1[\&@V@50\HM,TB5-'R(FR;=;O`2( M&_JKMI-#Q(E*HS`TIG4$4=K^(:(S%62/5-.VGO!X3'PY,:>TJ%9SLDI)(A>= MK6:JI+JFF?=+.V=][K&=[%%[%$CDY8HL%@7!W/0@?Y4RC,IE690#3)^5W@^Q%^C+Y4Q3[RQZ-)LEC.BF M/ZW:Z2B4FHE-3Y.E5)=6*>)%HF,"_^5)LJN)?T:E2T`\B4OZF][<5P^=L'%HEZ<&V#YO7VHWDZRLP_HW_`Z(/:6] M"*X-\F6T/*#E`,_;YKT8D3&:+_Q1X'L^<%G*!@[AE=64W&V7]O(+9']">[B& M!,QADKOCA2`KD\`C+ESJ^J:B63T/@47;4W:&#QE=\]#LRG2K!XK^&MD!<-(% MD80W?]ZPF3::E3;#GZ-=]ZH%R=`U&A/A=66AD)(9S79D$J9_!603@E5^"UU1 M6,N3;E`4@9'^_P5X<6,?"<.?4>A%@2/WF,2?6+FK?4-:3H16G-/L3<)%SB^O9+VG&JQ%-T.T9LEE MY@24^Q')U#CY/G&I1&XUE;DR2D8X;I*N`#9>5')@$7)9V8'*$T^`_`[]6)3X MP@0):-]2J;5L_%NU=WHH8\^\0Q+J3FZ\F8I=RGBE=3]>$`NWR323>9U@I\K) M'^[P_.'&])BG>PC3GMGI)Z:UM*Q>7Z/RC2"CFU#E8T,UAH@APEH5)<,![]CT':Z4V)W:$Q=?%B%I(2I.)FG=@`<7MA@-QT=U/S) M<:)-_FA(12^1YFI.Z8VH:[,$W,]@"<6Q15UTI0TSC^4;I!M%.QM:HZ:T\+SC MEO",_9U7U8K!H,#T_!J+ZOM3X&'"E M`Z+`^=3X"''U@'=TZV9\E'B_]J+*^V#C8\P[&0_92$[C&*F>8GI2BN4QK<[ZE>)ZTF(E]P`EV56DCKF:YD,ZUKLN%=VU.[*AUA M"ICI+SCO;H*38,D>DJ=[7"HR#BT*$OU-1U[L> MT>0V'OVI!5LZP*O(TA MV^21.R_X$^YA@4M3UNU$%G=]B)C>8S*#R*'CI<&^5"V M]Q.R'?6N<]:VD'CYW/$DWNN.9.\FE/1R-G,-Q#P)N(M)K9:(@\2Y1$S6@71= M,@X2:V$,P5Y@KD'!*0]@1WD`,W;EU$],Q%N]A@[L2G$O-AKC8_SWCKM`QVX5 MO[\*!_'.M8T$O*-KG%8!_"?$50K]QD?PZYSX\O<>Q@?NZ]SPQ8)KJZC^:#.: M^(#X1S<`*K6'5I'\M,57?(0K0+%)PO@X_?V/0&UCA?%!^'T]![Y=MXRW-ULL MW8>'3:L`_!/\\A=^K0+ECUGB:>+Y8'RD?'V8&Q@;F\6_?XA0=.&2=GUM%K]<&NG_Q`4.ZTRXC=+YZ+*'.-F7.$P2L M"L-P-,N>8922/EY7\L9^RU"&59:TD47(W;*@'`KN.,P]O#QO,BM^QBPLS*&KD-73MC"HJUDJ^4),*+!=>ALH2TLC2D@O=C\V5TB`I;"H2/IQ9+ M::.T^`9I&9W;,CJHW-.3G@6^N^Y5!Y*";%>E&/#+*WG9=YM5N-!]X4:1V4RC-.TRK>R1^IK(R[32$?6T#]??L$XS_2X08:34H5^B'>,N M=_;(AVRBQP(GE=5TFI-+;7ZYYR2+YC;3,Z!R[(OYQV=K;IVFO[6I!K/\AFWZ M:D_RV0.5M.#5$IO(=3$!8F4)=./B3U=F^22E5?*'Z:#KMQB MO"/II`LEP?+R!&8#,#M?'LGPG.9ZX[F>BOT)F-O=UMS-UNE%GU MMP)?YH;;>-]&I>CM_X[1>"?(@QZ?.N]1F^I7V:\!E`K";>)M>1CI1?0,1C:)%@X`2S]_EZ3M`HG>&L]@7I*IJ!>33/=%-;=JW--\@4= M5`S',_0?J2!%3Y9P!@UM&T7T/;CA4WF=#7,0`32:W0'"TB^F?"QQX/*NT]6TK<6KODB*V&^`6USG8JWB(6>: M4S,+]F<0Z=ERI@<"LNC1?,LPI/Q&/U',EM@-"^A8VLHGL4;:"P!+LE"LI8,3 M.E/HZ8>7\)'O`ILOHX/*@EX997Z)):),\AVY86C8V*%LEH41-=T*7`>:IM/( M=$MM'0PKM[[]645UG[(/KAU0H#83.`]5+=<>K>C$"NUBGS=?(-,E5@N*#H'` MZXU(?8-#;2>BDV7%H"/)/M`%P<:V&C`H>F/L[@PYJ6YT$RR4@F]%LS+QG M`TA+W-#:5/PACVP%:]ID[P*"5^6!%J5%E$11A!>:-TS7)8@3JCR:Y]!%X72G;"?')T[LP^(O=J56@V MG]='X%U:=7HQ(+,;UY$H8V)`RB5XTRV`4M`(E`SC72%KZ/%M=SG3W30J9;L< MF/R)N3^<#MTB\D*P'5@^\X_18@QQ?8KN+\B&&=-W3%W9TJC2I9NWI\3,\N#^ M!JW0JPBND07#3*;!:N4(;2[5E;2D]XLFQHA,(&%D"32LTJ(::0X1C$CQA$HY MO_S)Y,4S^]1=8>D>DX59SAJDLJ_C,;-P]J8I`:Y'C\4E<+Y`)\&)ORT)RVN] MDFY[9E19+)H\08@]Q%S0^BU>B?;T7!0!?Q\U70*M/$*VVH[$66^Z:B@/EGCS M,5Y%[/+T+%FXA05^1,;#CO%M+) M_.,)\NB`75V.R!,F=%"FV`=./`CUS`(=62]T0LZP M@_`-(&3#IF;H]O\$?L.DRK+0JBDE?-S3*4P[XF.7+Z!#TDKVLBC?WSTF8VA!M*:G MWQAO@.-ORC8N?F$UM,S0'TRJD=U'A>7UV/HL/'=1E+VF,(!<^Y^@BA)4X\;B MCOZ`]H-[@UTWN@YGR6VNT*9/CP`(77^EZ7&%QU(QBN&':!W M5)I>#3EMJSC+;P:F&P6;H+>[09EN(6R"DD!4,MUN6!,N.7G(]%L=)?M876'- M]-S<\BJOO%QR++=H==3K[8RL9^PR_37(1A`VL'6:_D)D(QS%]@'3GXB4-B3) M;7PY7<3T*PZ6G-V;XGOD`I81T45-#CHK>#8CG=)06U/B!:B7O>`6>72]-S4?-7#DL8ZE&M<0OA:>'4 MIW\7Q'*R=\L=SK(IX?%X5TWYPR'I83ZE?7^F$^YW+0'^(4%5"=SSA?1D%9,% ML9P%^?I:0V=+1R.?@TH:A].*JP0IE(6UB'_=KSO.S53EHT3LU:',,V5A@:\N M"L.Y"J]K)9\SKT$E#];'!JI-B#!O@*HZ0?CE#_7EEY.6(%I/&K6"`UY5F<`+\3M#-:6V>JT= MRHILC-;QKM=B_I*>6-`..E>_!*1R;/3-DE8KV8T,"J=U)X!'WXFI/%&1_+FD MN+]>O!8C&R(I#U/CAGN!1WGZ;Y_JL*_AX8SO,8%H[FZSJA=S.]4&2F&/?3A1 M3'\@K],98[KM3FM&NN,QZ+6:SPU.A.,UT7$=]K1J*!)4E>_.$A4UYE?+A!I4 MG#*""CUXV4O`A\"OLX]*RD\7C.I7X$'ZG_\'4$L#!!0````(`'6*9D/:E)]P'I2=7@+ M``$$)0X```0Y`0``[5QM<^(X$OZ^5?L?=%3=[6S5$D(R,WM));-%`IEA*PD4 M,"]U7Z84NP'MV!(KR23LK[^6;(/!CC&$3)@J?TF,U=WJ[J?5>K&DLS\>?(], M02HF^'FE?G!8(<`=X3(^.J]\[%<;_+WC4Y.J@3,M9Z4'"=>74J@&JF)BTJOATX5*D!PKD%-R#2*BRQA+T(%?GE81]]\<'0HYJ6$6]]N7F.G1* MY>>?2$A[^G`G/;;$8=[$/,LZ6=/B; M6EB8H'8P/+6<+9,K<`Y&8EJ+"K.=X0128IM[C#4J-;Q'*5X76#8;%F37!@_. M.)O%E&3S,#X%I;.YPK)L/J4G,IO+E!B>>H('(V`$^I;Z&`?4@4WB`_.0#UQ? M">DW84@##Y7].Z`>&S)P*X1J+=E=H&&)(.`+DG=&RAGE7&B;4>QO\V8R87PH MHI_XPC2;4RD\&�$//PL==>HZJ.LF/-D->:P@F,LI2[+:Z9GK6Q`B0UU58( M<\\KN11S56)E7!@RSJS2]<,ZJ9*8/?F(HD@HBR2$G=56):P*#S"-=_@[^^Q0 MSPD\RWB-OR/FB"*/<8+N,.9LSKG0['&^Z&V,R2ZAZJ/.-K`ZPRO&,2,SZG6% ML@I=>E2I*+X,:#UD^%J0(1]#[.'(7!`^7W9N^YWK=K,Q:#7)1>.Z<7O9(OT/ MK=:@7P*X"P"[*(/K,6B&'MH83I\ M$-\6!_&R<]/MM3ZT;OOM3RURW>F78!8'\Y*J\94G[E6327!T-H:K1/G0_;X! M=(W^!W)UW?E<0K8&LENA00W$O`>;.UC=4AU(P(8V,;-XU$\E0-R(+1_6_YJ1 M*%..)Q0RFA^@',DF=NHNAN0B4(R#4B62VR)Y0153G6'#L1--QD>%@$QSY>-X MLHJC%6`0["9<6J*X+8I]+9QO8^&Y(%7K[P`G:X9VX?$!/.@+#VD*H5M<6B[J M]<-5U)."?R&AZ!+T;4%O40DP_ST2K,;>X&2LL9B63;A:%%1T[N9N0]B)&D MDS%S2$,"+7OEK>.@"4.0$MP>3($'6R?R`F+RH^!X-0JNF8,3*B"-D82PCA+D M9^^T!_3.@V(C[$UEYL/_ND@'3EZ%LLKUIMWWY!L@OTY&/M)OUO?J)<[?HWO? MI*T7EI:/_=L==/5E05+ M%N*3GP')JR9HRLIO#<5ACY9.DNL>A4`OS)6I%+7,EI@1\=X"GAV2%\"[* ME@]W:N$M:5"GSK5_41%6KS*\KD)^H%<(/#)V2)OER&).\EUA7O M#]F]V/RX2:WP/98S%G434SEAG)CJB:V?)!0PH16I0"(=RJ#:16IQQN`&'N"P M`*3-VMP)R3ZBQHU[*EW5X&XB=43>_\A1R+7@HP%(OXU,')LZ=*49U/L%DM+S MU)L?EJD5R81>OZA$.HN4LV.:A7I1;C,*DE!#.ZU9RGAQ;%HUB=&3&$7)7%,2 MJ5I&[\;1>PO:K"?$RQ.%QD"%>/*C)K6"F;&P40Y_G@ME,[EP,!,TF1=@PXJ* M+H7O"VX)UB"^GC\?_=0"9B;ZMA:;#:)Z%B1A5?$"6!D.&X9#O)(4+20ADHME MI(O98A')KB$52@D[D)@?,JF5T&U6P\J,\C(A-)\M15^\D.(2N85O1AW.TP.J MB/S\\-K)8NO2G"U6Q5#&RI!8FS+@OGO`X1#1#1QM--EUK"5%YX=9:F5WIV$6 MZ4&LM\L(^SX1UFF&!_5#SOR1IC-E0.AJ1>AM9L`W*KF M_/A,+4,_.3X32L[38'@6,U23U`__380D1E5#;Y6-H[H,XHV#.-H)LM@(4FCX M5I`K/WA2B]KI72GE"`Q?FS_F:&\/AL2>VCTUYU7/*XKY$P]S0_B.2L?PYY_W MK4VDP,:H&:A:+#86D.)>/F!LXV;%?Y%6L82QA.%YQ1SMK<:',[\BQ\&#[\4D MFFE3R^5"#C&"U&^$>EZEMK^6+\-8P'!DR#"\.1?S@]CMT3OP"IJ,M!DF7QL) M/XBUJ\V\@-'(DF'TTE?8#-O/:LF#Q?AK^>#Q&9HNI"8\\RST(W<%D/`Z@GC. MD,-B?E5COJIY5:T?58_K!P_*C53<1(.%IS?3(.;;5(/,@_A%ZXX93*5O"E67 M>Z7!8]7:*C/O4*B!I]5<5G4A:W/OI^XN*.2$52[CB1/C_OK;IZB0N'9A0S4$ MO]U.D[P[*IX`C'FS*2[K;GO(52>++_[Q-$4R[HXHIDF2NE%(ASF3?:HNV)/U M1_=O6`7.*PU'TRE3\2R!NV;]':39]\C^"?<\Q4/\&_#O0(;S"].Q?MV"-QPN MA)?#G+K"IXRW-?CAT@V]P_DH=?1Y14LSD[97[YSB(($)=V`9W4!&DQS./,_L M?XQI58#,3`?AIT\13,XK(3M#\;FF/V;6/JIL;S+H##]3:;Z;=J2][.@SF+_@ M-J8X=Q]!Z\%`H*"+61KFM"HB5@E#=R(M<@_Z9A)]0LKRSI!Z*M,]X=!&[\0[ M30KW0O!1$Z;@B4FTWK(Z`4[AO1G;/H5#]K;42(>DA?ETH4EA9?B.\='+6<10 M4["+"')FHRG=/G-H]@JN`)IZD\%ZF234DU$V\ M2SK7W-6W43K?J:)M_AR*12^%Y9E-R7P?N+,.D1RGWTR[) MS,?&^RNJULHOW*1EVK>`K(7O@`)OBD*8G9M33R>#* MH=FO[JH[9/^8@>2:"6$^V5ZA(X4#X*HK*?RXP86P!W;S>0_VE>`(2A&'/'#U'9I[HFV@\+/3(]O*`^&J&9@ MQN5]-$%_G$0';MA2^G^RI.=S%\Y[W>?R5WA2P`:]F8#%89_GF$=9?@@/+,Y4 MQ#N?P:Q@3M":<-9MSBPDSC-8`G.:P320'IB)IX/CM?DIC-5V$XWGXD-=]KCV MRFTBUJTOK,=2/M/Q^Y=+TH\XP:2FD:6[F"U(NG1F%TV,BY+F*FRQ5NN`>BLS MJV>2OU\]7;@L%B'?X7\&WJS/'@;W8C`6@:+;^-1UTYYCM4/J'_F$EC4@'SB[#O MDP-,'NH,%SOR$L:EB_8K70U@2E.()%_NE9\Q1A0.?'SJO0%$.V%7(>JE%7K;LKY;<)W5PD_E^/A_4$L!`AX#%``` M``@`=8IF0X$TD]^U90``[',$`!$`&````````0```*2!`````&%T&UL550%``-]P'I2=7@+``$$)0X```0Y`0``4$L!`AX#%`````@` M=8IF0W9'``$P#0``.Z0``!4`&````````0```*2!`&8``&%T`Q0````( M`'6*9D.E*.K^41(``*@1`0`5`!@```````$```"D@7]S``!A=')S+3(P,3,P M.3,P7V1E9BYX;6Q55`4``WW`>E)U>`L``00E#@``!#D!``!02P$"'@,4```` M"`!UBF9#>XJCL8)$``#/KP,`%0`8```````!````I($?A@``871R&UL550%``-]P'I2=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`=8IF0T?#ZR@J(@``PFL"`!4`&````````0```*2!\,H``&%T`Q0` M```(`'6*9D/: XML 36 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8 Description of Business - Additional Information (Detail) 9 Months Ended Sep. 30, 2013 site Facility Customer Patient Description Of Business [Abstract] Number of primary customers 2 Number of patients enrolled in the study 45 Number of investigative sites 8 Number of facility locations 2 X - Details Name: atrs_DescriptionOfBusinessAbstract Namespace Prefix: atrs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Number of facility locations. + References No definition available. + Details Name: atrs_NumberOfFacilityLocations Namespace Prefix: atrs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - Definition Number Of Investigative Sites + References No definition available. + Details Name: atrs_NumberOfInvestigativeSites Namespace Prefix: atrs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - Definition Number Of Patients Enrolled In Study + References No definition available. + Details Name: atrs_NumberOfPatientsEnrolledInStudy Namespace Prefix: atrs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - Definition Number of primary customers. + References No definition available. + Details Name: atrs_NumberOfPrimaryCustomers Namespace Prefix: atrs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration XML 37 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8 License Agreements 9 Months Ended Sep. 30, 2013 Revenue Recognition [Abstract] License Agreements 6. License Agreements Daewoong Development and License Agreement In January 2012, the Company entered into a licensing agreement with Daewoong Pharmaceuticals (“Daewoong”) under which Daewoong will commercialize the Company’s oxybutynin gel 3% product, once approved in South Korea. The agreement terms include an upfront payment, development and sales-based milestone payments and escalating royalties based on product sales in South Korea. Because the Company has no development responsibilities, the upfront and each milestone payment will be recognized as revenue when received. Royalties will be recognized as revenue when earned. The term of the agreement ends on the later of fifteen years following launch of the product or the expiration date of the last to expire patent. The Company recognized revenue of $442,859 in the nine months ended September 30, 2012 in connection with upfront and milestone payments. Pfizer License Agreement In December 2011, the Company licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. Pfizer assumed full cost and responsibility for all clinical development, manufacturing, and commercialization of the product in the licensed territory, which also includes certain non-exclusive territories outside of North America. The Company received an upfront payment, and will receive development milestones and sales based milestones, as well as royalties on net sales for three years post launch in the U.S. Because the Company has no development responsibilities, the upfront and each milestone payment will be recognized as revenue when received. Royalties will be recognized as revenue when earned. The Company recognized revenue of $750,000 in the nine months ended September 30, 2012, which was earned when Pfizer achieved a development milestone related to this undisclosed Consumer Healthcare product. Actavis License and Commercialization Agreement In July 2011, the Company entered into an exclusive licensing agreement with Actavis to commercialize, in the U.S. and Canada, the Company’s topical oxybutynin gel 3% product, which was subsequently approved by the FDA in December 2011. Under this agreement the Company received payments for certain manufacturing start-up activities and delivery of launch quantities, and has received and is entitled to receive future royalties on both the Company’s oxybutynin gel 3% product and Actavis’ oxybutynin gel product Gelnique^® 10%, and will potentially receive sales based milestone payments. The milestone payment based on the achievement of regulatory approval was subject to reimbursement to Actavis if launch quantities were not delivered within a certain defined time period. The term of the agreement ends on the later of April 2024 or the expiration date of the last to expire patent. The Company received a milestone payment from Actavis in December 2011 upon FDA approval, which was recorded as deferred revenue. This milestone payment was recognized as revenue in March of 2012, as launch quantities were delivered within the defined time period and the potential reimbursement liability was eliminated. In the nine months ended September 30, 2012, the Company recognized revenue of $5,859,488 in connection with product sales, development activities, and the milestone payment. In the nine months ended September 30, 2013, the Company recognized revenue of $1,301,929 in connection with product sales and royalties. Product sales to Actavis ended in the first quarter of 2013, as Actavis assumed all manufacturing of Gelnique 3% in 2013 as contracted. X - Definition The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.3(b).Q1(c),(b).Q2,(c).Q3) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 + Details Name: us-gaap_DeferredRevenueDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RevenueRecognitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 38 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8 Description of Business 9 Months Ended Sep. 30, 2013 Accounting Policies [Abstract] Description of Business 1. Description of Business Antares Pharma, Inc. (the “Company” or “Antares”) is an emerging specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies and topical gel-based products. The Company has numerous partnerships with pharmaceutical companies as well as multiple internal product development programs. The Company has developed both subcutaneous and intramuscular injection technology systems which include Vibex^® disposable pressure-assisted auto injectors, Vision™ reusable needle-free injectors, and disposable multi-use pen injectors. The Company has licensed its reusable needle-free injection device for use with human growth hormone (“hGH”) to Teva Pharmaceutical Industries, Ltd. (“Teva”), Ferring Pharmaceuticals BV (“Ferring”) and JCR Pharmaceuticals Co., Ltd. (“JCR”), with Teva and Ferring being two of the Company’s primary customers. The Company’s needle-free injection device is marketed by Teva as the Tjet^® injector system to administer their 5mg Tev-Tropin^® brand hGH marketed in the U.S. The Company’s needle-free injection device is marketed by Ferring with their 4mg and 10mg hGH formulations as Zomajet^® 2 Vision and Zomajet^® Vision X, respectively, in Europe and Asia. The Company has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices. In addition to development of products with partners, the Company is developing its own drug/device combination products. The Company’s lead product candidate, OTREXUP™, is a proprietary combination product comprised of a pre-filled methotrexate syringe and the Company’s Medi-Jet™ self-injection system. On October 14, 2013 the Company announced the approval of OTREXUP™ (methotrexate) injection by the U.S. Food and Drug Administration (“FDA”). OTREXUP™ is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. OTREXUP™ is indicated for adults with severe active rheumatoid arthritis or children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. The Company has worldwide marketing rights for OTREXUP™ and has provided Uman Pharma an exclusive license to commercialize the product in Canada. The Company’s strategy is to commercialize OTREXUP™ in the U.S. on its own and to enter into licensing or distribution agreements for commercialization outside the rheumatology area and outside the U.S. The Company is also developing Vibex^® QuickShot™ (“QST”) for testosterone replacement therapy for men suffering from symptomatic testosterone deficiency and announced on September 16, 2013 that the first patients have been dosed in a clinical study evaluating testosterone administered weekly by subcutaneous injection via the Vibex^® QST auto injector device. Up to 45 patients will be enrolled in the study at approximately eight investigative sites in the United States. In the gel-based product area, the Company announced with Actavis (formerly Watson Pharmaceuticals) on April 26, 2012, the launch of Gelnique 3%™, the Company’s topical oxybutynin gel product for the treatment of overactive bladder (“OAB”). The Company has a licensing agreement with Actavis under which Actavis is currently marketing Gelnique 3%™ in the U.S. In January 2012, the Company entered into a licensing agreement with Daewoong Pharmaceuticals under which Daewoong will commercialize this product, once approved in South Korea. The Company’s gel portfolio also includes Elestrin^® (estradiol gel) currently marketed by Meda Pharma in the U.S. for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. The Company has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted auto injector and pen injector systems. The Company’s corporate head office and Product Development and Commercial Groups are located in Ewing, New Jersey, where the Company’s gel based products were developed and where the Product Development and Commercial Groups direct the clinical, regulatory and commercial development of the Company’s internal drug/device combination products. X - Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592 + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 39 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 40 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8 Stockholders' Equity - Summary of Stock Option Activity (Detail) (USD $) 9 Months Ended Sep. 30, 2013 Stockholders Equity Note [Abstract] Aggregate Intrinsic Value, Exercised $ 2,379,554 Aggregate Intrinsic Value Outstanding, Ending 17,703,665 Aggregate Intrinsic Value Exercisable, Ending $ 16,696,929 Weighted Average Remaining Contractual Term Outstanding, Ending 6 years 4 months 24 days Weighted Average Remaining Contractual Term Exercisable, Ending 5 years 8 months 12 days Weighted Average Exercise Price Outstanding, Beginning Balance $ 1.49 Weighted Average Exercise Price Granted $ 4.01 Weighted Average Exercise Price Exercised $ 0.72 Weighted Average Exercise Price Cancelled $ 3.49 Weighted Average Exercise Price Outstanding, Ending Balance $ 1.80 Weighted Average Exercise Price Exercisable, Ending Balance $ 1.38 Number of Shares Outstanding, Beginning 7,814,561 Number of Shares Granted 904,380 Number of Shares Exercised (707,285) Number of Shares Cancelled (197,276) Number of Shares Outstanding, Ending 7,814,380 Number of Shares Exercisable, Ending 6,234,160 X - Definition Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - Definition Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Definition Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(3) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Gross number of share options (or share units) granted during the period. + References No definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Number of options outstanding, including both vested and non-vested options. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i)-(ii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - Definition Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Definition Weighted average price at which option holders acquired shares when converting their stock options into shares. + References No definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - Definition Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + References No definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + References No definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Number of share options (or share units) exercised during the current period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28,29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 41 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8 Industry Segment and Operations by Geographic Areas (Tables) 9 Months Ended Sep. 30, 2013 Segment Reporting [Abstract] Summary of Revenues by Customer Location Revenues by customer location are summarized as follows: Three Months Ended September 30, Nine Months Ended September 30, 2013 2012 2013 2012 United States of America $ 4,390,966 $ 4,881,106 $ 13,063,929 $ 13,083,259 Europe 1,047,748 787,368 2,585,655 3,448,121 Other 69,110 17,443 224,006 543,021 $ 5,507,824 $ 5,685,917 $ 15,873,590 $ 17,074,401 Summary of Revenues by Product Type Revenues by product type: Three Months Ended September 30, Nine Months Ended September 30, 2013 2012 2013 2012 Injection devices and supplies $ 5,100,253 $ 3,600,400 $ 13,882,973 $ 9,505,344 Transdermal products 407,571 2,085,517 1,990,617 7,569,057 Summary of Significant Customers Comprising 10% or More of Total Revenue Significant customers comprising 10% or more of total revenue are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2013 2012 2013 2012 Teva $ 4,004,531 $ 2,797,761 $ 11,196,559 $ 5,966,246 Ferring 1,047,750 783,757 2,511,332 3,444,510 Actavis (Watson) 202,813 1,171,633 1,301,929 5,859,488 X - Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599 + Details Name: us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer. + References No definition available. + Details Name: us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599 + Details Name: us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 42 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8 Net Loss Per Share - Additional Information (Detail) 9 Months Ended Sep. 30, 2013 Sep. 30, 2012 Earnings Per Share [Abstract] Dilutive stock options and warrants excluded from dilutive loss per share 9,595,808 12,765,470 X - Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Antidilution -URI http://asc.fasb.org/extlink&oid=6505113 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Diluted Earnings Per Share -URI http://asc.fasb.org/extlink&oid=6510752 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Contingent Stock Agreement -URI http://asc.fasb.org/extlink&oid=6508534 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 43 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8 Stockholders' Equity - Assumptions Used in Fair Value Measurement of Options Granted (Detail) 9 Months Ended Sep. 30, 2013 Sep. 30, 2012 Stockholders Equity Note [Abstract] Risk-free interest rate 0.70% 0.70% Annualized volatility 62.50% 61.00% Weighted average expected life, in years 6 years 5 years Expected dividend yield 0.00% 0.00% X - Definition The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - Definition Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.D.2) -URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section D -Subsection 2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Definition The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - Definition The risk-free interest rate assumption that is used in valuing an option on its own shares. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: num:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 44 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8 Document and Entity Information 9 Months Ended Sep. 30, 2013 Nov. 06, 2013 Document And Entity Information [Abstract] Document Type 10-Q Amendment Flag false Document Period End Date Sep. 30, 2013 Document Fiscal Year Focus 2013 Document Fiscal Period Focus Q3 Trading Symbol ATRS Entity Registrant Name ANTARES PHARMA, INC. Entity Central Index Key 0001016169 Current Fiscal Year End Date --12-31 Entity Filer Category Accelerated Filer Entity Common Stock, Shares Outstanding 127,613,404 X - Details Name: atrs_DocumentAndEntityInformationAbstract Namespace Prefix: atrs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition If the value is true, then the document is an amendment to previously-filed/accepted document. + References No definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition End date of current fiscal year in the format --MM-DD. + References No definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - Definition This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY. + References No definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - Definition This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + References No definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - Definition The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD. + References No definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - Definition The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other". + References No definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - Definition A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - Definition Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + References No definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References No definition available. + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - Definition The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Trading symbol of an instrument as listed on an exchange. + References No definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration XML 45 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8 Stockholder's Equity - Schedule of Performance Stock Unit Awards and Stock Option Granted Under Long Term Incentive Program (Detail) (USD $) 9 Months Ended Sep. 30, 2013 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Stock Options 904,380 Exercise Price $ 4.01 Long Term Incentive Program [Member] | Grant Date May 17, 2011 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Grant Date May 17, 2011 Long Term Incentive Program [Member] | Grant Date May 17, 2012 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Grant Date May 17, 2012 Long Term Incentive Program [Member] | Grant Date July 6, 2012 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Grant Date Jul. 06, 2012 Long Term Incentive Program [Member] | Grant Date May 22, 2013 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Grant Date May 22, 2013 Performance Stock Units [Member] | Long Term Incentive Program [Member] | Grant Date May 17, 2011 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock Units 182,000 Fair Value on Grant Date $ 1.66 Performance Stock Units [Member] | Long Term Incentive Program [Member] | Grant Date May 17, 2012 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock Units Fair Value on Grant Date Performance Stock Units [Member] | Long Term Incentive Program [Member] | Grant Date July 6, 2012 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock Units 137,715 Fair Value on Grant Date $ 4.26 Performance Stock Units [Member] | Long Term Incentive Program [Member] | Grant Date May 22, 2013 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock Units 185,185 Fair Value on Grant Date $ 3.96 Restricted Stock [Member] | Long Term Incentive Program [Member] | Grant Date May 17, 2011 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock Units Fair Value on Grant Date Restricted Stock [Member] | Long Term Incentive Program [Member] | Grant Date May 17, 2012 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock Units Fair Value on Grant Date Restricted Stock [Member] | Long Term Incentive Program [Member] | Grant Date July 6, 2012 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock Units Fair Value on Grant Date Restricted Stock [Member] | Long Term Incentive Program [Member] | Grant Date May 22, 2013 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock Units 185,185 Fair Value on Grant Date $ 3.96 Stock Options [Member] | Long Term Incentive Program [Member] | Grant Date May 17, 2011 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Stock Options 317,000 Exercise Price $ 1.66 Stock Options [Member] | Long Term Incentive Program [Member] | Grant Date May 17, 2012 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Stock Options 470,000 Exercise Price $ 2.94 Stock Options [Member] | Long Term Incentive Program [Member] | Grant Date July 6, 2012 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Stock Options 178,731 Exercise Price $ 4.26 Stock Options [Member] | Long Term Incentive Program [Member] | Grant Date May 22, 2013 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Stock Options 327,381 Exercise Price $ 3.96 X - Definition Grant Date + References No definition available. + Details Name: atrs_GrantDate Namespace Prefix: atrs_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - Definition The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Gross number of share options (or share units) granted during the period. + References No definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + References No definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (do not check if a smaller reporting company)

Smaller reporting company

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue:
Product sales	$ 3,047,091	$ 2,052,398	$ 10,052,458	$ 7,758,463
Development revenue	1,299,328	2,606,482	2,681,202	6,329,967
Licensing revenue	69,231	77,284	207,238	812,196
Royalties	1,092,174	949,753	2,932,692	2,173,775
Total revenue	5,507,824	5,685,917	15,873,590	17,074,401
Cost of revenue:
Cost of product sales	1,909,060	1,673,849	6,519,468	5,071,007
Cost of development revenue	1,095,542	1,622,640	1,992,959	2,747,424
Total cost of revenue	3,004,602	3,296,489	8,512,427	7,818,431
Gross profit	2,503,222	2,389,428	7,361,163	9,255,970
Operating expenses:
Research and development	4,318,011	3,900,475	11,786,224	9,260,422
Sales and marketing	2,576,247	237,067	4,615,736	527,953
Business development	142,017	219,953	486,732	784,661
General and administrative	1,836,127	1,551,147	5,375,610	5,089,744
Total operating expenses	8,872,402	5,908,642	22,264,302	15,662,780
Operating loss	(6,369,180)	(3,519,214)	(14,903,139)	(6,406,810)
Other income (expense)	9,223	(15,025)	31,478	(8,895)
Net loss	$ (6,359,957)	$ (3,534,239)	$ (14,871,661)	$ (6,415,705)
Basic and diluted net loss per common share	$ (0.05)	$ (0.03)	$ (0.12)	$ (0.06)
Basic and diluted weighted average common shares outstanding	127,162,064	108,961,792	126,581,018	105,735,855

Industry Segment and Operations by Geographic Areas - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2013 Segment
Segment Reporting [Abstract]
Number of operating segment	1
Total revenue	10.00%

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:
Net loss	$ (14,871,661)	$ (6,415,705)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	288,188	178,030
Stock-based compensation expense	1,534,100	1,464,225
Changes in operating assets and liabilities:
Accounts receivable	(1,176,745)	484,020
Inventories	(804,009)	(2,736)
Prepaid expenses and other current assets	(349,833)	(663,796)
Deferred costs	440,051	423,856
Other assets	(11,844)	(27,322)
Accounts payable	1,387,543	321,607
Accrued expenses and other current liabilities	1,946,548	404,423
Deferred revenue	(1,676,365)	(4,143,463)
Net cash used in operating activities	(13,294,027)	(7,976,861)
Cash flows from investing activities:
Purchases of equipment, molds, furniture and fixtures	(2,184,568)	(2,425,454)
Additions to patent rights	(195,558)	(283,871)
Proceeds from maturities of investment securities	15,000,000	9,000,000
Purchases of investment securities	(9,118,161)	(15,077,176)
Net cash provided by (used in) investing activities	3,501,713	(8,786,501)
Cash flows from financing activities:
Proceeds from exercise of stock options and warrants	756,611	9,601,723
Taxes paid related to net share settlement of equity awards	(104,329)	(28,916)
Net cash provided by financing activities	652,282	9,572,807
Effect of exchange rate changes on cash and cash equivalents	3,454	(7,475)
Net decrease in cash and cash equivalents	(9,136,578)	(7,198,030)
Cash and cash equivalents:
Beginning of period	52,097,064	19,357,932
End of period	42,960,486	12,159,902
Noncash investing activities:
Purchases of equipment, molds, furniture and fixtures recorded in accounts payable and accrued expenses	$ 437,504	$ 358,828

License Agreements - Additional Information (Detail) (USD $)	1 Months Ended	9 Months Ended
	Jan. 31, 2012 Daewoong Development And License Agreement [Member]	Sep. 30, 2012 Daewoong Development And License Agreement [Member]	Sep. 30, 2013 Actavis License And Commercialization Agreement [Member]	Sep. 30, 2012 Actavis License And Commercialization Agreement [Member]	Sep. 30, 2013 Pfizer License Agreement [Member]	Sep. 30, 2012 Pfizer License Agreement [Member]
Deferred Revenue Arrangement [Line Items]
Revenue recognized under licensing agreement		$ 442,859
Term of the agreement	15 years
Period for receiving royalties					3 years
Recognition of deferred revenue						750,000
Revenue recognized			$ 1,301,929	$ 5,859,488

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]
Preferred Stock, par value	$ 0.01	$ 0.01
Preferred Stock, shares authorized	3,000,000	3,000,000
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$ 0.01	$ 0.01
Common Stock, shares authorized	150,000,000	150,000,000
Common Stock, shares issued	127,230,176	125,949,024
Common Stock, shares outstanding	127,230,176	125,949,024

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current Assets:
Cash and cash equivalents	$ 42,960,486	$ 52,097,064
Short-term investments	27,053,333	21,112,623
Accounts receivable, net	3,405,395	2,228,650
Inventories, net	1,804,695	1,002,703
Deferred costs	317,514	755,159
Prepaid expenses and other current assets	1,001,195	463,033
Total current assets	76,542,618	77,659,232
Equipment, molds, furniture and fixtures, net	6,013,707	3,583,104
Patent rights, net	1,217,720	1,123,652
Goodwill	1,095,355	1,095,355
Long-term investments	0	12,015,906
Other assets	61,241	49,361
Total Assets	84,930,641	95,526,610
Current Liabilities:
Accounts payable	4,689,615	2,864,507
Accrued expenses and other liabilities	4,863,980	2,916,700
Deferred revenue	633,970	2,157,016
Total current liabilities	10,187,565	7,938,223
Deferred revenue - long term	874,596	1,037,795
Total liabilities	11,062,161	8,976,018
Stockholders' Equity:
Preferred Stock: $0.01 par, authorized 3,000,000 shares, none outstanding	0	0
Common Stock: $0.01 par; authorized 150,000,000 shares; 127,230,176 and 125,949,024 issued and outstanding at September 30, 2013 and December 31, 2012, respectively	1,272,302	1,259,490
Additional paid-in capital	240,919,182	238,745,612
Accumulated deficit	(167,660,826)	(152,789,165)
Accumulated other comprehensive loss	(662,178)	(665,345)
Total Stockholders' Equity	73,868,480	86,550,592
Total Liabilities and Stockholders' Equity	$ 84,930,641	$ 95,526,610

Description of Business - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2013 site Facility Customer Patient
Description Of Business [Abstract]
Number of primary customers	2
Number of patients enrolled in the study	45
Number of investigative sites	8
Number of facility locations	2

Stockholders' Equity - Summary of Stock Option Activity (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Stockholders Equity Note [Abstract]
Aggregate Intrinsic Value, Exercised	$ 2,379,554
Aggregate Intrinsic Value Outstanding, Ending	17,703,665
Aggregate Intrinsic Value Exercisable, Ending	$ 16,696,929
Weighted Average Remaining Contractual Term Outstanding, Ending	6 years 4 months 24 days
Weighted Average Remaining Contractual Term Exercisable, Ending	5 years 8 months 12 days
Weighted Average Exercise Price Outstanding, Beginning Balance	$ 1.49
Weighted Average Exercise Price Granted	$ 4.01
Weighted Average Exercise Price Exercised	$ 0.72
Weighted Average Exercise Price Cancelled	$ 3.49
Weighted Average Exercise Price Outstanding, Ending Balance	$ 1.80
Weighted Average Exercise Price Exercisable, Ending Balance	$ 1.38
Number of Shares Outstanding, Beginning	7,814,561
Number of Shares Granted	904,380
Number of Shares Exercised	(707,285)
Number of Shares Cancelled	(197,276)
Number of Shares Outstanding, Ending	7,814,380
Number of Shares Exercisable, Ending	6,234,160

Net Loss Per Share - Additional Information (Detail)	9 Months Ended
Net Loss Per Share - Additional Information (Detail)	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share [Abstract]
Dilutive stock options and warrants excluded from dilutive loss per share	9,595,808	12,765,470

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2013	Nov. 06, 2013
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Trading Symbol	ATRS
Entity Registrant Name	ANTARES PHARMA, INC.
Entity Central Index Key	0001016169
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		127,613,404

Stockholder's Equity - Schedule of Performance Stock Unit Awards and Stock Option Granted Under Long Term Incentive Program (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock Options	904,380
Exercise Price	$ 4.01
Long Term Incentive Program [Member] \| Grant Date May 17, 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Date	May 17, 2011
Long Term Incentive Program [Member] \| Grant Date May 17, 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Date	May 17, 2012
Long Term Incentive Program [Member] \| Grant Date July 6, 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Date	Jul. 06, 2012
Long Term Incentive Program [Member] \| Grant Date May 22, 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Date	May 22, 2013
Performance Stock Units [Member] \| Long Term Incentive Program [Member] \| Grant Date May 17, 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Units	182,000
Fair Value on Grant Date	$ 1.66
Performance Stock Units [Member] \| Long Term Incentive Program [Member] \| Grant Date May 17, 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Units
Fair Value on Grant Date
Performance Stock Units [Member] \| Long Term Incentive Program [Member] \| Grant Date July 6, 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Units	137,715
Fair Value on Grant Date	$ 4.26
Performance Stock Units [Member] \| Long Term Incentive Program [Member] \| Grant Date May 22, 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Units	185,185
Fair Value on Grant Date	$ 3.96
Restricted Stock [Member] \| Long Term Incentive Program [Member] \| Grant Date May 17, 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Units
Fair Value on Grant Date
Restricted Stock [Member] \| Long Term Incentive Program [Member] \| Grant Date May 17, 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Units
Fair Value on Grant Date
Restricted Stock [Member] \| Long Term Incentive Program [Member] \| Grant Date July 6, 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Units
Fair Value on Grant Date
Restricted Stock [Member] \| Long Term Incentive Program [Member] \| Grant Date May 22, 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Units	185,185
Fair Value on Grant Date	$ 3.96
Stock Options [Member] \| Long Term Incentive Program [Member] \| Grant Date May 17, 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock Options	317,000
Exercise Price	$ 1.66
Stock Options [Member] \| Long Term Incentive Program [Member] \| Grant Date May 17, 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock Options	470,000
Exercise Price	$ 2.94
Stock Options [Member] \| Long Term Incentive Program [Member] \| Grant Date July 6, 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock Options	178,731
Exercise Price	$ 4.26
Stock Options [Member] \| Long Term Incentive Program [Member] \| Grant Date May 22, 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock Options	327,381
Exercise Price	$ 3.96